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Abstract 
Studies with APCMin/+ mice and APCMin/+ 33$5Į-/- mice were 
undertaken to investigate whether polyp development in the mouse gut 
was mediated by 33$5Į Additionally, the effect of piroxicam treatment 
dependency on 33$5Į was assessed.  
Results showed the number of polyps in the colon was significantly 
higher in APCMin/+ PPARĮ-/- mice than in APCMin/+ mice, whilst in the 
small bowel the difference was not significant.  
Analysis of gene expression in the colon with Affymetrix® microarrays 
demonstrated the largest source of variation was between tumour and 
normal tissue. Deletion of PPARĮ had little effect on gene expression in 
normal tissue but appeared to have more effect in tumour tissue.  
Ingenuity pathway analysis of these data showed the top biological 
processes were growth & proliferation and colorectal cancer. 
Collectively, these data may indicate that deletion of 33$5Į 
exacerbates the existing APCMin/+ mutation to promote tumorigenesis in 
the colon. 
95 genes from Affymetrix® microarray data were selected for further 
analysis on Taqman® low density arrays. There was good correlation of 
expression levels between the two array types. Expression data of two 
genes proved particularly interesting; Onecut homeobox 2 (Onecut2) 
and Apolipoprotein B DNA dC Æ dU - editing enzyme, catalytic 
polypeptide 3 (Apobec3). Onecut2 was highly up-regulated in tumour 
tissue. Apobec3 was up-regulated in APCMin/+ PPARĮ-/- mice only; 
suggesting expression was mediated via PPARĮ.   
There was a striking increase in survival accompanied by a marked 
reduction in small intestinal polyp numbers in mice of either genotype 
that received piroxicam. Taqman® low density array analysis of the 
same 95 genes as previously showed similar expression levels in 
piroxicam-treated APCMin/+ mice and APCMin/+ PPARĮ-/- mice. Taken 
together, these data indicated that the effect of piroxicam treatment was 
not mediated via PPARĮ.  
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1 Introduction 
 
Colon cancer (colorectal or bowel cancer) is the third most common 
cancer in the United Kingdom (UK), with 22,517 male, and 17,864 
female (based on 3 year average) new cases diagnosed annually 
between 2008-2010.  
Incidences of cancer diagnoses in order of prevalence were prostate, 
lung and colon cancer in males, and breast, lung and colon cancer in 
females (Office for National Statistics, 2012).   
Colon cancer was also the third most common cause of mortality in 
both sexes. Average annual deaths were 8,569 in males and 7,207 in 
females within the same time period. Lung cancer was the largest 
cause of mortality from cancer in both sexes, with prostate cancer in 
males, and breast cancer in females being the second largest causes 
(Office for National Statistics, 2012).  
Worldwide, colon cancer is the third most common form of cancer, and 
the second leading cause of cancer-related mortality (Ferlay et al., 
2010). 
The human cost revealed by these statistics makes for sobering reading 
and shows how continued research into improving detection and 
treatment of cancer is necessary.   
An earlier study by (Jackson et al., 2003) identified peroxisome 
proliferator activated receptor alpha (PPARĮ) activation as important in 
preventing neoplastic transformation and growth in the colon of APCMin/+ 
mice.  
The work described and discussed in this thesis builds on the findings 
of Jackson, to investigate and identify pathways for therapeutic 
intervention of colon cancer. The APCMin/+ mouse model was used, both 
with and without a functional PPARĮ gene. Mice were also treated 
with/without the non-selective cyclooxygenase (Cox) inhibitor piroxicam. 
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1.1 Function, structure & histology of the small bowel & colon  
 
The small bowel has three parts, the duodenum, jejunum and ileum. It 
is the major site of digestion and absorption. The major functions of the 
colon are reabsorption of electrolytes and water, and the elimination of 
undigested food and waste. 
The small bowel and colon are comprised of layers of mucosa, sub-
mucosa, muscularis externa and either a serosa or adventitia. 
The mucosa is made up of three parts; the epithelium and basement 
membrane, lamina propria and muscularis mucosa.  
The epithelium lines organ cavities and forms glands. The basement 
membrane anchors the epithelial layer to the underlying connective 
tissue. As epithelial layers are avascular and innervated, nutrients 
diffuse through the basement membrane which acts as a selectively 
permeable membrane. 
Epithelial layers in both the small bowel and colon are comprised of 
densely packed simple columnar, non-ciliated cells, with very little 
intercellular space. The main cell types are: 
Enterocytes; these cells have a life-span of 5 ± 6 days and are 
absorptive cells. Each cell has ~ 3000 microvilli at the luminal surface. 
In the small bowel enterocytes absorb amino acids and 
monosaccharides by active transport, and monoglycerides and fatty 
acids by passive transport. In the colon, active transport of electrolytes 
and passive absorption of water occurs in these cells.   
Goblet cells; these cells have a life-span of 5 ± 6 days and secrete 
mucus. The mucus acts as a lubricant to facilitate passage of the food 
bolus and faecal matter. In the colon, goblet cells are more abundant in 
the crypts of Lieberkühn (crypts) and the number increases distally 
towards the rectum. 
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Paneth cells; these cells have a life-span of ~ 4 weeks and are only 
found at the base of crypts. They produce the anti-bacterial enzyme, 
lysozyme. Paneth cells are usually absent in the colon. 
Enteroendocrine cells; these cells produce cholecystokinine (CKK), 
secretin and gastric inhibitory peptide (GIP ± also known as glucose-
dependent insulinotropic peptide). CKK stimulates pancreatic enzyme 
secretion and gall bladder contraction. Secretin stimulates pancreatic 
and biliary bicarbonate secretion. GIP induces insulin secretion (Baggio 
and Drucker, 2007). Enteroendocrine cells are rarely found in the colon.    
Microfold (M) cells; these cells endocytosise antigens and transport 
them to the underlying lymphoid cells where the immune response is 
initiated. In the small bowel they overlie Peyers patches. Peyers 
patches are aggregated lymphoid nodules found in the ileum.  
Undifferentiated cells; these are stem cells and are found at the base of 
crypts.   
The lamina propria is a loose, connective tissue with numerous blood 
and lymphatic vessels. Gut-associated lymphatic tissue (GALT) acts as 
an immunological barrier to pathogens. Cells in the lamina propria 
include lymphocytes, plasma cells, eosinophils and macrophages. In 
the colon, extensive development of GALT reflects the abundance of 
micro-organisms.  
The muscularis mucosa is a thin layer of smooth muscle separating the 
lamina propria from the sub-mucosa. 
There are major differences in the mucosa in the small bowel and 
colon. In the small bowel, the mucosa is highly modified with the luminal 
surface covered by villi. The core of the villi is an extension of the 
lamina propria and is covered in simple, columnar epithelium. Crypts 
open onto the surface of the lumen at the base of the villi. The crypts 
extend downwards into the muscularis mucosae and are also covered 
in simple, columnar epithelium. Colonic mucosa has no villi and has 
numerous, straight, tubular glands that extend to the muscularis 
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mucosae. The glands are also covered with a simple, columnar 
epithelium.    
The sub-mucosa is a dense, irregular connective tissue which contains 
blood and lymph vessels, nerve fibres and glands. In the duodenum, 
BrunnHU¶V JODQGV VHFUHWH DONDOLQH JO\FRSURWHLQV DQG ELFDUERQDWH LRQV
which neutralise acid from the stomach and raise the pH for pancreatic 
enzyme activity. 
The muscularis externa allows for movement that is independent of the 
digestive tract. It is comprised of an inner circular layer, and an outer 
longitudinal layer. In the colon there are three very thick bands called 
teniae coli; these allow segments of the colon to contract independently 
and facilitate mass movement of colonic contents.  
The serosa or adventitia is the outermost layer which comprises of a 
small amount of connective tissue that contains major blood vessels 
and nerves (van Lommel, 2003, Seeley, 2002). 
 
1.2 Early detection & screening for colon cancer 
 
Several studies have shown that screening programmes for colon 
cancer are both beneficial (Levin et al., 2008, Hewitson et al., 2008, 
Atkin et al., 2010) and cost-effective (Heitman et al., 2010) in the 
average-risk population.   
Screening methods entail either stool testing, flexible sigmoidoscopy or 
colonoscopy. Stool tests such as faecal immunochemical testing (FIT) 
and the guaiac faecal occult blood test (gFOBT) detect haemoglobin in 
occult blood but are less effective than sigmoidoscopy and colonoscopy 
in neoplastic detection. However, evidence appears to indicate these 
tests are more readily accepted for screening programmes (Hol et al., 
2010, Quintero et al., 2012). This is likely to be due to the invasive 
nature of sigmoidoscopy and colonoscopy.  
5 
 
Colonoscopy is considered to be the optimum procedure for early 
detection and prevention of colon cancer. Several population-based 
case-control studies 1  suggest incidence and mortality due to colon 
cancer were substantially reduced when colonoscopy screening was 
routinely employed (Brenner et al., 2011b, Brenner et al., 2010, Baxter 
et al., 2009). Also, recent evidence appears to support the use of 
screening colonoscopy; several studies report that patients with no 
detected abnormalities on a previous colonoscopy have a substantially 
reduced risk of developing colon cancer (Brenner et al., 2010, Brenner 
et al., 2011a, Imperiale et al., 2008).  
Polypectomy2 has proven to be an effective prophylactic treatment in 
prevention of colon cancer. Cohort studies 3  with patients presenting 
with adenomas have suggested the procedure can prevent 
approximately 80% of colon cancers (Citarda et al., 2001, Zauber et al., 
2012).  
 
1.3 Pathogenesis of colon cancer 
 
The development of colon cancer can be affected by both hereditary 
conditions which predispose to cancer, and environmental factors such 
as diet.  
However, colonic tumours arise due to an accumulation of genetic 
changes including mutational activation of oncogenes and mutational 
inactivation of tumour suppressor genes; reviewed in (Fearon and 
Vogelstein, 1990, Kinzler and Vogelstein, 1996).  
Figure 1-1 (page 7) shows a schematic diagram of genetic changes 
associated with progression of normal epithelium through to 
development of colon cancer and metastasis.  
                                            
1
 Case-control studies investigate existing records of medical conditions (in lieu of new information). Control 
is obtained by comparison to people without the condition 
2
 Polypectomy: Colonoscopic removal of adenomatous polyps 
3
 Cohort study investigates a linked group of people exposed to a variable over time. They are compared to 
a similar group not exposed to the variable 
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Mutations in the tumour suppressor gene Adenomatous Polyposis Coli 
(APC) are the first event in colorectal cancer formation. K-ras is an 
oncogene that only requires a single genetic event for its activation. It is 
a GTPase involved in signal transduction. K-ras mutations are 
predictive of a poor response to the Epidermal Growth Factor Receptor 
(EGFR)-inhibiting drugs panitumumab and cetuximab that are used in 
the treatment of metastatic colon cancer (Dempke and Heinemann, 
2010). 
Mutations in DNA mismatch repair enzymes (MMR) accelerate the 
progression to tumour development.  
p53 is also a tumour suppressor gene requiring two genetic events (one 
in each allele) for inactivation. Other genes that have been implicated in 
colorectal neoplasia are the tumour suppressor genes DCC (deleted in 
colorectal carcinoma), DPC4 (SMAD4 - mothers against 
decapentaplegic homolog 44) and JV18-1 (SMAD2 - mothers against 
decapentaplegic homolog 2). The sequence of these events and 
possible other unidentified genetic changes may be accountable for the 
heterogeneity of characteristics seen in different cancers (Fearon and 
Vogelstein, 1990, Kinzler and Vogelstein, 1996). Cyclooxygenase-2 
(Cox-2) mutations are not acquired during the progression to cancer. 
However, expression of Cox-2 progressively increases which directly 
correlates with colorectal adenomatous polyp size and grade of 
dysplasia (Sheehan et al., 2004). Therefore, inhibition of Cox-2 is a 
potential target for the arrest or reduction of the progression to 
carcinogenesis. 
                                            
4
 mothers against decapentaplegic homolog 4 - The SMAD genes are homologs of both the Drosophila 
melanogaster gene MAD (mothers against decapentaplegic) and the Caenorhabditis elegans gene sma 
(small body size). The name is a combination of the two. A mutation in the maternal MAD gene represses 
the decapentaplegic (dpp) gene in the embryo. The dpp gene is a growth factor involved in cell-cell 
signalling. The sma gene is involved in body size regulation.  
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Figure 1-1 Genetic changes associated with colorectal tumorigenesis
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1.4 Adenomatosis polyposis coli gene (APC gene) & the Min 
mouse model 
 
The APC gene is a human gene found on chromosome 5q, and is 
classified as a tumour suppressor gene. The protein product of the APC 
gene is a large protein of approximately 310 kDa. It contains seven 20 
amino acid beta-FDWHQLQȕ-catenin) binding repeats. It plays a key role 
in the regulation of cell growth and differentiation, adhesion, signalling 
and apoptosis in the colon (Kinzler and Vogelstein, 1996). APC together 
with the protein kinases glycogen synthase kinase ȕ *6.ȕ DQG
casein kLQDVHDOSKD&.ĮDQGWKHVFDIIROGLQJSURWHLQD[LQIRUPWKH
beta-catenin-GHVWDELOLVLQJ FRPSOH[ *6.ȕ ZLWKLQ WKLV FRPSOH[
phosphorylates the N-tHUPLQDO VHULQHWKUHRQLQH UHVLGXHV RI ȕ-catenin, 
accelerating its rapid degradation through ubiquitylation (Polakis, 1999). 
If the APC JHQH LVPXWDWHGȕ-catenin is deSKRVSKRU\ODWHGE\*6.ȕ
and so accumulates in the cytoplasm, where it translocates to the 
nucleus to initiate transcription of Wnt target genes via activation of T-
cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors 
(Korinek et al., 1997). A key process in polyp formation in colonic 
epithelium appears to require activation of the canonical Wnt pathway 
(Oshima et al., 1997).  
Figure 1-2 is a schematic illustration of the canonical Wnt pathway.  
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Figure 1-2 Canonical Wnt pathway 
Cell signalling via WKH)UL]]OHG)]DQG/53UHFHSWRUFRPSOH[LQGXFHVWDELOL]DWLRQRIȕ-catenin via 
the DIX and PDZ domains of Dishevelled (Dsh) with Axin, APC, glycogen synthase kinase 3 (GSK3) 
DQGFDVHLQNLQDVH&.ȕ-catenin translocates to the nucleus where it complexes with members 
RIWKH/()7&)IDPLO\RIWUDQVFULSWLRQIDFWRUVWRPHGLDWHWUDQVFULSWLRQDOLQGXFWLRQRIWDUJHWJHQHVȕ-
catenin is then exported from the nucleus and degraded.  
 
 
1.4.1 Min mice as a model for Familial Adenomatous Polyposis 
(FAP) & colon cancer 
 
FAP is a human hereditary disease that causes numerous colonic 
polyps which develop into malignant adenocarcinomas if left untreated.  
The APC gene has been identified as a gene commonly mutated in 
some FAP kindreds and sporadic colon cancer (Kinzler et al., 1991). 
70 ± 80% of colon cancer cases in humans have APC mutations. Of 
these; 
x 80% are sporadic 
x 1 ± 5% are hereditary, for example FAP and HNPCC (hereditary 
nonpolyposis colorectal cancer) 
x ~ 20% have a family history; people are more at risk if they have 
2 or more 1st or 2nd degree relatives with the disease. For 
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example, an APC mutation in 6% of Ashkenazi Jewish ancestry 
is seen in ~ 28% of Ashkenazi Jewish colon cancer patients who 
have a family history of the disease (Locker and Lynch, 2004).  
A transversion from T to A at nucleotide 2549, that converts codon 850 
from leucine (TTG) to a stop codon (TAG) in the APC gene in the Min 
mouse model (APCMin/+) of this condition, predispose this animal model 
to the development of multiple intestinal neoplasia (Min) (Su et al., 
1992). The Min mutation is found on chromosome 18 and is a fully 
penetrant autosomal dominant trait, transmitted by affected mice to 50% 
of progeny with an unbiased sex distribution (Moser et al., 1990). 
Heterozygote APCMin/+ mice on a C57BL/6 background typically develop 
~30 polyps throughout the intestinal tract and most die by 120 days 
(Moser et al., 1990).  
Thus, the phenotypic and genetic similarities of the Min mutation to 
human FAP and sporadic colon cancer, suggest that the APCMin/+ 
mouse is an excellent animal model for investigation into these 
conditions in humans.  
Models such as the APCMin/+ mouse provide a major resource for 
investigation into the pathways involved in tumorigenesis. Other mice 
have been genetically modified so that one or more oncogenes have a 
germ-line mutation, which lead to different phenotypes. Mouse models 
with a truncated APC gene at position 716, 1309 or 1638, and mutated 
Mlh1 (mutL homolog 1, colon cancer, nonpolyposis type 2) or Msh2 
(mutS homolog 2, colon cancer, nonpolyposis type 1) genes and Cox-1 
and Cox-2 have been engineered; reviewed by (Corpet and Pierre, 
2003, Taketo and Edelmann, 2009). 
Other APC mutant animal models are the PIRC (Polyposis in Rat Colon) 
rat and the Kyoto APC Delta (KAD) rat. The PIRC rat spontaneously 
develops polyps in the colon. It is heterozygous as the recessive 
phenotype is lethal (Amos-Landgraf et al., 2007). The KAD rat does not 
develop colonic tumours spontaneously, but it has enhanced 
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susceptibility to agents that promote their development. This rat is 
homozygous (Yoshimi et al., 2009).  
These rats may be better models for human colon cancer as tumours 
occur more frequently in the colon and are more frequent in male rats, 
which more closely mimic the human condition.  
Although the phenotypes of these rodents are not identical to the 
human condition, they provide a useful vehicle for the identification and 
manipulation of genes integral to the process of tumorigenesis and for 
testing of potential preventative and therapeutic agents.  
 
1.5 Metabolism of Arachidonic Acid  
 
The progressive up-regulation of Cox-2 during the development of 
cancer, has led to investigation of the mechanisms by which this could 
cause malignant change. 
Arachidonic acid (AA) is metabolised via three main pathways; by 
cyclooxygenase (Cox), lipoxygenase (Lox) and cytochrome P-450 
epoxygenase (Cyp) enzymes to produce a variety of derivative lipid 
signalling molecules (see Figure 1-3 and Figure 1-4a). 
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Figure 1-3 Metabolic pathways of arachidonic acid 
KEY: COX Cyclooxygenase, LOX Lipoxygenase, CYP 450 Cytochrome P450, EET   Epoxyeicosatrienoic acid, H(P)ETE Hydroperoxy-eicosatetraenoic acid, PGI2 Prostacyclin, PGE2 
Prostaglandin E2, TXA2 Thromboxane A2, PGD2 Prostaglandin D2, 15 Epi LXA4 Aspirin-triggered 15 epimer lipoxin A4 (ATL), PGDH Prostaglandin dehydrogenase, 15 DH K PGA2 Di-
hydro 15-keto prostaglandin A2, LTB4 Leukotriene B4, EPHX2 Soluble epoxide hydrolase, DHET Di-hydroxy eicosatrienoic acid, LTC synthase Leukotriene C synthase, LTB4 
Leukotriene B4 
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Arachidonic acid (AA) is a 20-carbon omega-6 (Ȧ-6) essential fatty acid 
with four double bonds (de Leval et al., 2006, Zeldin, 2001). The AA 
pathway metabolises a diverse variety of eicosanoids via three 
pathways that are involved in inflammation and cancer (Greene et al., 
2011);  
x Cyclooxygenase (Cox) pathway, produces prostanoids 
x Lipoxygenase (Lox) pathway, produces hydroxyeicosatetraenoic 
acids (HETEs) and leukotrienes 
x Cytochrome P-450 (Cyp) pathway, produces epoxyeicosatrienoic 
acids (EETs) and omega-K\GUR[\ODVHVȦ-hydroxylases) 
There are two isoforms of cyclooxygenase (Cox) enzymes 5 ; Cox-1, 
which is constitutively expressed in most tissue types, and Cox-2, 
expression of which is mostly induced (Needleman et al., 1976, Fu et al., 
1990). Cox-2 however, is also constitutively expressed in the brain, 
spinal cord (Hoffmann, 2000) and kidneys (Harris et al., 1994).   
Cox enzymes catalyse the irreversible, rate-limiting reaction of 
arachidonic acid to prostaglandin H synthase (PGH2), which is further 
converted to a variety of prostanoids such as PGD2, PGE2, PGF2Į, 
prostacyclin (PGI2) and thromboxane A2 (TXA2). These bind to seven 
transmembrane G protein-coupled rhodopsin cell surface receptors, 
and also to PPAR nuclear receptors, to produce various biological 
effects (Cathcart et al., 2011, Ricciotti and FitzGerald, 2011).  
Lipoxygenase (Lox) enzymes metabolise arachidonic acid to 
hydroperoxyeicosatetraenoic acids (HPETEs), which are subsequently 
reduced to their corresponding HETEs; 5-, 8-, 12- and 15-HETE are the 
predominant arachidonic acid metabolites produced by Lox enzymes 
(Cathcart et al., 2011). 
The cytochrome P-450 (Cyp) pathway has two main branches; 
epoxygenases metabolise arachidonic acid (AA) to four regioisomeric 
epoxyeicosatrienoic acids; 5,6-EET, 8,9-EET, 11,12-EET and 14,15-
                                            
5
 Cox-3 is a splice variant of Cox-1 
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EET, and omega-hydroxylases (Ȧ-hydroxylases), convert AA to 
hydroxyeicosatetraenoic acids (HETEs) (Panigrahy et al., 2010).  
Linoleic acid is an 18-carbon Ȧ-6 essential fatty acid and is a pre-cursor 
of arachidonic acid. Conversely, metabolism of linoleic acid by Lox 
enzymes produces hydroxy-octadecadienoic acids (HODEs); 9-HODE 
and 13-HODE (Cathcart et al., 2011). 
Figure 1-3 shows a schematic diagram of the three arachidonic acid 
metabolic pathways described above. However, these enzymes also 
metabolise 20-carbon essential fatty acids with three or five double 
bonds, (dihomo-gamma-linolenic acid, DGLA and eicosapentaenoic 
acid, EPA, respectively) to analogous compounds (Figure 1-4b and d).  
In addition, EPA and the related omega-3 (Ȧ-3) fatty acid 
docosahexaenoic acid (DHA) can be converted to a group of 
metabolites called resolvins (Bannenberg and Serhan, 2010), as follows; 
x Acetylated Cox-2 and cytochrome P450 metabolise EPA to 
produce E-series resolvins E1 and E2 (Figure 1-4d) 
x Lipoxygenases metabolise DHA to produce D-series resolvins 
D1, D2, D3, D4 and aspirin-triggered resolvin D1 (Figure 1-4c) 
Resolvins are generated during the resolution phase of acute 
inflammation and have been shown to have potent anti-inflammatory 
properties in animal models of inflammation, thus restoring homeostasis 
in affected tissue (Ji et al., 2011). 
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Figure 1-4 Metabolism of fatty acids 
KEY: COX Cyclooxygenase, LOX Lipoxygenase, CYP 450 Cytochrome P450, H(P)ETE Hydroperoxy-eicosatetraenoic acid, 15 Epi LXA4 Aspirin-triggered 15 epimer lipoxin A4 (ATL), 
LTB4 Leukotriene B4, ATRVD1-6 D-series resolvins, RVE1/2 E-series resolvins, DGLA Dihomo-gamma-linolenic acid, HODE Hydroxy-octadecadienoic acid, DHA Docosahexaenoic acid, 
HDHA Hydroxy-docosahexaenoic acid, H(P)DHA Hydroperoxy-docosahexaenoic acid, EPA Eicosapentanoic acid
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1.6 Eicosanoid pathways in colorectal cancer development & 
progression 
 
1.6.1 Cyclooxygenase pathway 
 
Cox derived prostanoids, especially prostaglandin E2 (PGE2), and also 
prostacyclin (PGI2), thromboxane (TXA2), prostaglandin D2 (PGD2) and 
prostaglandin F2Į 3*)2Į DUH LQYROYHG LQ FRORUHFWDO FDQFHU
development and progression and mediate the pro-inflammatory and 
tumour-promoting effects of Cox-2 (Cathcart et al., 2011). 
 
1.6.1.1 Prostaglandin E2 (PGE2) 
 
Prostaglandins are produced by nucleated cells throughout the body. 
They act via autocrine and paracrine signalling on platelets, 
endothelium, uterine and mast cells to induce change in the cell. 
PGE2 is produced by the action of prostaglandin E synthases on 
prostaglandin H2 (PGH2). PGE2 is the most dominantly expressed 
prostanoid in human colorectal cancer, with endogenous levels 
significantly higher in colon cancer mucosa than in matched normal 
mucosa (Mal et al., 2011).  
Levels of PGE2 are modulated by a synergy of Cox-2/prostaglandin E 
synthase (PGE synthase)-dependent biosynthesis and 15-hydroxy-
prostaglandin dehydrogenase (15-PGDH)-dependent degradation. 15-
PGDH is expressed in normal colon mucosa. However, expression is 
lost in tumour tissue, suggesting a regulatory role of 15-PGDH in 
tumour development (Backlund et al., 2005). A study by (Myung et al., 
2006) demonstrated that 15-PGDH suppressed colon tumorigenesis in 
APCMin/+ mice; the study showed that disruption of 15-PGDH function, 
with a consequential increase in PGE2 expression, led to a large 
increase in the number of colon tumours. 
In another study, (Hansen-Petrik et al., 2002) demonstrated that PGE2 
expression in APCMin/+ mice protected small bowel adenomas from 
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NSAID-induced regression. Also, (Wang et al., 2004) found APCMin/+ 
mice treated with PGE2 had a significant increase in intestinal tumour 
burden compared to untreated controls. Another study with PGE2 and 
azoxymethane (AOM) - treated APCMin/+ mice recorded a significant 
increase in colon tumour incidence and number in these mice when 
compared to controls (Kawamori et al., 2003).   
Microsomal prostaglandin E synthase 1 (mPGES-1) plays a critical role 
in the production of PGE2, and therefore may be a factor in the effects 
of PGE2 in tumorigenesis. This is supported by a study that found 
mPGES-1 deletion and subsequent reduction of PGE2, suppressed 
intestinal tumour formation in APCMin/+ and AOM-treated mice 
(Nakanishi et al., 2008). Two further studies also reinforced these 
findings which demonstrated that mPGES-1 deletion led to reduced 
colon tumour number and area in AOM-treated mice (Nakanishi et al., 
2011, Sasaki et al., 2011).   
Therefore, a potential target for therapeutic intervention is a novel, 
selective mPGES-1 inhibitor (Mbalaviele et al., 2010). 
 
1.6.1.2 Prostacyclin (PGI2) 
 
Prostacyclin is produced in endothelial cells from metabolism of PGH2 
by prostacyclin synthase. It inhibits platelet activation and acts as a 
vasodilator.  
(Mal et al., 2011) showed that the PGI2 metabolite, 6-keto-PGFĮ was 
significantly reduced in colonic tumour mucosa relative to normal 
mucosa.  
Additionally, hyper-methylation of the prostacyclin synthase promoter 
(PTGIS) is frequently observed in colorectal carcinogenesis (Frigola et 
al., 2005).  
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1.6.1.3 Thromboxane A2 (TXA2) 
 
TXA2 is formed in platelets from PGH2 via thromboxane synthase 
(TXAS). It facilitates platelet aggregation and is a vasoconstrictor.  
TXAS expression has been shown to be significantly higher in human 
colorectal cancer tissue, when compared to normal tissue (Sakai et al., 
2006).    
 
1.6.1.4 Prostaglandin D2 (PGD2) 
 
Prostaglandin D2 (PGD2), which is also derived from PGH2, has been 
shown to have anti-tumorigenic properties. A study by (Dionne et al., 
2010) in human colorectal cancer demonstrated that PGD2 promoted 
apoptosis via activation of the caspase-dependent pathway. Additionally, 
15-deoxy-ǻ12.14-PGJ2 (15d-PGJ2), which is a product of PGD2 
metabolism, was shown to promote colon cancer apoptosis (Koyama et 
al., 2010). 
 
1.6.1.5 Other prostaglandins 
 
Another PGH2 product is prostaglandin F2Į (PGF2Į3*)2ĮKDVEHHQ
postulated as contributing to tumorigenesis by promotion of Cox-2 
synthesis (Jabbour et al., 2005).  
Further, expression of prostaglandin D (DP) and prostaglandin F (FP) 
receptors were found to be significantly reduced in colorectal tumour 
tissue compared to normal tissue (Gustafsson et al., 2007).  
 
1.6.2 Lipoxygenase pathway 
 
In human epithelial tissue, 15-Lox-1 and -2 (leucocyte 12-Lox and 8-Lox 
respectively, in the mouse) are usually expressed in normal tissue but 
not in colon cancer (Shureiqi et al., 1999, Subbarayan et al., 2005). A 
prospective study (cohort study) by (Shureiqi et al., 2010) demonstrated 
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that expression of the 15-Lox-1 metabolite 13(S)-hydroxy-
octadecadienoic acid (13S-HODE) was progressively lost in the 
transition from normal mucosa to cancer mucosa. Expression of 5-Lox 
and 12-Lox however, was found to be absent in normal tissue, but often 
constitutively expressed in colon cancer (Ohd et al., 2003). A study by 
(Melstrom et al., 2008) found that 5-Lox was progressively over-
expressed in human colon polyps and cancer compared to expression 
levels in normal mucosa. This finding was supported by another study 
which showed a relationship between increasing polyp size and higher 
tumour grade, and increased 5-Lox expression (Wasilewicz et al., 2010).  
 
1.6.3 Cytochrome P-450 pathway 
 
P-450-derived epoxyeicosatrienoic acids (EETs) are involved in many 
processes linked to cancer, including regulation of signalling pathways, 
gene expression, cell proliferation and inflammation (Spector et al., 
2004). A recent study by (Jiang et al., 2009) showed that the P-450 
epoxygenase Cyp2J2 was highly expressed in colorectal cancer; 
however, the small sample size in this study necessitates further 
investigation.  
Another study demonstrated that the Cyp2J2 metabolites 8-9 and 11-12 
EETs abolished the Interleukin 1 beta (Ilȕ) induction of NFț%(nuclear 
factor kappa light polypeptide gene enhancer in B-cells) via activation of 
PPARɲ (Wray et al., 2009).  
 
1.7 Mechanism of action of Cyclooxygenase-2  
 
1.7.1 Apoptosis 
 
Several studies have shown that cyclooxygenase (Cox) derivatives, 
such as 15-deoxy-ǻ12.14-PGJ2 (15d-PGJ2), a metabolite of PGD2, induce 
apoptosis in colorectal cancer cells (Koyama et al., 2010, Shimada et 
al., 2002, Shin et al., 2009). Investigations into the effect of 15d-PGJ2 
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on apoptosis demonstrated 15d-PGJ2 treatment caused a decrease in 
expression levels of the anti-apoptotic genes, NFțB  and bcl-2 (B-cell 
leukaemia/lymphoma 2) (Chen et al., 2002), c-Myc (cellular 
myelocytomatosis oncogene) (Shimada et al., 2002), and hTERT 
(telomerase reverse transcriptase) (Moriai et al., 2009), and an increase 
in expression of the proto-oncogene c-jun and DDIT3 (DNA-damage-
inducible transcript 3) (Shimada et al., 2002). Also, an in vivo study by 
(Shin et al., 2009) showed treatment with 15d-PGJ2 induced apoptosis 
by production of reactive oxygen species (ROS) through activation of 
JNK (c-Jun N-terminal kinase) and inactivation of Akt (alpha 
serine/threonine protein kinase).  
By contrast, PGE2 appears to have anti-apoptotic effects, with a recent 
study postulating this may be mediated through P-13 kinase and Wnt 
signalling pathways (Kaur and Sanyal, 2010).  
Another study showed apoptosis in colorectal adenoma cells was 
suppressed by PGE2-mediated down-regulation of Bcl2l11 (bcl2-
interacting mediator of cell death) (Greenhough et al., 2010).  
(Wu and Liou, 2009) showed that inhibition of another Cox derivative, 
PGI2, led to induction of apoptosis via DFWLYDWLRQRI33$5GHOWD33$5į
and increased expression of Bad protein (BCL2-associated agonist of 
cell death).  
 
1.7.2 Angiogenesis 
 
PGE2 has also been shown to be involved in angiogenesis in colorectal 
cancer. PGE2 induces expression of pro-angiogenic factors such as 
VEGF (vascular endothelial growth factor) and CXCL1 (chemokine C-X-
C motif ligand 1) (Fukuda et al., 2003, Wang et al., 2006).  
By contrast, the anti-tumour properties of 15d-PGJ2 appear to be 
mediated via inhibition of AP-1 and VEGF or Cox-2 (Grau et al., 2006).  
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1.7.3 Metastasis 
 
PGE2 expression levels have been shown to be significantly higher in 
metastatic colorectal tumours, compared to non-metastatic tumours, 
which indicates that PGE2 has a role in tumour metastasis (Cianchi et 
al., 2001). However, PGI2 is thought to inhibit cancer cell-cell 
interactions to confer a protective effect against metastasis in colorectal 
cancer (Yoshida et al., 1999). 
Platelet activation plays a crucial role in metastasis; circulating tumour 
cells express high levels of tissue factor (TF) and adhesion molecules, 
for example P-selectin ligands, which bind and activate platelets. This 
accelerates tumour growth and metastasis by an increase in platelet 
activation and blood clotting which can lead to thromboembolic disease 
(Gay and Felding-Habermann, 2011). 
Many cancer patients present with signs of thrombosis which is more 
severe if tumours have metastasised. Thrombocytosis (high platelet 
count) indicates a poor prognosis in colon cancer. Therefore, platelets 
are a potential target for anti-metastatic therapy. Options for treatment 
include anti-thrombotic therapies such as aspirin, lipoxygenase 
inhibitors and cyclooxygenase inhibitors (Sierko and Wojtukiewicz, 
2007). 
 
1.7.4    Immune effects 
 
Cox-2 and PGE2 effects are mediated through regulatory T cells, which 
act to prevent anti-tumour immune responses. Adaptive and induced 
regulatory T cells express Cox-2 (and thus PGE2), that suppress 
effector T cells. MCP-1 (monocyte chemoattractant protein-1), a 
chemoattractant for monocytes and macrophages, has been shown to 
be more highly expressed in colonic adenoma tissue than in normal 
tissue. MCP-1 induces Cox-2 expression, leading to the release of 
PGE2 and VEGF from human macrophages (Tanaka et al., 2006).  
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1.7.5 Resolution of inflammation 
 
Inflammation as a key factor in development of cancer is mediated or 
resolved by many metabolites of the arachidonic pathways.  
Resolvins, derived from biosynthesis of omega-3 fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) by Cox-
2 and Lox pathways (Figure 1-4c & d), are potent regulators of 
inflammation in colon cancer (Ji et al., 2011). Also, the cytochrome P-
450 derived epoxyeicosatrienoic acids (EETs) are known to be anti-
inflammatory. However, metabolism of EETs by soluble epoxide 
hydrolase (Ephx2), converts EETs to the pro-inflammatory 
dihydroxyeicosatrienoic acids (DHETs). A study by (Norwood et al., 
2010) showed that inhibition of Ephx2 led to increased production of 
EETs with a concomitant decrease in inflammation, which suggests 
inhibition of Ephx2 could be a potential target for treatment of 
inflammation and colon cancer.     
 
1.8 Cyclooxygenase inhibitors as cancer treatment & prevention 
 
Chronic inflammation is a tumour promoter in almost all tissues. It is 
implicated in the pathogenesis of several cancers associated with the 
gastrointestinal tract (Coussens and Werb, 2002). Cox-2 is over-
expressed in many colonic cancers and considered as having an 
essential role in cancer progression (Xu, 2002).  
 
1.8.1 Aspirin 
 
Evidence from laboratory studies suggested that aspirin use could 
potentially reduce cancer risk via inhibition of Cox-2 (Wang and Dubois, 
2006, Doherty and Murray, 2009) or initiation of apoptosis (Elwood et al., 
2009). Aspirin irreversibly inhibits Cox-2; the acetyl group of aspirin 
attaches to serine in the active site of the Cox-2 enzyme.  
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Subsequent randomised trials demonstrated that daily aspirin prevented 
colorectal polyps (Cole et al., 2009) and reduced colorectal cancer 
incidence and mortality, at up to 20 years follow-up (Rothwell et al., 
2010, Rothwell et al., 2011).  
(Thun et al., 2012) argue that these effects are mediated via platelets; 
irreversible cyclooxygenase acetylation results in prolonged functional 
effects since there is no capacity for re-synthesis of the Cox enzyme 
(platelets lack a nucleus). Thus, reversal depends on the release of 
fresh platelets. Consequently, platelets are susceptible to long-lasting 
effects of low-dose (75 ± 100 mg daily) aspirin.  
Platelets release a number of mediators, such as thromboxane A2 
(TXA2), interleukin 1ȕ (Il1ȕ) and platelet-derived growth factor (PDGF), 
under the influence of Cox activity that could affect tumour growth. 
Therefore, inhibition of platelet activation may mediate the cancer-
preventative effects of low dose aspirin. 
 
1.8.2 Non-selective non-steroidal anti-inflammatory drugs 
(NSAIDs) 
 
Two randomised clinical trials with the non-selective NSAID sulindac 
indicated it caused suppression of adenomatous polyps, and reduction 
of existing polyps in patients of Familial Adenomatous Polyposis (FAP) 
(Giardiello et al., 1993, Nugent et al., 1993). However, a later study of 
four years duration showed that sulindac did not slow the development 
of adenomas in FAP patients (Giardiello et al., 2002).  
Also, a trial by (Ladenheim et al., 1995) with patients who had a prior 
history of adenomatous polyps, showed higher dose sulindac did not 
significantly decrease the number or size of polyps.  
Although there appears to be some beneficial effects of long term use 
of aspirin and NSAIDs, unfortunately, there are negative side-effects. 
Both drugs can cause inflammation and bleeding in the stomach, 
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probably because of the concomitant inhibition of Cox-1, which exerts a 
protective effect.  
 
1.8.3 Selective cyclooxygenase 2 (Cox-2) inhibitors 
 
Selective Cox-2 NSAIDs were developed as a way to overcome the 
side-effects caused by aspirin and non-selective NSAIDs.  
A study by (Bertagnolli et al., 2006) reported a reduction in adenoma 
incidence in patients receiving celecoxib, compared to patients 
receiving placebo. 
Two studies that randomised patients with a previous history of colonic 
adenomas onto either treatment or placebo; the Prevention of 
Colorectal Sporadic Adenomatous Polyps (PreSAP) trial (Arber et al., 
2006), which used celecoxib, and the Adenomatous Polyp Prevention 
on Vioxx (APPROVe) trial (Baron et al., 2006), which used rofecoxib, 
both demonstrated reductions in adenoma recurrence, and in advanced 
adenomas, compared to patients taking placebo.  
Rofecoxib was subsequently found to cause serious cardiovascular 
problems and was withdrawn from clinical use.  
 
1.8.4 PPARĮ as a target for eicosanoids 
 
As Cox-2 metabolites of arachidonic acid (AA) such as PGE2 are known 
to be pro-inflammatory and enhance tumorigenesis, and 15-Lox and 
CYP derived AA derivatives such as HETEs and EETs are thought to 
have anti-neoplastic and anti-inflammatory properties, a potential 
mechanism for the effects of HETEs and EETs is via activation of the 
nuclear receptor PPARĮ which has previously been shown to be 
involved in reduction of tumour burden in the APCMin/+ mouse model of 
colon cancer (Jackson et al., 2003).  
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1.8.5 PPARs as a target for NSAIDs 
 
Some NSAIDs directly interact with PPARs. For example, 100 µM 
concentrations of indomethacin, piroxicam and other NSAIDs were 
shown to be efficacious activators of PPARĮ and PPARȖ to promote 
peroxisome proliferation and adipocyte differentiation respectively 
(Lehmann et al., 1997).  
In another study, sulindac inhibited PPARȕį activation, thus preventing 
the binding of this PPAR/RXR heterodimer to its recognition site in DNA 
(He et al., 1999).  
Also, (Wick et al., 2002)  demonstrated inhibition of lung cancer cell 
growth via activation of PPARȖ by sulindac.  
NSAIDs are used as cancer chemopreventative agents. These studies 
have shown that NSAIDs may inhibit tumorigenesis by direct interaction 
with PPARs, independent of Cox enzyme activation.  
 
1.9 Peroxisome proliferator activated receptors (PPARs) 
 
In 1992, (Dreyer et al., 1992) identified three novel receptors in 
Xenopus laevis; they closely resembled a previously identified 
mammalian receptor that had been shown to induce proliferation of 
peroxisomes in cells when activated by a diverse class of rodent 
hepatocarcinogens (Issemann and Green, 1990).  
These receptors were subsequently termed peroxisome proliferator 
activated receptorV DOSKDEHWDGHOWD DQG JDPPD 33$5Į 33$5ȕį
33$5Ȗ 
Peroxisome proliferator activated receptors (PPARs) are part of the 
nuclear hormone receptor superfamily of ligand-activated transcription 
factors which includes retinoic acid receptors (RARs), steroid hormone 
receptors and thyroid hormone receptors (TRs) (Laudet et al., 1992, 
Lemberger et al., 1996).  
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When a ligand binds, the PPARs form a heterodimer with the retinoid X 
receptor (RXR), whereupon they bind to genes with recruitment of 
cofactors to initiate transcription of genes involved in energy 
homeostasis (Wahli et al., 1995).  
Figure 1-5 shows a schematic diagram of the gene transcription 
mechanism of PPARs.  
Peroxisome proliferator response elements (PPREs) in PPAR-RXR 
heterodimers have an exclusive directly repeating sequence (DR-1) of 
WZR KH[DQXFOHRWLGHV ¶ $**7&$ ¶ VHSDUDWHG E\ RQH QXFOHRWLGH
(Lemberger et al., 1996, Juge-Aubry et al., 1997). 
Several proteins function as co-factors in a ligand-dependent way to 
mediate the effects of PPARs to either inhibit or initiate transcription 
(Lemberger et al., 1996). When unliganded, the PPAR/RXR dimer 
associates with a co-repressor with histone deacetylase activity, for 
example, nuclear receptor co-repressor (NCoR) or silencing mediator 
for retinoid and thyroid hormone receptor (SMRT). This inhibits 
transcription. The opposite effect is achieved when a co-activator such 
as steroid receptor co-activator (SRC)-1 or PPAR binding protein (PBP) 
which has histone acetylase activity, associates with the ligand bound 
dimer to initiate transcription (Ricote and Glass, 2007, Pascual and 
Glass, 2006). Table 1-1 summarises transcriptional co-factors, 
mechanism of action and their effects in PPARs.  
Table 1-1 Transcriptional co-factors of PPARs 
Heterodimerized 
nuclear receptor Cofactors
Mechanism of 
action Effect
Co-repressors
Nuclear receptor co-repressor 
(NCor)
Silencing mediator for retinoid 
and thyroid hormone receptor 
(SMRT)
Co-activators
Steroid receptor co-activator 
(SRC)-1
PPAR binding protein (PBP)
No ligand
Histone 
deacetylase 
activity
Inhibition of 
transcription
+ Ligand
Histone 
acetylase 
activity
Initiation of 
transcription
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Figure 1-5 Gene transcription mechanisms of PPARs 
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Peroxisomes are ubiquitous organelles found in eukaryotic cells. They 
are rich in peroxidise, catalase and d-amino oxidase enzymes which 
carry out oxidative reactions such as metabolism of fatty acids and 
hydrogen peroxide.  
There are marked species differences in response to peroxisome 
proliferators; rodents demonstrate high peroxisomal enzyme induction, 
whereas humans do not. This may be due to the lower expression of 
PPARɲ in the human liver compared to rodents, or the possible 
existence of an inactive PPARɲ splice variant in the human liver 
(Cattley et al., 1998).  
(Ammerschlaeger et al., 2004) demonstrated that PPARɲ and the 
PPRE of target genes are important determinants for species-specificity 
of peroxisome proliferation. 
Activation by endogenous and synthetic ligands of PPARĮDQGPPARȖ
regulates the transcription of genes involved in lipid and glucose 
metabolism respectively. Activation of PPARȕ DOVR UHJXODWHV JOXFRVH
metabolism and fatty acid oxidation (Kersten et al., 2000).  
The three PPAR subtypes, PPARĮ 15& PPARįȕ 15& DQG
PPARȖ 15& DUH WKH SURGXFWV RI GLIIHUHQW JHQHV (Michalik and 
Wahli, 1999). They are differentially expressed in various tissues (Table 
1-2, (Braissant et al., 1996, Auboeuf et al., 1997, Inoue et al., 1998, 
Chinetti et al., 1998, Diep et al., 2000, Heneka and Landreth, 2007). 
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Table 1-2 Location of PPARs in the body 
 
 
PPARs also share a common structure with four functional domains 
identified as A/B, C, D and E/F. Figure 1-6 shows a schematic 
representation of the functional domains of PPARs.  
Briefly, the schematic shows the A/B domain contains a ligand-
independent activation function 1 (AF-1) (Werman et al., 1997), which, 
ZKHQ SKRVSKRU\ODWHG DLGV WKH UHJXODWLRQ RI 33$5Į DQG 33$5Ȗ
activation (Shalev et al., 1996, Juge-Aubry et al., 1999, Zhang et al., 
1996). The C domain or DNA-binding domain (DBD) is highly 
conserved between the three PPAR isotypes and binds to the PPRE in 
the promoter region of the target gene (Kliewer et al., 1992).  The D 
domain is a docking site for co-factors. The E/F domain or the ligand 
binding domain (LBD) has ligand specificity which when bound 
activates PPAR binding to the PPRE.  This domain also contains the 
ligand-dependent transactivation function 2 (AF-2) which recruits PPAR 
co-factors (Berger and Moller, 2002).  
PPAR 
subtype Expression Tissue/Organ/Cells
Ȗ
Brown & white adipose tissue
CNS
Peripheral nervous system (PNS)
Colon
Retina
Parts of immune system
ȕ Ubiquitously expressed
Į
Brown adipose tissue
Central nervous system (CNS)
Liver
Kidney
Colon
Duodenum
Heart
Skeletal muscle
Endothelial cells
Vascular smooth muscle cells (VSMCs)
Monocytes/Macrophages
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Figure 1-6 Schematic representation of the functional domains of PPARs 
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1.10 PPARs ± Role in Cancer and Inflammation 
 
PPARs are ligand-activated transcription factors that were originally 
recognised as playing a central role in glucose and lipid homeostasis. It 
became apparent that PPARs modulate activity of a wider range of 
functions including cell proliferation, differentiation, adipogenesis and 
inflammatory signalling. This led to consideration of their role as 
potential therapeutic targets in cancer pathogenesis chemo-prevention, 
inflammatory conditions, atherosclerosis, obesity and diabetes; 
reviewed in (Peters et al., 2012).  
 
1.10.1 PPAR alpha (PPARĮ) 
 
PPARĮ levels of expression are high in the liver (Peters et al., 2000) 
and also the heart, kidney, intestine, and brown adipose tissue; all of 
which are tissues with high oxidative capacity (Bookout et al., 2006). 
Consequently these tissues may be more susceptible to cancer 
development. Therefore, targeted activation of PPARĮPD\EHDXVHIXO
strategy for cancer prevention and therapy.  
Agonists of PPARĮ include the synthetic fibrate drugs, for example, 
bezafibrate, clofibrate, fenofibrate and Wy 14, 643 (Kersten et al., 2000, 
Willson et al., 2000, Berger and Moller, 2002). Endogenous ligands of 
PPARĮ include fatty acids and eicosanoids (Yu et al., 1995, Khan and 
Vanden Heuvel, 2003). 
The discovery of PPARĮ agonist drugs now used in the treatment of 
chronic disorders associated with the metabolic syndrome6 has enabled 
the elucidation of their mechanism of action. Fibrate drugs have been 
used clinically since the 1930s but their mechanism of action was only 
HVWDEOLVKHG LQ WKH V 7KH\ ELQG DQG DFWLYDWH 33$5Į UHVXOWLQJ LQ
raised high-density lipoprotein (HDL) levels, reduced hepatic triglyceride 
VHFUHWLRQ DQG HOHYDWHG ȕ-oxidation in the liver; effects that underpin 
                                            
6
 The metabolic syndrome: A group of at least 3 risk factors that raise the probability of developing coronary 
heart disease, insulin resistance, diabetes and stroke. Risk factors include abdominal obesity, high 
triglyceride level, low HDL cholesterol, high blood pressure and high fasting blood sugar. 
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their use for treatment of dyslipidaemia, which is primarily associated 
with type 2 diabetes mellitus (Kersten et al., 2000, Willson et al., 2000, 
Berger and Moller, 2002).  
Initially it would seem PPARĮ would not be an obvious target for cancer 
therapy and chemoprevention since the early recognition that the 
receptor mediated development of liver cancers in mice, induced by 
long-term administration of PPARĮ agonists such as clofibrate and 
bezafibrate (Reddy et al., 1980). This effect appeared to be PPARĮ 
specific in that it was not seen in PPARĮ null mice (Morimura et al., 
2006, Shah et al., 2007). However, this effect is not evident in humans, 
probably as murine but not human PPARĮ causes down-regulation of 
let-7c micro RNA cluster. The let-7c miRNA destabilises Myc 
(myelocytomatosis oncogene) mRNA, so stability of this mitogen is 
increased with a concomitant reduction in let-7c. This may in turn lead 
to increased mitogenic signalling that causes hepatocyte proliferation 
(Shah et al., 2007). 
Identification and activation of PPARĮ-dependent pathways may be 
useful in prevention of tumorigenesis or tumour growth. The nuclear 
factor±ț% 1)-ț% and AP-1 signalling pathways activation of PPARĮ 
have been shown to inhibit inflammation; reviewed in (Ricote and Glass, 
2007, Pascual and Glass, 2006).  
NF-ț%DFWLYLW\LVFRQWUROOHGE\WKHGHJUDGDWLRQRI,ț%ĮZKLFKVHTXHVWHUV
inactive NF-ț% GLPHUV LQ WKH F\WRSODVP. ,QGXFWLRQ RI ,ț%Į E\ ILEUDWHV
requires PPARĮH[SUHVVLRQDQG WKH LQFUHDVH LQ ,ț%Į UHVXOWV LQ1)-țȕ
nuclear deactivation, thus reducing the duration of the inflammatory 
response LQD33$5Į-dependent manner (Delerive et al., 2001).  
The inhibition of AP-1-dependent activity by PPARĮ DFWLYDWRUV PD\
occur by reducing the intrinsic c-Jun transactivating activity (Karin et al., 
1997) and also by c-Jun inhibiting the ability of PPARs to activate 
PPRE-driven genes (Delerive et al., 1999). A study using the human 
colorectal carcinoma cell line SW620, demonstrated that the PPARĮ
ligands LY-171883 and WY-14643, inhibited the induction of AP-1-
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mediated transcriptional activation of Cox-2and vascular endothelial 
growth factor (VEGF) and other genes involved in inflammation and 
tumour progression. Thus, this established the existence of a negative 
cross-talk between the PPARĮ DQG $3-1-dependent signalling 
pathways in these cells. This effect was also found to be dependent on 
PPARĮH[SUHVVLRQ (Grau et al., 2006). 
A previous study (Jackson et al., 2003) determined a functional PPARĮ
receptor was necessary in preventing neoplastic transformation or 
growth in the gastrointestinal tract. This led to further investigations 
using a PPARĮ null mouse model that are reported in this thesis. 
The present study concentrated on the effects of PPARĮ, but the two 
other PPAR receptors, PPAR gamma (PPARȖ and PPAR beta/delta 
(PPARȕį have also been the subject of research into their 
involvement in carcinogenesis. 
 
1.10.2 PPAR beta/delta (PPARȕ/į) 
 
Ligand activation of PPARȕį LQKLELWVRUSUHYHQWVPHWDEROLFV\QGURPe, 
obesity, dyslipidaemia, glucose intolerance and inflammation; all of 
which are associated with development of cancer (Mantovani et al., 
2008, Tsugane and Inoue, 2010, Wolin et al., 2010).  
However, there are conflicting conclusions as to whether PPARȕį
agonists promote or attenuate most types of cancer, although PPARȕį
agonists have been successfully used in the treatment of non-
melanoma skin cancer (Bility et al., 2010, Zhu et al., 2010).  
Early attention focused on PPARȕį because it was up-regulated in 
cancer cells by the APC-beta catenin-TCF pathway and was capable of 
enhancing proliferation by activation of Cyclin D1 ((He et al., 1999).  
There is some controversy regarding the effect of ligand activation of 
PPARȕį RQ FROon carcinogenesis. Some evidence indicates that 
PPARȕį DWWHQXDWHV FRORUHFWDO FDQFHU Two studies showed that 
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expression of PPARȕį LQ FRORQ WXPRXUV IURP PRXVH DQG KXPDQ
models was lower than in normal colon epithelium (Chen et al., 2004, 
Marin et al., 2006).  
In addition, (Marin et al., 2006) showed that specific ligand activation of 
PPARȕį LQGXFHG H[SUHVVLRQ RI JHQHV DVVRFLDWHG ZLWK WHUPLQDO
differentiation of colonocytes.  
Results from a study by (Hollingshead et al., 2008) also confirmed a 
direct role of ligand activation of PPARȕį LQ FHOOXODU WHUPLQDO
differentiation, and that PPARȕį DFWLYDWion and Cox-2 inhibition act 
independently to attenuate colon carcinogenesis.  
Conversely, results from (Gupta et al., 2004) who subjected APCMin/+ 
mice to the selective PPARȕįDJRQLVW*:VKRZHGDVLJQLILFDQW
increase in the number and size of intestinal polyps.  
A Phase 11 trial for dyslipidaemia using GW501516 was abandoned 
due to the formation of tumours in the mouse model that was used 
(Mackenzie and Lione, 2013).  
GW501516 has been used as a performance-enhancing drug in sport. It 
activates 33$5ȕįDQG¶$03-activated protein kinase (AMPK). AMPK 
UHJXODWHVXSWDNHRIJOXFRVHȕ-oxidation of fatty acids and biogenesis of 
Glucose Transporter Type 4 (GLUT4) (Pokrywka et al., 2014). 
The PPARȕį DQWDJRQLVW *6. ZDV IRXQG WR LQKLELW PPARȕį-
dependent activity in vivo and in vitro but with concomitant weak PPARȖ
agonist activity (Palkar et al., 2010).  Studies using antagonists of 
PPARȕį LQKXPDQFDQFHUFHOOVZHUHVKRZQ WRKDYHQRHIIHFWRQFHOO
proliferation (Shearer et al., 2010, Palkar et al., 2010).   
The development of chemo-prevention using PPARȕį ligands is 
unlikely due to the differing effects seen in studies using PPARȕį 
agonists and antagonists. 
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1.10.3 PPAR gamma (PPAR Ȗ) 
 
Thiazolidinediones (TZDs) are used in the treatment of diabetes 
mellitus type 2. They bind to PPARȖWRUHGXFHLQVXOLQUHVLVWDQFHUDLVH
adiponectin levels, and inhibit vascular endothelial growth factor 
(VEGF)-induced angiogenesis. (Panigrahy et al., 2002)   
Studies have shown that PPARȖ agonists inhibited cell growth and 
increased apoptosis in cancer cell lines, as well as inhibiting tumour 
growth in animal models of cancer; reviewed in (Blanquicett et al., 
2008).  
In human chemo-prevention trials PPARȖ agonists have shown modest 
efficacy, although PPARȖ expression in colon cancer is generally 
associated with improved survival (Koeffler, 2003, Grommes et al., 
2004).  
However, clinical trials using TZDs have shown there are increased 
risks of negative side effects; cardiovascular effects, bone mineral 
density loss, bladder cancer (Piccinni et al., 2011, Erdmann et al., 2009, 
Grey et al., 2007, Schwartz and Sellmeyer, 2007). It is not clear 
ZKHWKHU WKHVHQHJDWLYHVLGHHIIHFWVDUH33$5Ȗ UHODWHG UHODWHG WR WKH
TZDs themselves, or off target effects.  It may be possible to develop 
33$5Ȗ DJRQLVWV WKDW UHWDLQ FKHPR-preventative effects without side 
effects. 
Ascribing a role to PPARȖ in tumorigenesis is made difficult by virtue 
that ligands are promiscuous and have specific effects on PPARȖ, but 
may also influence PPARĮ (for example, bezafibrate), or act through 
non-PPAR mechanisms.  
6WXGLHV LQYHVWLJDWLQJ 33$5Ȗ DQWDJRQLVWV (for example, GW9662 and 
T0070907) as inhibitors of tumorigenesis have not conclusively 
GHPRQVWUDWHGWKDWWKHHIIHFWVVHHQDUH33$5ȖGHSHQGHQWDQGPD\EH
due to independent mechanisms (Burton et al., 2008). However, the 
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XVH RI 33$5Ȗ DQWDJRQLVWV IRU FDQFHU FKHPR-prevention remains a 
possibility. 
 
1.10.4 Pan & dual-PPAR agonists 
 
The use of pan and dual-PPAR agonists as prophylaxis or treatment of 
cancer is a realistic and attractive option. Studies using bezafibrate, 
which is a pan-PPAR agonist, have demonstrated inhibition of colon 
tumorigenesis in rodent (Kohno et al., 2005, Niho et al., 2003) and 
human cancer models (Tenenbaum et al., 2008).  
Some of the effects of bezafibrate appear to be attributable to activation 
of PPARĮ (Peters et al., 2003). This is supported by findings from 
(Jackson et al., 2003) that showed the selective PPARĮ DJRQLVW
methylclophenapate (MCP) inhibited intestinal tumorigenesis.  
2WKHU HIIHFWV DSSHDU WR EH PHGLDWHG E\ DFWLYDWLRQ RI 33$5Ȗ E\ -
deoxy prostaglandin J2 (15d-3*- ZKLFK LV DQ HQGRJHQRXV 33$5Ȗ
ligand (Khanim et al., 2009, Hayden et al., 2009). 
Studies using high-affinity dual-PPAR agonists demonstrated 
development of tumours in long-term bioassays (Rubenstrunk et al., 
2007). However, development of low-affinity pan-PPAR agonists for 
chemo-prevention treatment is supported by results of a clinical trial 
using bezafibrate for treatment of colon cancer in humans (Tenenbaum 
et al., 2008). 
There are serious safety issues with pan and dual-PPAR agonist drugs 
and several Phase 111 clinical trials have been halted; ragaglitizar, due 
to formation of bladder tumours in mice, tesaglitizar, due to kidney 
toxicity and imiglitizar, due to liver toxicity (Fievet et al., 2006).  
Saroglitizar (lipaglyn) is the first dual-PPAR (ɲ DQGȖDSSURYHGGUXJLW
was licensed for the treatment of Type 11 diabetes in June 2013 in 
India (Agrawal, 2014). 
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In summary, the use of synthetic and endogenous agonists and 
antagonists for chemo-preventative or chemo-therapeutic treatment of 
colon cancer remains a possibility.  
However, further research to determine ligand-dependent and ligand-
independent effects of activation of PPARs, and to reduce negative side 
effects is necessary.  
 
1.11 Hypothesis 
 
The development and progression of colon cancer is attenuated via 
activation of peroxisome activator receptor alpha (PPARɲ) by the non-
steroidal anti-inflammatory drug (NSAID) piroxicam 
 
1.12 Aims and Objectives  
 
1. To investigate the role of PPARĮ in the APCMin +/- mouse model 
of colon cancer by: 
x Determining whether the reduction of tumour number 
observed in APCMin +/- mice is dependent on a functional 
PPARĮ locus 
x Determining whether differential gene expression observed in 
APCMin +/- mice is dependent on a functional PPARĮ locus 
 
2. To validate levels of gene expression in the APCMin +/- mouse 
model of colon cancer by: 
x Determining and comparing gene expression of a sub-set of 
genes on 2 different platforms; Affymetrix Genechip® 
microarrays and Taqman® low-density arrays  
 
3. To investigate the role of PPARĮ in the effect of a Cox inhibitor in 
the APCMin +/- mouse model of colon cancer by: 
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x Determining whether the reduction in tumour number 
observed in APCMin +/- mice is dependent on activation of 
33$5ĮE\D&R[LQKLELWRU 
x Determining whether differential gene expression of the same 
sub-set of genes in APCMin +/- mice is dependent on activation 
of PPARĮ by a Cox inhibitor 
 
4. To validate the APCMin +/-  mouse model used in these studies by: 
x Comparison of observed tumour numbers in 2 matched 
cohorts of APCMin +/- mice and APCMin +/- 33$5Į-/- mice 
x Comparison of differential gene expression of the same 
sub-set of genes in 2 matched cohorts of APCMin +/- mice 
and APCMin +/- 33$5Į-/- mice 
 
5. To investigate the role of PPARĮ in gene expression of Apobec3 
and Onecut2 in the APCMin +/- mouse model of colon cancer by: 
x Determining gene expression of these 2 genes in 2 
matched cohorts of APCMin +/- mice and APCMin +/- 33$5Į-/- 
mice 
 
6. To validate levels of Apobec3 and Onecut2 gene expression in 
the APCMin +/- mouse model of colon cancer by: 
x Determining gene expression of these 2 genes using 3 
different platforms; Affymetrix Genechip® microarrays, 
Taqman® low-density arrays and Real Time Quantitative 
PCR 
 
7. To investigate Apobec3 isotypes in the APCMin +/- mouse model of 
colon cancer by: 
x Determining the sequence of the Apobec3 gene in the 
APCMin +/- mouse model of colon cancer using Sanger 
sequencing (Sanger and Coulson, 1975) 
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2 Materials 
 
This chapter lists the reagents used in these studies and describes the 
preparation of solutions and buffers used throughout the experimental 
work.  
 
 
2.1 Reagents 
 
Reagent           Supplier 
  
       All from Sigma-Aldrich 
        unless otherwise stated 
Acetone        
Acrylamide/bis-Acrylamide   
ACTB (beta Actin)   Applied Biosystems 
Agarose             Melford 
Ammonium persulfate (APS)                 Promega 
Boric acid         Fisher Scientific 
Calcium chloride        Fisher Scientific 
Chloroform          Fisher Scientific 
*
1Deoxynucleotide triphosphates (dNTPs) 400 µl    Promega 
Deoxyribonuclease 1 (RNase-free) 1 U/µl             Fermentas 
*
2Diethylpyrocarbonate (DEPC) 
DNA ladder 1 kb 500 µg/ml (N32325)      New England Biolabs 
DNA ladder 50 bp 100 µg/ml (N0473G)      New England Biolabs 
Dimethyl sulfoxide (DMSO) D2650 
Ethanol 100% (EtOH)                BDH 
Ethidium bromide 10 mg/ml      Fisher Scientific 
*
3Ethylenediamine tetraacetic acid (EDTA) E5134 
Formaldehyde F8923 
Gel loading (blue) dye 6x (B70215)      New England Biolabs 
Hind111 restriction enzyme 
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Propan-2-ol         Fisher Chemical 
N, N, N', N'-tetramethylethylenediamine (TEMED) 
Magnesium chloride 
Methylene blue 
*
4Mouse ACTB (beta actin) 20x Taqman® endogenous control assay; 
FAM dye-labeled TaqMan MGB probe and two unlabeled PCR primers 
4352933E              Applied Biosystems 
Phosphate buffered saline (PBS) 
Piroxicam P5654  
Proteinase K, recombinant PCR grade          Roche Diagnostics 
*
5Random hexadeoxynucleotides 20 µg         Promega 
RNase OUTRecombinant ribonuclease inhibitor    Invitrogen 
40 U/µl (10777-019) 
*
6Sybr® Green 1 nucleic acid gel stain     BioWhittaker Molecular  
        Applications (BMA) 
Sodium chloride (NaCl)                 Fisher Scientific 
Sodium hydroxide        Fisher Scientific 
TaqMan Fast universal PCR Master mix (2x)        Applied Biosystems 
(4352042) 
Tri reagent 
Tris (hydroxymethyl) aminomethane (Tris) base        Melford 
2018 Tekland Global 18% protein rodent diet          Harlan 
Rat and mouse standard diet         BEEKAY 
3-Aminopropyl triethoxysilane (APES) 
Water HPLC grade        Fisher scientific 
 
* see 2.2 for protocols for preparation of solutions and buffers 
  
 
KITS 
 
Affinity Script                     Agilent Technologies 
M-MLV Reverse Transcriptase (28025-013)    Invitrogen 
Phusion® High-Fidelity DNA Polymerase  
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(M0530L)          New England Biolabs 
QIAquick® gel extraction kit (28704)         Qiagen 
RNAse ± free DNAse set (79254)          Qiagen 
RNeasy mini kit (74101)           Qiagen 
SuperScript® lll RT (18080-093)      Invitrogen 
 
 
2.2 Protocols for preparation of working solutions & buffers 
 
 
1. Deoxynucleotide triphosphates (Promega) 
5 µl of each of dATP, dCTP, dGTP and dTTP (all at 100 mM) were 
added to 180 µl of water to give 10 mM concentration. 20 µl aliquots 
were prepared and stored at -200C. 
2. Diethylpyrocarbonate (DEPC) water (Sigma-Aldrich) 
DEPC water was prepared at 0.1% by adding 200 µl of DEPC to 200 
ml of HPLC water (Fisher Scientific). This was then incubated 
overnight at 420C, then autoclaved.  
3. Ethylenediamine tetra-acetic acid solution (Sigma-Aldrich) 
EDTA does not go completely into solution until pH is adjusted to 
8.0. To prepare a 500 ml stock solution of 0.5 M EDTA, 93.05 g of 
EDTA disodium salt was dissolved in 400 ml of deionized water. pH 
was adjusted with sodium hydroxide, and the solution topped up to a 
final volume of 500 ml.  
4. Mouse ACTB (beta actin) 20x Taqman® endogenous control 
assay; FAM dye-labeled TaqMan MGB probe and two 
unlabeled PCR primers (Applied Biosystems) 
To prepare a working assay, 10 µl of 20x reagent was added to 190 
µl of HPLC water in an amber eppendorf tube (to protect the probe) 
and stored at -200C. 
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5. Random hexadeoxynucleotides (Promega) 
The initial concentration of 500 µg/ml was diluted 1:5 to give 100 
µg/ml. 20 µl (at 100 µg/ml) was added to 80 µl of water, and aliquots 
of 10 µl were prepared and stored at -200C.    
6. Sybr® Green 1 nucleic acid gel stain (BioWhittaker 
Molecular Applications) 
To make a working stock of Sybr Green, 1 µl of concentrated Sybr 
Green (10 000x in DMSO) was added to 99 µl of dimethyl sulfoxide 
(DMSO) in a dark glass vial and stored at room temperature.  
7. %DNHU¶VIRUPRO-calcium (modified) 
100 ml of 40% formaldehyde and 100 ml of 10% calcium chloride 
were added together. Distilled water was added to make up to 1 
litre.  
8. Tris-acetate-EDTA (TAE) buffer 
A 50x stock solution of TAE was prepared by adding 242 g of Tris 
base to 750 ml of distilled water. 57.1 ml of glacial acetic acid and 
100 ml of 0.5 M EDTA (pH 8.0) was added, and the final volume 
adjusted to 1 litre with distilled water.  
A working solution of 1x TAE buffer was prepared by adding 20 ml 
of 50x stock solution to 980 ml of distilled water.  
9. Tris-Borate-EDTA (TBE) buffer 
A 10x stock solution of TBE buffer was prepared by adding 108 g of 
Tris base, 55 g of boric acid and 40 ml of 0.5 M EDTA (pH 8.0) to 
distilled water to make up 1 litre.  
A working solution of 1x TBE buffer was prepared by adding 100 ml 
of 10x stock solution to 900 ml of distilled water.  
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3 7KH UROH RI 33$5Į LQ PDOLJQDQW SDWKRORJ\ RI WKH
mouse colon 
 
3.1 Introduction 
 
Peroxisome proliferator-activated receptor alpha (PPARĮ) is a ligand-
activated transcription factor involved in regulation of lipid uptake and 
metabolism, and inflammation (Desvergne and Wahli, 1999, Kersten et 
al., 2000).  
PPARĮ is expressed in many tissues, particularly those that utilise fatty 
acid oxidation as a source of energy (Bookout et al., 2006). The 
receptor is activated by endogenous fatty acids and fatty acid 
derivatives, also synthetic agonists such as the fibrate class of drugs. 
Ligand-mediated activation of 33$5Į results in increased oxidation of 
fatty acids, reduction in serum lipids, improvement in insulin resistance 
and prevention of weight gain and adiposity (Kersten et al., 2000). 
33$5Į can also inhibit expression of pro-inflammatory genes in a 
ligand-dependent manner (ligand-dependent trans-repression) by 
inhibiting the activities of other transcription factors, such as members 
of NF-ț% DQG $3-1 families (Pascual and Glass, 2006, Ricote and 
Glass, 2007).  
APCMin/+ mice were used for these studies, as this mouse has a 
mutated APC gene similar to the mutation observed in human familial 
adenomatous polyposis (FAP) and sporadic colon cancer (Moser et al., 
1990).  
Previous work has shown that the potent PPARĮ agonist, 
methylclophenapate (MCP) reduced both the number and size of 
colonic polyps in APCMin/+ mice (Jackson et al., 2003). Therefore, the 
hypothesis that PPARĮ has a restraining effect on polyp development 
was investigated by comparing polyp development in APCMin/+ mice with 
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those in which PPARĮ had been deleted (APCMin/+PPARĮ-/-) mice 
(Study 1A).  
To identify changes in gene expression related to deletion of PPARĮ 
and with polyp growth in the colon in APCMin /+ and APCMin/+ PPARĮ-/- 
mice, normal and polyp tissue was collected. Affymetrix® GeneChip® 
mouse genome 430 2.0 microarrays were used to investigate 
differential gene expression (Study 1B). 
 
3.2 Aims of Study 
 
x 7R LQYHVWLJDWH WKH HIIHFW RI 33$5Į deletion on development of 
polyps in APCMin/+ mice. 
x To identify changes in gene expression associated with loss of 
PPARĮ and with polyp development in APCMin/+ and APCMin/+ 
PPARĮ-/- mice.  
 
3.3 Methods 
 
APCMin/+ and APCMin/+ PPARĮ-/- mice of 28-30 days old were 
randomised onto study 1 (A and B) as shown in Table 3-1. Husbandry 
of the mice was as described in Methods 3.3.3.   
 
Table 3-16WXG\WRLQYHVWLJDWHWKHUROHRI33$5ĮLQpolyp development in the mouse colon 
 
Number of APCMin/+ mice and APCMin/+ 33$5Į-/- mice on study 1A (polyp number) and 1B (gene 
expression)  
 
All animal work was carried out at the Biomedical Science Unit (BMSU), 
University of Nottingham following the regulations and procedures of 
the Animals (Scientific Procedures) Act 1986 (ASPA). Studies 1A and 
APC
Min/+ 
APC 
Min/+ WWZɲ-/-
1A 20 20
1B 5 5
Genotype                     
Number of mice on studySTUDY 
NUMBER
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1B were managed in collaboration with Dr Tony Shonde and animal 
technicians at the BMSU, University of Nottingham. 
 
3.3.1 The Min mouse model 
 
Male PPARĮ-/- mice were a kind gift from Dr J. M. Peters, Pennsylvania 
State University, United States, and designated C57BL/6J 
33$5ĮTm1Gonz/Tm1Gonz (Akiyama et al., 2001).  
These mice (Pennsylvania male PPARĮ-/-) were crossed with C57BL/6J 
females to produce F1 offspring. Heterozygous F1 were backcrossed 
with C57BL/6J mice to produce F2 offspring.  This process was 
repeated to the F10 generation. This was to restore the C57BL/6J 
background as in-breeding using a limited number of breeding pairs 
would have led to the original background genetics of the strains being 
altered.7  F10 mice were then crossed to produce homozygous wild-
type or PPARĮ-/- mice. F11 mice were used for breeding to obtain F12 
mice for phenotypic analysis.  
Min mice (APCMin/APC/+) on a C57BL/6J background were a kind gift 
from Professor A. Gescher at the University of Leicester, England. 
(Perkins et al., 2002).  
The (Leicester) Min mice were crossed with PPARĮ-/- mice to obtain 
APCMin/+PPARĮ/+, which were then crossed with PPARĮ-/- homozygote 
to obtain homozygous APCMin/+ PPARĮ-/- on a C57BL/6J background.  
The colonies of mice were managed and maintained by animal 
technicians at the BMSU, University of Nottingham. 
 
3.3.2 Genotyping of mice 
 
Ear snips from 21 day old male and female mice were used to 
determine the genotype of APCMin/+ and APCMin/+33$5Į-/- mice. 
                                            
7
 Inbreeding can lead to unwanted genetic drift. Genetic drift is a change in a populations allele frequency 
resulting from a random variation in the distribution of alleles from one generation to the next; it can cause 
some gene variants to disappear completely thereby reducing genetic variation 
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Genotyping was performed by Mr Declan Brady, School of Biology, 
University of Nottingham, England, using primers as described 
previously (Lee et al., 1995, Jeffery et al., 2004). 
 
3.3.3 Husbandry of mice 
 
Genotyped mice at 28-30 days old were introduced to the study over a 
period of eight months, whilst ensuring adequate breeding stock was 
maintained. Standard chow (Rat and mouse standard diet, BEEKAY, 
Humberside) and water was available ad libitum. Mice were subject to a 
light/dark cycle of 12 hours each. Date of birth (DOB) and date of death 
(DOD) were recorded for each mouse. Mice were weighed at the start 
of the study, and on a weekly basis thereafter, until sacrifice by cervical 
dislocation. They were terminated if they showed signs of suffering, 
anaemia (pale foot pads - white paw), rectal prolapse or >15% weight 
loss. Animal technicians in collaboration with the animal unit on-call 
veterinary surgeon independently monitored the mice twice daily. They 
advised if and when it became necessary for a mouse to be sacrificed. 
Reasons for sacrifice of each mouse were recorded.  
 
3.3.4 Quantification of mouse intestinal polyps  
 
Whole intestines from mice on Study 1A (20 from APCMin/+ mice, 20 
from APCMin/+PPARĮ-/- mice, Table 3-1) were removed immediately 
after sacrifice and flushed with saline. The intestines were separated 
into colon and small bowel, and opened lengthways with scissors. All 
tissue was fixed in 70% formol calcium (page 42).  
50 mg of methylene blue hydrate (Sigma-Aldrich) was dissolved in 20 
ml of phosphate buffered saline (PBS) to give a 0.25% methylene blue 
staining solution. Fixed tissue was immersed in PBS for a few minutes 
then briefly immersed in methylene blue stain, rinsed with water, then 
destained with 70% ethanol. This methodology differentially stained 
normal mucosa from polyp tissue.  
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Tissue was pinned out flat and observed through a Karl Zeiss Tessovar 
macroscope (x4.2 magnification). Images were acquired using a Q 
imaging micropublisher 5.0 RTV camera with Improvision Openlab 
software. Each colon and small bowel was imaged sequentially along 
its length. A pin placed at the edge of HDFKµIUDPH¶ indicated where the 
next image was taken from (the pin could be clearly seen on the 
images). Images were viewed on a computer. Polyps were quantified by 
counting each individual polyp, up and down, left to right, on each 
image, then a total polyp count calculated for each piece of tissue. Extra 
care was taken at the longitudinal cut edges of the tissue to ensure 
polyps were not counted twice. Figure 3-1 shows typical images of 
colonic polyps and small bowel polyps. 
 
 
Figure 3-1 Methylene blue staining of polyps in the mouse colon & small bowel 
Blue circles have been added to the images to highlight the polyps 
 
 
Polyps in the mouse colon (x4.2 magnification)
Polyps in the mouse small bowel (x4.2 magnification)
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3.3.5 Processing, Cutting and Haematoxylin & Eosin staining of 
mouse colonic mucosa  
 
After completion of polyp number evaluation, two mouse colons from 
storage in formol calcium (one representative colon from each genotype; 
APCMin/+ and APCMin/+ PPARĮ-/-) were selected. Colons were pinned out 
flat onto cork boards; samples of tumour and normal tissue (at least 2 
cm away from visible polyps) were excised with scissors and stored in 
formol saline.  
For processing, samples were placed into secure cassettes and 
processed overnight in a Leica TP1020 tissue processor. Stations 1 and 
2 (fixing stations) were not required as tissue was previously fixed in 
formol calcium (Table 3-2A).   
After processing, the dehydrated tissue was carefully positioned 
centrally into a wax mould. The mould was filled with molten wax and 
left to set on a cold plate.  A Leica RM2145 microtome was used to cut 
4 µm thick sections from the wax embedded tissue samples. Sections in 
ribbons of 3-4 were cut and floated out into a paraffin section mounting 
bath (400C), which were then attached to an APES (3-Aminopropyl 
triethoxysilane) coated slide. Slides were dried on a Leica EG1120 
hotplate (680C). Before staining the sections were rehydrated (Table 
3-2B). Slides were then ready for Haematoxylin & Eosin staining (Table 
3-2C).  
After staining, slides were viewed on a Leica DM 4000 light microscope. 
Images were captured and saved using Openlab on a Q imaging 
Micropublisher 3.3RTV camera.  
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Table 3-2 Preparation of mouse colon tissue for Haematoxylin & Eosin staining 
A. Tissue process steps on Leica TP1020 
 
B. Rehydration steps for wax sections (pre-staining procedure) 
 
C. Haematoxylin & Eosin stain protocol 
 
Station Process chemical Time (hours)
1
2
3 70% alcohol 1.5
4 80% alcohol 1.5
5 96% alcohol 1.5
6 100% alcohol 1
7 100% alcohol 1
8 100% alcohol 1
9 xylene 1.5
10 xylene 1.5
11 paraffin 2
12 paraffin 2
Leica TP1020 tissue processor sequence
Reagent Time (minutes)
xylene 5
100% IMS 0.5
100% IMS 0.5
90% IMS 0.5
70% IMS 0.5
50% IMS 0.5
running tap water 0.5
Rehydration of wax sections
Process Time
Submerge slides in Harris Haematoxylin 5 minutes
Dip in Acid Alcohol 10 seconds
Dip in Lithium Carbonate/Scott's tap water 10 seconds
Submerge slides in 1% Eosin 5 minutes
Dip into 50% IMS 10 seconds
Dip into 70% IMS 10 seconds
Dip into 90% IMS 10 seconds
Dip into 100% IMS 10 seconds
Dip into fresh Xylene 2 minutes
Dip into finishing Xylene 2 minutes
Wash in a bath of running tap water until water clears
Add few drops of DPX to appropriately sized coverslip to mount section
Haematoxylin & Eosin Stain protocol
Wash in bath of running tap water until water clears
Wash in bath of running water until no streaks on the slides
Wash in bath of running tap water
Check samples are blue under microscope
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3.3.6 RNA extraction from mouse colonic mucosa 
 
Colons from mice on Study 1B were removed immediately after 
sacrifice and flushed with saline. Colons were opened lengthways with 
scissors and laid flat for examination by eye. Samples of normal (at 
least 2 cm away from visible polyps) and tumour tissue were excised 
with scissors and separately flash frozen in liquid nitrogen, before 
storage at -800 C.  
Samples taken from storage were homogenisHGLQPORI7ULUHDJHQW
and extraction of RNA performed according to the manufacturer¶s 
instruction (Sigma-Aldrich). Samples were further purified using the 
RNeasy mini kit, incorporating the additional DNAse treatment step as 
outlined in the manufacturer¶V LQVWUXFWLRQ (Qiagen). A NanoDrop® ND-
1000 Spectrophotometer was used to determine the 260/280 ratio8 and 
the concentration in ng/µl of all of the samples. 1 µl of each mouse RNA 
sample was analysed on an Agilent Bioanalyser using a RNA Nano 
6000 chip. Analysis produced the RIN (RNA Integrity Number).9 RNA 
was aliquoted into smaller volumes and stored at -800C. Table 3-3 
shows sample identification numbers, genotype, tissue type and RIN.
                                            
8
 The ratio of absorbance at 260 nm and 280 nm is used to assess the purity of RNA. A ratio of ~2.0 
signifies pure RNA. A ratio that is lower indicates the presence of protein, phenol or other contaminants that 
absorb at or near 280 nm. 
 
9
 The 28S/18S rRNA (ribosomal RNA) ratio is used to determine integrity; rRNA makes up > 80% of total 
RNA in a ~ 2:1 ratio 
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Table 3-3 Identification & RNA integrity number of samples for Affymetrix® microarray 
 
 
Nine pairs of samples, tumour and normal from four APCMin/+ mice and 
five APCMin/+ 33$5Į-/- mice were selected for further analysis (Table 
3-3). Paired samples from an APCMin/+ mouse (72.1/2) were excluded 
as the RIN was low indicating degradation of the samples (highlighted 
in red). 
 
3.3.7 Affymetrix® microarray analysis of mouse colon normal & 
tumour mucosa 
 
Mouse colon RNA samples (Study 1B, Table 3-3) were processed at 
the Paterson Institute, Manchester on Affymetrix® GeneChip® Mouse 
Genome 430.2 high-density oligonucleotide arrays (one sample per 
array).  
 
Sample 
identification Genotype
Tissue 
type
RNA Integrity 
Number (RIN)
44b.3/4 APCMin/+ normal 8.8
44b.3/4 APCMin/+ tumour 8.5
70.3/2 APCMin/+ normal 9.1
70.3/2 APCMin/+ tumour 9.2
76.4/1 APCMin/+ normal 8.4
76.4/1 APCMin/+ tumour 9.0
76.4/3 APCMin/+ normal 8.5
76.4/3 APCMin/+ tumour 9.1
72.1/2 APCMin/+ normal 6.6
72.1/2 APCMin/+ tumour 5.3
115.4/1 APCMin/+ 33$5Į-/- normal 9.1
115.4/1 APCMin/+ 33$5Į-/- tumour 9.6
11a.3/4 APCMin/+ 33$5Į-/- normal 9.3
11a.3/4 APCMin/+ 33$5Į-/- tumour 9.4
121.1/2 APCMin/+ 33$5Į-/- normal 8.7
121.1/2 APCMin/+ 33$5Į-/- tumour 9.0
121.1/3 APCMin/+ 33$5Į-/- normal 8.3
121.1/3 APCMin/+ 33$5Į-/- tumour 8.5
121.1/5 APCMin/+ 33$5Į-/- normal 8.6
121.1/5 APCMin/+ 33$5Į-/- tumour 9.1
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The array uses 45,101 probe sets selected from sequences derived 
from GenBank®, dbEST and RefSeq to analyze the expression level of 
over 39,000 transcripts and variants from over 34,000 well 
characterized mouse genes (Affymetrix, 2003).  
Microarray studies involve a multi-step process; these are experimental 
design, array design, sample preparation and labelling, hybridisation 
procedures and parameters, measurements, normalisation controls, 
data processing and analysis. It is, therefore, important to minimise 
variation by the use of good laboratory protocols. Microarray standard 
operating procedures (mSOPs) were implemented to verify that each 
step was accurately and consistently carried out (Forster et al., 2003). 
This ensured compliance of µ0LQLPXP ,nformation About a Microarray 
E[SHULPHQW¶0,$0( requirements; these are necessary for publication 
of microarray data and ensure uniformity of standards in production and 
analysis of microarray data that can be readily interpreted and 
independently verified (Brazma et al., 2001). 
The quality of data from microarrays is highly dependent on RNA quality. 
Mouse RNA samples for gene array were sent on dry ice at a 
concentration of ~ 1 µg/µl and greater than or equal to 5 µg of RNA with 
a 260/280 ratio of 1.9 ± 2.1 and a RIN of greater than or equal to 8.0.  
Figure 3-2 shows an overview of the protocol for sample preparation & 
analysis on Affymetrix GeneChip® arrays.  
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Figure 3-2 Protocol for sample preparation & analysis on Affymetrix GeneChip® arrays  
RNA was reverse transcribed then labelled with Biotin-UTP and Biotin-CTP in an in-vitro 
transcription reaction. After heating with Mg2+, fragmented cRNA was hybridized onto a GeneChip 
before washing, staining and scanning for data analysis 
 
Briefly, Figure 3-2 portrays how cDNA was synthesised from mouse 
RNA samples using reverse transcriptase and a T7 oligo-dT 
(deoxythymine) promoter primer. cDNA was then used in an Affymetrix 
¶in-vitro transcription (IVT) reaction to produce amplified biotin-labelled 
antisense mRNA (cRNA)  ± the array targets.  
Cells
RNA
cDNA
Biotin labelled target (cRNA)
Fragmented cRNA
Data analysis
Isolate RNA
AAAA
Reverse 
transcription
Biotin-UTP
Biotin-CTP
Fragment 
(heat, Mg2+)
GeneChip
Hybridise 
(16 hrs)
Wash & stain
Scan
IVT
54 
 
The T7 oligo-dT primer is designed to incorporate a T7 promoter 
sequence during cDNA synthesis. The sequence has high affinity for 
the T7 RNA polymerase, and therefore, promotes a high level of 
expression. The primer contains an oligo-dT 24 sequence at its 3 prime 
¶HQGIRUVSHFLILFELQGLQJ WR WKHSRO\$ WDLORIP51$DQGWKHFRUH
VHTXHQFHRIWKH751$SRO\PHUDVHSURPRWHUDWLWVSULPH¶HQG 
Essentially, this means that the cDNA yield from sequences close to the 
¶HQGRISDUWLDOO\GHJUDGHGP51$ZRXOGEHVLJQLILFDQWO\OHVVWKDQWKDW
near the poly (A) tail (Swift et al., 2000). Affymetrix arrays are designed 
with oligo probes that are close WRWKH¶HQGRIDWUDQVFULSW+RZHYHU
additional probe sets for reference genes including glyceraldehyde 3-
SKRVSKDWHGHK\GURJHQDVH*$3'+DQGDFWLQDUHGHVLJQHGDW WKH¶
end of the transcript (Affymetrix, 2001). The signal intensity ratio of the 
¶ SUREH VHW WR WKH ¶ SUREH VHW ¶¶ UDWLR LV XVHG WR YHULI\ 51$
integrity, efficiency of first strand cDNA synthesis, and in vitro 
transcription of cRNA (Copois et al., 2007). RNA is deemed to be 
GHJUDGHGLIWKH¶¶UDWLRLVJUHDWHUWKDQWKUHH(Affymetrix, 2001). 
After the reverse transcription step, the cDNA and a mixture of 
nucleotides and biotinylated nucleotide analogues were then used in a 
¶,97UHDFWLRQWRSURGXFHELRWLQODEHOOHGFRPSOHPHQWDU\RNA (cRNA). 
Antisense RNA amplification improves the sensitivity of the microarray.  
Prior to hybridisation the biotinylated cRNA was heated with an 
endonuclease and Mg2+ to produce 25 ± 200 base pair fragments. 
Fragmentation improves hybridisation to target probes to produce an 
enhanced signal. The cRNA fragments were then added to a 
hybridisation master mix before being injected into a Genechip® 
chamber for hybridisation for 18 hours at 450C.  
After hybridisation the chip was processed with a series of staining and 
washes; the chip was stained with streptavidin-phycoerythrin, a 
fluorescent molecule that binds to biotin, and washed with anti-
streptavidin antibody (goat) and biotinylated IgG antibody (goat).  
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The chips were scanned and processed using GeneChip® Operating 
Software (GCOS).  
GCOS computed a detection call (present, absent or marginal), 
detection p value and average intensity value (signal) for each probe 
set to generate a table of 45,101 entities. Detection calls were used to 
determine whether a probe set was reliably detected and selected for 
further analysis. GCOS quality control data indicated between 55% - 60% 
of probe sets were detected as present in the 18 arrays.  
GCOS also produced image data files (.DAT files) which provided an 
assessment of the quality of the scanning event; and cell intensity files 
(.CEL files) that were binary files derived from the .DAT files. .CEL files 
were the base files for further analysis using GeneSpring®.  
  
3.3.8 Rationale for methodology of analysis of Affymetrix® 
microarray data 
 
Affymetrix® microarray data were analysed to determine if there were 
any differences in gene expression in the colon between APCMin/+ and 
APCMin/+ PPARɲ-/- mice, and between tumour and normal tissue.  
GeneSpring®GX 11.0.2 software was used for the analysis. Data from 
each of the 18 samples were categorised into groups; that is, 4 APCMin/+ 
normal samples, 4 APCMin/+ tumour samples, 5 APCMin/+ PPARɲ-/- 
normal samples, 5 APCMin/+ PPARɲ-/- tumour samples (Table 3-3). 
Comparison of these data generated lists of differentially expressed 
genes (DEG lists), as below; 
x Comparison 1: APCMin/+ 33$5Į-/- normal vs. APCMin/+ normal 
x Comparison 2: APCMin/+ 33$5Į-/- tumour vs. APCMin/+ tumour 
x Comparison 3: APCMin/+ normal vs. APCMin/+ tumour 
x Comparison 4: APCMin/+ 33$5Į-/- normal vs. APCMin/+ 33$5Į-/- 
tumour 
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These data were further interrogated to determine whether any 
differences were significant in development and progression of colon 
cancer in the mouse colon. 
DEG list data were input into Ingenuity Pathway Analysis (IPA) to 
produce networks of genes; these were then annotated with pathways 
known to be involved in tumorigenesis and PPARɲ; Wnt/beta catenin, 
ERK/MAPK, p53 (Fearon and Vogelstein, 1990) and PPARɲ/RXRɲ 
(Kersten et al., 2000, Jackson et al., 2003). 
A sub-set of these genes were then selected for further investigation.    
 
3.3.9 GeneSpring®GX 11.0.2 analysis of Affymetrix® microarray 
data 
 
GeneSpring® is software for importing and analysing gene array data 
within a single platform. It supports Affymetrix® data format with guided 
workflows specific to GeneChip® gene expression arrays. 
GeneSpring® makes optimal use of Affymetrix®-specific quality control 
and other optimisations, for example, sample preparation, hybridisation, 
staining and washing.  
Table 3-4 shows an overview of the guided workflow for GeneChip® 
mouse genome 430.2 arrays.  
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Table 3-4: GeneSpring® guided workflow for GeneChip Mouse Genome 430.2 arrays 
 
Overview of workflow protocol for preparation and analysis of gene array data using GeneSpring® 
 
As can be seen from Table 3-4 the first process for preparation and 
analysis of array data was creation of a new experiment. All 18 .CEL 
files were imported from GCOS, and the appropriate technology 
selected (Affymetrix GeneChip® Mouse genome 430.2).  
Robust Multichip Averaging (RMA) algorithm (Irizarry et al., 2003) was 
used to perform three key tasks; background correction, normalisation 
and probe summarisation.  
 
PROCESS STEP TASK SELECTION
1 Load data Import .CEL files 
2 Select technology Affymetrix® GeneChip® Mouse Genome 430. 2
3 Select summarization 
algorithm
Robust Multichip Averaging 
(RMA)
4 Select baseline transformation Baseline to median for all samples
1 Define experiment grouping
 i. Tumour or Normal 
ii. APC Min/+ 33$5Į-/- or APC Min/+
2 Create interpretation
i. Tissue type only 
ii. Genotype only 
iii. Tissue type & Genotype
Experiment 
quality 1
Validation of 
biological replicates Pivot table
1 QC on samples
i. Internal controls
ii. Hybridization control 
iii. Principle component analysis (PCA)
2 QC on entities Filter probesets by expression; ± percentile
1 Fold change >= 2
2 t test p < 0.005 Multiple testing correction not used
Quality 
control 
(QC)
Analysis
Create new 
experiment
Experiment 
setup
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Background correction was performed on each chip. The method is 
based on the distribution of only the perfect match (PM) values of 
probes; probe intensity values consist of the actual signal and a 
background signal comprised of non-specific binding of the fluorophore 
and optical noise. The background signal was corrected for by the RMA 
algorithm.  
Normalisation was performed before analysis to ensure that apparent 
differences in intensities, both within and between arrays, were due to 
differential expression and not hybridisation or scanning variations. The 
RMA algorithm uses Quantile normalisation and utilises all arrays to 
perform normalisation on raw intensities, regardless of variance.  
Briefly, 
1. The intensity values were ranked in each array 
2. The average of the intensity values was calculated for each 
probe 
3. The intensity values were substituted with the calculated average 
4. The ranked average intensity values were returned to the original 
order 
This effectively caused all the distributions to be the same and 
corrected for array biases. 
Probe summarisation estimated the actual expression value of a probe 
by aggregation of the expression value on the log scale with an 
independent noise value. Log-transformed intensity values result in a 
normal distribution. 
Baseline transformation completed the creation of the new experiment. 
Baseline to median for all samples was selected; comparable to 
normalisation for each gene. 
The next process was to set up the experiment by defining experimental 
groups and the interpretations to be analysed. There were four groups; 
APCMin/+ normal, APCMin/+ tumour, APCMin/+PPARĮ-/- normal and 
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APCMin/+PPARĮ-/- tumour. Interpretations were; the effects of tissue type 
only, genotype only, and tissue type & genotype (Table 3-4). 
The quality of the experiment was assessed. The similarity within each 
group of biological replicates was examined; that is, APCMin/+ normal 
group (four replicates), APCMin/+ tumour group (four replicates), APCMin/+ 
PPARɲ-/- normal group (five replicates) and APCMin/+ PPARɲ-/- tumour 
group (five replicates).  
This was done by ranking (highest to lowest) the normalised expression 
values of every probe for each replicate within a group. For each group, 
data were input into a pivot table (Excel). The pivot table presents the 
data to show the ranking of every probe in each sample of a group. 
Thus, the ranking of any probe can be compared simultaneously across 
all samples within a group. This allows for easy identification of an 
outlier sample. 
Quality control (QC) of samples was performed to assess the 
reproducibility of gene expression measurements across replicates. QC 
of samples comprised of three steps. Firstly, internal controls assessed 
51$VDPSOHTXDOLW\E\GHWHUPLQLQJWKHSULPHSULPH¶¶UDWLRIRU
GAPDH and actin for each sample. A ratio of more than three would 
indicate sample degradation. Secondly, hybridisation controls showed 
the quality of hybridisation and the washing process. Hybridisation 
controls were composed of a mixture of biotin-labelled cRNA transcripts 
of bioB, bioC, bioD and cre, at known staggered concentrations that 
were spiked into the hybridisation reaction. The signal intensity of the 
controls should increase as expected in line with the known 
concentrations. Lastly, Principal Component Analysis (PCA) which is 
suitable for large data sets such as gene expression data from 
microarrays, was performed. A covariance analysis was calculated to 
discover correlations between samples or conditions. PCA scores were 
visually represented on a 3D scatter plot. Samples from the same 
experimental condition group together on the plot.    
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The QC analysis of our samples led to exclusion of one APCMin/+ tumour 
(70.3/2) sample from further analysis.  
Quality control of entities was performed by filtering probe sets by 
expression. This operation removes by default the lowest 20 percentile 
of all intensity values. The lowest 45 percentile was removed as GCOS 
QC data indicated between 55% - 60% of probe sets were detected as 
present in the 18 arrays (3.3.7, page 51).  
Comparison of groups and interpretations as defined in the experiment 
set up (Table 3-4) produced lists of differentially expressed genes (DEG 
lists). The lists from APCMin/+33$5Į-/- normal vs. APCMin/+ normal 
(Comparison 1), APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour 
(Comparison 2), APCMin/+ normal vs. APCMin/+ tumour (Comparison 3) 
and APCMin/+33$5Į-/- normal vs. APCMin/+33$5Į-/- tumour  
(Comparison 4) were subject to statistical analyses; genes were 
excluded from the list if they did not fulfil specified criteria; that are, fold 
change (FC) greater than or equal to two, followed by unpaired t test, 
where p was less than or equal to 0.005. 
Initial statistical analysis of gene lists was carried out using unpaired t 
test with incorporated multiple testing correction (MTC).  
MTC adjusts p-values to correct for the occurrence of false positives; 
these occur when the null hypothesis is true, but is rejected. The null 
hypothesis states that there is no significant difference in gene 
expression between specified groups. 
The false positive rate is proportional to the number of tests performed 
and the p-value cut-off. A microarray experiment simultaneously 
performs a t-test or ANOVA on all genes. A p-value of 0.05 denotes a 
5% probability that the expression value of a gene in one condition is 
different than the expression value in the other condition, by chance 
alone. For example, if 10,000 genes were tested, 5% (or 500 genes) 
would be deemed significant by chance alone.  
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GeneSpring® has a choice of four types of MTC which are listed below 
in order of stringency; Bonferroni is the most stringent, and the 
Benjamini and Hochberg False Discovery Rate (FDR) the least 
stringent. 
x Bonferroni 
x Bonferroni Step-down (Holm) 
x Westfall and Young Permutation 
x Benjamini and Hochberg FDR 
 
The more stringent a MTC, the fewer false positive genes are identified. 
Benjamini and Hochberg FDR (Benjamini and Hochberg, 1995) was 
selected as the MTC; the method is explained briefly below. 
For example, when p < 0.05 
1. p-values of each gene are ranked (smallest to largest)  
2. Largest p-value is unchanged 
3. Second largest p-value is multiplied by the total number of genes (n) 
and divided by its rank (n-1).  
That is, corrected p-value = p-value*(n/n-1). Gene is significant if p < 
0.05  
4. Third largest p-value is multiplied as in step 3:  
Corrected p-value = p-value*(n/n-2). Gene is significant if p < 0.05 
And so on...... 
Initial statistical analysis of differentially expressed gene lists 
(Comparisons 1-4) produced zero results. To attempt to overcome this 
problem, the p value stringency was changed to less than or equal to 
0.05. However, this too produced zero results. Further analysis was 
carried out without MTC, and with FC >= 2, followed by unpaired t test, 
where p <= 0.005, as defined earlier (Table 3-4). 
To increase the number of potential differentially expressed genes in 
APCMin/+33$5Į-/- normal vs. APCMin/+ normal (Comparison 1), and 
APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour (Comparison 2), less 
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stringent criteria for selection was applied. Comparison 1 and 
Comparison 2 were re-analysed using FC >= 1.7, p <= 0.05, also 
without MTC. 
To ensure these data were valid and comparable as multiple testing 
correction (MTC) was not used in statistical analysis, differentially 
expressed gene (DEG) lists were cross-referenced against ranked lists 
of genes, as described; briefly, normalised probe intensity values10 of 
pairs of groups (comparable to comparison groups 1 - 4) of 
APCMin/+33$5Į-/- normal and APCMin/+ normal, APCMin/+33$5Į-/- tumour 
and APCMin/+ tumour, APCMin/+ normal and APCMin/+ tumour, and 
APCMin/+33$5Į-/- normal and APCMin/+33$5Į-/- tumour, were listed. The 
difference between probe intensity values (that is, the intensity value for 
a probe in one group minus the intensity value of the same probe in the 
other group, for each pair of groups) was ranked, highest to lowest. The 
ranking of five reference genes were determined in each list; 18s 
(ribosomal RNA), Actb (beta actin), GAPDH (glyceraldehyde-3-
phosphate dehydrogenase), Tfrc (transferrin receptor protein) and Pcx 
(pyruvate carboxylase). Reference genes were selected as expression 
of each was similar in all four lists. Genes were selected and listed from 
each of the four ranked lists if they were above a reference gene in the 
ranking. Genes were excluded from DEG lists if they did not appear on 
at least one of the ranked lists. These edited DEG lists can be viewed in 
Appendices (pages 311-377). 
Figure 3-3 and Figure 3-4 show a flow-chart sequence of GeneSpring 
analysis of comparison group 1 (APCMin/+ PPARɲ-/- normal vs. APCMin/+ 
normal), comparison group 2 (APCMin/+ PPARɲ-/- tumour vs. APCMin/+ 
tumour), comparison group 3 (APCMin/+ normal vs. APCMin/+ tumour) and 
comparison group 4 (APCMin/+ PPARɲ-/- normal vs. APCMin/+ PPARɲ-/- 
tumour). 
                                            
10
 The average of probe intensity values corresponds to the expression level of the hybridised gene of 
interest  
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Figure 3-3: Enrichment of differentially expressed genes by GeneSpring® quality control & analysis  
Numbers of differentially expressed genes were sequentially reduced by increasing the stringency 
of quantity control and statistical analyses 
 
 
 
Figure 3-4: Enrichment of differentially expressed genes in Comparison 1 & Comparison 2 by 
GeneSpring® quality control & analysis  
Numbers of differentially expressed genes in Comparison 1 and Comparison 2 were increased by 
decreasing the stringency of statistical analyses 
 
Comparison 1:
APC Min/+ PPARĮ-/- normal
vs.
APC Min/+ normal
Comparison 2:
APC Min/+ PPARĮ-/- tumour
vs.
APC Min/+ tumour
Comparison 3:
APC Min/+ normal
vs.
APC Min/+ tumour
Comparison 4:
APC Min/+ PPARĮ-/- normal
vs.
APC Min/+ PPARĮ-/- tumour
Filtered probe sets
25131
Filtered probe sets
24765
Filtered probe sets
25464
Filtered probe sets
25081
Dif ferentially expressed 
genes
Fold change >= 2
201
Dif ferentially expressed 
genes
Fold change >= 2
852
Dif ferentially expressed 
genes
Fold change >= 2
2708
Dif ferentially expressed 
genes
Fold change >= 2
1667
Dif ferentially 
expressed genes
p < = 0.005
17
Dif ferentially 
expressed genes
p < = 0.005
47
Dif ferentially 
expressed genes
p < = 0.005
1141
Dif ferentially 
expressed genes
p < = 0.005
1181
Comparison 1:
APC Min/+ PPARĮ-/- normal
vs.
APC Min/+ normal
Comparison 2:
APC Min/+ PPARĮ-/- tumour
vs.
APC Min/+ tumour
Filtered probe sets
25131
Filtered probe sets
24765
Dif ferentially expressed 
genes
Fold change >= 1.7
411
Dif ferentially expressed 
genes
Fold change >= 1.7
1577
Dif ferentially 
expressed genes
p < = 0.05
52
Dif ferentially 
expressed genes
p < = 0.05
504
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3.3.10 Ingenuity® Pathway Analysis (IPA®) of Affymetrix® 
microarray data (Study 1B)  
 
Ingenuity® Pathway Analysis (IPA®) is a bioinformatics tool based on 
the Ingenuity Pathway Knowledge Base (IPKB). The IPKB is a 
repository of expertly curated biological and chemical interactions, and 
functional annotations. It is produced from over 200,000 peer-reviewed 
scientific publications which are manually reviewed for accuracy.  
IPA utilises IPKB to generate network maps; a biological interaction 
network map is a graphical representation of the molecular relationships 
between genes. Genes are represented as nodes, and the biological 
relationship between two nodes by a line. All lines are supported by at 
least one reference stored in the IPKB. The degree of upͲ (red) or 
downͲ (green) regulation is indicated by the intensity of node colour. 
Nodes are displayed using different shapes to represent the functional 
class of a gene product (see Figure 3-5). Lines describe the nature of 
the relationship between the nodes, that is, a solid line indicates a direct 
interaction and a dashed line indicates an indirect interaction between 
genes. 
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Figure 3-5 Key to symbols on Ingenuity Pathway Analysis networks 
IPA was used to analyse Affymetrix® microarray data and also to aid 
selection of genes of interest for further investigation on Taqman® low 
density arrays.   
Data sets comprised of the edited DEG lists (Appendices, pages 311-
377) from Comparison 1 (APCMin/+33$5Į-/- normal vs. APCMin/+ normal), 
Comparison 2 (APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour), 
Comparison 3 (APCMin/+ normal vs. APCMin/+ tumour) and Comparison 4 
(APCMin/+33$5Į-/- normal vs. APCMin/+33$5Į-/- tumour), containing 
gene identifiers and corresponding fold change and p values were 
separately uploaded into IPA. Each gene identifier was mapped to its 
corresponding gene in the IPKB to generate a series of biological 
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interaction network maps and list of biological processes, all with 
corresponding lists of genes, for each data set.  
IPA computed a score for each network based on the input data. The 
score was derived from the p value and indicated the likelihood of the 
genes in a network being found together as a result of random chance. 
A score of 2 indicates that there is a 1-in-100 chance that the genes 
were together in a network as a result of random chance. Therefore, the 
higher the score the greater statistical significance that genes 
represented in a network were interconnected.  
The IPA data of Comparison 3 (APCMin/+ normal vs. APCMin/+ tumour) 
and Comparison 2 (APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour), were 
mined to extract data from the two top biological processes highlighted 
in these analyses; growth & proliferation and colorectal cancer. 
Separate networks showing the interaction of genes involved in both 
processes were generated.  
Additionally, the growth & proliferation and colorectal cancer networks 
from Comparison 3 and Comparison 2 were separately annotated with;  
x The Wnt/ beta Catenin signalling pathway  
This pathway is known to be deregulated when the Adenomatous 
Polyposis Coli (APC) gene is mutated, leading to development of polyps 
in the colonic epithelium (Korinek et al., 1997, Oshima et al., 1997).  
x The ERK/MAPK (ras) pathway 
The ERK/MAPK canonical pathway is involved in regulation of gene 
expression. Mutations or aberrant expression of components of the 
pathway (for example ras and b-raf) have been revealed in human 
cancers (McCubrey et al., 2007).  
The ERK/MAPK pathway is activated when a signalling molecule binds 
to the receptor on the cell membrane. This initiates a cascade of 
signalling events beginning with Ras (a GTPase). Ras exchanges GDP 
(guanosine diphosphate) for GTP (guanosine triphosphate) which 
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activates MAP3K. This in turn activates MAP2K, then MAPK (mitogen-
activated protein kinase, also known as ERK). MAPK then activates a 
transcription factor, for example, Myc (Seger and Krebs, 1995). 
x The p53 pathway 
SLVDWXPRXUVXSSUHVVRUJHQHDQGLVNQRZQDVWKHµJXDUGLDQRIWKH
JHQRPH¶ (Lane, 1992). Mutation of the p53 gene can lead to loss of 
function, deregulated transcription of target genes and cancer (Hollstein 
et al., 1991). 
x The 33$5ĮSDWKZD\ 
A previous study (Jackson et al., 2003) VXJJHVWHGWKDW33$5ĮOLJDQGV
GHFUHDVHG SRO\S QXPEHUDQG WKDW 33$5ĮH[SUHVVLRQ ZDV UHGXFHG LQ
human tumour samples.  
In addition, data from Comparison 3 and Comparison 2 were overlaid 
onto IPA generated canonical pathways for Wnt/ beta Catenin, 
ERK/MAPK (ras) p53 and PPARĮ to create further networks.  
These data are presented in Results 3.4.5 page 77. 
To validate Affymetrix® microarray data, a sub-set of 95 genes was 
selected for subsequent analysis with Taqman® low density arrays.  
All IPA networks, with a score of ten or above were analysed for genes 
involved with colorectal cancer, growth & proliferation and PPARĮ 
pathways. However, as IPA is dependent on the IPKB, only networks 
and results based on peer-reviewed research within that database were 
generated. Several novel genes were significantly differentially 
regulated in the DEG lists (Comparison 1-4, Appendices pages 311-
377), but did not appear on IPA networks. Therefore, although IPA is a 
useful source of information for validation of data for established 
pathways, such as the Wnt/ beta Catenin, ERK/MAPK (ras), p53 and 
PPARĮ pathways, it cannot be used exclusively for determination of 
genes of interest for further investigation. 
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Two novel genes of interest, Onecut2 and Apobec3 were included in 
the final list of genes to be validated on Taqman® low density arrays.  
The National Centre for Biotechnology Information (NCBI) gene 
database (http://www.ncbi.nlm.nih.gov/gene) was accessed for 
information on nomenclature, reference sequences (RefSeqs) and 
pathways for each selected gene.  
The 95 genes selected for verification of expression level by Taqman® 
low density arrays were categorised into functional groups; see Results 
3.4.6 page 104, Table 3-15-Table 3-23.  
 
3.4 Results 
 
3.4.1 Age & Weight of mice at sacrifice: Study 1A 
 
The mean age at sacrifice for APCMin/+ mice was 29.49 +/- 0.93 weeks 
(Mean +/- Standard Error, Table 3-5). All mice in this group were 
sacrificed due to development of white paw (pale foot pads that 
indicates anaemia) except one which had rectal prolapse (Table 3-5).   
APCMin/+ PPARĮ-/- mice mean age at sacrifice was 28.87 +/- 1.24 weeks 
(Table 3-6). All mice in this group were sacrificed due to white paw 
(Table 3-6). There was no significant difference in ages of mice at 
sacrifice between the two groups (Figure 3-6A).  
The mean weight at death of APCMin/+ mice was 22.35 +/- 0.99 g, Table 
3-5. The mean weight at death of APCMin/+ PPARĮ-/- mice was 
significantly heavier 29.91 +/- 1.49 g, Table 3-6, p = 0.0001, Figure 
3-6B. 
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Table 3-5: Age, weight & disposition at sacrifice of APCMin/+ mice on study 1A 
 
Table 3-6: Age, weight & disposition at sacrifice of APCMin/+ 33$5Į-/- mice on study 1A  
Mouse ID Genotype Age at death (weeks)
Weight at death 
(grams)
Disposition of 
mouse at death
35 1/1 M APC Min/+ 28.50 21.10 white paw
36 1/4 F APC Min/+ 31.30 23.20 white paw
31 1/3 M APC Min/+ 31.40 20.00 white paw
29b 3/3 F APC Min/+ 28.20 26.30 white paw
31 1/2 F APC Min/+ 30.00 22.50 rectal prolapse
35 1/4 M APC Min/+ 30.10 18.60 white paw
27b 4/2 M APC Min/+ 23.00 22.70 white paw
24a 5/3 M APC Min/+ 25.30 23.30 white paw
30 1/2 F APC Min/+ 30.00 20.25 white paw
31 6/1 M APC Min/+ 32.80 29.40 white paw
31 2/1 m APC Min/+ 32.30 30.40 white paw
37 1/2 M APC Min/+ 23.50 32.80 white paw
37 1/3 M APC Min/+ 23.50 16.80 white paw
35 1/5M APC Min/+ 27.00 21.10 white paw
28c. 4/1F APC Min/+ 27.80 20.30 white paw
34 2/1 F APC Min/+ 31.20 15.60 white paw
27b 4/1 F APC Min/+ 29.80 18.40 white paw
24a 5/2 M APC Min/+ 36.00 19.20 white paw
31 1/2 M APC Min/+ 28.00 21.40 white paw
21 2/3 F APC Min/+ 40.00 23.60 white paw
MEAN 29.49 22.35
Mouse ID Genotype Age at death (weeks)
Weight at death 
(grams)
Disposition of 
mouse at death
40 2/3 M APC Min/+ 33$5Į-/- 15.3 20.2 white paw
37 3/2 M APC Min/+ 33$5Į-/- 28 32.1 white paw
47b 1/3 M APC Min/+ 33$5Į-/- 30.5 28.6 white paw
47a 1/1 M APC Min/+ 33$5Į-/- 28.5 34.2 white paw
47b1/1 F APC Min/+ 33$5Į-/- 32.5 35.5 white paw
40 1/4 F APC Min/+ 33$5Į-/- 30.4 28.1 white paw
41 1/3 M APC Min/+ 33$5Į-/- 29.4 20.7 white paw
44 1/2 F APC Min/+ 33$5Į-/- 23.7 31.8 white paw
42 2/1 F APC Min/+ 33$5Į-/- 21.7 39.3 white paw
40 2/2 M APC Min/+ 33$5Į-/- 36.7 38.75 white paw
40 2/1 M APC Min/+ 33$5Į-/- 30.7 43.1 white paw
52b 1/5 M APC Min/+ 33$5Į-/- 21.5 18.7 white paw
47b 1/1M APC Min/+ 33$5Į-/- 30.8 26.6 white paw
31 2/3 F APC Min/+ 33$5Į-/- 22.5 26.55 white paw
41.1/2 M APC Min/+ 33$5Į-/- 28 35.3 white paw
42 2/3 M APC Min/+ 33$5Į-/- 28 29.9 white paw
37 2/2 M APC Min/+ 33$5Į-/- 35.5 31.8 white paw
37 2/2F APC Min/+ 33$5Į-/- 34.5 25.5 white paw
35 2/3F APC Min/+ 33$5Į-/- 35.5 21.8 white paw
31 2/4F APC Min/+ 33$5Į-/- 33.6 29.7 white paw
MEAN 28.87 29.91
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Figure 3-6 Distribution of age (A) & weight (B) of APCMin/+ & APCMin/+ PPARĮ-/- mice at sacrifice: Study 
1A 
Unpaired t test, *** p <= 0.0001 
 
 
A. Age at sacrifice of mice on Study  1A
B. Weight of mice at sacrifice on Study 1A
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3.4.2 Number of polyps in the mouse colon 
 
The mean number of polyps in the colon of APCMin/+ mice was 0.60 +/- 
0.17, Table 3-7. However, in APCMin/+ PPARĮ-/- mice the mean number 
of polyps (2.10 +/- 0.28) was significantly higher (p < 0.0001, Table 3-8, 
Figure 3-7A). 
A similar profile of results was seen when age of the mice at sacrifice 
was considered. Mean number of polyps per week in the colon of 
APCMin/+ mice was 0.019 +/- 0.006 (Table 3-7), but significantly higher in 
APCMin/+ PPARĮ-/- mice, 0.077 +/- 0.011 (p < 0.0001, Table 3-8, Figure 
3-7B). 
 
3.4.3 Number of polyps in the mouse small bowel 
 
The mean number of polyps in the small bowel of APCMin/+ mice was 
17.80 +/- 1.23 and 19.65 +/- 1.72 in APCMin/+ PPARĮ-/- mice. There was 
no significant difference in number of polyps between the two 
genotypes (Table 3-8, Figure 3-8C).  
Similarly when age of mice at death was considered, there was no 
significant difference in mean number of polyps per week in the small 
bowel, (Figure 3-8D). Number of polyps per week in APCMin/+ mice was 
0.61 +/- 0.04 (Table 3-7), and in APCMin/+ PPARĮ-/- mice was 0.69 +/- 
0.06 (Table 3-8). 
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Table 3-7 Number of polyps in the colon & small bowel of APCMin/+ mice on study 1A 
 
Table 3-8 Number of polyps in the colon & small bowel of APCMin/+ 33$5Į-/- mice on study 1A 
Mouse ID Genotype Colon polyp 
number
Colon polyp 
number/ week
Small bowel 
polyp number
Small bowel polyp 
number/ week
35 1/1 M APC Min/+ 2 0.07 21 0.74
36 1/4 F APC Min/+ 2 0.06 22 0.70
31 1/3 M APC Min/+ 1 0.03 14 0.45
29b 3/3 F APC Min/+ 0 0.00 14 0.50
31 1/2 F APC Min/+ 1 0.03 19 0.63
35 1/4 M APC Min/+ 0 0.00 28 0.93
27b 4/2 M APC Min/+ 0 0.00 19 0.83
24a 5/3 M APC Min/+ 0 0.00 11 0.43
30 1/2 F APC Min/+ 0 0.00 13 0.43
31 6/1 M APC Min/+ 0 0.00 6 0.18
31 2/1 m APC Min/+ 2 0.06 18 0.56
37 1/2 M APC Min/+ 1 0.04 15 0.64
37 1/3 M APC Min/+ 0 0.00 14 0.60
35 1/5M APC Min/+ 0 0.00 20 0.74
28c. 4/1F APC Min/+ 0 0.00 24 0.86
34 2/1 F APC Min/+ 0 0.00 19 0.61
27b 4/1 F APC Min/+ 0 0.00 12 0.40
24a 5/2 M APC Min/+ 1 0.03 18 0.50
31 1/2 M APC Min/+ 1 0.04 22 0.79
21 2/3 F APC Min/+ 1 0.03 27 0.68
MEAN 0.60 0.02 17.80 0.61
Mouse ID Genotype Colon polyp 
number
Colon polyp 
number/ week
Small bowel 
polyp number
Small bowel polyp 
number/ week
40 2/3 M APC Min/+ 33$5Į-/- 1 0.07 14 0.92
37 3/2 M APC Min/+ 33$5Į-/- 5 0.18 20 0.71
47b 1/3 M APC Min/+ 33$5Į-/- 2 0.07 6 0.20
47a 1/1 M APC Min/+ 33$5Į-/- 2 0.07 22 0.77
47b1/1 F APC Min/+ 33$5Į-/- 4 0.12 33 1.02
40 1/4 F APC Min/+ 33$5Į-/- 2 0.07 24 0.79
41 1/3 M APC Min/+ 33$5Į-/- 2 0.07 34 1.16
44 1/2 F APC Min/+ 33$5Į-/- 2 0.08 20 0.84
42 2/1 F APC Min/+ 33$5Į-/- 4 0.18 16 0.74
40 2/2 M APC Min/+ 33$5Į-/- 2 0.05 8 0.22
40 2/1 M APC Min/+ 33$5Į-/- 1 0.03 12 0.39
52b 1/5 M APC Min/+ 33$5Į-/- 2 0.09 20 0.93
47b 1/1M APC Min/+ 33$5Į-/- 3 0.10 10 0.32
31 2/3 F APC Min/+ 33$5Į-/- 2 0.09 13 0.58
41.1/2 M APC Min/+ 33$5Į-/- 2 0.07 19 0.68
42 2/3 M APC Min/+ 33$5Į-/- 3 0.11 25 0.89
37 2/2 M APC Min/+ 33$5Į-/- 0 0.00 24 0.68
37 2/2F APC Min/+ 33$5Į-/- 1 0.03 20 0.58
35 2/3F APC Min/+ 33$5Į-/- 2 0.06 24 0.68
31 2/4F APC Min/+ 33$5Į-/- 0 0.00 29 0.86
MEAN 2.10 0.08 19.65 0.70
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Figure 3-7 Polyp number in the colon of APCMin/+ mice and APCMin/+ PPARĮ-/- mice 
Unpaired t test, *** p < 0.0001 
A. Polyp number in the mouse 
colon
B. Polyp number per week of life 
in the mouse colon
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Figure 3-8 Polyp number in the small bowel of APCMin/+ mice and APCMin/+ PPARĮ-/- mice 
Unpaired t test, ns p > 0.05  
 
 
C. Polyp number in the mouse 
small bowel
D. Polyp number per week of life 
in the mouse small bowel
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3.4.4 Haematoxylin & Eosin staining of mouse colonic tissue 
 
Figure 3-9 (A ± E) shows representative examples of Methylene Blue 
and Haematoxylin and Eosin (H & E) stained normal, polyp and 
adenocarcinoma tissue from the colons of APCMin/+ or APCMin/+ PPARĮ-/- 
mice.  
 
A is an H & E stain of normal colon tissue showing simple columnar 
epithelium (Wheater et al., 1990). 
B shows a colonic polyp with methylene blue stain. C is an H & E stain 
of B. The tissue shows dysplasia indicated by cellular pleomorphism11, 
an increase in nuclear/cytoplasmic ratio12, hyperchromatism of nuclei, 
reduction of goblet cells and infiltration of lamina propria by 
lymphocytes and plasma cells (Wheater et al., 1990).  
D shows an image of a colonic tumour with methylene blue stain from 
an APCMin/+ PPARĮ-/- mouse. The tumour had locally invaded the 
colonic wall to the serosal surface. E is an H & E stain of D showing an 
adenocarcinoma. Tissue is well differentiated as glandular pattern of 
original normal tissue is still apparent, but with hyperchromatism of 
nuclei and a high nuclear/cytoplasmic ratio (Wheater et al., 1990). 
                                            
11
 Pleomorphism: variable size & shape of cells 
12
 Increase in nuclear/cytoplasmic ratio: indicates immature cells 
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Figure 3-9 Methylene blue and Haematoxylin & Eosin stains of mouse colonic tissue  
A. Haematoxylin & Eosin stain of normal 
colon tissue from an APCMin/+ 33$5Į-/-
mouse
B. Methylene Blue 
stained colon 
tissue from an 
APCMin/+ mouse 
showing a polyp 
(x4.2 magnification)
C. Haematoxylin & Eosin stain of colonic 
polyp tissue from an APCMin/+ mouse
D. Methylene blue 
stained colon tissue 
from an APCMin/+
33$5Į-/- mouse 
showing a tumour (x4.2 
magnification)
E. Haematoxylin & 
Eosin stain of 
adenocarcinoma tissue 
from the colon of an 
APCMin/+ 33$5Į-/-
mouse
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3.4.5 Ingenuity® Pathway Analysis (IPA®) of Affymetrix® 
microarray data (Study 1B) 
 
IPA networks of the edited DEG lists from Comparison 1 
(APCMin/+33$5Į-/- normal vs. APCMin/+ normal), Comparison 2 
(APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour), Comparison 3 (APCMin/+ 
normal vs. APCMin/+ tumour) and Comparison 4 (APCMin/+33$5Į-/- 
normal vs. APCMin/+33$5Į-/- tumour), (Appendices pages 311-377) 
were generated (networks not shown).  
The two top scoring biological processes after IPA of both Comparison 
2 and Comparison 3 were growth & proliferation and colorectal cancer. 
Networks of these data only were created and annotated with the 
Wnt/beta catenin, ERK/MAPK (ras) and p53 pathways. Additionally, 
canonical pathways overlaid with Comparison 2 and Comparison 3 data 
were produced. All of these networks are shown and discussed. 
Also, IPA of Comparison 1 and Comparison 4 are reviewed. 
All IPA networks (of Comparisons 1 ± 4, and colorectal cancer, growth 
& proliferation networks of Comparison 2 and Comparison 3) were 
analysed for genes of interest that may be involved in colonic cancer, 
growth & proliferation and 33$5Į pathways.  
Genes from networks and other novel genes were selected for further 
analysis on Taqman® low density arrays based on fold change, p value 
and function, as described previously.  
 
3.4.5.1 Colonic tumorigenesis & the APCMin/+ mouse model 
 
Affymetrix® microarray analysis of colon tissue from Comparison 3 
mice (APCMin/+ normal vs. APCMin/+ tumour) showed there were 1141 
differentially regulated genes between normal and tumour tissue (Figure 
3-3 and Appendices page 378).  
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IPA of these data showed the top biological processes affected by the 
differential expression of genes between normal and tumour tissue in 
APCMin/+ mice, were cellular growth & proliferation (p = 1.03E-10) and 
colorectal cancer (p = 1.66E-07). IPA networks showing gene 
expression data from these two processes were produced (Figure 3-10, 
Figure 3-14). 
Each network was also annotated with the Wnt/beta catenin, 
ERK/MAPK (ras) and p53 canonical pathways. Additionally, gene 
expression data from Comparison 3 was overlaid onto IPA generated 
canonical pathways to produce corresponding networks.   
Table 3-9 and Table 3-10 detail expression data for genes involved in 
cell growth & proliferation. These data were extracted from IPA of 
Comparison 3 Affymetrix® microarray data. 
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Table 3-9 Growth & Proliferation network data for up-regulated genes(Comparison 3 APCMin/+ normal 
vs. APCMin/+ tumour) 
 
Gene Symbol Entrez Gene Name Fold Change p-value
Abcc4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 4.78 2.07E-04
Abcg1 ATP-binding cassette, sub-family G (WHITE), member 1 2.31 3.54E-03
Adam12 ADAM metallopeptidase domain 12 2.89 2.06E-04
Apex1 APEX nuclease (multifunctional DNA repair enzyme) 1 2.16 2.03E-03
Arntl2 aryl hydrocarbon receptor nuclear translocator-like 2 6.70 1.29E-04
Axin2 axin 2 9.42 3.94E-05
Bcl2l11 BCL2-like 11 (apoptosis facilitator) 4.11 1.01E-03
Bmf Bcl2 modifying factor 3.59 3.89E-03
Casp6 caspase 6, apoptosis-related cysteine peptidase 3.16 1.26E-03
Cd47 CD47 molecule 2.07 1.61E-03
Cxcl1 chemokine (C-X-C motif) ligand 2 24.79 2.42E-04
Cxcl2 chemokine (C-X-C motif) ligand 3 20.48 3.26E-03
Dbn1 drebrin 1 2.93 4.02E-04
Dusp4 dual specificity phosphatase 4 7.86 3.70E-04
Ets2 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 2.48 2.05E-04
Gpc1 glypican 1 5.55 1.52E-04
Gpld1 glycosylphosphatidylinositol specific phospholipase D1 3.04 5.53E-04
Gpx1 glutathione peroxidase 1 2.02 1.45E-04
Hoxa9 homeobox A9 2.46 1.92E-03
Htra1 HtrA serine peptidase 1 4.95 4.25E-04
Hunk hormonally up-regulated Neu-associated kinase 3.31 1.62E-04
Il11 interleukin 11 3.96 3.17E-03
Il1rl1 interleukin 1 receptor-like 1 11.33 3.54E-03
Itga6 integrin, alpha 6 2.22 1.31E-03
Jub ajuba LIM protein 7.08 6.56E-06
Lama5 laminin, alpha 5 2.85 3.86E-04
Lcn2 lipocalin 2 22.67 3.14E-03
Mafg v-maf musculoaponeurotic fibrosarcoma oncogene homolog G (avian) 2.97 4.97E-04
Metap2 methionyl aminopeptidase 2 2.05 4.10E-04
Mllt3 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 3 3.01 5.30E-03
Mmp12 matrix metallopeptidase 12 (macrophage elastase) 18.20 5.40E-06
Mmp13 matrix metallopeptidase 13 (collagenase 3) 49.90 1.13E-05
Mmp3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) 8.52 5.45E-03
Myc v-myc myelocytomatosis viral oncogene homolog (avian) 2.40 4.30E-03
Nap1l1 nucleosome assembly protein 1-like 1 2.19 2.75E-03
Pdgfb platelet-derived growth factor beta polypeptide 2.09 1.84E-03
Pea15a phosphoprotein enriched in astrocytes 15 2.92 1.38E-03
Plat plasminogen activator, tissue 14.32 2.71E-04
Prmt1 protein arginine methyltransferase 1 4.75 1.06E-03
Prox1 prospero homeobox 1 34.48 3.11E-06
Ptpre protein tyrosine phosphatase, receptor type, E 3.44 1.23E-03
Ptprz1 protein tyrosine phosphatase, receptor-type, Z polypeptide 1 9.44 4.03E-03
Reg3b regenerating islet-derived 3 alpha 132.99 2.29E-03
Sdc1 syndecan 1 2.04 3.02E-03
Serpine2 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 3.33 4.41E-03
Sox17 SRY (sex determining region Y)-box 17 14.56 4.55E-03
Sox4 SRY (sex determining region Y)-box 4 10.95 4.19E-04
Spp1 secreted phosphoprotein 1 35.21 1.60E-04
T T, brachyury homolog (mouse) 15.53 7.99E-04
Tcf7 transcription factor 7 (T-cell specific, HMG-box) 4.54 5.23E-03
Timp1 TIMP metallopeptidase inhibitor 1 3.82 5.29E-04
Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b 25.72 2.21E-04
Tnfrsf12a tumor necrosis factor receptor superfamily, member 12A 4.03 5.91E-04
Tnfsf9 tumor necrosis factor (ligand) superfamily, member 9 5.42 2.58E-04
Wdr6 WD repeat domain 6 2.51 4.76E-03
Wisp1 WNT1 inducible signaling pathway protein 1 2.29 4.76E-04
UP-REGULATED IN TUMOURS (RED)
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Table 3-10 Growth & Proliferation network data for down-regulated genes(Comparison 3 APCMin/+ 
normal vs. APCMin/+ tumour) 
Gene Symbol Entrez Gene Name Fold Change p-value
Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1 -10.24 2.29E-03
Abcc3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 -4.72 1.43E-03
Abcc9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 -4.30 2.46E-03
Abcg2 ATP-binding cassette, sub-family G (WHITE), member 2 -6.87 3.89E-03
Akap12 A kinase (PRKA) anchor protein 12 -3.43 1.51E-03
Ank2 ankyrin 2, neuronal -2.53 3.87E-03
Bin1 bridging integrator 1 -2.15 1.55E-03
Cacna2d2 calcium channel, voltage-dependent, alpha 2/delta subunit 2 -2.49 1.55E-03
Cbs cystathionine-beta-synthase -3.23 1.78E-03
Ccng2 cyclin G2 -2.13 2.88E-03
Cd36 CD36 molecule (thrombospondin receptor) -5.35 5.60E-04
Cspg4 chondroitin sulfate proteoglycan 4 -2.76 6.30E-04
Cth cystathionase (cystathionine gamma-lyase) -5.55 4.50E-04
Ddr2 discoidin domain receptor tyrosine kinase 2 -3.04 7.76E-04
Des desmin -10.37 2.78E-03
Entpd5 ectonucleoside triphosphate diphosphohydrolase 5 -7.05 1.57E-03
Epas1 endothelial PAS domain protein 1 -2.29 3.65E-04
Epb4.1l3 erythrocyte membrane protein band 4.1-like 3 -2.49 1.96E-03
Esrrg estrogen-related receptor gamma -5.04 2.78E-04
Fbln2 fibulin 2 -2.06 5.78E-03
Fgf13 fibroblast growth factor 13 -2.82 2.97E-03
Foxo3 forkhead box O3 -2.07 5.72E-04
Fxyd1 FXYD domain containing ion transport regulator 1 -4.55 1.53E-04
Fzd5 frizzled family receptor 5 -3.10 8.61E-04
Gli2 GLI family zinc finger 2 -2.28 1.71E-03
Gstm2 glutathione S-transferase mu 1 -4.81 8.06E-04
Hhip hedgehog interacting protein -3.91 4.26E-04
Hlx H2.0-like homeobox -2.06 1.96E-03
Hnf4a hepatocyte nuclear factor 4, alpha -2.35 1.50E-03
Ifi30 interferon, gamma-inducible protein 30 -2.02 5.79E-04
L1cam L1 cell adhesion molecule -3.42 5.66E-03
Mxd1 MAX dimerization protein 1 -3.37 1.62E-03
Myh14 myosin, heavy chain 14, non-muscle -2.17 1.50E-03
Myl9 myosin, light chain 9, regulatory -6.94 4.31E-04
Nr1i2 nuclear receptor subfamily 1, group I, member 2 -2.03 2.02E-03
Nr3c1 nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) -2.24 5.22E-03
Nr3c2 nuclear receptor subfamily 3, group C, member 2 -4.48 1.97E-03
Ntn1 netrin 1 -5.71 4.21E-04
Pde3a phosphodiesterase 3A, cGMP-inhibited -2.65 3.97E-03
Postn periostin, osteoblast specific factor -2.58 3.09E-03
Sdc2 syndecan 2 -3.10 4.34E-03
Slc22a18 solute carrier family 22, member 18 -2.28 9.25E-04
Synm synemin, intermediate filament protein -13.41 1.28E-03
Tgfb1i1 transforming growth factor beta 1 induced transcript 1 -2.51 1.19E-04
Tgfb3 transforming growth factor, beta 3 -2.14 4.85E-03
Tgfbr3 transforming growth factor, beta receptor III -5.61 1.94E-03
Trpm6 transient receptor potential cation channel, subfamily M, member 6 -7.92 4.12E-03
Txnip thioredoxin interacting protein -2.31 3.67E-03
Vip vasoactive intestinal peptide -20.36 5.45E-03
DOWN-REGULATED IN TUMOURS (GREEN)
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Figure 3-10 shows a network of differentially expressed genes 
associated with growth & proliferation between tumour and normal 
colonic tissue in the APCMin/+ mouse. The network was annotated with 
the Wnt/ȕ catenin, ERK/MAPK and p53 pathways.  
Figure 3-11, Figure 3-12 and Figure 3-13 show Comparison 3 gene 
expression data overlaid onto IPA canonical Wnt/ȕ catenin, ERK/MAPK 
and p53 pathways respectively. 
Figure 3-10 and Figure 3-11 show the Wnt/ȕ catenin pathway affected 
the differential regulation of several genes in tumour tissue that have 
previously been shown to be involved in development of cancer 
(Doucas et al., 2005, Zhai et al., 2002).  
These genes are listed below. The figures in brackets are fold change 
and p value of expression of each gene in tumour tissue compared to 
normal tissue (Table 3-9 and Table 3-10).  
x Myelocytomatosis oncogene (Myc, fold change (FC) 2.40ј, p = 
4.30E-03) 
x CyclinD1 (Ccnd1, FC 2.85ј, p = 2.60E-03) 
x Transcription factor 4 (Tcf4, FC 4.11ј, p = 2.18E-04) 
x Axin2 (FC 9.42ј, p = 3.94E-05) 
x Sox4 (SRY-sex determining region Y ± box 4, FC 10.95ј, p = 
4.19E-04) 
x Sox17 (SRY-sex determining region Y) ± box 17, FC 14.56ј, p 
= 4.55E-03) 
x Matrix metallopeptidase 7 (Mmp7, FC 78.28ј, p = 1.86E-04) 
x Frizzled family receptor 5 (Fzd5, FC 3.10љ, p = 8.61E-04) 
Myc is well known to be a critical mediator of neoplasia in the 
gastrointestinal tract when function of the APC gene is lost (Sansom et 
al., 2007).  
Another study by (Sansom et al., 2005) demonstrated that up-regulation 
of Cyclin D1 was not an immediate effect of APC loss of function, 
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suggesting the gene may be involved in tumour progression but not 
initiation.  
Also, an earlier study by (Roose et al., 1999) showed that mutations in 
the APC or ȕ catenin genes and aberrant Wnt/ȕ catenin signalling 
caused inappropriate activation of Tcf4. Thus, deregulated Tcf4 
expression was shown to affect transformation of intestinal epithelial 
cells in mice via up-regulation of target genes, for example Myc.  
Axin2 is known to act as a negative regulator of canonical Wnt/ȕ catenin 
signalling in normal cells (Leung et al., 2002). However, a recent study 
has demonstrated that in tumour cells Axin2 acts as a potent tumour 
promoter via up-regulation of transcriptional repressor Snai1 which 
drives metastatic activity (Wu et al., 2012). 
The SOX family of transcription factors has emerged as modulators of 
ȕ-catenin/TCF activity. SOX proteins are able to repress or enhance 
Wnt transcriptional responses, and expression of several Sox genes are 
regulated by Wnts (Kormish et al., 2010). 
Several studies have shown that Sox gene expression is deregulated in 
human cancers. SOX proteins can be either transcriptional activators or 
repressors depending on cell type. Sox17 has been shown to be 
epigenetically silenced13 in human colorectal cancer and appears to act 
as a tumour suppressor (Zhang et al., 2008). However, Sox4 was 
shown to be over expressed in tumours and appears to act as an 
oncogene (Reichling et al., 2005, Andersen et al., 2009).  
Mmp7 is known to be up-regulated in colon cancer  (Kioi et al., 2003). 
Elevated expression of Mmp7 has been shown to be a poor prognostic 
indicator in colon cancer (Koskensalo et al., 2011).  
Lastly, Fzd5 is a 7-transmembrane domain protein which functions as 
the receptor for the Wnt5A ligand as part of the Wnt/ȕ catenin signalling 
pathway (Saitoh et al., 2001).  
                                            
13
 Epigenetic silencing: change in gene expression caused by mechanisms other than alteration of the DNA 
sequence 
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Figure 3-10 and Figure 3-12 show Myc may also be up-regulated by 
ERK/MAPK signalling (Seger and Krebs, 1995, Cheng et al., 1999). As 
discussed earlier, mutations of components of the ERK/MAPK pathway, 
such as ras or b-raf can lead to deregulated activation of target genes 
such as Myc, and development of cancer (McCubrey et al., 2007). 
v-ets erythroblastosis virus E26 oncogene homolog 2 (Ets2, FC 2.48ј, 
p = 2.05E-04) has also been shown to have a role in tumorigenesis in 
the colon. A study by (Munera et al., 2011) showed that loss of Ets2 in 
colonic stem cells may increase the number or sensitivity of these cells 
for tumour initiation. Indeed, their study demonstrated that mice with 
Ets2 deficient intestinal cells developed more colonic tumours in 
response to treatment with azoxymethane and dextran sulfate sodium 
(DSS). An earlier study identified intestinal stem cells as the cell of 
origin of intestinal tumorigenesis in mice (Barker et al., 2009). 
Figure 3-10 and Figure 3-13 show Caspase 6, apoptosis-related 
cysteine peptidase (Casp6, FC 3.16ј, p = 1.26E-03) and Apoptotic 
peptidase activating factor 1 (Apaf1, FC 2.44ј, p = 3.00E-03) were 
transcriptional targets of the p53 pathway (Hammond et al., 2006).  
Both genes have a role in apoptosis within the cell. Induction of Casp6 
expression which has an important role in the execution phase of 
apoptosis, has been shown to lower the cell death threshold in 
response to activation by apoptotic signals (MacLachlan and El-Deiry, 
2002).  
However, data from the present study showed up-regulation of Casp6 in 
tumour tissue that may be explained by the findings of a study by (Lee 
et al., 2006) which demonstrated Casp6 was up-regulated in human 
colorectal and gastric carcinomas. Their study identified mutations in 
the Casp6 gene that could be implicated in the development of these 
cancers. 
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Figure 3-10 Growth & Proliferation network from Comparison 3 (APCMin/+ normal vs. APCMin/+ tumour) annotated with the Wnt/beta catenin, p53 & ERK/MAPK pathways 
Genes in red are up-regulated in tumours, genes in green are down-regulated in tumours. Network p value, p = 1.03E-10 
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Figure 3-11 Canonical Wnt/beta catenin pathway & gene expression data from Comparison 3 (APCMin/+ normal vs. APCMin/+ tumour) Genes in red are up-regulated in tumours, genes in 
green are down-regulated in tumours.
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Figure 3-12 Canonical ERK/MAPK (ras) pathway & gene expression data from Comparison 3 (APCMin/+ normal vs. APCMin/+ tumour) Genes in red are up-regulated in tumours, genes in 
green are down-regulated in tumours.
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Figure 3-13 Canonical p53 pathway & gene expression data from Comparison 3 (APCMin/+ normal vs. APCMin/+ tumour) Genes in red are up-regulated in tumours, genes in green are 
down-regulated in tumours.
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Table 3-11 details gene expression data from Comparison 3 for genes 
involved in colorectal cancer. These data were extracted from IPA of 
Comparison 3 Affymetrix® microarray data.  
Figure 3-14 shows a network of differentially expressed genes 
associated with colorectal cancer between tumour and normal colonic 
tissue in the APCMin/+ mouse. The network was annotated with the 
Wnt/beta catenin, ERK/MAPK and p53 pathways as before.  
Figure 3-14 (see also Figure 3-11 and Figure 3-12) shows Myc (FC 
2.40ј, p = 4.30E-03) was targeted by Wnt/ȕ catenin and ERK/MAPK 
signalling as described previously. 
Other targets of Wnt/ȕ catenin signalling were Transforming growth 
factor beta 3 (Tgfȕ3, FC 2.14љ, p = 4.85E-03) and Transforming growth 
factor receptor beta 3 (Tgfrȕ3, FC 5.61љ, p = 1.94E-03), which are part 
of the Transforming growth factor beta (Tgfȕ) signalling pathway.  
The Tgfȕ pathway is involved in many cellular processes including cell 
differentiation, cell growth, apoptosis, cellular homeostasis and other 
cellular functions.  
A study by (Mishra et al., 2005) suggests there is an interaction 
between Tgfȕ signalling and Wnt ȕ catenin signalling in development of 
intestinal cancers. In normal intestinal epithelial cells growth inhibition is 
the predominant influence. Briefly, Tgfȕ ligands bind to a type II 
serine/threonine kinase receptor, which then attach and phosphorylate 
a type I receptor. The type I receptor then phosphorylates a receptor-
regulated SMAD gene, for example SMAD2 (JV18-1) which then bind 
SMAD4 (DPC4). These SMAD/SMAD4 complexes translocate to the 
nucleus and activate target genes including p53 and Tgfȕ 11 receptor 
(Shi and Massague, 2003).  
Mutations frequently occur in Tgfȕ 11 receptors (Massague et al., 2000), 
SMAD2 and SMAD4 (Fearon and Vogelstein, 1990, Kinzler and 
Vogelstein, 1996).  Therefore, this would make the Tgfȕ signalling 
pathway vulnerable to disruption in colorectal cancer (CRC). Also, 
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constitutive activation of ȕ catenin/Tcf4 complexes leading to 
unregulated transcription of Myc is characteristic of CRC (Doucas et al., 
2005, Zhai et al., 2002).  
Figure 3-14 shows that Wnt ȕ catenin signalling affected down-
regulation of components of the Tgfȕ signalling pathway with 
concomitant up-regulation of Myc in tumour tissue.  
Figure 3-14 (see also Figure 3-13) shows Cyclin-dependent kinase 4 
(Cdk4, FC 2.72ј, p = 4.47E-03) was a target of p53 signalling. Cdk4 is 
a cell cycle regulator involved in early G1 cell cycle progression. A 
study by (Abedin et al., 2010) suggests deregulated Cdk4 expression 
plays an important role in angiogenesis during intestinal tumour 
formation via the up-regulation of E2F transcription factor 1 (E2F114) 
target proteins Vascular endothelial growth factor b (Vegf-b) and Cyclin 
A (Ccna). 
Figure 3-10 and Figure 3-11 show that several ATP-binding cassette 
(ABC) genes were differentially expressed in tumour tissue compared to 
normal tissue; Abcc4 (FC 4.78ј, p = 2.07E-04), Abcg1 (FC 2.31ј, p = 
3.54E-03), Abcb1a (FC 10.24љ, p = 2.29E-03), Abcc3 (FC 4.72љ, p = 
1.43E-03), Abcc9 (FC 4.30љ, p = 2.46E-03) and Abcg2 (FC 6.87љ, p = 
3.89E-03). 
The ABC superfamily of genes code for membrane proteins that play an 
important role in normal tissue throughout the body. They regulate the 
transport of substrates including fats, sugars, amino acids, 
phospholipids and drugs. They protect the blood-brain barrier (BBB), 
blood-cerobrospinal fluid (CSF) barrier and placenta from cytotoxins, 
and excrete toxins from the liver, gastrointestinal tract and kidneys.  
The proteins all share a common domain that binds ATP; they are 
divided into subfamilies based on their structure and phylogenetic 
analysis (Dean, 2005). 
                                            
14
 E2F1 transcription activator, major role in G1/S transition 
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Many of these proteins are important in the development of resistance 
to cancer therapies (multidrug resistance ± MDR). Cancer cells can 
become resistant by increased activity of different ABC transporter 
proteins; for example, the protein product of Abcb1, a P-glycoprotein is 
a broad spectrum multidrug efflux pump. Also, the Abcc sub-group of 
transporters are known to be multidrug resistance proteins. Some anti-
cancer therapies are poor substrates for certain transporters; multi-drug 
resistance is acquired by cancer cells by expression of other 
transporters such as Abcg2 (also known as mitoxanthrone-resistance 
gene) (Gottesman et al., 2002). 
Detection and expression levels of ABC genes could be used as 
candidate markers for colorectal cancer and to inform the 
chemotherapy that would be most effective in treatment.  
The differences in expression of the ABC genes seen in this study may 
imply that they have important pharmacological and physiological roles 
in colon cancer in the mouse.   
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Table 3-11 Colorectal Cancer network data (Comparison 3 APCMin/+ normal vs. APCMin/+ tumour)  
Gene Symbol Entrez Gene Name Fold Change p-value Gene Symbol Entrez Gene Name Fold Change p-value
CDK4 cyclin-dependent kinase 4 2.72 4.47E-03 ABCB1A ATP-binding cassette, sub-family B (MDR/TAP), member 1 -10.24 2.29E-03
GPX1 glutathione peroxidase 1 2.02 1.45E-04 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 -4.72 1.43E-03
HDAC2 histone deacetylase 2 2.12 2.96E-03 ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 -6.87 3.89E-03
HOXA9 homeobox A9 2.46 1.92E-03 ACTA2 actin, alpha 2, smooth muscle, aorta -3.88 2.10E-04
ITGA6 integrin, alpha 6 2.22 1.31E-03 CACNB2 calcium channel, voltage-dependent, beta 2 subunit -2.26 3.54E-03
KRT18 keratin 18 2.25 8.48E-04 CAR2 carbonic anhydrase II -2.81 2.24E-03
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 2.40 4.30E-03 CD36 CD36 molecule (thrombospondin receptor) -5.35 5.60E-04
PATZ1 POZ (BTB) and AT hook containing zinc finger 1 2.77 1.19E-03 CLCN2 chloride channel, voltage-sensitive 2 -2.85 6.10E-04
SDC1 syndecan 1 2.04 3.02E-03 CLIC5 chloride intracellular channel 5 -6.87 5.21E-03
TUBB5 tubulin, beta class I 2.81 1.05E-03 CRYL1 crystallin, lambda 1 -3.78 9.53E-04
WISP1 WNT1 inducible signaling pathway protein 1 2.29 4.76E-04 DES desmin -10.37 2.78E-03
ZC3H12C zinc finger CCCH-type containing 12C 2.22 5.08E-03 DPYD dihydropyrimidine dehydrogenase -11.78 1.33E-03
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 -4.50 7.11E-04
Gene Symbol Entrez Gene Name Fold Change p-value EPAS1 endothelial PAS domain protein 1 -2.29 3.65E-04
EPB4.113 erythrocyte membrane protein band 4.1-like 3 -2.49 1.96E-03
ARID5B AT rich interactive domain 5B (MRF1-like) 2.70 0.11 GLI2 GLI family zinc finger 2 -2.28 1.71E-03
EIF1AD eukaryotic translation initiation factor 1A domain containing 1.18 0.24 GREM2 gremlin 2 -9.75 5.37E-04
HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 1.36 0.37 GSTM2 glutathione S-transferase mu 1 -4.81 8.06E-04
KIAA1704 RIKEN cDNA 1200011I18 gene 1.14 0.36 GSTT1 glutathione S-transferase theta 1 -4.50 1.35E-05
PAQR7 progestin and adipoQ receptor family member VII 1.00 0.99 GUCY2C guanylate cyclase 2C (heat stable enterotoxin receptor) -2.49 1.82E-03
PSME4 proteasome (prosome, macropain) activator subunit 4 1.19 0.43 HHIP hedgehog interacting protein -3.91 4.26E-04
RNF6 ring finger protein (C3H2C3 type) 6 1.11 0.68 HNF4A hepatocyte nuclear factor 4, alpha -2.35 1.50E-03
SERINC2 serine incorporator 2 1.43 0.25 LPAR1 lysophosphatidic acid receptor 1 -2.35 5.05E-03
STAT1 signal transducer and activator of transcription 1 1.47 0.65 MEIS1 Meis homeobox 1 -3.72 2.46E-04
TGFB transforming growth factor, beta 1.07 0.74 MGLL monoglyceride lipase -6.03 3.44E-03
UBC ubiquitin C 1.18 0.63 MYLK myosin light chain kinase -6.59 3.44E-04
ZFP161 zinc finger protein 161 1.08 0.78 NDRG4 NDRG family member 4 -2.56 3.41E-03
CROT carnitine O-octanoyltransferase -1.21 0.78 PLD1 phospholipase D1, phosphatidylcholine-specific -2.25 1.65E-03
MLC1 myosin, light polypeptide 1 -1.22 0.28 PLSCR4 phospholipid scramblase 4 -2.04 1.43E-03
progesterone progesterone -1.03 0.93 PPARa peroxisome proliferator-activated receptor alpha -3.94 5.57E-03
SLC26A1 solute carrier family 26 (sulfate transporter), member 1 -2.14 0.47 QPCT glutaminyl-peptide cyclotransferase -3.08 2.31E-03
TLR4 toll-like receptor 4 -1.01 0.66 SELENBP1 selenium binding protein 1 -16.93 2.47E-03
UST uronyl-2-sulfotransferase -1.24 0.31 SGK2 serum/glucocorticoid regulated kinase 2 -8.09 5.39E-03
SLC26A2 solute carrier family 26 (sulfate transporter), member 2 -7.37 4.69E-03
STMN2 stathmin-like 2 -3.39 3.38E-03
SYNE1 spectrin repeat containing, nuclear envelope 1 -2.06 2.35E-03
SYNM synemin, intermediate filament protein -13.41 1.28E-03
TGFB3 transforming growth factor, beta 3 -2.14 4.85E-03
TGFBR3 transforming growth factor, beta receptor III -5.61 1.94E-03
VDR vitamin D (1,25- dihydroxyvitamin D3) receptor -7.48 2.50E-03
UP-REGULATED IN TUMOURS (RED) DOWN-REGULATED IN TUMOURS (GREEN)
NO SIGNIFICANT CHANGE IN EXPRESSION (NO COLOUR)
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Figure 3-14 Colorectal Cancer network of Comparison 3 (APCMin/+ normal vs. APCMin/+ tumour) annotated with the ERK/MAPK, Wnt/beta catenin & p53 pathways 
Genes in red are up-regulated in tumours, genes in green are down-regulated in tumours. Network p value, p = 1.66E-07 
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3.4.5.2 The effect of PPARĮ deletion in the APCMin/+ mouse model; 
tumorigenesis & gene expression in the colon 
 
Affymetrix® microarray analysis of Comparison 2 (APCMin/+33$5Į-/- 
tumour vs. APCMin/+ tumour) tumour tissue from the colons of mice 
found 504 genes were differentially regulated between APCMin/+PP$5Į-
/-
 mice and APCMin/+ mice (Figure 3-4 and Appendices page 378).  
IPA analysis showed the top biological processes affected by the 
differential expression of genes between tumour tissue in 
APCMin/+33$5Į-/- mice and APCMin/+ mice, were also cellular growth & 
proliferation (p = 3.14E-10) and colorectal cancer (p = 5.67E-04). 
Networks showing gene expression data from these two processes 
were generated (Figure 3-15 and Figure 3-18).  
Each network was also annotated with the Wnt/beta catenin and 
PPARĮ canonical pathways. Additionally, gene expression data from 
Comparison 2 was overlaid onto IPA generated canonical pathways to 
produce corresponding networks.   
Table 3-12 details gene expression data for cell growth & proliferation of 
genes from Comparison 2 (APCMin/+33$5Į-/- tumour vs. APCMin/+ 
tumour). These data were extracted from IPA of Comparison 2 
Affymetrix® microarray data. 
Figure 3-15 shows a network of differentially expressed genes 
associated with growth & proliferation between tumours in 
APCMin/+33$5Į-/- mice and APCMin/+ mice. The network was annotated 
with the Wnt/ȕ catenin and 33$5Į pathways.  
Figure 3-15 and Figure 3-16 show genes targeted by Wnt/ȕ catenin 
signalling;  
x Transforming growth factor beta receptor 3 (Tgfȕr3, FC 2.57ј, p 
= 0.03)  
x Gap protein alpha 1/Connexin 43 (GjĮ1/CX43, FC 2.48ј, p = 
0.02)  
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x Secreted frizzled-related protein 1 (Sfrp1, FC 6.15ј, p = 0.05) 
Tgfȕr3 and the associated signalling pathway were described previously. 
Data from the present study showed that in APCMin/+ mice (Comparison 
3), Tgfȕr3 was down-regulated in tumour tissue compared to normal 
tissue.  
However, Tgfȕr3 was up-regulated in tumour tissue in APCMin/+33$5Į-/- 
mice compared to tumour tissue in APCMin/+ mice (Comparison 2).  
Figure 3-15 shows Tgfȕr3 was also a target of 33$5Į/RXRĮ signalling. 
Taken together, these data may infer 33$5Į exerts an inhibitory effect 
in expression of Tgfȕr3. 
GjĮ1 functions in control of cell growth and differentiation, and has been 
shown to be down-regulated in human cancers (Mesnil et al., 2005). A 
recent study by (Sirnes et al., 2012) found that GjĮ1 was down-
regulated in colon cancer cell lines and colorectal carcinomas. Further, 
their study demonstrated that GjĮ1 co-ORFDOLVHGZLWKȕ-catenin to down-
regulate the Wnt signalling pathway and increase apoptosis. Therefore, 
they concluded that GjĮ1 functions as a colorectal cancer tumour 
suppressor protein. 
A recent study has presented evidence to suggest that Sfrp1 may 
suppress tumour formation by functioning as a mediator of senescence 
via LQKLELWLRQ RI :QWȕ FDWHQLQ VLJQDOOLQJ DQG DFWLYDWLRQ RI WKH
retinoblastoma (Rb) pathway. In addition, mutations in the Sfrp1 gene, 
as have previously been identified in human cancers (Bovolenta et al., 
2008), may impair the senescence-inducing activity of Sfrp1 (Elzi et al., 
2012).  
Figure 3-15 and Figure 3-17 show Interleukin 6 (Il6, FC 7.36ј, p = 
7.34E-03) was targeted by 33$5Į/RXRĮ signalling. 
Il6 has been shown to be an important tumour promoting cytokine. 
Briefly, Il6 is secreted by cells of the innate or adaptive immune system 
and then binds to soluble Il6 receptor (sIl6r). This complex interacts with 
gp130 on tumour cells to induce activation of Janus kinases (JAKs) and 
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phosphorylation of signal transducer and activator transcription 3 
(STAT3). Phosphorylated STAT3 then translocates to the nucleus to 
induce transcription of target genes to promote proliferation, cell growth 
and inhibition of apoptosis (Waldner et al., 2012).  
Il6 expression has been demonstrated to be associated with tumour 
stage, size, metastasis and prognosis in patients with colorectal cancer 
(Knupfer and Preiss, 2010). 
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Table 3-12 Growth & Proliferation network data (Comparison 2 APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour) 
 
Gene Symbol Entrez Gene Name Fold Change p value
CCL11 chemokine (C-C motif) ligand 11 3.58 8.54E-03
CCL13 chemokine (C-C motif) ligand 13 4.07 1.05E-02
CNTN1 contactin 1 4.66 5.42E-03
COL14A1 collagen, type XIV, alpha 1 3.74 3.03E-02
CSF2 colony stimulating factor 2 (granulocyte-macrophage) 2.43 1.41E-02
Cxcl12 chemokine (C-X-C motif) ligand 12 2.47 1.43E-02
DCN decorin 1.77 8.12E-03
EDNRA endothelin receptor type A 2.22 4.91E-02
ELN elastin 1.93 4.56E-02
GHR growth hormone receptor 2.23 2.68E-03
GJA1 gap junction protein, alpha 1, 43kDa 2.48 1.50E-02
HIF1A hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) 1.78 4.45E-02
IL13RA1 interleukin 13 receptor, alpha 1 1.90 4.60E-03
IL13RA2 interleukin 13 receptor, alpha 2 1.90 4.79E-02
IL6 interleukin 6 (interferon, beta 2) 7.36 7.34E-03
ITGAM integrin, alpha M (complement component 3 receptor 3 subunit) 2.40 2.86E-02
ITGAV integrin, alpha V 1.77 1.34E-02
LILRB3 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3 2.57 6.41E-03
LOX lysyl oxidase 1.75 2.10E-02
LUM lumican 9.47 2.30E-02
OSMR oncostatin M receptor 2.50 1.58E-02
PLAUR plasminogen activator, urokinase receptor 2.44 1.13E-03
PYCARD PYD and CARD domain containing 2.03 3.67E-02
RECK reversion-inducing-cysteine-rich protein with kazal motifs 1.91 1.40E-02
S1PR3 sphingosine-1-phosphate receptor 3 2.21 4.88E-02
SOCS2 suppressor of cytokine signaling 2 1.87 2.61E-02
TGFBR3 transforming growth factor, beta receptor III 2.57 3.34E-02
TNC (includes EG:116640) tenascin C 2.23 4.68E-02
VCAN versican 2.48 5.25E-03
Gene Symbol Entrez Gene Name Fold Change p value
CISH cytokine inducible SH2-containing protein -1.84 9.69E-03
EDN3 endothelin 3 -1.96 3.15E-02
GPNMB glycoprotein (transmembrane) nmb -6.69 8.33E-05
IRAK4 interleukin-1 receptor-associated kinase 4 -3.90 9.91E-04
MMP14 matrix metallopeptidase 14 (membrane-inserted) -2.20 3.46E-02
TBX3 T-box 3 -2.95 3.15E-02
UP-REGULATED IN APCMin/+ 33$5Į-/- TUMOURS (RED)
DOWN-REGULATED IN APC Min/+ 33$5Į-/- TUMOURS (GREEN)
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Figure 3-15 Growth & Proliferation network of Comparison 2 (APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour) annotated with the Wnt/beta catenin & 33$5Į5;5Į pathways 
Network p value, p = 3.14E-10 
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Figure 3-16 Canonical Wnt/beta catenin pathway & gene expression data from Comparison 2 (APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour)
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Figure 3-17 Canonical PPAR signalling & gene expression data from Comparison 2 (APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour
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Table 3-13 details gene expression data for colorectal cancer of genes 
from Comparison 2 (APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour). 
These data were extracted from IPA of Comparison 2 Affymetrix® 
microarray data. 
Figure 3-18 shows a network of differentially expressed genes 
associated with colorectal cancer between tumours in APCMin/+33$5Į-/- 
mice and APCMin/+ mice. The network was annotated with the Wnt/beta 
catenin and 33$5Į pathways as before.  
Figure 3-18 (see also Figure 3-16) show Wnt/ȕ catenin signalling 
targeted Sfrp1 (FC 6.15ј, p = 0.05) and GjĮ1 (FC 2.48, p = 0.02) as 
explained before.  
Also, 33$5Į5;5Į signalling (see Figure 3-17) targeted Il6 (FC 7.36ј, 
p = 7.34E-03) as described previously. 
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Table 3-13 Colorectal Cancer network data (Comparison 2 APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour) 
Gene Symbol Entrez Gene Name Fold change p-value
ANGPTL4 angiopoietin-like 4 2.16 3.55E-02
CNNM4 cyclin M4 2.07 4.03E-02
EPB41L3 erythrocyte membrane protein band 4.1-like 3 1.76 1.04E-02
GJA1 gap junction protein, alpha 1, 43kDa 2.48 1.50E-02
GSTM1 glutathione S-transferase mu 1 1.77 1.62E-02
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 2.17 7.58E-03
HIF1A hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) 1.78 4.45E-02
IGFBP5 insulin-like growth factor binding protein 5 2.48 4.58E-02
IL6 interleukin 6 (interferon, beta 2) 7.36 7.34E-03
KLF6 Kruppel-like factor 6 1.98 1.88E-02
NDRG4 NDRG family member 4 1.91 4.02E-02
NRP1 (includes EG:18186) neuropilin 1 1.79 4.43E-02
OSMR oncostatin M receptor 2.50 1.58E-02
P4HA1 prolyl 4-hydroxylase, alpha polypeptide I 2.17 1.84E-02
PLAUR plasminogen activator, urokinase receptor 2.44 1.13E-03
PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 1.97 1.31E-02
SFRP1 secreted frizzled-related protein 1 6.15 4.73E-02
TBC1D4 TBC1 domain family, member 4 2.03 4.87E-02
TFF3 trefoil factor 3 (intestinal) 2.15 3.46E-02
TNC (includes EG:116640) tenascin C 2.23 4.68E-02
Gene Symbol Entrez Gene Name Fold change p-value
B3GNT2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 1.18 > 0.05
GALE UDP-galactose-4-epimerase 1.24 0.07
IL17RC interleukin 17 receptor C 1.04 0.63
KIAA1522 C77080 1.32 > 0.05
POU2F1 POU class 2 homeobox 1 1.00 0.97
SNX10 sorting nexin 10 1.64 > 0.05
TMEM9B TMEM9 domain family, member B 1.32 0.13
UBC ubiquitin C 1.20 0.27
GINS1 GINS complex subunit 1 (Psf1 homolog) -1.29 0.09
KLK8 kallikrein-related peptidase 8 -1.02 0.84
MARCH7 membrane-associated ring finger (C3HC4) 7, E3 ubiquitin protein ligase -1.08 0.41
SLC39A14 solute carrier family 39 (zinc transporter), member 14 -1.13 0.43
SMOX spermine oxidase -1.18 > 0.05
TBC1D9 TBC1 domain family, member 9 (with GRAM domain) -1.07 0.03
TTYH1 tweety homolog 1 (Drosophila) -1.42 0.51
NO SIGNIFICANT CHANGE IN EXPRESSION (NO COLOUR)
UP-REGULATED IN APCMin/+ 33$5Į-/- TUMOURS (RED)
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Figure 3-18 Colorectal Cancer network of Comparison 2 (APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour) annotated with the Wnt/beta catenin & 33$5Į5;5ĮSDWKZD\V 
Network p value, p = 5.67E-04
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3.4.5.3 Ingenuity® Pathway Analysis (IPA®) of Comparison 1 & 
Comparison 4 
 
An overview of results for IPA of Comparison 1 (APCMin/+33$5Į-/- 
normal vs. APCMin/+ normal) and Comparison 4 (APCMin/+33$5Į-/- 
normal vs. APCMin/+33$5Į-/- tumour) are below.  
x Comparison 1 (APCMin/+PPARĮ-/- normal vs. APCMin/+ normal) 
Affymetrix® microarray analysis of normal colonic tissue found only 52 
genes were differentially expressed between APCMin/+33$5Į-/- mice 
and APCMin/+ mice (Figure 3-4 and Appendices page 378). IPA of these 
data showed the top biological function was lipid metabolism (p = 
6.10E-03). However, the IPA network showed no genes were 
highlighted when annotated with the 33$5Į/RXRĮ and Wnt/ȕ catenin 
signalling pathways.  
Therefore, these data taken together indicate that deletion of PPARĮ 
had little effect on gene expression in normal tissue of the colon. 
x Comparison 4 (APCMin/+PPARĮ-/- normal vs. APCMin/+PPARĮ-/- 
tumour) 
Affymetrix® microarray analysis of colon tissue from APCMin/+33$5Į-/- 
mice found there were 1181 differentially regulated genes between 
normal and tumour tissue in these mice (Figure 3-3 and Appendices 
page 378).  
IPA analysis of these data indicated the two top biological processes 
affected by the differential expression of genes between normal and 
tumour tissue in APCMin/+33$5Į-/- mice, were cancer (p = 1.61E-21) 
and cellular growth & proliferation (p = 1.47E-14).  
Expression of several genes was significantly up-regulated in tumour 
tissue. Genes included GjĮ1 (FC 2.12ј, p = 7.28E-04), Mmp7 (FC 
63.93ј, p = 1.26E-08) and Myc (FC 2.40ј, p = 1.55E-06). Also, two 
genes associated with the Wnt/ȕ Catenin signalling pathway were 
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differentially-regulated in tumour tissue including Myc and Tgfȕr (FC 
2.5љ, p = 6.65E-04). Expression of these genes in tumour tissue has 
been discussed previously. 
In summary, IPA results and analysis of Comparison 3 (APCMin/+ normal 
vs. APCMin/+ tumour) growth & proliferation and colorectal cancer 
networks, and canonical pathways associated with tumorigenesis; 
Wnt/beta catenin, ERK/MAPK and p53, clearly demonstrated the 
differential expression of genes and activation of pathways involved in 
these processes. IPA highlighted many genes that have previously 
been shown to be involved in tumorigenesis in the colon. In addition, 
the high number of differentially expressed genes in tumour tissue 
compared to normal tissue is as would be expected in the APCMin/+ 
mouse model used in these studies. 
Also, IPA results and analysis of Comparison 2 (APCMin/+33$5Į-/- 
tumour vs. APCMin/+ tumour) growth & proliferation and colorectal cancer 
networks, the Wnt/ȕ catenin and 33$5Į/RXRĮ pathways, showed 
there were far fewer differentially expressed genes between 
APCMin/+33$5Į-/- tumour tissue and APCMin/+ tumour tissue (504), than 
between APCMin/+ normal tissue and  APCMin/+ tumour tissue (1141).  
Therefore, genes highlighted on the IPA networks may indicate that any 
differential expression is due to the effect of 33$5Į. A key regulatory 
gene was demonstrated to be Il6.  
 
3.4.6 Genes selected for analysis & verification on Taqman® low 
density arrays 
 
Table 3-14 lists the reference genes chosen for normalisation of the 95 
genes selected for validation by Taqman® low density arrays.  
Expression data from all 18 arrays (samples) for each of the selected 
reference genes is shown. The antilog2 of intensity values were 
calculated which were used to determine the mean and standard 
deviation for each reference gene for all 18 samples. These data 
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confirmed that the expression level for each reference gene in all 
samples were within three standard deviations of the mean (three-
sigma rule15, (Ruan, 2005). Therefore, this showed expression of each 
reference gene was invariant across each array. 
The final list of genes selected for analysis and verification on Taqman® 
low density arrays are presented in Table 3-15 to Table 3-23.
                                            
15
 The three-sigma rule (empirical rule) states that for a normal distribution, nearly all values lie within 3 
standard deviations of the mean. 
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Table 3-14 Reference gene selection for normalisation of Taqman® low density arrays 
 
 
 
Function
Process
Cytoskeletal protein
Cell structure
Hydrolase, Deaminase
Coenzyme and prosthetic group metabolism
Transferase, Glycosyltransferase
Nucleoside, nucleotide and nucleic acid 
metabolism
Isomerase
Protein metabolism and modification
Gene 
Symbol Gene Name
Ppia peptidylprolyl isomerase A 
Actb actin, beta
Hmbs
Hprt1 hypoxanthine guanine phosphoribosyl transferase 1
hydroxymethylbilane 
synthase
Reference genes for Taqman® low density arrays
Affymetrix® microarray expression data of selected reference genes
Actb Hmbs Hprt1 Ppia Actb Hmbs Hprt1 Ppia
1 APC Min/+ normal -0.07 -0.14 0.02 -0.25 0.96 0.91 1.01 0.84
2 APC Min/+ normal 0.09 0.08 0.08 0.03 1.07 1.06 1.06 1.02
3 APC Min/+ normal 0.02 -0.08 -0.02 0.02 1.02 0.94 0.99 1.01
4 APC Min/+ normal -0.02 0.12 -0.30 -0.02 0.98 1.08 0.81 0.99
5 APC Min/+ tumour -0.05 -0.27 0.14 -0.05 0.97 0.83 1.10 0.97
6 APC Min/+ tumour 0.03 0.25 -0.04 -0.04 1.02 1.19 0.97 0.97
7 APC Min/+ tumour 0.02 -0.12 0.04 0.09 1.01 0.92 1.03 1.07
8 APC Min/+ tumour -0.02 0.12 -0.25 0.04 0.99 1.09 0.84 1.03
9 APC Min/+ 33$5Į-/- normal -0.04 0.06 0.21 -0.04 0.97 1.04 1.16 0.97
10 APC Min/+ 33$5Į-/- normal 0.00 -0.03 -0.07 0.00 1.00 0.98 0.95 1.00
11 APC Min/+ 33$5Į-/- normal -0.04 -0.07 0.00 -0.04 0.97 0.95 1.00 0.97
12 APC Min/+ 33$5Į-/- normal 0.00 0.04 -0.18 0.00 1.00 1.03 0.88 1.00
13 APC Min/+ 33$5Į-/- normal 0.08 0.00 0.20 0.08 1.06 1.00 1.15 1.06
14 APC Min/+ 33$5Į-/- tumour 0.05 0.00 0.03 -0.08 1.04 1.00 1.02 0.95
15 APC Min/+ 33$5Į-/- tumour 0.01 0.10 0.07 -0.01 1.01 1.08 1.05 0.99
16 APC Min/+ 33$5Į-/- tumour -0.12 -0.02 -0.02 0.02 0.92 0.98 0.99 1.01
17 APC Min/+ 33$5Į-/- tumour 0.00 0.00 0.00 0.06 1.00 1.00 1.00 1.04
18 APC Min/+ 33$5Į-/- tumour -0.07 0.00 -0.22 0.00 0.95 1.00 0.86 1.00
Mean 1.00 1.00 0.99 0.99
Standard Deviation 
(SD) 0.04 0.08 0.10 0.05
Upper limit 
(Mean + 3SD) 1.11 1.25 1.28 1.14
Lower limit 
(Mean - 3SD) 0.89 0.76 0.70 0.84
(antilog2) of expression dataGenotype Tissue type
Expression data of reference genes 
(intensity values from Affymetrix® microarrays)Samples
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Table 3-15 Genes implicated in fatty acid & lipid metabolism 
 
Comparison group refers to;  
APCMin/+33$5Į-/- normal vs. APCMin/+ normal (Comparison 1)  
APCMin/+PPARĮ-/- tumour vs. APCMin/+ tumour (Comparison 2)  
APCMin/+ normal vs. APCMin/+ tumour (Comparison 3)  
APCMin/+PPARĮ-/- normal vs. APCMin/+PPARĮ-/- tumour  (Comparison 4). 
p value and fold change values are from Affymetrix microarray expression data 
 
Function
Process
Hydrolase, Esterase, Enzyme
Lipid, fatty acid and steroid metabolism
Oxidoreductase activity, Enzyme
Lipid, fatty acid and steroid metabolism
Enzyme inhibitor activity, Receptor binding
Negative regulation of apoptosis. 
Fatty acid & lipid metabolism
Oxidoreductase, Dehydrogenase, Enzyme
Lipid, fatty acid and steroid metabolism
Oxidoreductase, Oxygenase, Enzyme
Fatty acid and lipid metabolism
Oxidoreductase, Enzyme
Lipid, fatty acid and steroid metabolism, Fatty 
acid beta-oxidation
Hydrolase, Lipase, Enzyme
Lipid, fatty acid and steroid 
metabolism,Phospholipid metabolism,Signal 
transduction
Oxidoreductase, Oxygenase, Enzyme
Lipid, fatty acid and steroid metabolism
Oxidoreductase, Oxygenase, Enzyme
Lipid, fatty acid and steroid metabolism
Oxidoreductase, Oxygenase, Enzyme
Lipid, fatty acid and steroid metabolism, Electron 
transport
Oxidoreductase, Oxygenase, Enzyme
Fatty acid and lipid metabolism
Lyase, Hydratase, Enzyme
Lipid, fatty acid and steroid metabolism, Fatty 
acid beta-oxidation
Catalytic activity, Lyase activity, Enzyme
Lipid & fatty acid metabolism
3-hydroxyacyl-CoA dehydrogenase activity, 
Enzyme
Carbohydrate metabolism,Lipid, fatty acid and 
steroid metabolism, Fatty acid beta-oxidation, 
Vitamin metabolism
Transmembrane receptor
Lipid, fatty acid and steroid metabolism
Oxidoreductase, Isomerase, Enzyme
Lipid, fatty acid and steroid metabolism, Electron 
transport
Enzyme binding
Lipid, fatty acid and steroid metabolism
Oxidoreductase activity, Enzyme
Lipid, fatty acid and steroid metabolism
Ion binding, oxidoreductase
Oxidation reduction, homeostasis, ion transport. 
Fatty acid & lipid metabolism
Ptgis prostaglandin I2 (prostacyclin) 
synthase
Steap4 STEAP family member 4
Pla2g2a phospholipase A2, group IIA (platelets, synovial fluid)
Ptgs1
Ptgs2
prostaglandin-endoperoxide 
synthase 1
prostaglandin-endoperoxide 
synthase 2
Decr1 2,4-dienoyl CoA reductase 1, 
mitochondrial
Ech1 enoyl coenzyme A hydratase 1, peroxisomal
Echdc2 enoyl Coenzyme A hydratase domain containing 2
Lrp1 low density lipoprotein 
receptor-related protein 1
Cyp2c55 cytochrome P450, family 2, 
subfamily c, polypeptide 55
Angptl4 angiopoietin-like 4
Bdh1 3-hydroxybutyrate dehydrogenase, type 1
Cyp11a1 cytochrome P450, family 11, 
subfamily a, polypeptide 1
Acot2 acyl-CoA thioesterase 2
Alox15 arachidonate 15-lipoxygenase
Alox5ap arachidonate 5-lipoxygenase 
activating protein
Cyp2b10 cytochrome P450, family 2, 
subfamily b, polypeptide 10
Alox12 arachidonate 12-lipoxygenase
Gene 
Symbol Gene Name
Hadha
hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-
Coenzyme A hydratase 
(trifunctional protein), alpha 
subunit
Comparison 
group p value 
fold 
change
1
3
3
4
3.40E-021.8
2.04E-0523.8
4.00E-022.8
2.00E-021.7
Regulation
down
2 4.00E-022.2
2 5.00E-022.3
3 1.00E-033.7
2 4.00E-024.9
3 2.00E-0242.5
2 7.81E-043.2
3 2.00E-032.1
2 5.40E-042.2
3 4.00E-033.2
3 2.00E-032.5
3 4.00E-033.9
3 4.00E-032
1 5.00E-021
4 3.17E-049.2
4 7.36E-042.9
up
up
down
up
down
down
down
down
up
up
down
up
up
up
down
down
down
-
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Table 3-16 Genes implicated in signal transduction 
 
Comparison group refers to;  
APCMin/+33$5Į-/- normal vs. APCMin/+ normal (Comparison 1)  
APCMin/+PPARĮ-/- tumour vs. APCMin/+ tumour (Comparison 2)  
APCMin/+ normal vs. APCMin/+ tumour (Comparison 3)  
APCMin/+PPARĮ-/- normal vs. APCMin/+PPARĮ-/- tumour  (Comparison 4). 
p value and fold change values are from Affymetrix microarray expression data 
Function
Process
Wnt-protein binding
Wnt receptor signalling pathway
Growth factor
Angiogenesis, cytokine-mediated signaling 
pathway
Transmembrane receptor
Signal transduction
Signaling molecule, Cytokine
Signal transduction, Cytokine and chemokine 
mediated signaling pathway,Intracellular signaling 
cascade,MAPKKK cascade, JNK cascade, JAK-
STAT cascade, Apoptosis
Signaling molecule, Transmembrane receptor
Signal transduction
Signaling molecule, Protein receptor
Signal transduction, Receptor protein tyrosine 
kinase signaling pathway,Intracellular signaling 
cascade,MAPKKK cascade, Apoptosis
Signaling molecule, Cytokine, Growth factor
Signal transduction
Protein binding
Apoptosis. Signal transduction
Extracellular matrix linker protein
Signal transduction,Cell communication,Cell 
adhesion-mediated signaling
G-protein coupled receptor
Signal transduction, G-protein mediated signaling, 
Apoptosis
Select regulatory molecule, Enzyme
Signal transduction,Cell surface receptor 
mediated signal transduction,G-protein mediated 
signaling
Signaling molecule, Cytokine
Signal transduction, Cytokine and chemokine 
mediated signaling pathway
Protein binding
Cell adhesion, Regulation of cell migration. Signal 
transduction
Chemokine, Cytokine
Signal transduction, Cytokine and chemokine 
mediated signaling pathway
Signaling molecule, Cytokine
Signal transduction, Cytokine and chemokine 
mediated signaling pathway, Apoptosis
Rhoj ras homolog gene family, 
member J
Tnf tumor necrosis factor
Sfrp1 secreted frizzled-related protein 1
Ghr growth hormone receptor
Krt18 keratin 18
Lama1 laminin, alpha 1
Lama5 laminin, alpha 5
Apcdd1 adenomatosis polyposis coli down-regulated 1
Inhba inhibin beta-A
Ppbp pro-platelet basic protein
Ptger3 prostaglandin E receptor 3 (subtype EP3)
Gene 
Symbol Gene Name
Ereg epiregulin
Il1b interleukin 1 beta
Il6 interleukin 6
Gulp1 GULP, engulfment adaptor PTB domain containing 1
Comparison 
group p value 
fold 
change
2 3.00E-028.5
2 4.00E-022.9
Regulation
2 3.00E-032.2
3 7.12E-042.5
4 1.11E-0611.3
2 7.00E-037.4
3 5.17E-066.4
3 8.48E-042.3
4 9.35E-064
3 3.86E-042.9
4 2.67E-046.4
down
down
down
3 8.00E-035.6
3 2.00E-032.9
2 5.00E-026.2
down
down
down
up
down
4 1.42E-042down
down
up
up
up
up
up
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Table 3-17 Genes implicated in transcription 
 
 
Comparison group refers to;  
APCMin/+33$5Į-/- normal vs. APCMin/+ normal (Comparison 1)  
APCMin/+PPARĮ-/- tumour vs. APCMin/+ tumour (Comparison 2)  
APCMin/+ normal vs. APCMin/+ tumour (Comparison 3)  
APCMin/+PPARĮ-/- normal vs. APCMin/+PPARĮ-/- tumour  (Comparison 4). 
p value and fold change values are from Affymetrix microarray expression data 
Function
Process
Transcription factor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription,mRNA 
transcription regulation
Select regulatory molecule, Enzyme
Nucleoside, nucleotide and nucleic acid 
metabolism, Angiogenesis, Transcription
Transcription factor, Enzyme
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription
Transcription factor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription,mRNA 
transcription regulation
Transcription factor
Carbohydrate metabolism,Nucleoside, nucleotide 
and nucleic acid metabolism,mRNA transcription, 
Signal transduction, Embryogenesis, 
Neurogenesis, Cell cycle, Cell proliferation and 
differentiation
Receptor, Kinase
Transcription
Transcription factor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription,mRNA 
transcription regulation
Transcription factor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription, Oncogenesis, 
Cell proliferation and differentiation
Transcription factor 
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription,mRNA 
transcription regulation
Transcription factor 
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription,mRNA 
transcription regulation
Transcription factor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription
Transcription factor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription, Signal 
transduction, JNK cascade,Oncogenesis, Cell 
cycle, Cell proliferation and differentiation
Transcription factor
Transcription
Transcription factor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription
Transcription factor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription,mRNA 
transcription regulation
Transcription factor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription
Nucleic acid binding
Transcription
Transcription factor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription, Oncogenesis, 
Cell cycle, Apoptosis
Transcription factor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription, Signal 
transduction, NF-kappaB cascade
Ligand dependent nuclear receptor
receptor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription
Ligand dependent nuclear receptor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription, Oncogenesis
Ligand dependent nuclear receptor
Nucleoside, nucleotide and nucleic acid 
metabolism,mRNA transcription,mRNA 
transcription regulation
Rorc RAR-related orphan receptor gamma
Rarb retinoic acid receptor, beta
Rbms1 RNA binding motif, single 
stranded interacting protein 1
Tcf12 transcription factor 12
Nr1d1 nuclear receptor subfamily 1, group D
Myc myelocytomatosis oncogene
Pou2af1 POU domain, class 2, 
associating factor 1
Onecut2 one cut domain, family 
member 2
Foxc2 forkhead box C2
Gucy2c guanylate cyclase 2c
Meis1 Meis homeobox 1
Chd8 chromodomain helicase DNA binding protein 8
Nfkbie
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, epsilon
Phf17 PHD finger protein 17
Cbx7 chromobox homolog 7
Crem cAMP responsive element 
modulator
Id4 inhibitor of DNA binding 4
Jun Jun oncogene
Arnt2 aryl hydrocarbon receptor 
nuclear translocator 2
Baz1a bromodomain adjacent to zinc finger domain 1A
Ang angiogenin, ribonuclease, RNase A family, 5
Gene 
Symbol Gene Name
Klf4 Kruppel-like factor 4 (gut)
1 4.00E-032.1down
down
Comparison 
group p value 
fold 
change
2 3.00E-0247.8
Regulation
2 5.00E-032.5
4 1.66E-042.4
3 1.30E-044.2
down
4 1.36E-065.6
4 1.70E-062.1
3 2.00E-032.5
2 8.00E-032.9
4 4.00E-032.2
up
down
up
3 3.00E-033.2
3 2.46E-043.7
up
up
down
down
down
down
3.00E-032.1
4 1.94E-052.7
3 3.95E-0441.7
1 2.00E-032.3
3 5.00E-024.8
up
4 1.55E-062.4
4 2.76E-042.2
4 3.56E-042.1
2 4.00E-022down
down
up
down
down
down
up
down
up
4 1.85E-045.5
3
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Table 3-18 Genes implicated in the cell cycle 
 
 
Table 3-19: Genes implicated in apoptosis 
 
 
Table 3-20: Genes implicated in protein transport 
 
Comparison group refers to;  
APCMin/+33$5Į-/- normal vs. APCMin/+ normal (Comparison 1)  
APCMin/+PPARĮ-/- tumour vs. APCMin/+ tumour (Comparison 2)  
APCMin/+ normal vs. APCMin/+ tumour (Comparison 3)  
APCMin/+PPARĮ-/- normal vs. APCMin/+PPARĮ-/- tumour  (Comparison 4). 
p value and fold change values are from Affymetrix microarray expression data 
 
Function
Process
Cytidine deaminase, Enzyme
Innate inhibitor of retroviral replication. Cell cycle
Membrane traffic protein
Oncogenesis,Tumor suppressor, Cell cycle, Cell 
proliferation and differentiation
Select regulatory molecule
Cell cycle, Cell proliferation and differentiation
Select regulatory molecule
Oncogenesis,Cell cycle, Cell proliferation and 
differentiation
Cdkn1c cyclin-dependent kinase inhibitor 1C (P57)
Ccnd1 cyclin D1
Bin1 bridging integrator 1
Apobec3
apolipoprotein B mRNA 
editing enzyme, catalytic 
polypeptide 3
Gene 
Symbol Gene Name
Comparison 
group p value 
fold 
change
1 4.10E-031.7
Regulation
down
3 1.00E-032.2
3 2.00E-032.9
4 4.00E-033.1
up
down
down
Function
Process
Protein binding
Apoptosis
Select regulatory molecule
Intracellular protein traffic, Apoptosis
Protein binding
Oncogenesis, Apoptosis
Protein binding
Apoptosis
Endonuclease, Hydrolase, Nuclease, Enzym;e
Apoptosis
RNA binding
Apoptosis
Kinase, Transferase, Nucleotide binding
Phosphorylation. ApoptosisSbk1 SH3-binding kinase 1
Bmf BCL2 modifying factor
Endod1 endonuclease domain 
containing 1
Bik BCL2-interacting killer
Khdc1a KH domain containing 1A
Bcl2l11 BCL2-like 11 (apoptosis facilitator)
Apaf1 apoptotic peptidase activating factor 1
Gene 
Symbol Gene Name
Comparison 
group p value 
fold 
change
3 3.00E-032.4
3 1.00E-034.1
Regulation
2 6.34E-042.4
3 4.00E-033.6
3 4.00E-032.4
down
down
down
down
up
3 1.89E-0420.4
4 1.47E-042.2
down
down
Function
Process
Nucleotide binding, ATP binding, Transporter
Protein transport
Transfer/carrier protein, Transporter
Protein transport
Membrane traffic protein, Transporter
Intracellular protein traffic, Transport
Ion binding
Protein transportCrip1
cysteine-rich protein 1 
(intestinal)
Alb albumin
Gene 
Symbol Gene Name
adaptor-related protein 
complex AP-1, sigma 3Ap1s3
Abcc4
ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 4
Comparison 
group p value 
fold 
changeRegulation
3
3
3
4
2.10E-04
2.90E-04
3.00E-02
1.55E-04
4.8
20.9
1.9
2.4
down
down
up
up
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Table 3-21 Genes implicated in protein metabolism & modification 
 
Table 3-22 Genes implicated in cell adhesion 
 
Table 3-23 Genes involved in various cellular functions 
 
Comparison group refers to;  
APCMin/+33$5Į-/- normal vs. APCMin/+ normal (Comparison 1)  
APCMin/+PPARĮ-/- tumour vs. APCMin/+ tumour (Comparison 2)  
APCMin/+ normal vs. APCMin/+ tumour (Comparison 3)  
APCMin/+PPARĮ-/- normal vs. APCMin/+PPARĮ-/- tumour  (Comparison 4). 
p value and fold change values are from Affymetrix microarray expression data 
Function
Process
Protein kinase receptor
Protein metabolism and modification
Phosphatase
Protein metabolism and modification
Protease, Peptidase
Protein metabolism and modification, Apoptosis
Protease, Peptidase
Protein metabolism and 
modification,Proteolysis,Signal transduction
Protease, Peptidase
Protein metabolism and modification,Proteolysis
Protease, Peptidase
Protein metabolism and modification,Proteolysis, 
Oncogenesis, Angiogenesis
Protease, Peptidase
Protein metabolism and modification, 
Oncogenesis
Kinase
Protein metabolism and modification,Protein 
modification
Protease, Peptidase
Protein metabolism and modification,Proteolysis
Select regulatory molecule
Protein metabolism and modification
Kinase
Protein metabolism and modification, 
Oncogenesis, Cell cycle,Apoptosis,Cell 
proliferation and differentiation
Transferase, Glycosyltransferase, Enzyme
Protein metabolism and modification,Protein 
modification,Protein glycosylation
Kinase
Protein metabolism and modification, 
Oncogenesis,Cell cycle, Cell proliferation and 
differentiation
protein tyrosine phosphatase, 
receptor type, GPtprg
Mmp2 matrix metallopeptidase 2
Mmp7 matrix metallopeptidase 7
Plat plasminogen activator, tissue
Mep1b meprin 1 beta
Cdk4 cyclin-dependent kinase 4
Pdk2 pyruvate dehydrogenase kinase, isoenzyme 2
Timp1 tissue inhibitor of 
metalloproteinase 1
Casp6 caspase 6
Htra1 HtrA serine peptidase 1
B4galt6
UDP-Gal:betaGlcNAc beta 
1,4-galactosyltransferase, 
polypeptide 6
Akt3 thymoma viral proto-oncogene 3
Irak4 interleukin-1 receptor-
associated kinase 4
Gene 
Symbol Gene Name
Comparison 
group p value 
fold 
change
4 4.00E-032.1
4 7.27E-052.1
Regulation
4 5.16E-042.2
3 4.25E-044.9
up
down
down
1 1.56E-052.7
3 2.00E-035.9
3 8.00E-031.7
down
2 3.00E-022.6
3 1.86E-0478.3
3
3
1
3
2.00E-03
2.71E-04
4.00E-03
5.29E-04
2.8
14.3
1.8
3.8
down
down
down
up
up
down
up
down
down
Function
Process
Signaling molecule, Growth factor
Cell adhesion
Cell adhesion molecule
Cell adhesion
Cell adhesion molecule
Cell adhesion
Ctgf connective tissue growth factor
Itga6 integrin alpha 6
Sell selectin, lymphocyte
Gene 
Symbol Gene Name
Comparison 
group p value 
fold 
change
3
3
4
5.00E-02
1.00E-03
5.00E-03
2.1
2.2
1.7
Regulation
down
down
down
Function
Process
Select regulatory molecule, Transmembrane 
Cell structure and motility
Oxidoreductase, Oxidase, Enzyme
Amino acid metabolism
Oxidoreductase, Reductase, Enzyme
Toxin metabolism
Structural protein
Cellular structure
Nisch nischarin
Cryab crystallin, alpha B
Cbr1 carbonyl reductase 1
Aoc3 amine oxidase, copper 
containing 3
Gene 
Symbol Gene Name
Comparison 
group p value 
fold 
change
3
3
4
2
1.31E-05
1.96E-04
9.72E-04
3.00E-03
6.5
2.9
2.9
2.3
Regulation
down
up
up
up
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3.5 Discussion 
 
This study determined what effect PPARĮ may have on polyp burden 
and expression of genes in the colon of APCMin/+ mice and APCMin/+ 
PPARĮ-/- mice.  Age and disposition at death of these mice were also 
compared.  
At the conclusion of the mouse study there was no significant difference 
in age at sacrifice between APCMin/+ mice and APCMin/+ PPARĮ-/- mice 
(Figure 3-6A). All of the mice except one APCMin/+ mouse (rectal 
prolapse) were sacrificed due to white paw (Table 3-5, Table 3-6).  
However, APCMin/+ PPARĮ-/- mice were significantly heavier than 
APCMin/+ mice at sacrifice (p < 0.0001, Figure 3-6B). This corresponds 
with the role of PPARĮ in lipid and fatty acid metabolism as APCMin/+ 
PPARĮ-/- mice do not have a functional PPARĮ gene (Desvergne and 
Wahli, 1999, Kersten et al., 2000). However, it must also be noted that 
food consumption was not monitored. Mice were fed ad libitum. 
Therefore, it may be that APCMin/+ PPARĮ-/- mice consumed more feed 
than APCMin/+ mice. 
The mean polyp numbers (lowest number counted and highest number 
counted in brackets) of APCMin/+ mice in this study at death were 0.6 
(0.0, 2.0) in the colon, and 17.8 (6.0, 28.0) in the small bowel (Table 
3-7). These numbers were lower than those in an earlier study by 
(Jackson et al., 2003), using the same mouse model, where numbers 
were 6.5 (4.1, 10.0) and 24.0 (15.8, 30.3) in the colon and small bowel 
respectively. The polyp numbers in these two studies were considerably 
fewer than the first Leicester University study using this mouse model; 
2.5 (0.0, 5) in the colon and 120 (70, 170) in the small bowel (Perkins et 
al., 2002).  
In other studies that have used the APCMin/+ mouse model, polyp 
numbers were highly variable. However, this is likely to be due to 
differing experimental protocols.  These other studies differed in their 
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duration, the agent and dose used in treatment and are reviewed in 
(Corpet and Pierre, 2003). 
The reduction in polyp numbers seen in the present studies may be due 
to the in-breeding of the mouse colony over many generations, which 
has afforded a survival advantage to mice with fewer polyps. This may 
have perpetuated the decline of the phenotypic effects of the Min 
mutation, evident in fewer polyp numbers.  
At sacrifice, both mouse genotypes had a similar disposition and 
number of polyps in the small bowel and were of similar age. However, 
in the colon there were more polyps in APCMin/+ PPARĮ-/- mice than in 
APCMin/+ mice which may suggest that PPARĮ has a role in preventing 
initiation or growth of tumours in the colon.   
Microarray technology has facilitated the analysis of whole 
transcriptomes, leading to recognition and understanding of the 
functional roles that PPARs play in gene expression. Affymetrix® 
microarrays were used in this study to evaluate gene expression levels 
in normal and tumour tissue from the colons of APCMin/+ mice and 
APCMin/+ PPARĮ-/- mice.  
A critique of the method used for tissue collection, preparation and 
subsequent RNA extraction, could be that as tissue is a heterogeneous 
mix of cell types (see 1.1, page 2),  it was not known which cell types, 
or proportion of these, were present in each tissue sample, and hence, 
which genes were expressed in the different cells. However, the method 
for tissue collection and preparation was consistent. Also, RNA samples 
were rigorously checked for integrity before analysis. In addition, after 
analysis, Affymetrix® quality control systems assessed groups of 
samples for any outliers.    
If future studies required cell types and numbers to be known, tissue 
would be mixed with a dissociation enzyme such as collagenase, 
centrifuged, then re-suspended in culture medium for subsequent 
analysis via fluorescence ± activated cell sorting (FACs).       
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Affymetrix® microarray results from the present study showed that the 
largest source of variation in gene expression was between tumour and 
normal samples.  
Ingenuity® Pathway Analysis (IPA®) of Comparison 3 (APCMin/+ normal 
vs. APCMin/+ tumour) showed growth & proliferation and colorectal 
cancer were the two top scoring biological processes. Myc, CyclinD1, 
Tcf4, Axin2 and Mmp7 were significantly up-regulated in tumour tissue; 
this was shown in the IPA® networks of these functions and the 
Wnt/beta catenin, ERK/MAPK (ras) and p53 canonical pathways; all of 
which are known pathways linked to tumorigenesis (Fearon and 
Vogelstein, 1990, Kinzler and Vogelstein, 1996). 
Similarly, IPA® of Comparison 4 (APCMin/+33$5Į-/- normal vs. 
APCMin/+33$5Į-/- tumour) showed growth & proliferation and colorectal 
cancer were the two top scoring biological processes. Myc and Mmp7 
were again shown to be significantly up-regulated in tumour tissue. 
Other microarray studies have demonstrated a similar profile of gene 
expression involved in colonic tumorigenesis to that shown in our study; 
(Paoni et al., 2003) used Affymetrix® Mouse Genome ± U74Av2 (MG-
U74Av2)16 GeneChip® arrays to analyse gene expression in tumour 
tissue compared to normal tissue in the colons of APCMin/+ mice.  Many 
differentially expressed genes were shown to be involved in pathways 
that regulate cell growth and proliferation. In agreement with findings 
from the present study, significantly up-regulated genes included Casp6 
(Caspase 6) and Sox17 (SRY-box containing gene 17). 
A study by (Williams et al., 2003) used microarrays to investigate gene 
expression in human tumour and normal colon tissue. A sub-set of 
genes from the arrays were selected based on expression levels, their 
association with aberrant cellular growth and to assess their importance 
in the pathogenesis of colorectal cancer. Real time quantitative PCR 
was used to validate expression levels of the selected genes in the 
                                            
16
 Affymetrix® MG-U74Av2 GeneChip® array is the predecessor of the Affymetrix® MG-430.2 GeneChip® 
arrays used in this study  
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human tissue samples. Expression of the same genes were also 
determined in HCT116 cells (Brattain et al., 1981) and found to be 
comparable to levels in human tumour tissue.  Genes that were found 
to be differentially-regulated in the present study and also highlighted in 
the (Williams et al., 2003) study included down-regulated Tnfsf10 
(tumour necrosis factor (ligand) superfamily member 10) and Myc which 
is well documented for its role in cell growth and proliferation was up-
regulated.  
The differentially Expressed Gene (DEG) lists; Comparison 1 
(APCMin/+33$5Į-/- normal vs. APCMin/+ normal) and Comparison 2 
(APCMin/+33$5Į-/- tumour vs. APCMin/+ tumour), Appendices pages 311-
377, list the PPARĮ GHSHQGHQW JHQHV that were identified on 
Affymetrix® microarrays after filtering by statistical analysis for fold 
change and p value (as defined previously 3.3.9, page 56).   
These DEG lists were compared to PPARĮ WDUJHW JHQHV identified in 
previous studies (Mandard et al., 2004, Rakhshandehroo et al., 2010). 
Twelve genes on the DEG lists had been previously identified; 
interleukin 6 (Il6), acyl-CoA thioesterase 2 (Acot2), 2,4-dienoyl CoA 
reductase 1 (Decr1), 3-hydroxybutyrate dehydrogenase, type 1 (Bdh1), 
angiopoietin-like 4 (Angptl4), epoxide hydrolase 2 (Ephx2), acyl-CoA 
synthetase short-chain family member 2 (Acss2), fatty acid binding 
protein 5 (Fabp5), thioredoxin interacting protein (TXNIP), 
phosphoenolpyruvate carboxykinase 1 (PCK1), interleukin 1 receptor 
antagonist (Il1rn) and chemokine (C-C motif) ligand 2 (Ccl2).   
Only two genes from the (Mandard et al., 2004, Rakhshandehroo et al., 
2010) studies; Fabp5 and Acot2, were highlighted on Comparison 1 
(APCMin/+33$5Į-/- normal vs. APCMin/+ normal) DEG list. As discussed 
earlier (Results 3.4.5.3, page 103) this DEG list identified only 52 genes 
differentially expressed between normal colon tissue in APCMin/+33$5Į-
/-
 mice and APCMin/+ mice. Therefore, these data show that in general, 
deletion of PPARĮ had little effect on gene expression in normal tissue 
of the colon.  
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However, as discussed previously (Results 3.4.5.2, page 93), 
Ingenuity® Pathway Analysis (IPA®) of Comparison 2 (APCMin/+33$5Į-
/-
 tumour vs. APCMin/+ tumour) highlighted many more differentially 
expressed genes between tumour colon tissue in APCMin/+33$5Į-/- 
mice and APCMin/+ mice; including ten that had been identified in 
previous studies by (Mandard et al., 2004, Rakhshandehroo et al., 
2010). IPA® networks showing genes involved in growth & proliferation 
(Figure 3-15) and colorectal cancer (Figure 3-18) highlighted interleukin 
6 (Il6) as a key regulatory gene involved in these processes. 
Previous microarray analyses of gene expression in the liver and 
skeletal muscle have confirmed PPARĮ is involved in many regulatory 
pathways; lipid metabolism, cell death, signal transduction, cell cycle 
and DNA repair. However, differences in gene expression profiles and 
levels could be explained by how fatty acids are metabolised in different 
tissues. Fatty acid metabolism provides a major source of energy for 
the body. The colon metabolises short chain fatty acids from dietary 
fibre, whereas long chain fatty acids are firstly metabolised in the liver 
before being transported to other tissues in the blood.  
A study by (Rakhshandehroo et al., 2007) investigated gene expression 
in the liver of Sv129 mice (Lee et al., 1995) and Sv129 PPARĮ-/- mice. 
Results from this study demonstrated a major role for PPARĮ in hepatic 
gene expression, liver homeostasis and regulation of lipogenesis.    
A study by (Finck et al., 2005) demonstrated the role of PPARĮ in 
skeletal muscle using transgenic MCK PPARĮ (muscle-specific creatine 
kinase promoter PPARĮ) mice. These mice over-express PPARĮ in 
skeletal muscle. PPARĮ was shown to cause increased muscle fatty 
acid oxidation, decreased AMP-activated protein kinase activity and 
glucose uptake via transcriptional repression of GLUT4 (Slc2a4, solute 
carrier family 2 (facilitated glucose transporter), member 4). Thus, their 
study established a potential link between PPARĮ, obesity, level of 
glucose intolerance and insulin resistance.   
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A potential mechanism for the effects seen in the present study could 
be as explained in Figure 1-3 (page 12). Briefly, arachidonic acid (AA) is 
converted to prostaglandins by cyclooxygenase enzymes (Cox) and to 
epoxyeicosatrienoic acids (EETs) by cytochrome P450 enzymes 
(CYPs). EETs are regulated and degraded by soluble epoxide 
hydrolase (Ephx2), which is activated by PPARĮ. Increased production 
of EETs or inhibition of Ephx2 leads to repression of Cox2 induction 
(Inceoglu et al., 2008). EETs are pro-angiogenic, however, when 
degraded by Ephx2, there is a reduction in tumour angiogenesis and 
growth (Pozzi et al., 2007).   
The study by (Pozzi et al., 2007) also investigated whether the anti-
angiogenic effects of Wyeth-14643 (Wy-14643), a PPARĮ-selective 
ligand, were associated with altered Cyp2c expression. Their study 
using mice injected with tumour cells, and treated with Wy-14643, 
recorded marked reductions in tumour growth and vascularization, with 
concomitant reductions in epoxygenase metabolites, 5,6-EET, 8,9-EET, 
11,12-EET and 14,15-EET, hepatic EET biosynthesis and Cyp2c29, - 
2c38, -2c40 and -2c44  epoxygenase transcripts. Similar effects were 
seen when primary cultures of mouse lung endothelial cells were 
treated with Wy-14643. Cell proliferation was reduced in the cells when 
treated with Wy-14643. However, the effects were reversed on addition 
of synthetic 5,6-, 8,9-, 11,12- and 14,15- EETs. None of these effects 
were seen in cells obtained from PPARĮ-/- mice, which confirmed 
PPARĮ as having an involvement in cell proliferation and angiogenesis 
via its relationship with Cyp2c epoxygenase expression and EET 
biosynthesis (Pozzi et al., 2007).  
Another study by (Pozzi et al., 2010) used a mouse xenograft model of 
tumorigenesis, to show that activation of murine Cyp2c44 epoxygenase 
by PPARĮ produced a reduction in tumour volume, mass and 
vascularisation. Cyp2c44 is expressed in endothelial cells (Pozzi et al., 
2007) and generates 11,12- and 14,15-EET as its major products 
(Pozzi et al., 2010). Their study also showed that CYP2C9, a previously 
identified human catalytic homologue of murine Cyp2c44 (Zeldin et al., 
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1995) is an endothelial epoxygenase expressed in the vasculature of 
several human tumours (clear cell renal carcinoma, metastatic 
melanoma, lung adenoma), and was confirmed as a regulatory target of 
human PPARĮ (Pozzi et al., 2010). 
In conclusion, the studies discussed here show that PPARĮ is 
instrumental in regulation of many biological pathways within different 
tissues in the body. Results from the present study clearly demonstrate 
that deletion of PPARĮ led to differential expression of genes involved 
in biological functions linked with cancer and a concomitant increase in 
tumour burden in the colon. Therefore, these data and the studies 
discussed here support the hypothesis that PPARĮ has a role in the 
pathophysiology of cancer and further endorses the possibility that 
ligands of PPARĮ could be viable candidates for cancer prevention and 
treatment. 
To validate and verify Affymetrix® microarray results, 95 significantly 
differentially expressed genes were selected from Ingenuity® Pathway 
Analysis networks, selected canonical signalling pathways and novel 
genes of interest from differentially expressed gene (DEG) lists (Table 
3-14 - Table 3-23).  
Chapter 4 describes how these genes were assayed on Taqman® low 
density arrays to determine expression levels. Also, expression levels 
for each gene as determined on Affymetrix® microarrays and Taqman® 
low density arrays were compared. 
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4 Gene quantitation with Taqman® low density arrays: 
Study 1B 
 
4.1 Introduction 
 
Microarray based assays allow the global changes in gene expression 
caused by disease or defined experimental conditions to be measured. 
In Chapter 3, Affymetrix® microarray analysis and results of gene 
expression for the whole transcriptome in colons of APCMin/+ mice and 
APCMin/+ PPARĮ-/- mice were presented and discussed. These data 
identified many differentially expressed genes in APCMin/+ mice and 
APCMin/+ PPARĮ-/- mice, and in tumour and normal tissue, which may be 
involved in PPARĮ signalling and tumorigenesis.  
Therefore, Taqman® low density arrays were used to determine and 
verify gene expression of a selected sub-set of these genes. Taqman® 
low density arrays are microfluidic cards that function as miniaturised 
reaction wells for PCR of target genes. Each well of the array contains a 
Taqman® Gene Expression Assay that detects the real-time 
amplification of a target gene. Relative levels of gene expression are 
determined from the fluorescence data that is generated during PCR 
cycling.  
7KHSULQFLSOHRIWKH7DTPDQSUREHUHOLHVRQWKH¶± ¶QXFOHDVHDFWLYLW\
of the enzyme Taq-polymerase and fluorophore based detection. 
TaqMan probes are oligonucleotide probes with a fluorophore/reporter 
(6-FDUER[\ IOXRUHVFHLQ )$0 DW WKH ¶ HQG, and a quencher 
WHWUDPHWK\OUKRGDPLQH 7$05$ DW WKH ¶ HQG 7KH SUREH DQQHDOV
within the DNA region between forward and reverse specific primers. 
Taq-polymerase extends the primer and synthesises the nascent strand 
¶ ± ¶RI WKHFRPSOHPHQWDU\ VWUDQG). TKH¶ ± ¶QXFOHDVHDFWLYLW\RI
the enzyme degrades the probe annealed to the template. This 
releases the fluorophore from the close proximity of the quencher 
allowing fluorescence (see Figure 4-1). The level of detected 
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fluorescence is directly proportional to the amount of template DNA 
(Holland et al., 1991). 
 
 
Figure 4-1 Schematic of the principle of a Taqman probe  
Figure from (Yuan et al., 2000) 
 
Genes to be assayed and endogenous control genes are preloaded 
onto one card which facilitates a high throughput of samples. Taqman® 
low density arrays are very economical with reagents and samples. 
They are also very easy to use; samples to be assayed are simply 
mixed with master mix and loaded into fill reservoirs using a 
micropipette. Once the array is sealed and centrifuged, it is ready to 
run. The whole assay is automated with decreased assay time and 
without loss of fidelity. This contrasts with the assay of samples on 
individual arrays, which would be very time consuming and expensive. 
Analysis of Taqman® low density array results using SDS RQ Manager 
Version 1.2 (Applied Biosystems) allows up to ten assays at once to be 
reviewed. This means array to array reproducibility and stringency of 
reference genes can be checked across all arrays simultaneously.  
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The main disadvantage of Taqman® low density arrays is cost. The 
requirement for the sophisticated and expensive 7900HT system and 
software, and peripheral equipment for preparation, assay and analysis 
of arrays, means initial set-up costs are very high.    
Applied Biosystems Taqman® low density arrays were used to analyse 
and verify gene expression levels of 95 selected genes that had 
previously been determined by Affymetrix® microarrays (Chapter 3). 
 
4.2 Aims of study 
 
x To determine gene expression of selected genes in the colon of 
APCMin/+ and APCMin/+ 33$5Į-/- mice using TaqMan® low density 
arrays. 
x To compare and validate the expression level of selected genes 
on Taqman® low density arrays against expression level of the 
same genes on Affymetrix® microarrays. 
 
4.3 Methods 
 
The customised Taqman® low density arrays used in the present study 
were 384-well microfluidic cards that enabled 384 simultaneous Real-
Time PCR reactions to be performed. Four duplicated cDNA samples 
were run in parallel against 96 (including one mandatory control gene, 
18s) pre-loaded Taqman® gene expression assay targets. Figure 4-2 
shows an image of a Taqman® low density array.   
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Figure 4-2 Taqman® low density array 
(appliedbiosystems.com, 2012) 
 
Taqman® low density arrays can be customised by selecting genes of 
interest to fit research goals and criteria dictated by the user; genes for 
the arrays were selected based on function and statistical relevance 
following GeneSpring® and Ingenuity® Pathway analysis of Affymetrix® 
microarray data (Table 3-15-Table 3-23). 
TaqMan® low density arrays perform relative quantitation (RQ) of gene 
targets using the comparative CT (ǻǻCT) method17 (as opposed to an 
absolute quantitation method that uses a standard curve) Applied 
Biosystems 7900HT fast real-time PCR system with sequence detection 
system (SDS) software v2.1 was used to detect RQ of gene expression 
from fluorescence data generated during the real-time amplification of 
gene targets. SDS also alerts the user to any errors or faults within the 
run, array or samples.  
 
4.3.1 Preparation & assay of Taqman® low density arrays 
 
Aliquots of RNA samples extracted from colon tissue of mice on Study 
1B (3.3.6, page 50, Table 3-3) were removed from storage at -800C. 
                                            
17
 Comparative CT method: is an approximation method that assumes the amplification efficiencies of target 
and reference genes are equal. Expression of a target gene is normalised to a reference gene. Expression 
is then compared to expression of that target in a nominated reference sample 
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RNA concentration was assessed on a NanoDrop® ND-1000 
Spectrophotometer. Two samples were found to have a very low 
concentration and there was insufficient quantity to prepare cDNA 
(44b.3/4 APCMin/+ normal & 115.4/1 APCMin/+ PPARĮ-/- tumour). The 
remaining 16 samples were diluted to 250 ng/µl and cDNA prepared, in 
duplicate using 500 ng of RNA with random primers (Promega, page 
41) and SuperScript® lll RT (Invitrogen). The manufacturer¶V protocol 
was followed with some modification; reagent and sample volumes 
were scaled-up to produce a cDNA reaction volume of 30 µl instead of 
20 µl.  
Four samples at a time were prepared for a TaqMan® low density array 
by combining the duplicate cDNA reactions and adding 50 µl of RNase-
free water (to give 110 µl). An equal volume of TaqMan® Fast universal 
PCR master mix (Applied Biosystems) was added. Samples were 
thoroughly mixed by vortexing, and centrifuged to remove any bubbles.  
A TaqMan® low density array equilibrated to room temperature was 
carefully removed from protective packaging. 100 µl of the first sample 
was loaded into the first fill reservoir on the array using a micropipette. 
Another 100 µl of the same sample was loaded into the adjacent fill 
reservoir. The process was repeated for the other three samples to 
complete the loading of the array.   
The array was centrifuged on a Sorvall® centrifuge with custom-made 
buckets and array holders for 2 x 1 minute. The array was checked to 
ensure the fill reservoirs had correctly distributed the cDNA samples to 
the reaction wells. The array was then sealed and fill reservoirs were 
removed using scissors.  
All TaqMan® low density arrays are shipped with an Array Information 
CD, which contains an SDS setup file. The SDS software on the 
7900HT system used this file to configure the plate document grid and 
setup table. The plate document was saved as a plate document 
template for use with further assays with identical assay configurations.  
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The completed sealed array was loaded into the 7900HT instrument 
and the run commenced.  
A total of four arrays were completed to assay all 16 samples.  
 
4.3.2 Interpretation & Analysis of TaqMan® low density array data 
 
All four arrays (16 sample results) were analysed simultaneously using 
SDS RQ Manager software. Average Ct (cross threshold)18 values of 
each target gene (average calculated from Ct value from each sample 
across all 4 arrays) were copied into an Excel spreadsheet.  
Consistency of average Ct value of each selected reference gene 
(Table 3-14) and 18s were checked for outliers before further analysis 
(Table 4-1). To justify their use for normalisation the expression level of 
reference genes must not alter across arrays. Outliers were defined as 
an average Ct value not within three standard deviations of the mean 
(three-sigma rule19), (Ruan, 2005). 18s was not used for normalisation 
as one sample average Ct value did not fulfil the stringency of the 
statistical testing (Table 4-1, shown in red).  
                                            
18
 The threshold value is a defined level of fluorescence set by the user. The point at which an 
amplification plot crosses the threshold is known as the Ct (cross threshold) value; the lower the Ct value for 
a sample the greater the starting amount of DNA in the sample.  
 
19
 The three-sigma rule (empirical rule) states that for a normal distribution, nearly all values lie within 3 
standard deviations of the mean. 
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Table 4-1 Expression (average Ct value) of reference genes in Study 1B samples 
 
 
The geometric mean 20  of the remaining four reference genes was 
calculated and used for normalisation of all average Ct values of target 
genes.  
The mean relative quantity (RQ) of gene expression in APCMin/+ tumour, 
APCMin/+PPARĮ-/- normal and APCMin/+PPARĮ-/- tumour samples to 
expression in APCMin/+ normal sample 76.4/1 was calculated from 
normalised average Ct values of Study 1B TaqMan® low density array 
results. SPSS 16.0.0.247 was used to perform univariate analysis of 
variance on the same data. Genes were determined as differentially 
expressed due to; the effect of PPARĮ status, or the effect of tissue, or 
the effect of an interaction between PPARĮ status and tissue, where p 
<= 0.05.  
                                            
20
 Geometric mean: normalises ranges of numbers to give an average that indicates a central tendency or 
typical value. Numbers are multiplied together, then the nth root (where n is the count of numbers in the 
range) is taken of the resultant product. 
18s Actb Hmbs Hprt1 Ppia
70.3/2 APCMin/+ normal 16.001 16.484 25.980 23.852 21.837
76.4/1 APCMin/+ normal 12.638 16.722 24.934 23.908 20.425
76.4/3 APCMin/+ normal 12.530 16.513 25.250 23.635 20.266
44b.3/4 APCMin/+ tumour 12.735 17.358 25.305 23.999 20.706
70.3/2 APCMin/+ tumour 12.790 16.474 24.471 23.300 20.197
76.4/1 APCMin/+ tumour 11.499 16.499 24.331 23.395 19.074
76.4/3 APCMin/+ tumour 12.564 16.938 25.028 23.761 19.976
115.4/1 APCMin/+  PPARɲ-/- normal 11.829 16.712 24.617 23.360 19.699
11a.3/4 APCMin/+  PPARɲ-/- normal 12.038 15.895 24.704 23.262 19.948
121.1/2 APCMin/+  PPARɲ-/- normal 11.263 16.431 24.710 23.684 19.894
121.1/3 APCMin/+  PPARɲ-/- normal 11.103 15.953 24.596 23.257 19.663
121.1/5 APCMin/+  PPARɲ-/- normal 11.561 16.927 24.878 23.489 20.156
11a.3/4 APCMin/+  PPARɲ-/- tumour 11.464 15.973 24.484 23.215 19.194
121.1/2 APCMin/+  PPARɲ-/- tumour 12.723 16.315 24.767 23.643 20.100
121.1/3 APCMin/+  PPARɲ-/- tumour 12.687 17.391 25.159 24.044 20.089
121.1/5 APCMin/+  PPARɲ-/- tumour 11.964 16.972 24.934 23.929 19.941
12.337 16.597 24.884 23.608 20.073
1.139 0.451 0.407 0.288 0.624
15.755 17.951 26.104 24.471 21.946
8.919 15.244 23.664 22.746 18.199
Mean
Standard Deviation (SD)
Upper limit (Mean + 3SD)
Lower limit (Mean - 3SD)
Reference Genes Average Ct valuesSample 
identification Genotype
Tissue 
type
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These data were presented in groups (as defined previously, Table 
3-15-Table 3-23) in Table 4-2-Table 4-10. Mean RQ data were 
presented as clustered bar graphs in similar groups (Figure 4-3-Figure 
4-11) using a log10 scale for genes where RQ was greater than or equal 
to two (fold change increase >= 2) or less than or equal to 0.5 (fold 
change decrease >=2).  
 
4.3.3 Ingenuity® Pathway Analysis (IPA®) of Taqman® low 
density array data   
 
Data from Taqman® low density arrays were analysed on IPA to 
generate networks showing genes influenced by PPARĮ and tissue 
type.  
Fold change (relative quantity of APCMin/+ PPARĮ-/- normal to APCMin/+ 
normal) and corresponding p values of significantly expressed genes (p 
<= 0.05) listed in Table 4-2-Table 4-10 were input into IPA to show the 
effect of PPARĮ status on gene expression. The generated network 
was annotated with the PPARĮ pathway. 
Similarly, fold change (relative quantity of APCMin/+ tumour to APCMin/+ 
normal) and corresponding p values (p <= 0.009) from Table 4-2-Table 
4-10 were input into IPA to show significantly expressed genes due to 
the effect of tissue. The generated network was annotated with the 
Wnt/beta catenin, p53 and ERK/MAPK signalling pathways.  
 
4.3.4 Comparison of Gene Expression in Affymetrix® Microarrays 
& TaqMan® Low Density Arrays 
 
To ascertain whether the two methodologies used to analyse the same 
sample set (Study 1B) produced similar results, gene expression results 
of the selected 95 genes (Table 3-15-Table 3-23) from Affymetrix® 
microarrays and Taqman® low density arrays were compared.  
Relative quantity (RQ) to APCMin/+ normal sample 76.4/1 was calculated 
for each selected gene from Affymetrix® microarray and Taqman® low 
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density array data. These data were presented on scatter plots and 
clustered bar charts. 
 
4.4 Results 
 
4.4.1 Gene expression on Taqman® low density arrays  
 
For simplicity all table and figure headings have been abbreviated as 
follows; APCMin/+ abbreviated to Min, and APCMin/+ PPARĮ-/- abbreviated 
to PPARĮ-/-. 
x Fatty acid & lipid metabolism 
Table 4-2 and Figure 4-3 show expression data for genes implicated in 
fatty acid and lipid metabolism.  
Hadha (hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional 
protein), alpha subunit) expression was reduced in APCMin/+ tumour 
samples only with a fold change reduction of 2.2 (p = 0.01).  
Expression of Ptgs1 (prostaglandin-endoperoxide synthase 1) was 
reduced 2.5 fold (p is ns) in APCMin/+PPARĮ-/- tumour samples.  
Echdc2 (enoyl Coenzyme A hydratase domain containing 2) and 
Steap4 (STEAP family member 4) expression increased in tumours with 
fold change increases of 4.2 and 3.0 in Echdc2 (p = 0.012) and 4.7 and 
5.8 in Steap4 (p = 0.002) in APCMin/+ tumour and APCMin/+PPARĮ-/- 
tumour samples respectively.  
Expression of Alox15 (arachidonate 15-lipoxygenase) and Ptgs2 
(prostaglandin-endoperoxide synthase 2) also increased with fold 
change increases of 4.3 and 2.0 in Alox15 (p is ns), and 5.1 and 6.5 in 
Ptgs2 (p = 0.001) in tumour samples as before.  
Large increases in expression of Alox12 (arachidonate 12-
lipoxygenase), Cyp2b10 (cytochrome P450, family 2, subfamily b, 
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polypeptide 10), Cyp11a1 (cytochrome P450, family 11, subfamily a, 
polypeptide 1) and Pla2g2a (phospholipase A2, group IIA) in tumours 
was observed, with fold change increases in expression of 36.3 and 
29.7 in Alox12 (p = 0.001), 97.3 and 37.6 in Cyp2b10 (p = 0.01), 17.0 
and 17.8 in Cyp11a1 (p < 0.0001), and 37.1 and 17.2 in Pla2g2a (p < 
0.0001) in respective tumour samples as previously.   
Expression of Angptl4 and Cyp2c55 was reduced in both normal and 
tumour APCMin/+PPARĮ-/- samples; fold change reductions of 7.3 and 
3.4 in Angptl4 (p is ns), and 2.0 and 10.7 in Cyp2c55 (p is ns) were 
recorded in APCMin/+PPARĮ-/- normal and APCMin/+PPARĮ-/- tumour 
samples respectively.  
There was significant interaction between PPARĮVWDWXVDQGWKHHIIHFWV
of tissue in the expression of Pla2g2a (p = 0.002).  
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Table 4-2 Genes implicated in fatty acid & lipid metabolism 
 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ tumour, APCMin/+33$5Į-/- normal and APCMin/+33$5Į-/- tumour samples to expression in APCMin/+ normal sample 76.4/1. 
Univariate analysis of variance of APCMin/+ and APCMin/+ PPARɲ-/- groups was used to determine differentially expressed genes with p <= 0.05 (ns - not significant) 
Min tumour 33$5ĮQRUPDO 33$5ĮWXPRXU Effect of 33$5Į
Effect of 
tissue
Interaction between 
33$5Į	WLVVXH
Acot2 0.65 0.80 0.54 ns 0.027 ns
Alox12 36.27 1.54 29.74 ns 0.001 ns
Alox15 4.30 1.35 2.02 ns ns ns
Alox5ap 1.70 1.04 1.78 ns 0.002 ns
Angptl4 0.39 0.14 0.29 ns ns ns
Bdh1 0.40 0.62 0.35 ns 0.014 ns
Cyp11a1 17.03 1.68 17.78 ns <0.0001 ns
Cyp2b10 97.33 0.91 37.63 ns 0.01 ns
Cyp2c55 0.04 0.50 0.09 ns ns ns
Decr1 0.41 0.70 0.45 ns <0.0001 ns
Ech1 0.45 0.63 0.30 0.024 0.001 ns
Echdc2 4.24 0.78 3.00 ns 0.012 ns
Hadha 0.45 0.88 0.63 ns 0.01 ns
Lrp1 0.59 1.13 0.78 ns 0.001 ns
Pla2g2a 37.14 1.13 17.23 0.002 <0.0001 0.002
Ptgis 0.11 1.41 0.15 ns 0.01 ns
Ptgs1 0.55 0.53 0.40 ns ns ns
Ptgs2 5.15 0.97 6.50 ns 0.001 ns
Steap4 4.74 1.74 5.84 ns 0.002 ns
Gene
Mean Relative Quantity of gene expression to Min normal p value
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Figure 4-3 Genes implicated in fatty acid & lipid metabolism 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of APCMin/+ 
tumour, APCMin/+33$5Į-/- normal and APCMin/+33$5Į-/- tumour groups to expression in APCMin/+ 
normal, where RQ was >= 2 or <= to 0.5 
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x Signal transduction 
Table 4-3 and Figure 4-4 show expression data for genes implicated in 
signal transduction.  
Expression of Ptger3 (prostaglandin E receptor 3, subtype EP3) was 
reduced in tumours with fold change decreases of 6.1 in APCMin/+ 
tumour samples and 5.5 in APCMin/+PPARĮ-/- tumour samples (p < 
0.0001). Expression of Gulp1 (GULP, engulfment adaptor PTB domain 
containing 1) was reduced in APCMin/+ tumour samples only with a fold 
change reduction of 2.8 (p is not significant, ns). However, expression 
of Ereg (epiregulin), Krt18 (keratin 18), Lama1 (laminin, alpha 1), 
Lama5 (laminin, alpha 5), Rhoj (ras homolog gene family, member J) 
and Tnf (tumour necrosis factor) were increased in tumours. Fold 
change increases in expression were 2.7 and 3.8 in Ereg (p = 0.007), 
2.2 and 2.0 in Krt18 (p < 0.0001), 5.1 and 6.0 in Lama1 (p < 0.0001), 
3.7 and 4.4 in Lama5 (p = 0.001), 3.2 and 2.3 in Rhoj (p = 0.001), and 
3.7 and 2.5 in Tnf (p = 0.002) in APCMin/+ tumour and APCMin/+PPARĮ-/- 
tumour samples respectively.  
Large increases in expression in tumours were observed in Apcdd1 
(adenomatosis polyposis coli down-regulated 1), Il1b (interleukin 1 
beta), Il6 (interleukin 6), Inhba (inhibin beta-A) and Ppbp (pro-platelet 
basic protein). Fold change increases of 18.0 and 10.0 in Apcdd1 (p = 
0.007), 6.7 and 15.9 in Il1b (p = 0.001), 7.9 and 19.9 in Il6 (p < 0.0001), 
12.2 and 20.5 in Inhba (p < 0.0001)) and 10.2 and 7.8 in Ppbp (p = 
0.003) were recorded in APCMin/+ tumour and APCMin/+PPARĮ-/- tumour 
samples respectively. Expression of Tnf was reduced 2.7 fold in 
APCMin/+PPARĮ-/- normal samples and increased 2.5 fold in 
APCMin/+PPARĮ-/- tumour samples (p is ns). There was also a fold 
change decrease of 2.4 in Apcdd1 expression in APCMin/+PPARĮ-/- 
normal samples, whilst in APCMin/+PPARĮ-/- tumour samples there was a 
fold change increase of 10.0 (p is ns). There was significant interaction 
between PPARĮ status and tissue type in the expression of Il6 (p = 
0.022).
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Table 4-3 Genes implicated in signal transduction 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ tumour, APCMin/+33$5Į-/- normal and APCMin/+33$5Į-/- tumour samples to expression in APCMin/+ normal sample 76.4/1. 
Univariate analysis of variance of APCMin/+ and APCMin/+ PPARɲ-/- groups was used to determine differentially expressed genes with p <= 0.05 (ns - not significant)
Min tumour 33$5ĮQRUPDO 33$5ĮWXPRXU Effect of 33$5Į
Effect of 
tissue
Interaction between 
33$5Į	WLVVXH
Apcdd1 17.95 0.42 9.96 ns 0.007 ns
Ereg 2.65 1.24 3.83 ns 0.007 ns
Ghr 0.69 0.85 0.67 ns 0.012 ns
Gulp1 0.36 0.77 0.68 ns ns ns
Il1b 6.75 0.74 15.86 ns 0.001 ns
Il6 7.88 1.40 19.92 0.016 <0.0001 0.022
Inhba 12.17 2.08 20.51 ns <0.0001 ns
Krt18 2.23 1.25 1.99 ns <0.0001 ns
Lama1 5.07 0.85 6.01 ns <0.0001 ns
Lama5 3.68 1.07 4.43 ns 0.001 ns
Ppbp 10.21 1.10 7.77 ns 0.003 ns
Ptger3 0.16 0.71 0.18 ns <0.0001 ns
Rhoj 3.17 1.05 2.26 ns 0.001 ns
Sfrp1 0.98 1.25 1.45 ns ns ns
Tnf 3.71 0.37 2.47 ns 0.002 ns
Gene
Mean Relative Quantity of gene expression to Min normal p value
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Figure 4-4 Genes implicated in signal transduction 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of APCMin/+ 
tumour, APCMin/+33$5Į-/- normal and APCMin/+33$5Į-/- tumour groups to expression in APCMin/+ 
normal, where RQ was >= 2 or <= to 0.5 
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x Transcription 
Table 4-4 and Figure 4-5 show expression data for genes implicated in 
transcription.  
Expression decreased in Gucy2c (guanylate cyclase 2c), Meis1 (Meis 
homeobox 1), Nr1d1 (nuclear receptor subfamily 1, group D), Id4 
(inhibitor of DNA binding 4), Klf4 (Kruppel-like factor 4, gut) and Rorc 
(RAR-related orphan receptor gammaRAR-related orphan receptor 
gamma); fold change decreases of 2.5 and 2.9 in expression of Gucy2c 
(p < 0.0001), 2.2 and 3.5 in Meis1 (p = 0.029), 3.4 and 3.5 in Nr1d1 (p = 
0.001), 4.1 and 4.5 in Id4 (p = 0.001), 4.1 and 6.1 in Klf4 (p < 0.0001), 
and 5.4 and 7.1 in Rorc (p < 0.0001) were recorded in APCMin/+ tumour 
and APCMin/+PPARĮ-/- tumour samples respectively.  
Expression of Ang (angiogenin), Cbx7 (chromobox homolog 7) and 
Pou2af1 (POU domain, class 2, associating factor 1) decreased in 
APCMin/+PPARa-/- tumour samples only with fold change reductions of 
4.5 in Ang (p is ns), 2.2 in Cbx7 (p is ns) and 2.5 in Pou2af1 (p is ns) 
respectively.  
Expression of Myc (myelocytomatosis oncogene), Rbms1 (RNA binding 
motif, single stranded interacting protein 1), Arnt2 (aryl hydrocarbon 
receptor nuclear translocator 2), Foxc2 (forkhead box C2) and Rarb 
(retinoic acid receptor, beta) increased in tumours. Fold change 
increases of 2.4 and 2.3 in Myc (p < 0.0001), 2.1 and 2.4 in Rbms1 (p = 
0.009), 3.5 and 6.8 in Arnt2 (p < 0.0001), 5.3 and 2.8 in Foxc2 (p = 
0.006), and 3.4 and 3.5 in Rarb (p = 0.019) were observed in APCMin/+ 
tumour and APCMin/+PPARĮ-/- tumour samples respectively.  
A massive increase of Onecut2 expression (p < 0.0001) in tumours was 
seen with fold change increases of 145.8 in APCMin/+ tumour and 196.8 
in APCMin/+PPARĮ-/- tumour samples.  
Expression of Tcf12 (transcription factor 12) increased in APCMin/+ 
tumour samples only with a fold change increase of 2.5 (p = 0.003). 
Expression of Arnt2 was reduced 2.1 fold in APCMin/+PPARĮ-/- normal 
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samples but increased 6.8 fold in APCMin/+PPARĮ-/- tumour samples (p 
is ns).  
A similar pattern was observed for expression of Rarb; expression in 
APCMin/+PPARĮ-/- normal samples decreased 2.3 fold, whereas 
expression increased 3.5 fold in APCMin/+PPARĮ-/- tumour samples (p is 
ns). 
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Table 4-4 Genes implicated in transcription 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ tumour, APCMin/+33$5Į-/- normal and APCMin/+33$5Į-/- tumour samples to expression in APCMin/+ normal sample 76.4/1. 
Univariate analysis of variance of APCMin/+ and APCMin/+ PPARɲ-/- groups was used to determine differentially expressed genes with p <= 0.05 (ns - not significant) 
Min tumour 33$5ĮQRUPDO 33$5ĮWXPRXU Effect of 33$5Į
Effect of 
tissue
Interaction between 
33$5Į	WLVVXH
Ang 0.78 0.61 0.22 0.014 ns ns
Arnt2 3.49 0.48 6.75 ns <0.0001 ns
Baz1a 1.37 0.76 1.46 ns 0.007 ns
Cbx7 1.45 0.61 0.45 0.002 ns ns
Chd8 1.01 0.85 0.82 ns ns ns
Crem 1.65 1.03 1.02 ns ns ns
Foxc2 5.27 0.65 2.83 ns 0.006 ns
Gucy2c 0.40 0.70 0.35 ns <0.0001 ns
Id4 0.24 1.20 0.22 ns 0.001 ns
Jun 1.49 0.61 1.36 ns 0.004 ns
Klf4 0.24 0.64 0.16 0.024 <0.0001 ns
Meis1 0.45 1.28 0.29 ns 0.029 ns
Myc 2.44 0.77 2.30 ns <0.0001 ns
Nfkbie 1.61 0.90 1.80 ns 0.014 ns
Nr1d1 0.30 0.73 0.28 ns 0.001 ns
Onecut2 145.82 1.01 196.83 ns <0.0001 ns
Phf17 0.58 0.88 0.56 ns 0.01 ns
Pou2af1 0.56 0.52 0.40 ns ns ns
Rarb 3.35 0.44 3.50 ns 0.019 ns
Rbms1 2.14 1.54 2.44 ns 0.009 ns
Rorc 0.19 0.55 0.14 0.021 <0.0001 ns
Tcf12 2.48 0.76 1.48 ns 0.003 ns
Gene
Mean Relative Quantity of gene expression to Min normal p value
137 
 
 
Figure 4-5 Genes implicated in transcription 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of APCMin/+ 
tumour, APCMin/+33$5Į-/- normal and APCMin/+33$5Į-/- tumour groups to expression in APCMin/+ 
normal, where RQ was >= 2 or <= to 0.5 
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x Cell cycle 
Table 4-5 and Figure 4-6 show expression data for genes implicated in 
the cell cycle.  
Expression of Bin1 (bridging integrator 1) decreased in tumours (p = 
0.003) with fold change decreases of 2.4 in APCMin/+ tumour samples 
and 7.7 in APCMin/+PPARĮ-/- tumour samples.  
However, expression of Apobec3 (apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide 3), Ccnd1 (cyclin D1) and Cdkn1c (cyclin-
dependent kinase inhibitor 1C, P57) increased in tumours. Fold change 
increases of 2.1 and 128.7 in Apobec3 (p = 0.035), 3.0 and 2.7 in 
Ccnd1 (p < 0.0001), and 2.2 and 2.1 in Cdkn1c (p = 0.001) were 
observed in APCMin/+ tumour and APCMin/+PPARĮ-/- tumour groups 
respectively.  
Expression of Cdkn1c decreased 2.1 fold in APCMin/+PPARĮ-/- normal 
samples and increased 2.1 fold in APCMin/+PPARĮ-/- tumour samples (p 
is not significant).  
There was a very large increase in expression of Apobec3 (p < 0.0001) 
in APCMin/+PPARĮ-/- normal samples and APCMin/+PPARĮ-/- tumour 
samples with fold change increases of 77.9 and 128.7 respectively.  
There was also significant interaction between PPARĮ status and tissue 
type in the level of expression of Apobec3 (p = 0.042). 
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Table 4-5 Genes implicated in the cell cycle 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ tumour, APCMin/+33$5Į-/- normal and 
APCMin/+33$5Į-/- tumour samples to expression in APCMin/+ normal sample 76.4/1. Univariate analysis 
of variance of APCMin/+ and APCMin/+ PPARɲ-/- groups was used to determine differentially expressed 
genes with p <= 0.05 (ns - not significant) 
 
 
Figure 4-6 Genes implicated in the cell cycle 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of APCMin/+ 
tumour, APCMin/+33$5Į-/- normal and APCMin/+33$5Į-/- tumour groups to expression in APCMin/+ 
normal, where RQ was >= 2 or <= to 0.5 
Min tumour 33$5ĮQRUPDO 33$5ĮWXPRXU Effect of 33$5Į
Effect of 
tissue
Interaction between 
33$5Į	WLVVXH
Apobec3 2.07 77.89 128.68 <0.0001 0.035 0.042
Bin1 0.42 0.87 0.13 ns 0.003 ns
Ccnd1 2.97 1.22 2.65 ns <0.0001 ns
Cdkn1c 2.22 0.47 2.08 ns 0.001 ns
Gene
Mean Relative Quantity of gene expression to Min normal p value
0.10 1.00 10.00 100.00 1000.00
Apobec3
Bin1
Ccnd1
Cdkn1c
Proportion of Min normal
G
e
n
e
Relative Quantity of Gene Expression to 
Min Normal samples
Min tumour PPARɲ-/- normal PPARɲ-/- tumour
140 
 
x Apoptosis 
Table 4-6 and Figure 4-7 show expression data for genes implicated in 
apoptosis.  
Expression of Endod1 (endonuclease domain containing 1) decreased 
in tumours (p < 0.0001) with fold change decreases of 3.2 in APCMin/+ 
tumour samples and 4.0 in APCMin/+PPARĮ-/- tumour samples.  
Expression of Bcl2l11 (BCL2-like 11, apoptosis facilitator) and Bmf 
(BCL2 modifying factor) increased in tumours. Bcl2l11 (p < 0.0001) and 
Bmf (p = 0.005) had fold change increases of 2.8 and 3.2, and 4.1 and 
3.6, in APCMin/+ tumour and APCMin/+PPARĮ-/- tumour groups 
respectively. Khdc1a (KH domain containing 1A) had decreased 
expression in APCMin/+PPARĮ-/- samples. Fold change decreases of 4.0 
in APCMin/+PPARĮ-/- normal and 3.4 in APCMin/+PPARĮ-/- tumour samples 
were observed (p = 0.005). Bik (BCL2-interacting killer) had a 2.2 fold 
decrease in expression in APCMin/+PPARĮ-/- normal samples only (p = 
0.001)
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Table 4-6 Genes implicated in apoptosis 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ tumour, APCMin/+33$5Į-/- normal and 
APCMin/+33$5Į-/- tumour samples to expression in APCMin/+ normal sample 76.4/1. Univariate analysis 
of variance of APCMin/+ and APCMin/+ PPARɲ-/- groups was used to determine differentially expressed 
genes with p <= 0.05 (ns - not significant) 
 
 
Figure 4-7 Genes implicated in apoptosis 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of APCMin/+ 
tumour, APCMin/+33$5Į-/- normal and APCMin/+P3$5Į-/- tumour groups to expression in APCMin/+ 
normal, where RQ was >= 2 or <= to 0.5 
Min tumour 33$5ĮQRUPDO 33$5ĮWXPRXU Effect of 33$5Į
Effect of 
tissue
Interaction between 
33$5Į	WLVVXH
Apaf1 1.89 0.86 1.51 ns <0.0001 ns
Bcl2l11 2.80 0.88 3.20 ns <0.0001 ns
Bik 1.82 0.46 0.72 0.001 0.016 ns
Bmf 4.13 1.08 3.60 ns 0.005 ns
Endod1 0.31 0.81 0.25 ns <0.0001 ns
Khdc1a 1.91 0.25 0.29 0.005 ns ns
Sbk1 1.85 0.98 1.70 ns 0.011 ns
Gene
Mean Relative Quantity of gene expression to Min normal p value
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x Protein transport 
Table 4-7 and Figure 4-8 show expression data for genes implicated in 
protein transport.  
Expression of Ap1s3 (adaptor-related protein complex AP-1, sigma 3) 
and Crip1 (cysteine-rich protein 1, intestinal) decreased in tumours. 
Fold change decreases of 2.2 and 3.0 in Ap1s3 (p < 0.0001) and 2.2 
and 2.3 in Crip1 (p = 0.001) in APCMin/+ tumour samples and 
APCMin/+PPARĮ-/- tumour samples respectively, were recorded. Large 
increases in Alb (albumin) expression in tumours were observed with 
fold change increases of 28.0 in  APCMin/+ tumour samples and 7.7 in 
APCMin/+PPARĮ-/- tumour samples (p = 0.003).  
Table 4-7 Genes implicated in protein transport 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ tumour, APCMin/+33$5Į-/- normal and 
APCMin/+33$5Į-/- tumour samples to expression in APCMin/+ normal sample 76.4/1. Univariate analysis 
of variance of APCMin/+ and APCMin/+ PPARɲ-/- groups was used to determine differentially expressed 
genes with p <= 0.05 (ns - not significant) 
 
 
Figure 4-8 Genes implicated in protein transport 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of APCMin/+ 
tumour, APCMin/+33$5Į-/- normal and APCMin/+33$5Į-/- tumour groups to expression in APCMin/+ 
normal, where RQ was >= 2 or <= to 0.5 
Min tumour 33$5ĮQRUPDO 33$5ĮWXPRXU Effect of 33$5Į
Effect of 
tissue
Interaction between 
33$5Į	WLVVXH
Abcc4 1.49 0.92 1.22 ns ns ns
Alb 28.02 1.17 7.65 0.046 0.003 0.043
Ap1s3 0.46 1.01 0.34 ns <0.0001 ns
Crip1 0.46 1.39 0.44 ns 0.001 ns
Gene
Mean Relative Quantity of gene expression to Min normal p value
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x Protein metabolism & modification 
Table 4-8 and Figure 4-9 show expression data for genes implicated in 
protein metabolism and modification.  
Expression of Pdk2 (pyruvate dehydrogenase kinase, isoenzyme 2) and 
Mep1b (meprin 1 beta) decreased in tumours with fold change 
decreases of 3.7 and 3.9 in Pdk2 (p < 0.0001), and 5.5 and 2.8 in 
Mep1b (p = 0.003) in APCMin/+ tumour and APCMin/+PPARĮ-/- tumour 
samples respectively.  
Expression of Akt3 (thymoma viral proto-oncogene 3) and Irak4 
(interleukin-1 receptor-associated kinase 4) decreased in 
APCMin/+PPARĮ-/- tumour samples only with fold change decreases of 
2.8 in Akt3 (p = 0.042) and 2.2 in Irak4 (p = 0.021). 
Expression of Casp6 (caspase 6), Cdk4 (cyclin-dependent kinase 4), 
Htra1 (HtrA serine peptidase 1), Timp1 (tissue inhibitor of 
metalloproteinase 1), Mmp7 (matrix metallopeptidase 7) and Plat 
(plasminogen activator, tissue) increased in tumours. Fold change 
increases were 2.9 and 2.5 in Casp6 (p = 0.001), 2.3 and 2.1 in Cdk4 (p 
< 0.0001), 4.6 and 2.6 in Htra1 (p = 0.014), and 4.9 and 5.1 in Timp1 (p 
= 0.019), and 21.0 and 20.8 in Plat (p = 0.001) in APCMin/+ tumour and 
APCMin/+PPARĮ-/- tumour samples respectively.  
There was a large increase in expression of Mmp7 (p < 0.0001); fold 
change increases of 185.4 in APCMin/+ tumour samples and 146.4 in 
APCMin/+PPARĮ-/- tumour samples were observed. Timp1 expression 
increased 2.4 fold in APCMin/+PPARĮ-/- normal samples and 5.1 fold in 
APCMin/+PPARĮ-/- tumour samples (p is ns). However, expression of 
Irak4 decreased approximately 2-fold in both APCMin/+PPARĮ-/- normal 
and tumour samples (p < 0.0001). 
144 
 
Table 4-8 Genes implicated in protein metabolism & modification 
 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ tumour, APCMin/+33$5Į-/- normal and 
APCMin/+33$5Į-/- tumour samples to expression in APCMin/+ normal sample 76.4/1. Univariate analysis 
of variance of APCMin/+ and APCMin/+ PPARɲ-/- groups was used to determine differentially expressed 
genes with p <= 0.05 (ns - not significant) 
 
 
Figure 4-9 Genes implicated in protein metabolism & modification 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of APCMin/+ 
tumour, APCMin/+33$5Į-/- normal and APCMin/+33$5Į-/- tumour groups to expression in APCMin/+ 
normal, where RQ was >= 2 or <= to 0.5 
Min tumour 33$5ĮQRUPDO 33$5ĮWXPRXU Effect of 33$5Į
Effect of 
tissue
Interaction between 
33$5Į	WLVVXH
Akt3 0.55 0.99 0.36 ns 0.042 ns
B4galt6 1.45 0.74 1.65 ns 0.001 ns
Casp6 2.85 0.90 2.47 ns 0.001 ns
Cdk4 2.29 0.90 2.14 ns <0.0001 ns
Htra1 4.56 0.98 2.61 ns 0.014 ns
Irak4 0.78 0.54 0.46 <0.0001 0.021 ns
Mep1b 0.18 0.94 0.35 ns 0.003 ns
Mmp2 1.57 1.18 1.58 ns ns ns
Mmp7 185.40 1.38 146.44 ns <0.0001 ns
Pdk2 0.27 0.72 0.26 ns <0.0001 ns
Plat 21.02 1.66 20.81 ns 0.001 ns
Ptprg 1.27 0.69 0.89 0.01 ns ns
Timp1 4.89 2.38 5.06 ns 0.019 ns
Gene
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x Cell adhesion 
Table 4-9 and Figure 4-10 show expression data for genes implicated in 
cell adhesion.  
Expression of Sell (selectin) decreased 2.9 fold in APCMin/+ tumour 
samples and approximately 2-fold in APCMin/+PPARĮ-/- tumour samples 
(p is ns). Expression of Itga6 (integrin alpha 6) increased 2.1 fold in 
APCMin/+ tumour samples only (p = 0.001). Sell expression also 
decreased in APCMin/+PPARĮ-/- normal samples with a fold change 
decrease of 4.2 (p is ns). 
Table 4-9 Genes implicated in cell adhesion 
 
 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ tumour, APCMin/+33$5Į-/- normal and 
APCMin/+33$5Į-/- tumour samples to expression in APCMin/+ normal sample 76.4/1. Univariate analysis 
of variance of APCMin/+ and APCMin/+ PPARɲ-/- groups was used to determine differentially expressed 
genes with p <= 0.05 (ns - not significant) 
 
 
 
 
Figure 4-10 Genes implicated in cell adhesion 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of APCMin/+ 
tumour, APCMin/+33$5Į-/- normal and APCMin/+33$5Į-/- tumour groups to expression in APCMin/+ 
normal, where RQ was >= 2 or <= to 0.5 
 
Min tumour 33$5ĮQRUPDO 33$5ĮWXPRXU Effect of 33$5Į
Effect of 
tissue
Interaction between 
33$5Į	WLVVXH
Ctgf 1.29 1.10 1.13 ns ns ns
Itga6 2.09 1.23 1.83 ns 0.001 ns
Sell 0.34 0.24 0.53 ns ns ns
Gene
Mean Relative Quantity of gene expression to Min normal p value
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x Various cellular functions 
Table 4-10 and Figure 4-11 show expression of genes implicated in 
toxin metabolism, amino acid metabolism and cellular structure.  
Expression of Aoc3 (amine oxidase, copper containing 3), Cbr1 
(carbonyl reductase 1) and Cryab (crystallin, alpha B) decreased in 
tumours with fold change decreases of 3.4 and 2.5 in Aoc3 (p = 0.013), 
3.5 and 3.6 in Cbr1 (p < 0.0001), and 3.2 and 3.3 in Cryab (p < 0.0001) 
in APCMin/+ tumour and APCMin/+PPARĮ-/- tumour samples respectively.   
Expression of Nisch (nischarin) was slightly elevated in tumour samples 
(p = 0.009).   
Expression of genes in this group did not appear to be affected by 
PPARĮ.  
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Table 4-10 Genes involved in various cellular functions 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ tumour, APCMin/+33$5Į-/- normal and 
APCMin/+33$5Į-/- tumour samples to expression in APCMin/+ normal sample 76.4/1. Univariate analysis 
of variance of APCMin/+ and APCMin/+ PPARɲ-/- groups was used to determine differentially expressed 
genes with p <= 0.05 (ns - not significant) 
 
.  
Figure 4-11 Genes involved in various cellular functions 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of APCMin/+ 
tumour, APCMin/+33$5Į-/- normal and APCMin/+33$5Į-/- tumour groups to expression in APCMin/+ 
normal, where RQ was >= 2 or <= to 0.5 
Min tumour 33$5ĮQRUPDO 33$5ĮWXPRXU Effect of 33$5Į
Effect of 
tissue
Interaction between 
33$5Į	WLVVXH
Aoc3 0.29 1.12 0.40 ns 0.013 ns
Cbr1 0.29 0.72 0.28 ns <0.0001 ns
Cryab 0.31 0.95 0.30 ns <0.0001 ns
Nisch 1.24 0.86 1.26 ns 0.009 ns
Gene
Mean Relative Quantity of gene expression to Min normal p value
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4.4.2 Ingenuity® Pathway Analysis (IPA®) networks of Taqman® 
low density array data 
 
Figure 4-12 and Figure 4-13 show IPA networks of Taqman® low 
density array data for genes where expression may be influenced by 
PPARĮ and tissue type respectively.  
Figure 4-12 was annotated with the PPARĮ signalling pathway and 
shows Il6 (interleukin 6) was a central regulatory gene in this network. 
This corresponds with IPA networks of Affymetrix® microarray data 
(Figure 3-15 and Figure 3-18) which indicate a similar regulatory role for 
Il6. 
Figure 4-13 was annotated with the Wnt/beta catenin, p53 and 
ERK/MAPK signalling pathways. These pathways targeted similar 
genes to IPA networks of Affymetrix® microarray data as shown 
previously.  
The Wnt/ȕ catenin and ERK/MAPK signalling pathways were 
associated with Myc (myelocytomatosis oncogene) gene expression as 
previously demonstrated. Similarly, p53 signalling targeted Casp6 
(caspase 6) as shown before (Figure 3-10 and Figure 3-14). 
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Figure 4-12 IPA network of significantly expressed genes (p <= 0.05) affected by PPARĮ 
Network is annotated with the 33$5Į/RXRĮ pathway. Network p value, p = 1.09E-05 
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Figure 4-13 IPA network of significantly expressed genes (p <= 0.009) affected by tissue type 
Network is annotated with the Wnt/beta ± catenin, p53 and ERK/MAPK signalling pathways. Network 
p value, p = 4.42E-09 
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4.4.3 Comparison of relative quantity of gene expression in 
Taqman® low density arrays & Affymetrix® microarrays 
 
Pairs of Relative Quantity (RQ) values from Taqman® low density 
arrays vs. Affymetrix® Microarrays (Table 4-11a-c) were compared on 
scatter plots and clustered bar charts.  
APCMin/+ tumour vs. APCMin/+ tumour was shown in Figure 4-14 and 
Figure 4-17.  
APCMin/+ PPARɲ-/- normal vs. APCMin/+ PPARɲ-/- normal was shown in 
Figure 4-15 and Figure 4-18.  
APCMin/+ PPARɲ-/- tumour vs. APCMin/+ PPARɲ-/- tumour was shown in 
Figure 4-16 and Figure 4-19. 
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Table 4-11 Comparison of relative quantity (to APCMin/+ normal) in Taqman® low density arrays & 
Affymetrix® microarrays (a) 
 
Relative quantity of gene expression in APCMin/+ tumour, APCMin/+ PPARɲ-/- normal and APCMin/+ 
PPARɲ-/- tumour groups to APCMin/+ normal; Affymetrix® microarrays and Taqman® low density 
arrays 
 
GENE
Min 
tumour 
33$5Į-/- 
normal 
33$5Į-/- 
tumour GENE 
Min 
tumour
33$5Į-/- 
normal 
33$5Į-/- 
tumour 
Abcc4 1.49 0.92 1.22 Abcc4 3.74 0.75 3.07
Acot2 0.65 0.80 0.54 Acot2 0.70 0.68 0.71
Akt3 0.55 0.99 0.36 Akt3 0.69 1.23 0.81
Alb 28.02 1.17 7.65 Alb 19.19 1.23 7.04
Alox12 36.27 1.54 29.74 Alox12 17.05 0.98 8.74
Alox15 4.30 1.35 2.02 Alox15 2.78 1.33 1.69
Alox5ap 1.70 1.04 1.78 Alox5ap 1.45 1.16 2.00
Ang 0.78 0.61 0.22 Ang 0.79 0.26 0.17
Angptl4 0.39 0.14 0.29 Angptl4 1.22 0.91 1.59
Aoc3 0.29 1.12 0.40 Aoc3 0.19 0.71 0.24
Ap1s3 0.46 1.01 0.34 Ap1s3 0.54 0.79 0.48
Apaf1 1.89 0.86 1.51 Apaf1 2.20 1.30 2.25
Apcdd1 17.95 0.42 9.96 Apcdd1 22.48 0.92 7.51
Apobec3 2.07 77.89 128.68 Apobec3 3.19 0.57 0.91
Arnt2 3.49 0.48 6.75 Arnt2 1.52 1.00 2.51
B4galt6 1.45 0.74 1.65 B4galt6 1.58 0.87 1.73
Baz1a 1.37 0.76 1.46 Baz1a 1.82 1.01 2.09
Bcl2l11 2.80 0.88 3.20 Bcl2l11 2.72 0.97 2.59
Bdh1 0.40 0.62 0.35 Bdh1 0.36 0.88 0.39
Bik 1.82 0.46 0.72 Bik 1.19 0.66 0.73
Bin1 0.42 0.87 0.13 Bin1 0.82 0.99 0.84
Bmf 4.13 1.08 3.60 Bmf 1.59 0.94 1.45
Casp6 2.85 0.90 2.47 Casp6 2.60 0.83 2.09
Cbr1 0.29 0.72 0.28 Cbr1 0.35 0.78 0.35
Cbx7 1.45 0.61 0.45 Cbx7 0.86 0.68 0.60
Ccnd1 2.97 1.22 2.65 Ccnd1 2.79 1.22 2.44
Cdk4 2.29 0.90 2.14 Cdk4 2.64 1.06 2.20
Cdkn1c 2.22 0.47 2.08 Cdkn1c 2.55 0.57 1.76
Chd8 1.01 0.85 0.82 Chd8 1.03 0.89 0.93
Crem 1.65 1.03 1.02 Crem 1.75 1.04 1.97
Crip1 0.46 1.39 0.44 Crip1 0.57 1.26 0.53
Cryab 0.31 0.95 0.30 Cryab 0.57 1.09 0.58
Ctgf 1.29 1.10 1.13 Ctgf 1.78 0.96 1.69
Cyp11a1 17.03 1.68 17.78 Cyp11a1 2.18 1.01 2.59
Cyp2b10 97.33 0.91 37.63 Cyp2b10 3.43 0.80 1.59
Cyp2c55 0.04 0.50 0.09 Cyp2c55 0.04 0.30 0.10
Decr1 0.41 0.70 0.45 Decr1 0.54 0.94 0.66
Ech1 0.45 0.63 0.30 Ech1 0.43 0.80 0.48
Echdc2 4.24 0.78 3.00 Echdc2 3.26 0.92 2.37
Taqman arrays 
Relative Quantity to APCMin/+  normal 
(76.4/1)
Microarrays 
Relative Quantity to APCMin/+  normal 
(76.4/1)
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Comparison of relative quantity (to APCMin/+ normal) in Taqman® low density arrays & Affymetrix® 
microarrays (b) 
 
 
 
Relative quantity of gene expression in APCMin/+ tumour, APCMin/+ PPARɲ-/- normal and APCMin/+ 
PPARɲ-/- tumour groups to APCMin/+ normal; Affymetrix® microarrays and Taqman® low density 
arrays 
GENE
Min 
tumour 
33$5Į-/- 
normal 
33$5Į-/- 
tumour GENE 
Min 
tumour
33$5Į-/- 
normal 
33$5Į-/- 
tumour 
Endod1 0.31 0.81 0.25 Endod1 0.45 0.99 0.59
Ereg 2.65 1.24 3.83 Ereg 2.79 1.33 6.08
Foxc2 5.27 0.65 2.83 Foxc2 3.97 0.94 2.27
Ghr 0.69 0.85 0.67 Ghr 0.68 0.87 0.87
Gucy2c 0.40 0.70 0.35 Gucy2c 0.45 0.80 0.49
Gulp1 0.36 0.77 0.68 Gulp1 0.54 0.91 0.83
Hadha 0.45 0.88 0.63 Hadha 0.53 0.84 0.60
Htra1 4.56 0.98 2.61 Htra1 4.01 0.96 3.14
Id4 0.24 1.20 0.22 Id4 0.28 1.20 0.35
Il1b 6.75 0.74 15.86 Il1b 5.71 1.09 12.77
Il6 7.88 1.40 19.92 Il6 3.95 0.96 17.16
Inhba 12.17 2.08 20.51 Inhba 3.47 1.38 5.12
Irak4 0.78 0.54 0.46 Irak4 0.95 0.53 0.50
Itga6 2.09 1.23 1.83 Itga6 1.84 1.19 1.83
Jun 1.49 0.61 1.36 Jun 1.95 0.79 1.71
Khdc1a 1.91 0.25 0.29 Khdc1a 16.15 1.07 3.85
Klf4 0.24 0.64 0.16 Klf4 0.35 1.00 0.33
Krt18 2.23 1.25 1.99 Krt18 2.11 1.20 2.07
Lama1 5.07 0.85 6.01 Lama1 3.31 1.10 4.39
Lama5 3.68 1.07 4.43 Lama5 2.19 1.02 1.74
Lrp1 0.59 1.13 0.78 Lrp1 0.59 0.94 0.69
Meis1 0.45 1.28 0.29 Meis1 0.50 0.90 0.53
Mep1b 0.18 0.94 0.35 Mep1b 0.23 0.76 0.33
Mmp2 1.57 1.18 1.58 Mmp2 1.74 1.10 1.80
Mmp7 185.40 1.38 146.44 Mmp7 77.85 0.95 62.22
Myc 2.44 0.77 2.30 Myc 2.55 1.07 2.56
Nfkbie 1.61 0.90 1.80 Nfkbie 1.81 0.95 1.90
Nisch 1.24 0.86 1.26 Nisch 1.36 0.82 1.05
Nr1d1 0.30 0.73 0.28 Nr1d1 0.55 0.92 0.45
Onecut2 145.82 1.01 196.83 Onecut2 30.66 1.02 44.91
Pdk2 0.27 0.72 0.26 Pdk2 0.42 0.97 0.32
Phf17 0.58 0.88 0.56 Phf17 0.76 1.30 1.10
Pla2g2a 37.14 1.13 17.23 Pla2g2a 45.93 1.71 23.99
Plat 21.02 1.66 20.81 Plat 6.43 1.07 8.11
Pou2af1 0.56 0.52 0.40 Pou2af1 0.41 0.60 0.75
Ppbp 10.21 1.10 7.77 Ppbp 5.95 0.99 6.44
Ptger3 0.16 0.71 0.18 Ptger3 0.58 1.13 0.63
Ptgis 0.11 1.41 0.15 Ptgis 0.61 1.02 0.65
Ptgs1 0.55 0.53 0.40 Ptgs1 0.59 0.63 0.47
Ptgs2 5.15 0.97 6.50 Ptgs2 3.84 1.03 8.85
Ptprg 1.27 0.69 0.89 Ptprg 1.56 0.73 0.99
Rarb 3.35 0.44 3.50 Rarb 2.44 0.63 3.56
Taqman arrays 
Relative Quantity to APCMin/+  normal 
(76.4/1)
Microarrays 
Relative Quantity to APCMin/+  normal 
(76.4/1)
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Comparison of relative quantity (to APCMin/+ normal) in Taqman® low density arrays & Affymetrix® 
microarrays (c) 
 
Relative quantity of gene expression in APCMin/+ tumour, APCMin/+ PPARɲ-/- normal and APCMin/+ 
PPARɲ-/- tumour groups to APCMin/+ normal; Affymetrix® microarrays and Taqman® low density 
arrays 
 
GENE
Min 
tumour 
33$5Į-/- 
normal 
33$5Į-/- 
tumour GENE 
Min 
tumour
33$5Į-/- 
normal 
33$5Į-/- 
tumour 
Rbms1 2.14 1.54 2.44 Rbms1 1.89 1.09 1.95
Rhoj 3.17 1.05 2.26 Rhoj 2.68 1.05 2.22
Rorc 0.19 0.55 0.14 Rorc 0.45 0.93 0.43
Sbk1 1.85 0.98 1.70 Sbk1 2.13 0.94 1.82
Sell 0.34 0.24 0.53 Sell 1.00 0.66 1.33
Sfrp1 0.98 1.25 1.45 Sfrp1 1.22 1.55 2.27
Steap4 4.74 1.74 5.84 Steap4 3.19 1.30 4.61
Tcf12 2.48 0.76 1.48 Tcf12 2.02 0.94 1.69
Timp1 4.89 2.38 5.06 Timp1 4.18 1.58 5.50
Tnf 3.71 0.37 2.47 Tnf 1.98 0.87 1.75
Taqman arrays 
Relative Quantity to APCMin/+  normal 
(76.4/1)
Microarrays 
Relative Quantity to APCMin/+  normal 
(76.4/1)
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Figure 4-14 Differential expression of genes in tumour vs. normal tissue taken from APCMin/+ mice as 
assessed by Taqman® low density arrays & Affymetrix® microarrays 
Relative Quantity (RQ) of gene expression in tumour tissue compared to normal tissue in APCMin/+ 
mice assessed by Taqman® low density arrays and Affymetrix® microarrays represented on a log10 
scatter plot 
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Figure 4-15 Differential expression of genes in normal tissue taken from APCMin/+ 33$5Į-/- mice vs. 
normal tissue taken from APCMin/+ mice as assessed by Taqman® low density arrays & Affymetrix® 
microarrays 
Relative Quantity (RQ) of gene expression in normal tissue of APCMin/+ 33$5Į-/- mice compared to 
normal tissue in APCMin/+ mice assessed by Taqman® low density arrays and Affymetrix® 
microarrays represented on a log10 scatter plot 
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Figure 4-16 Differential expression of genes in tumour tissue taken from APCMin/+ 33$5Į-/- mice vs. 
normal tissue taken from APCMin/+ mice as assessed by Taqman® low density arrays & Affymetrix® 
microarrays  
Relative Quantity (RQ) of gene expression in tumour tissue of APCMin/+ 33$5Į-/- mice compared to 
normal tissue in APCMin/+ mice assessed by Taqman® low density arrays and Affymetrix® 
microarrays represented on a log10 scatter plot 
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Figure 4-17 Differential expression of genes in tumour vs. normal tissue taken from APCMin/+ mice as 
assessed by Taqman® low density arrays & Affymetrix® microarrays 
Relative quantity (RQ) of gene expression in tumour tissue compared to normal tissue in APCMin/+ 
mice assessed by Taqman® low density array (blue bars) and Affymetrix® microarray (red bars) 
represented on log10 scale bar chart 
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Figure 4-18 Differential expression of genes in normal tissue taken from APCMin/+ 33$5Į-/- mice vs. 
normal tissue taken from APCMin/+ mice as assessed by Taqman® low density arrays & Affymetrix® 
microarrays 
Relative Quantity (RQ) of gene expression in normal tissue of APCMin/+ 33$5Į-/- mice compared to 
normal tissue in APCMin/+ mice assessed by Taqman® low density array (blue bars) and Affymetrix® 
microarrays (red bars) represented on a log10 scatter plot 
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Figure 4-19 Differential expression of genes in tumour tissue taken from APCMin/+ 33$5Į-/- mice vs. 
normal tissue taken from APCMin/+ mice as assessed by Taqman® low density arrays & Affymetrix® 
microarrays 
Relative Quantity (RQ) of gene expression in tumour tissue of APCMin/+ 33$5Į-/- mice compared to 
normal tissue in APCMin/+ mice assessed by Taqman® low density array (blue bars) and Affymetrix® 
microarrays (red bars) represented on a log10 scatter plot
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4.5 Discussion 
 
This study used Taqman® low density arrays to determine the 
expression level of 95 genes of interest from normal and tumour tissue 
from the colons of APCMin/+ mice and APCMin/+ PPARĮ-/- mice.  
Also, results were compared to see whether Taqman® low density 
arrays would produce similar gene expression levels of these genes to 
levels previously determined on Affymetrix® microarrays.    
The findings of Taqman® low density arrays were in agreement with 
data from Affymetrix® microarrays, in that the largest source of 
differential gene expression was between tumour and normal samples.  
Two genes, Onecut2 (one cut domain, family member 2) and Mmp7 
(matrix metallopeptidase 7) were highly up-regulated in tumour tissue.  
There has been much research into Mmp7 and it is known to be up-
regulated in colon cancer (Kioi et al., 2003). Mmp7 has been suggested 
as a potential target for colon cancer therapy, as high Mmp7 expression 
in tumours has been shown to be associated with a poor prognosis 
(Koskensalo et al., 2011). 
By contrast, there has been very little research into the role and function 
of Onecut2 in the intestine. One study by (Dusing et al., 2010) 
suggested Onecut2 may have a regulatory role in the expression of 
genes related to transport and lipid metabolism in the mouse intestine. 
Results from the present study showed a large increase in Onecut2 
expression in colonic tumours (p < 0.0001).  
To validate these findings further analyses into Onecut2 expression 
levels were carried out; these are described and discussed in Chapter 
6.      
In the absence of malignant change there were very few examples of 
genes differentially regulated by PPARĮ genotype (Figure 4-15, Figure 
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4-18). However, in tumour tissue, differences in the expression of 
PPARĮ dependent genes were evident (Figure 4-16, Figure 4-19).  
The lack of gene induction in normal tissue in APCMin/+ PPARĮ-/- mice 
meant there were few large excursions from expression levels seen in 
normal tissue from APCMin/+ mice. Apobec3 was a notable exception. 
Consequently, correlations between repeated measurements of gene 
expression in normal tissue were weak.  
Where malignant change produced observed differences in gene 
expression from normal mucosa in APCMin/+ mice (Figure 4-14, Figure 
4-17) and APCMin/+ PPARĮ-/- mice (Figure 4-16, Figure 4-19), correlation 
was generally good.  
These data show colon gene expression results from the same cohort 
of mice, using two alternative analysis techniques were comparable. 
Overall these results show there was good correlation (R2 = x to y21) 
between experiments employing Affymetrix® microarrays, and those 
employing Taqman® low density arrays. 
There was strong correlation between Affymetrix® microarrays and 
Taqman® low density arrays in APCMin/+ tumour and APCMin/+ PPARĮ-/- 
tumour groups (Figure 4-14, Figure 4-16). However, gene expression in 
Taqman® low density arrays was consistently higher compared to 
Affymetrix® microarrays.  
Apobec3 showed highly induced expression in APCMin/+ PPARĮ-/- mice 
compared to APCMin/+ mice in Taqman® low density arrays (p < 0.0001).  
However, in Affymetrix® microarrays Apobec3 expression was lower in 
APCMin/+ PPARĮ-/- mice compared to APCMin/+ mice. This discrepancy is 
investigated in Chapter 6, and may be explained by the sequences 
used for amplification by the two different methodologies which appear 
to have targeted different parts of the gene, or different isotypes of the 
gene.  
                                            
21
 R2 = x to y; this is the relationship between the 2 APCMin/+ PPARĮ-/- normal groups, 2 APCMin/+ PPARĮ-/- 
tumour groups and 2 APCMin/+ tumour groups. The R2 YDOXHPHDVXUHVKRZVXFFHVVIXOWKHµILW¶LVLQH[SODLQLQJ
the variation of the data. When R2 is 1.0 all points lie exactly on the line with no scatter. 
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There was good correlation of expression of Onecut2 in both 
methodologies, which confirmed the gene as being highly expressed in 
tumours. 
The focus of the present studies was to determine gene expression 
levels; protein levels of expression were not assessed. However, 
transcription data is useful for identifying potential candidates for follow-
up work at protein level. mRNA levels give an indication of the presence 
of a protein.  
As there are many processes between transcription and translation; the 
variety of translated proteins means correlation of a particular protein 
level with its related mRNA can be highly variable (Vogel and Marcotte, 
2012).  
Future work will determine protein levels of two genes initially, Apobec3 
and Onecut2 in the mouse, and also in human colonic tissue using 
immunoblotting and immunohistochemistry techniques.  
In summary, gene expression results from Taqman® low density arrays 
showed that overall the differential expression of selected genes of 
interest corresponded to their functional process and role in 
tumorigenesis.  Two genes which were highly up-regulated, namely 
Apobec3 and Onecut2, had greatly increased expression in PPARĮ 
samples and tumour samples respectively and are discussed in depth 
in Chapter 6. 
These data also demonstrated that analysis of the same sample set on 
Affymetrix® microarrays and Taqman® low density arrays showed 
comparable gene expression levels.  
Ingenuity® pathway analysis networks of Affymetrix® microarray data 
and Taqman® low density array data showed similar genes were 
highlighted when annotated with PPARĮ, Wnt/beta ± catenin, 
ERK/MAPK and p53 signalling pathways. Il6, Myc and Casp6 were 
three genes that featured on both sets of networks.  
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However, Onecut2 was not displayed on the IPA networks of Taqman® 
low density array data. This may be due to the selective nature of the 
data input. Or, that there is no current research in the Ingenuity 
Pathway Knowledge Base (IPKB) for interactions between Onecut2 and 
the other genes on the networks.  
The present studies with APCMin/+ mice and APCMin/+ PPARĮ-/- mice 
have shown PPARĮ may have a role in preventing initiation or growth of 
tumours in the mouse intestine. Additionally, previous work has 
demonstrated that the PPARĮ ligand methylclophenapate (MCP) 
reduced the number of polyps in the mouse colon and small bowel 
(Jackson et al., 2003).  
As discussed in Chapter 1, it is known that non-steroidal anti-
inflammatory drugs (NSAIDs) reduce the number and incidence of 
colonic polyps. Therefore, to investigate whether NSAIDs act through a 
functional PPARĮ gene to reduce intestinal polyp number and incidence 
APCMin/+ mice and APCMin/+ PPARĮ-/- mice were treated with the non-
selective Cox-inhibitor piroxicam. Polyp burden and expression of the 
same 95 genes as selected for Chapter 4 were analysed.  
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5 The role of PPARĮ in the effects of piroxicam on the 
APCMin/+ mouse colon & small bowel 
 
5.1 Introduction 
 
As discussed in Chapter 1 there is considerable evidence that aspirin, 
non-selective NSAIDs (non-steroidal anti-inflammatory drugs) and 
selective Cox-2 inhibitors can reduce development of colonic polyps 
and are associated with a reduced incidence of colorectal cancer. 
Results from Chapter 3 and Chapter 4 showed that PPARĮ status has 
an effect on tumorigenesis. Subsequently, this study was instigated to 
determine whether the effects produced by treatment with an NSAID act 
via a functional PPARĮ pathway.  
Piroxicam was selected for this study as the duration of the study 
necessitated the use of a drug that could be tolerated over a long period 
of time. Piroxicam is a non-selective Cox inhibitor with a good safety 
record in mice compared to other NSAIDs such as indomethacin which 
has a high rate of toxicity and ileal perforation (Trujillo et al., 1994). Also, 
piroxicam has been successfully used in previous mouse studies; 
(Jacoby and al., 1996) used piroxicam at 50, 100 and 200 ppm, (Jacoby 
et al., 2000) used the drug at 12, 25 and 50 ppm, and (Ritland and 
Gendler, 1999) used it at 200 ppm. The present study dosed mice with 
piroxicam at 100 ppm in their feed. This dose is comparable to that 
used in previous studies and has been shown to be efficacious. The 
study by (Jacoby et al., 2000) measured thromboxane B2 levels in 
plasma after different doses of piroxicam were given to mice. Their 
study demonstrated an increase in serum levels of piroxicam with 
increasing dose. There was also a significant dose-related reduction in 
plasma thromboxane levels.   
The possible role of PPARĮ in the action of piroxicam treatment on the 
mouse gut was therefore investigated.  
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5.2 Aim of study 
 
x To investigate the effect of piroxicam on polyp formation in 
APCMin/+ and APCMin/+ 33$5Į-/- mice. 
x To investigate the effect of piroxicam on gene expression in 
APCMin/+ and APCMin/+ 33$5Į-/- mice. 
x To determine whether the effects of piroxicam are mediated via 
DFWLYDWLRQRI33$5Į. 
 
5.3 Methods  
 
A study to determine the effect of piroxicam on polyp formation and 
gene expression in the colon and small bowel of APCMin/+ and APCMin/+ 
33$5Į-/- mice was established. Mice were allowed food and water ad 
libitum with half of the mice dosed with piroxicam at 100 ppm (parts per 
million) mixed in their feed. Mice were sacrificed at one year old if they 
were still on the study at that time. 
Polyp number at death in the colon and small bowel of APCMin/+ and 
APCMin/+ 33$5Į-/- mice from control and piroxicam-treated mice were 
compared (Study 2A). Expression of genes in the colon from similarly 
treated APCMin/+ and APCMin/+ 33$5Į-/- mice were analysed using 
Taqman® low density arrays (Study 2B). 
Table 5-1 shows the numbers of mice on study 2A and 2B.  
Table 5-1 Number of APCMin/+ mice & APCMin/+ PPARɲ-/- mice on Study 2A & Study 2B 
 
 
Feed regime control piroxicam 100 ppm control
piroxicam 
100 ppm
STUDY 2A 18 18 18 18
STUDY 2B 5 5 5 5
Number of mice on study
APCM in/+ APCM in/+  PPARɲ-/-Genotype
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Animal work using an APCMin/+ mouse model (3.3.1, page 45) was 
carried out at the Biomedical Science Unit (BMSU), University of 
Nottingham following Animals (Scientific Procedures) Act 1986 (ASPA) 
protocols and guidelines as before (3.3, page 44). Genotyping was 
performed as previously (3.3.2, page 45).   
Four groups of mice (aged 28-30 days) were allocated onto one year 
(maximum) studies (Table 5-1). Mice were dosed with piroxicam or 
control mixed in their feed (5.3.1, page 167). Food and water were 
available ad libitum. Husbandry of mice was as before (3.3.3, page 46). 
Mice were sacrificed by cervical dislocation at the end of the study or 
sooner if they showed signs of suffering, anaemia, rectal prolapse 
or >15% weight loss as previously. Mesenteric fat22 was collected from 
all mice after sacrifice (5.3.2, page 168); as PPARɲ is known to be 
involved in lipid metabolism, it would be expected that there would be 
more mesenteric fat in APCMin/+PPARĮ-/- mice (as this mouse model 
does not have a functional PPARɲ gene). 
Two mice on the studies were sacrificed prematurely; one APCMin/+ 
control mouse was found to have hydrocephalus, and an 
APCMin/+PPARĮ-/- piroxicam-treated mouse was found to have a red, 
sore eye which was not due to the Min mutation (assessment was 
made by the on-call veterinary surgeon). Two other mice, an APCMin/+ 
control mouse and an APCMin/+PPARĮ-/- control mouse, were found 
dead in their cages. 
 
5.3.1 Preparation of mouse feed with piroxicam  
 
To prepare mouse feed with piroxicam at 100 parts per million (ppm) 
200 mg of piroxicam was dissolved in 4 ml of chloroform. 1.2 ml of this 
was added to 300 ml of acetone. The resultant solution was then 
thoroughly mixed with 600 g of ground mouse feed and left to dry in a 
fume hood. Control feed was prepared by mixing 300 ml of acetone with 
600 g of ground mouse feed and left to dry in a fume hood.  
                                            
22
 Mesenteric fat ± fat in the folds of the peritoneum (serous membrane encasing the intestines) 
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5.3.2 Mesenteric fat collection 
 
Mesenteric fat was collected from mice on Study 2A (polyp number) 
and Study 2B (gene expression). After sacrifice all visible mesenteric fat 
surrounding the intestines was removed with scissors and forceps and 
placed on a Petri dish.  
The fat was weighed (fat mass calculated by subtraction of the mass of 
the Petri dish) and the mass recorded. The fat was then disposed of as 
appropriate to tissue disposal protocols within the animal unit.  
 
5.4 Evaluation of polyp number in the mouse colon & small 
bowel: Study 2A 
 
Whole intestines from mice on Study 2A were removed immediately 
after sacrifice and separated into small bowel and colon. Tissue was 
processed for quantification of mouse intestinal polyps as described 
previously (3.3.4, page 46).  
Tissue was pinned out flat and observed through a Karl Zeiss Tessovar 
macroscope (x4.2 magnification). Images were acquired using a Q 
imaging micropublisher 5.0 RTV camera with Improvison Openlab 
programme as described previously. Saved images were analysed for 
polyp number, polyp size and area using Aperio ImageScope® software.  
 
5.5 Gene expression in the mouse colon: Study 2B 
 
Colons from mice on Study 2B were removed immediately after 
sacrifice. Paired samples of normal and tumour mucosa, (paired 
samples each from APCMin/+ control, APCMin/+ piroxicam, APCMin/+ 
PPARɲ-/- control and APCMin/+ PPARɲ-/- piroxicam groups) were 
identified and collected for RNA extraction as before (3.3.6, page 50).  
From the twenty mice on the study, seventeen pairs of normal and 
tumour mucosa samples were collected. Tumour tissue was not 
apparent in three of the colons collected. From the seventeen pairs of 
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samples, twelve pairs (twenty four samples) were selected for analysis 
on Taqman® low density arrays based on RNA integrity number (RIN), 
concentration and 260/280 ratio (to give n = 3 in each group).  
Twenty four RNA samples were prepared and analysed on Taqman® 
arrays (six arrays, four samples per array) as previously (4.3.1, page 
122). Taqman® arrays were designed with identical gene assays as 
before (Table 3-14 - Table 3-23).  
All six arrays (24 sample results) were analysed simultaneously using 
SDS RQ Manager software as previously (4.3.2, page 124). Average Ct 
(cross threshold) values of each target gene (average calculated from 
Ct value from each sample across all six arrays) were copied into an 
Excel spreadsheet.  
The expression level of reference genes must not alter across arrays. 
Therefore, average Ct values of each selected reference gene (Table 
3-14) and 18s were checked for outliers before further analysis (Table 
5-2). 
As previously, outliers were defined as an average Ct value not within 
three standard deviations of the mean (three-sigma rule 23 ), (Ruan, 
2005). All five reference genes were used in analysis. One sample 
(123.35, highlighted in red) had outlying average Ct values for four of 
the reference genes. However, as the values were consistently higher 
in each case, the sample was not excluded from analysis. 
The geometric mean24 of all five reference genes was calculated and 
used for normalisation of all average Ct values of target genes.  
 
                                            
23
 The three-sigma rule (empirical rule) states that for a normal distribution, nearly all values lie within 3 
standard deviations of the mean. 
 
24
 Geometric mean: normalises ranges of numbers to give an average that indicates a central tendency or 
typical value. Numbers are multiplied together, then the nth root (where n is the count of numbers in the 
range) is taken of the resultant product. 
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Table 5-2 Expression (average Ct value) of reference genes in Study 2B samples 
 
 
18s Ct Actb Ct Hmbs Ct Hprt1 Ct Ppia Ct
121.46 APC Min/+ Control Normal 13.80 17.52 26.32 24.63 21.38
119.33 APC Min/+ Control Normal 13.26 16.98 25.97 24.72 20.93
122.37 APCMin/+ Control Normal 13.86 17.49 26.24 24.65 21.39
119.33 APCMin/+ Control Tumour 13.37 17.27 26.90 25.11 22.60
119.34 APCMin/+ Control Tumour 13.52 18.34 26.50 25.15 21.88
122.37 APCMin/+ Control Tumour 13.67 16.55 25.98 24.23 21.00
113.22b APCMin/+ 33$5Į-/- Control Normal 13.84 16.80 26.06 24.71 21.93
113.23 APCMin/+ 33$5Į-/- Control Normal 12.54 16.63 25.08 24.21 20.17
113.23b APCMin/+ 33$5Į-/- Control Normal 12.91 17.31 25.91 24.58 20.87
113.22b APCMin/+ 33$5Į-/- Control Tumour 14.49 17.54 26.60 25.18 21.65
113.22 APCMin/+ 33$5Į-/- Control Tumour 12.66 17.36 26.39 25.00 21.21
113.23b APCMin/+ 33$5Į-/- Control Tumour 13.94 17.97 26.76 25.94 21.66
123.35 APCMin/+ Piroxicam Normal 13.38 20.18 29.64 28.03 24.81
123.36 APCMin/+ Piroxicam Normal 12.90 18.94 27.18 26.19 22.73
114.44 APCMin/+ Piroxicam Normal 14.02 18.57 26.67 25.78 21.79
113.44 APCMin/+ Piroxicam Tumour 12.92 18.32 26.51 25.34 21.46
113.45 APCMin/+ Piroxicam Tumour 12.58 17.90 26.15 24.90 21.34
114.44 APCMin/+ Piroxicam Tumour 13.37 17.52 26.54 25.10 21.91
119.17 APCMin/+ 33$5Į-/- Piroxicam Normal 12.13 17.73 25.59 24.48 21.04
120.15 APCMin/+ 33$5Į-/- Piroxicam Normal 11.30 17.64 25.55 24.38 20.78
112.33 APCMin/+ 33$5Į-/- Piroxicam Normal 12.67 17.84 26.21 25.07 21.80
119.17 APCMin/+ 33$5Į-/- Piroxicam Tumour 13.75 17.71 25.77 24.28 20.55
120.15 APCMin/+ 33$5Į-/- Piroxicam Tumour 12.99 17.97 25.94 24.53 20.76
120.17 APCMin/+ 33$5Į-/- Piroxicam Tumour 12.68 17.96 25.96 24.28 20.54
13.19 17.75 26.35 25.02 21.51
0.71 0.78 0.84 0.84 0.94
15.31 20.08 28.88 27.52 24.33
11.07 15.42 23.82 22.51 18.68
Standard Deviation (SD)
Upper limit (Mean + 3SD)
Lower limit (Mean - 3SD)
Reference Genes Average Ct valuesTissue 
typeGroupGenotype
Sample 
identification
Mean
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5.5.1 The effect of piroxicam on gene expression  
 
To determine effect of piroxicam on gene expression, relative quantity 
(RQ) of gene expression in the piroxicam-treated mouse groups of 
APCMin/+ normal, APCMin/+ tumour, APCMin/+ PPARĮ-/- normal and 
APCMin/+ PPARĮ-/- tumour groups to expression in the corresponding 
control groups were calculated from normalised average Ct values (to 
sample 121.46 APCMin/+ normal control).  
Mean RQ was determined for each group.  
Normalised average Ct values of all groups were analysed using SPSS 
16.0.0.247 to calculate univariate of analysis of variance for effects of 
piroxicam only, piroxicam with PPARĮ effects, and piroxicam with tissue 
type effects.  
 
5.6 Validation of Taqman® low density array data: Correlation 
between Study 1B & control groups of Study 2B  
 
The reliability and reproducibility of Taqman® low density arrays was 
assessed by comparing expression of selected genes as determined in 
Study 1B (Chapter 4) to the gene expression of similar genes in Study 
2B.  
 
5.7 Results 
 
5.7.1 Survival of mice  
 
The mean age at sacrifice for APCMin/+ control mice was 23.7 +/- 0.7 
weeks (mean +/- Standard Error). This was significantly older than 
APCMin/+ PPARĮ-/- control mice which had a mean age at sacrifice of 
21.0 +/- 1.1 weeks (p = 0.043, Figure 5-1A, Table 5-3, Table 5-4). All 
mice in control groups were sacrificed due to white paw (Table 5-3, 
Table 5-4).  
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The mean age at sacrifice of mice treated with piroxicam was much 
higher than mean age at sacrifice of control mice. The mean age of 
piroxicam-treated APCMin/+ mice at sacrifice was 52.3 +/- 0.5 weeks 
compared to 23.7 +/- 0.7 weeks in control mice (p < 0.0001, Figure 5-1A, 
Table 5-5). APCMin/+ PPARĮ-/- mice treated with piroxicam had a mean 
age at sacrifice of 46.5 +/- 2.1 weeks, whereas control mice had a mean 
age of 21.0 +/-1.1 weeks at sacrifice (p < 0.0001, Figure 5-1A, Table 
5-6).  
Piroxicam-treated APCMin/+ mice were significantly older at sacrifice than 
piroxicam-treated APCMin/+ PPARĮ-/-mice (p = 0.019, Figure 5-1A). 72% 
of APCMin/+ mice and 61% of APCMin/+ PPARĮ-/- mice were sacrificed 
due to achieving the experimental cut off age of one year. The 
remainder of the mice in these groups were sacrificed earlier due to 
white paw or rectal prolapse (Table 5-5, Table 5-6). 
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Table 5-3 Age, weight & disposition of APCMin/+ control group mice at sacrifice 
 
Table 5-4 Age, weight & disposition of APCMin/+ PPARɲ-/- control group mice at sacrifice 
 
 
Mouse Group Genotype
Age at death 
(weeks)
Weight at start 
(grams)
Weight at death 
(grams)
Disposition at 
death
97.3/5 control APC Min/+ 24.4 16.5 26.3 white paw
104.6/8 control APC Min/+ 17.7 14.3 20.0 white paw
101.6/6 control APC Min/+ 26.1 20.0 23.2 white paw
104.5/7 control APC Min/+ 31.6 15.7 24.5 white paw
116.1/3 control APC Min/+ 24.0 21.1 27.1 white paw
122.1/7 control APC Min/+ 24.9 14.5 18.7 white paw
122.1/1 control APC Min/+ 23.9 20.0 31.6 white paw
122.1/3 control APC Min/+ 22.9 17.5 26.0 white paw
122.1/5 control APC Min/+ 18.7 17.4 27.8 white paw
122.1/6 control APC Min/+ 23.9 18.2 33.4 white paw
123.1/3 control APC Min/+ 24.9 14.0 25.0 white paw
114.3/4 control APC Min/+ 21.9 17.0 21.2 white paw
114.3/5 control APC Min/+ 20.0 17.2 20.6 white paw
114.3/6 control APC Min/+ 26.1 17.4 23.4 white paw
122.3/9 control APC Min/+ 23.1 18.2 20.9 white paw
119.3/1 control APC Min/+ 26.1 22.1 26.0 white paw
120.3/6 control APC Min/+ 22.0 17.2 22.6 white paw
121.4/7 control APC Min/+ 25.1 17.5 17.4 white paw
MEAN 23.7 17.5 24.2
Mouse Group Genotype
Age at death 
(weeks)
Weight at start 
(grams)
Weight at death 
(grams)
Disposition at 
death
76b.4/2 control APC Min/+ PPARɲ -/- 16.4 19.5 27.7 white paw
108.1/5 control APC Min/+ PPARɲ -/- 18.3 20.4 21.7 white paw
102.1/6 control APC Min/+ PPARɲ -/- 23.4 18.3 21.8 white paw
102.1/8 control APC Min/+ PPARɲ -/- 25.0 20.6 26.1 white paw
101.1/3 control APC Min/+ PPARɲ -/- 31.1 24.2 37.8 white paw
103.2/7 control APC Min/+ PPARɲ -/- 31.3 19.5 23.1 white paw
108.1/6 control APC Min/+ PPARɲ -/- 21.4 17.4 20.5 white paw
104.3/4 control APC Min/+ PPARɲ -/- 19.1 21.5 26.9 white paw
104.3/5 control APC Min/+ PPARɲ -/- 19.3 24.7 29.4 white paw
107.1/3 control APC Min/+ PPARɲ -/- 17.4 21.6 24.8 white paw
107.1/9 control APC Min/+ PPARɲ -/- 17.3 16.7 19.9 white paw
115.1/2 control APC Min/+ PPARɲ -/- 15.4 21.1 27.8 white paw
107.3/1 control APC Min/+ PPARɲ -/- 18.9 21.8 21.9 white paw
116.1/1 control APC Min/+ PPARɲ -/- 22.9 22.4 27.6 white paw
116.1/3 control APC Min/+ PPARɲ -/- 25.1 20.4 22.7 white paw
118.2/9 control APC Min/+ PPARɲ -/- 17.4 17.9 20.0 white paw
118.2/3 control APC Min/+ PPARɲ -/- 18.7 20.7 24.0 white paw
118.2/7 control APC Min/+ PPARɲ -/- 18.7 21.7 23.2 white paw
MEAN 21.0 20.6 24.8
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Table 5-5 Age, weight & disposition of APCMin/+ piroxicam group mice at sacrifice 
 
 
Table 5-6 Age, weight & disposition of APCMin/+ PPARɲ-/- piroxicam group mice at sacrifice 
 
 
Mouse Group Genotype
Age at death 
(weeks)
Weight at start 
(grams)
Weight at death 
(grams)
Disposition at 
death
98b.4/1 piroxicam APC Min/+ 55.1 13.9 33.4 culled due to age
98b.4/2 piroxicam APC Min/+ 55.1 11.0 31.0 culled due to age
98b.4/5 piroxicam APC Min/+ 55.1 14.3 30.2 culled due to age
98b.4/6 piroxicam APC Min/+ 46.0 13.3 30.6 white paw
104.5/1 piroxicam APC Min/+ 52.9 22.2 37.4 culled due to age
104.5/2 piroxicam APC Min/+ 52.9 24.1 35.6 culled due to age
104.5/3 piroxicam APC Min/+ 52.9 22.3 32.5 culled due to age
104.5/8 piroxicam APC Min/+ 52.9 22.3 32.9 culled due to age
101.6/2 piroxicam APC Min/+ 51.6 23.9 32.8 white paw
101.6/3 piroxicam APC Min/+ 51.6 25.3 32.1 white paw
115.2/3 piroxicam APC Min/+ 52.1 13.1 27.3 culled due to age
115.2/6 piroxicam APC Min/+ 52.1 13.6 28.3 rectal prolapse
118.2/5 piroxicam APC Min/+ 50.9 14.0 26.3 rectal prolapse
120.1/1 piroxicam APC Min/+ 52.1 23.2 24.2 culled due to age
120.1/2 piroxicam APC Min/+ 52.1 19.9 36.3 culled due to age
120.1/3 piroxicam APC Min/+ 52.1 20.0 37.6 culled due to age
113.4/1 piroxicam APC Min/+ 52.0 18.7 30.0 culled due to age
113.4/2 piroxicam APC Min/+ 52.0 20.1 32.7 culled due to age
MEAN 52.3 18.6 31.7
Mouse Group Genotype
Age at death 
(weeks)
Weight at start 
(grams)
Weight at death 
(grams)
Disposition at 
death
102.1/3 piroxicam APC Min/+ PPARɲ -/- 23.3 22.7 30.0 white paw
101.1/5 piroxicam APC Min/+ PPARɲ -/- 52.4 17.6 25.6 culled due to age
101.1/6 piroxicam APC Min/+ PPARɲ -/- 52.4 18.4 25.7 culled due to age
101.1/7 piroxicam APC Min/+ PPARɲ -/- 52.4 18.7 24.0 culled due to age
94.3/2 piroxicam APC Min/+ PPARɲ -/- 52.0 23.6 42.3 culled due to age
98.3/2 piroxicam APC Min/+ PPARɲ -/- 41.0 16.0 25.6 rectal prolapse
98.3/3 piroxicam APC Min/+ PPARɲ -/- 41.0 14.7 24.7 rectal prolapse
108.1/1 piroxicam APC Min/+ PPARɲ -/- 52.1 21.7 29.8 culled due to age
108.1/2 piroxicam APC Min/+ PPARɲ -/- 34.3 21.8 32.2 rectal prolapse
108.1/3 piroxicam APC Min/+ PPARɲ -/- 52.1 19.8 33.0 culled due to age
102.4/2 piroxicam APC Min/+ PPARɲ -/- 52.1 21.1 47.4 culled due to age
102.4/3 piroxicam APC Min/+ PPARɲ -/- 52.1 19.3 30.0 culled due to age
104.3/6 piroxicam APC Min/+ PPARɲ -/- 46.9 18.5 27.9 rectal prolapse
115.1/7 piroxicam APC Min/+ PPARɲ -/- 52.0 17.9 35.1 culled due to age
115.1/8 piroxicam APC Min/+ PPARɲ -/- 52.0 16.6 36.9 culled due to age
115.1/9 piroxicam APC Min/+ PPARɲ -/- 52.0 18.3 26.7 culled due to age
107.3/2 piroxicam APC Min/+ PPARɲ -/- 31.3 23.4 40.5 rectal prolapse
116.2/2 piroxicam APC Min/+ PPARɲ -/- 45.0 21.8 27.2 rectal prolapse
MEAN 46.5 19.6 31.4
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Figure 5-1 Distribution of age & mesenteric fat in APCMin/+ & APCMin/+ 33$5Į-/- mice after treatment 
with piroxicam or control diet 
Unpaired t test, * p <= 0.05, ** p <= 0.001, *** p <= 0.0001 
 
 
A
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Figure 5-2 Distribution of weight in APCMin/+ & APCMin/+ 33$5Į-/- mice after treatment with piroxicam 
or control diet 
Unpaired t test, * p <= 0.05, ** p <= 0.001, *** p <= 0.0001 
C
D
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5.7.2 Weight of mice 
 
The mean weight of APCMin/+ 33$5Į-/- mice was more than APCMin/+ 
mice at the beginning of the study (20.1 +/- 0.4 grams in APCMin/+ 
33$5Į-/- mice compared to 18.1 +/- 0.6 grams in APCMin/+ mice, p = 
0.0083, Figure 5-1C, Table 5-3-Table 5-6).   
However, at time of sacrifice, there was no significant difference in 
mean weight between APCMin/+ control mice or APCMin/+ 33$5Į-/- 
control mice. The mean weight of APCMin/+ 33$5Į-/- control mice was 
24.8 +/- 1.0 grams and in APCMin/+ control mice was 24.2 +/- 1.0 grams 
(p was not significant, Figure 5-1C, Table 5-3, Table 5-4).  
Mice treated with piroxicam were significantly heavier at sacrifice than 
control mice at sacrifice. Mean weight at sacrifice in piroxicam-treated 
APCMin/+ 33$5Į-/- mice was 31.4 +/- 1.6 grams (p = 0.0014, Figure 
5-1C, Table 5-6). Similarly, the mean weight at sacrifice in piroxicam-
treated APCMin/+ mice was 31.7 +/- 0.9 grams (p < 0.0001, Figure 5-1C, 
Table 5-5).  
There was no significant difference in weight between piroxicam-treated 
APCMin/+ mice and piroxicam-treated APCMin/+ 33$5Į-/- mice at time of 
sacrifice. 
When age at sacrifice was considered, growth rate (weight per week of 
life, wt/wk) in control mice was significantly higher in APCMin/+ 33$5Į-/- 
mice (1.21 +/- 0.065 grams) than APCMin/+ mice (1.033 +/- 0.048 grams, 
p = 0.028, Figure 5-1D). 
Mice receiving piroxicam treatment had a significantly reduced growth 
rate (wt/wk) to 0.711 +/- 0.058 grams in APCMin/+ 33$5Į-/- mice (p < 
0.0001) and 0.600 +/- 0.018 grams in APCMin/+ mice (p < 0.0001). 
However, there was no significant difference in weight at sacrifice 
(wt/wk) between APCMin/+ mice and APCMin/+ 33$5Į-/- mice after 
piroxicam treatment (Figure 5-1D). 
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5.7.3 Mesenteric fat in mice (Study 2A and Study 2B) 
 
Mesenteric fat mass readings from study 2A and 2B were amalgamated 
for analysis. However, mesenteric fat was not collected at sacrifice for 
all mice which is the reason for the difference in sample numbers in this 
analysis*. 
(* Sacrifice of mice and tissue/fat collection was performed by me. However, at times 
when I was absent due to holiday or illness, mice were sacrificed and gut tissue only 
was collected by BMSU technical staff).  
At the end of the study, mean mesenteric fat mass in APCMin/+ control 
mice (n = 18) was 0.12 +/- 0.02 grams, whereas in APCMin/+ 33$5Į-/- 
control mice (n = 19) mean mesenteric fat mass was significantly higher 
at 0.25 +/- 0.04 grams (p = 0.004, Figure 5-1B).  
However, the mean mesenteric fat mass in APCMin/+ mice receiving 
piroxicam (n = 20) was 0.95 +/- 0.13 grams, which was a large increase 
compared to the corresponding control group, APCMin/+ control mice, 
0.12 +/- 0.02 grams (p < 0.0001).  
Similarly, the mean mesenteric fat mass in APCMin/+ 33$5Į-/- mice 
receiving piroxicam (n = 22) was 0.99 +/- 0.18 grams and also 
increased compared to the corresponding control group, APCMin/+ 
33$5Į-/- control mice, 0.25 +/- 0.04 grams (p = 0.0003, Figure 5-1B). 
The difference in mean mesenteric fat mass between piroxicam-treated 
APCMin/+ mice and piroxicam-treated APCMin/+ 33$5Į-/- mice was not 
significant (p = 0.42).  
 
5.7.4 Number of polyps in the mouse colon: Study 2A  
 
There was no significant difference in mean polyp number in the mouse 
colon of APCMin/+ mice and APCMin/+ 33$5Į-/- mice, whether they had 
received piroxicam treatment or not. The mean number of polyps in 
control groups were 1.50 +/- 0.28 in APCMin/+ mice and 1.22 +/- 0.26 in 
APCMin/+ 33$5Į-/- mice, and in piroxicam groups, 1.17 +/- 0.29 in 
179 
 
APCMin/+ mice and 1.22 +/- 0.32 in APCMin/+ 33$5Į-/- mice (Figure 5-3A, 
Table 5-7-Table 5-10). 
When age at sacrifice was considered (mean number of polyps per 
week of life, mean number polyps/week), piroxicam-treated mice had 
significantly reduced mean polyp number compared to control mice.  
APCMin/+ mice had 0.06 +/- 0.011 mean number polyps/week in control 
mice compared to 0.02 +/- 0.006 in piroxicam-treated mice (p = 0.0042, 
Figure 5-3B, Table 5-7-Table 5-10). Also, APCMin/+ 33$5Į-/- mice had 
0.06 +/- 0.014 mean number polyps/week in control mice compared to 
0.03 +/- 0.006 in piroxicam-treated mice (p = 0.028, Figure 5-3B, Table 
5-7-Table 5-10). However, there was no significant difference in mean 
number of polyps/week between APCMin/+ control mice and APCMin/+ 
33$5Į-/- control mice, or piroxicam-treated APCMin/+ mice and 
piroxicam-treated APCMin/+ 33$5Į-/- mice. 
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Table 5-7 Polyp number & Area in the colon of APCMin/+ control group mice at sacrifice 
 
 
Table 5-8 Polyp number & Area in the colon of APCMin/+ PPARĮ-/- control group mice at 
sacrifice 
 
Mouse Group Genotype Polyp 
number
Polyp 
number/week 
of life
Total area 
(mm2)
Total area/ 
week of 
life (mm2)
Average 
polyp size 
(mm2) 
Average polyp 
size/ week of 
life (mm2)
97.3/5 control APC Min/+ 2 0.08 1.97 0.08 0.99 0.04
101.6/6 control APC Min/+ 2 0.08 1.78 0.07 0.89 0.03
104.5/7 control APC Min/+ 4 0.13 4.39 0.14 1.10 0.03
104.6/8 control APC Min/+ 1 0.06 0.66 0.04 0.66 0.04
114.3/4 control APC Min/+ 1 0.05 1.10 0.05 1.10 0.05
114.3/5 control APC Min/+ 2 0.10 0.46 0.02 0.23 0.01
114.3/6 control APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
116.1/3 control APC Min/+ 4 0.17 2.62 0.11 0.66 0.03
119.3/1 control APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
120.3/6 control APC Min/+ 2 0.09 4.17 0.19 2.08 0.09
121.4/7 control APC Min/+ 2 0.08 13.43 0.53 6.71 0.27
122.1/1 control APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
122.1/3 control APC Min/+ 1 0.04 0.69 0.03 0.69 0.03
122.1/5 control APC Min/+ 1 0.05 0.66 0.04 0.66 0.04
122.1/6 control APC Min/+ 2 0.08 7.28 0.30 3.64 0.15
122.1/7 control APC Min/+ 2 0.08 0.35 0.01 0.17 0.01
122.3/9 control APC Min/+ 1 0.04 0.37 0.02 0.37 0.02
123.1/3 control APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
MEAN 2 0.06 2.22 0.09 1.11 0.05
Mouse Group Genotype Polyp 
number
Polyp 
number/week 
of life
Total area 
(mm2)
Total area/ 
week of 
life (mm2)
Average 
polyp size 
(mm2) 
Average polyp 
size/ week of 
life (mm2)
79.4/2 control APC Min/+ 33$5Į -/- 0 0.00 0.00 0.00 0.00 0.00
101.1/3 control APC Min/+ 33$5Į -/- 0 0.00 0.00 0.00 0.00 0.00
102.1/6 control APC Min/+ 33$5Į -/- 1 0.04 14.35 0.61 14.35 0.61
102.1/8 control APC Min/+ 33$5Į -/- 0 0.00 0.00 0.00 0.00 0.00
103.2/7 control APC Min/+ 33$5Į -/- 2 0.06 0.52 0.02 0.26 0.01
104.3/4 control APC Min/+ 33$5Į -/- 1 0.05 0.93 0.05 0.93 0.05
104.3/5 control APC Min/+ 33$5Į -/- 1 0.05 1.36 0.07 1.36 0.07
107.1/3 control APC Min/+ 33$5Į -/- 1 0.06 5.40 0.31 5.40 0.31
107.1/9 control APC Min/+ 33$5Į -/- 3 0.17 5.09 0.29 1.70 0.10
107.3/1 control APC Min/+ 33$5Į -/- 2 0.11 5.76 0.30 2.88 0.15
108.1/5 control APC Min/+ 33$5Į -/- 1 0.05 1.52 0.08 1.52 0.08
108.1/6 control APC Min/+ 33$5Į -/- 0 0.00 0.00 0.00 0.00 0.00
115.1/2 control APC Min/+ 33$5Į -/- 1 0.06 5.57 0.36 5.57 0.36
116.1/3 control APC Min/+ 33$5Į -/- 2 0.08 0.41 0.02 0.20 0.01
116.1/1 control APC Min/+ 33$5Į -/- 2 0.09 10.41 0.45 5.21 0.23
118.2/3 control APC Min/+ 33$5Į -/- 1 0.05 14.29 0.76 14.29 0.76
118.2/7 control APC Min/+ 33$5Į -/- 4 0.21 9.92 0.53 2.48 0.13
118.2/9 control APC Min/+ 33$5Į -/- 0 0.00 0.00 0.00 0.00 0.00
MEAN 1 0.06 4.20 0.21 3.12 0.16
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Table 5-9 Polyp number & Area in the colon of APCMin/+ piroxicam group mice at sacrifice 
 
 
Table 5-10 Polyp number & $UHDLQWKHFRORQRI$3&0LQ33$5Į-/- piroxicam group mice at 
sacrifice 
Mouse Group Genotype Polyp 
number
Polyp 
number/week 
of life
Total area 
(mm2)
Total area/ 
week of 
life (mm2)
Average 
polyp size 
(mm2) 
Average polyp 
size/ week of 
life (mm2)
98b.4/1 piroxicam APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
98b.4/2 piroxicam APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
98b.4/5 piroxicam APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
98b.4/6 piroxicam APC Min/+ 1 0.02 3.82 0.08 3.82 0.08
101.6/2 piroxicam APC Min/+ 4 0.08 9.01 0.17 2.25 0.04
101.6/3 piroxicam APC Min/+ 1 0.02 0.74 0.01 0.74 0.01
104.5/3 piroxicam APC Min/+ 2 0.04 9.28 0.18 4.64 0.09
104.5/1 piroxicam APC Min/+ 1 0.02 3.23 0.06 3.23 0.06
104.5/2 piroxicam APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
104.5/8 piroxicam APC Min/+ 2 0.04 7.38 0.14 3.69 0.07
113.4/1 piroxicam APC Min/+ 1 0.02 1.99 0.04 1.99 0.04
113.4/2 piroxicam APC Min/+ 1 0.02 8.34 0.16 8.34 0.16
115.2/3 piroxicam APC Min/+ 1 0.02 1.56 0.03 1.56 0.03
115.2/6 piroxicam APC Min/+ 1 0.02 0.96 0.02 0.96 0.02
118.2/5 piroxicam APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
120.1/1 piroxicam APC Min/+ 2 0.04 24.05 0.46 12.03 0.23
120.1/2 piroxicam APC Min/+ 4 0.08 30.07 0.58 7.52 0.14
120.1/3 piroxicam APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
MEAN 1 0.02 5.58 0.11 2.82 0.05
Mouse Group Genotype Polyp 
number
Polyp 
number/week 
of life
Total area 
(mm2)
Total area/ 
week of 
life (mm2)
Average 
polyp size 
(mm2) 
Average polyp 
size/ week of 
life (mm2)
94.3/2 piroxicam APC Min/+ 33$5Į -/- 0 0.00 0.00 0.00 0.00 0.00
98.3/2 piroxicam APC Min/+ 33$5Į -/- 1 0.02 7.95 0.19 7.95 0.19
98.3/3 piroxicam APC Min/+ 33$5Į -/- 1 0.02 10.00 0.24 10.00 0.24
101.1/5 piroxicam APC Min/+ 33$5Į -/- 5 0.10 40.75 0.78 8.15 0.16
101.1/6 piroxicam APC Min/+ 33$5Į -/- 3 0.06 13.44 0.26 4.48 0.09
101.1/7 piroxicam APC Min/+ 33$5Į -/- 2 0.04 11.68 0.22 5.84 0.11
102.1/3 piroxicam APC Min/+ 33$5Į -/- 0 0.00 0.00 0.00 0.00 0.00
102.4/2 piroxicam APC Min/+ 33$5Į -/- 2 0.04 3.34 0.06 1.67 0.03
102.4/3 piroxicam APC Min/+ 33$5Į -/- 0 0.00 0.00 0.00 0.00 0.00
104.3/6 piroxicam APC Min/+ 33$5Į -/- 0 0.00 0.00 0.00 0.00 0.00
107.3/2 piroxicam APC Min/+ 33$5Į -/- 0 0.00 0.00 0.00 0.00 0.00
108.1/1 piroxicam APC Min/+ 33$5Į -/- 1 0.02 1.94 0.04 1.94 0.04
108.1/2 piroxicam APC Min/+ 33$5Į -/- 2 0.06 17.06 0.50 8.53 0.25
108.1/3 piroxicam APC Min/+ 33$5Į -/- 2 0.04 13.00 0.25 6.50 0.12
115.1/7 piroxicam APC Min/+ 33$5Į -/- 1 0.02 0.82 0.02 0.82 0.02
115.1/8 piroxicam APC Min/+ 33$5Į -/- 0 0.00 0.00 0.00 0.00 0.00
115.1/9 piroxicam APC Min/+ 33$5Į -/- 2 0.04 1.25 0.02 0.63 0.01
116.2/2 piroxicam APC Min/+ 33$5Į -/- 0 0.00 0.00 0.00 0.00 0.00
MEAN 1 0.03 6.73 0.14 3.14 0.07
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Figure 5-3 Polyp number in the colon of APCMin/+ & APCMin/+ 33$5Į-/- mice after treatment with 
piroxicam or control diet 
Unpaired t test, * p <= 0.05, ** p <= 0.001 
 
A
B
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Figure 5-4 Polyp size in the colon of APCMin/+ & APCMin/+ 33$5Į-/- mice after treatment with piroxicam 
or control diet 
Unpaired t test, ns not significant 
C
D
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Figure 5-5 Tumour burden in the colon of APCMin/+ & APCMin/+ 33$5Į-/- mice after treatment with 
piroxicam or control diet 
Unpaired t test, ns not significant 
E
F
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5.7.5 Average polyp size in the mouse colon (tumour 
burden/number of polyps): Study 2A 
 
Mean average polyp size was not significantly different in APCMin/+ mice 
and APCMin/+ PPARĮ-/- mice or whether they had received piroxicam 
treatment or not (Figure 5-3C, Table 5-7-Table 5-10). 
Mean average polyp size was larger in APCMin/+ PPARĮ-/- control mice 
(3.12 +/- 1.06 mm2) than in APCMin/+ control mice (1.11 +/- 0.39 mm2) 
but the difference was not significant (Figure 5-3C, Table 5-7-Table 
5-10). Also, piroxicam-treated APCMin/+ mice had larger mean average 
polyp size than APCMin/+ control mice but the increase was not 
significant (2.82 +/- 0.81 mm2). 
However, the mean average polyp size in piroxicam-treated APCMin/+ 
PPARĮ-/- mice (3.14 +/- 0.86 mm2) was very similar to mean average 
polyp size in APCMin/+ PPARĮ-/- control mice (Figure 5-3C, Table 5-7-
Table 5-10). 
Similarly, when age at sacrifice was considered (mean average polyp 
size per week of life), there was no significant difference between 
APCMin/+ mice and APCMin/+ PPARĮ-/- mice or whether they had received 
piroxicam or not (Figure 5-3D, Table 5-7-Table 5-10).  
Mean average polyp size/week was larger in APCMin/+ PPARĮ-/- control 
mice (0.16 +/- 0.05 mm2) than in APCMin/+ control mice (0.05 +/- 0.02 
mm2) but the difference was not significant (Figure 5-3D, Table 5-7-
Table 5-10).  
Also, piroxicam-treated APCMin/+ PPARĮ-/- mice had a lower mean 
average polyp size/week (0.07 +/- 0.02 mm2) than APCMin/+ PPARĮ-/- 
control mice (p was not significant).  
However, mean average polyp size/week in piroxicam-treated APCMin/+ 
mice (0.05 +/- 0.02 mm2) was identical in APCMin/+ control mice (Figure 
5-3D, Table 5-7-Table 5-10). 
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5.7.6 Tumour burden (total area) in the mouse colon: Study 2A 
 
At sacrifice there was no significant difference in mean tumour burden 
in the mouse colon between APCMin/+ mice and APCMin/+ 33$5Į-/- mice, 
or whether the mice were in a control group or piroxicam-treated group.  
Mean tumour burden in APCMin/+ control mice was 2.22 +/- 0.80 mm2 
and in APCMin/+ 33$5Į-/- control mice it was 4.19 +/- 1.18 mm2. In 
piroxicam-treated mice, mean tumour burden was 5.58 +/- 2.02 mm2 in 
APCMin/+ mice and 6.74 +/- 2.43 mm2 in APCMin/+ 33$5Į-/- mice (Figure 
5-3E, Table 5-7-Table 5-10).  
The same profile of results were seen when age at sacrifice was 
considered (mean tumour burden per week of life, mean tumour 
burden/week). There was no significant difference in mean tumour 
burden/week between APCMin/+ mice and APCMin/+33$5Į-/- mice, or 
whether the mice were in a control group or piroxicam-treated group.   
Mean tumour burden/week in control mice was 0.09 +/- 0.03 mm2 in 
APCMin/+ mice and 0.21 +/- 0.06 mm2 in APCMin/+ 33$5Į-/- mice. In 
piroxicam-treated mice, tumour burden/week was 0.11 +/= 0.04 mm2 in 
APCMin/+ mice and 0.14 +/- 0.05 mm2 in APCMin/+ 33$5Į-/- mice (Figure 
5-3F, Table 5-7-Table 5-10). 
 
5.7.7 Number of polyps in the mouse small bowel: Study 2A 
 
The mean number of polyps in the mouse small bowel between control 
groups was not significantly different; 7.39 +/- 1.61 in APCMin/+ mice and 
14.28 +/- 3.62 in APCMin/+ PPARĮ-/- mice, Figure 5-6A, Table 5-11-Table 
5-14). Also, there was no significant difference in the mean number of 
polyps in piroxicam-treated mice. However, mice treated with piroxicam 
had significantly fewer mean polyp numbers than in control mice; 2.11 
+/- 0.57 in APCMin/+ mice (p = 0.0055) and 1.50 +/- 0.41 in APCMin/+ 
PPARĮ-/- mice (p = 0.0006, Figure 5-6A, Table 5-11-Table 5-14).
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The mean polyp number per week of life (mean polyp number/week) 
was also reduced in mice treated with piroxicam compared to control 
mice. The mean number of polyps/week in piroxicam-treated APCMin/+ 
mice was 0.04 +/- 0.01 and 0.30 +/- 0.06 in APCMin/+ control mice (p = 
0.0003, Figure 5-6B, Table 5-11-Table 5-14). Similarly, in piroxicam-
treated APCMin/+ PPARĮ-/- mice, the mean number of polyps/week was 
0.04 +/- 0.01 and 0.71 +/- 0.19 in APCMin/+ PPARĮ-/- control mice (p = 
0.0003, Figure 5-6B, Table 5-11-Table 5-14). There was no significant 
difference in the mean number of polyps/week between APCMin/+ control 
mice and APCMin/+ PPARĮ-/- control mice, or APCMin/+ piroxicam-treated 
mice and APCMin/+ PPARĮ-/- piroxicam-treated mice. 
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Table 5-11 Polyp number & Area in the small bowel of APCMin/+ control group mice at sacrifice 
 
 
Table 5-12 Polyp number & Area in the small bowel of APCMin/+ PPARɲ-/- control group mice at 
sacrifice 
 
 
Mouse Group Genotype Polyp 
number
Polyp 
number/week 
of life
Total 
area 
(mm2)
Total 
area/week of 
life (mm2)
Average 
polyp size 
(mm2)
Average polyp 
size/week of 
life (mm2)
104.5/7 control APC Min/+ 23 0.73 39.92 1.26 1.74 0.05
122.1/5  control APC Min/+ 12 0.64 15.42 0.82 1.28 0.07
114.3/4 control APC Min/+ 10 0.46 8.58 0.39 0.86 0.04
122.1/7  control APC Min/+ 11 0.44 13.59 0.55 1.24 0.05
116.1/3 control APC Min/+ 11 0.46 13.04 0.54 1.19 0.05
122.1/6 control APC Min/+ 8 0.33 19.69 0.82 2.46 0.10
97.3/5 control APC Min/+ 10 0.41 18.07 0.74 1.81 0.07
104.6/8 control APC Min/+ 2 0.11 2.55 0.14 1.28 0.07
101.6/6 control APC Min/+ 22 0.84 72.99 2.80 3.32 0.13
123.1/3 control APC Min/+ 4 0.16 3.30 0.13 0.82 0.03
114.3/5 control APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
122.1/3 control APC Min/+ 5 0.22 15.34 0.67 3.07 0.13
120.3/6 control APC Min/+ 1 0.05 0.32 0.01 0.32 0.01
122.1/1 control APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
114.3/6 control APC Min/+ 6 0.23 53.57 2.05 8.93 0.34
119.3/1 control APC Min/+ 2 0.08 29.11 1.12 14.56 0.56
121.4/7 control APC Min/+ 5 0.20 30.34 1.21 6.07 0.24
122.3/9  control APC Min/+ 1 0.04 13.23 0.57 13.23 0.57
MEAN 7 0.30 19.39 0.77 3.45 0.14
Mouse Group Genotype Polyp 
number
Polyp 
number/week 
of life
Total 
area 
(mm2)
Total 
area/week of 
life (mm2)
Average 
polyp size 
(mm2)
Average polyp 
size/week of 
life (mm2)
116.1/3  control APC Min/+ 33$5Į 3 0.13 16.21 0.68 5.40 0.23
101.1/3 control APC Min/+ 33$5Į 11 0.35 53.07 1.71 4.82 0.16
103.2/7  control APC Min/+ 33$5Į 15 0.48 21.86 0.70 1.46 0.05
107.1/3  control APC Min/+ 33$5Į 34 1.95 140.18 8.06 4.12 0.24
108.1/5  control APC Min/+ 33$5Į 10 0.55 34.04 1.86 3.40 0.19
79b.4/2  control APC Min/+ 33$5Į 19 1.16 77.50 4.73 4.08 0.25
104.3/5 control APC Min/+ 33$5Į 16 0.83 45.10 2.34 2.82 0.15
107.1/9  control APC Min/+ 33$5Į 51 2.95 152.65 8.82 2.99 0.17
102.1/6 control APC Min/+ 33$5Į 6 0.26 15.10 0.65 2.52 0.11
104.3/4  control APC Min/+ 33$5Į 7 0.37 17.88 0.94 2.55 0.13
107.3/1 control APC Min/+ 33$5Į 11 0.58 16.01 0.85 1.46 0.08
118.2/3 control APC Min/+ 33$5Į 0 0.00 0.00 0.00 0.00 0.00
102.1/8 control APC Min/+ 33$5Į 48 1.92 219.55 8.78 4.57 0.18
108.1/6 control APC Min/+ 33$5Į 1 0.05 0.30 0.01 0.30 0.01
116.1/1  control APC Min/+ 33$5Į 16 0.70 83.00 3.62 5.19 0.23
118.2/7 control APC Min/+ 33$5Į 0 0.00 0.00 0.00 0.00 0.00
115.1/2 control APC Min/+ 33$5Į 0 0.00 0.00 0.00 0.00 0.00
118.2/9  control APC Min/+ 33$5Į 9 0.52 37.96 2.18 4.22 0.24
MEAN 14.3 0.71 51.69 2.55 2.77 0.13
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Table 5-13 Polyp number & Area in the small bowel of APCMin/+ piroxicam group mice at sacrifice 
 
 
Mouse Group Genotype Polyp 
number
Polyp 
number/week 
of life
Total 
area 
(mm2)
Total 
area/week of 
life (mm2)
Average 
polyp size 
(mm2)
Average polyp 
size/week of 
life (mm2)
98.3/3 piroxicam APC Min/+ 33$5Į 2 0.05 0.79 0.02 0.40 0.01
102.4/2 piroxicam APC Min/+ 33$5Į 2 0.04 2.26 0.04 1.13 0.02
102.4/3 piroxicam APC Min/+ 33$5Į 3 0.06 1.62 0.03 0.54 0.01
101.1/5  piroxicam APC Min/+ 33$5Į 5 0.10 4.34 0.08 0.87 0.02
108.1/2 piroxicam APC Min/+ 33$5Į 3 0.09 2.22 0.06 0.74 0.02
104.3/6 piroxicam APC Min/+ 33$5Į 5 0.11 4.32 0.09 0.86 0.02
107.3/2 piroxicam APC Min/+ 33$5Į 3 0.10 1.72 0.06 0.57 0.02
101.1/7 piroxicam APC Min/+ 33$5Į 1 0.02 0.31 0.01 0.31 0.01
108.1/3 piroxicam APC Min/+ 33$5Į 1 0.02 0.58 0.01 0.58 0.01
102.1/3  piroxicam APC Min/+ 33$5Į 2 0.09 0.73 0.03 0.37 0.02
116.2/2 piroxicam APC Min/+ 33$5Į 0 0.00 0.00 0.00 0.00 0.00
108.1/1  piroxicam APC Min/+ 33$5Į 0 0.00 0.00 0.00 0.00 0.00
94.3/2 piroxicam APC Min/+ 33$5Į 0 0.00 0.00 0.00 0.00 0.00
115.1/7 piroxicam APC Min/+ 33$5Į 0 0.00 0.00 0.00 0.00 0.00
101.1/6 piroxicam APC Min/+ 33$5Į 0 0.00 0.00 0.00 0.00 0.00
98.3/2 piroxicam APC Min/+ 33$5Į 0 0.00 0.00 0.00 0.00 0.00
115.1/8 piroxicam APC Min/+ 33$5Į 0 0.00 0.00 0.00 0.00 0.00
115.1/9 piroxicam APC Min/+ 33$5Į 0 0.00 0.00 0.00 0.00 0.00
MEAN 1.5 0.04 1.05 0.02 0.35 0.01
Mouse Group Genotype Polyp 
number
Polyp 
number/week 
of life
Total 
area 
(mm2)
Total 
area/week of 
life (mm2)
Average 
polyp size 
(mm2)
Average polyp 
size/week of 
life (mm2)
98b.4/2 piroxicam APC Min/+ 8 0.15 10.47 0.19 1.31 0.02
98b.4/5 piroxicam APC Min/+ 1 0.02 0.37 0.01 0.37 0.01
115.2/3 piroxicam APC Min/+ 4 0.08 9.28 0.18 2.32 0.04
104.5/2 piroxicam APC Min/+ 4 0.08 3.36 0.06 0.84 0.02
118.2/5 piroxicam APC Min/+ 3 0.06 6.68 0.13 2.23 0.04
104.5/3 piroxicam APC Min/+ 2 0.04 2.60 0.05 1.30 0.02
104.5/1 piroxicam APC Min/+ 3 0.06 1.08 0.02 0.36 0.01
98b.4/6 piroxicam APC Min/+ 3 0.07 1.84 0.04 0.61 0.01
101.6/3 piroxicam APC Min/+ 7 0.14 3.71 0.07 0.53 0.01
113.4/1 piroxicam APC Min/+ 1 0.02 0.54 0.01 0.54 0.01
113.4/2 piroxicam APC Min/+ 1 0.02 0.33 0.01 0.33 0.01
104.5/8 piroxicam APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
115.2/6 piroxicam APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
101.6/2 piroxicam APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
120.1/1 piroxicam APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
120.1/2 piroxicam APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
120.1/3 piroxicam APC Min/+ 1 0.02 0.50 0.01 0.50 0.01
98b.4/1 piroxicam APC Min/+ 0 0.00 0.00 0.00 0.00 0.00
MEAN 2.1 0.04 2.26 0.04 0.62 0.01
 
Table 5-14 Polyp number & Area in the small bowel of APCMin/+ PPARĮ-/- piroxicam group mice at sacrifice 
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Figure 5-6 Polyp number in the small bowel of APCMin/+ & APCMin/+ 33$5Į-/- mice after treatment with 
piroxicam or control diet 
Unpaired t test, ** p <= 0.001, *** p <= 0.0001, ns not significant 
A
B
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Figure 5-7 Polyp size in the small bowel of APCMin/+ & APCMin/+ 33$5Į-/- mice after treatment with 
piroxicam or control diet 
Unpaired t test, ** p <= 0.001, *** p <= 0.0001 
C
D
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5.7.8 Average polyp size in the mouse small bowel (tumour 
burden/number of polyps): Study 2A 
 
Piroxicam-treated APCMin/+ mice had a significantly reduced mean 
average polyp size of 0.62 +/- 0.17 mm2 compared to 3.45 +/- 1.04 mm2 
in APCMin/+ control mice (p = 0.004, Figure 5-6C, Table 5-11-Table 5-14). 
Similarly, the mean average polyp size of APCMin/+ PPARĮ-/- control 
mice was 2.77 +/- 0.44 mm2 which was far larger than in piroxicam-
treated mice. Piroxicam-treated APCMin/+ PPARĮ-/- mice had a mean 
average polyp size of 0.35 +/- 0.09 mm2 (p < 0.0001, Figure 5-6C, 
Table 5-11-Table 5-14). The mean average polyp size did not differ 
significantly between control groups or between piroxicam-treated 
groups. 
The same profile of results were seen when age at sacrifice was taken 
into consideration (mean average polyp size per week of life). 
Piroxicam-treated APCMin/+ mice had a mean average polyp size of 0.01 
+/- 0.003 mm2 compared to 0.14 +/- 0.04 mm2 in APCMin/+ control mice 
(p = 0.0001, Figure 5-6D, Table 5-11-Table 5-14). Also, mean average 
polyp size/week in piroxicam-treated APCMin/+ PPARĮ-/- mice was 0.009 
+/- 0.002 mm2 and 0.13 +/- 0.02 mm2 in APCMin/+ PPARĮ-/- control mice 
(p = 0.0003, Figure 5-6D, Table 5-11-Table 5-14). There was no 
significant difference in mean average polyp size/week between control 
groups or between piroxicam groups. 
 
5.7.9 Tumour burden (total area) in the mouse small bowel: Study 
2A 
 
Piroxicam treatment significantly reduced tumour burden. The mean 
tumour burden in APCMin/+ control mice was 19.39 +/- 4.64 mm2 and 
2.26 +/- 0.78 mm2 in APCMin/+ piroxicam-treated mice (p = 0.0007, 
Figure 5-6E, Table 5-11-Table 5-14). Similarly in APCMin/+ PPARĮ-/- 
control mice mean tumour burden was 51.69 +/- 14.57 mm2 and 1.05 
+/- 0.34 mm2 in APCMin/+ PPARĮ-/- piroxicam-treated mice (p = 0.0004, 
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Figure 5-6E, Table 5-11-Table 5-14). However, there was no significant 
difference in mean tumour burden between control groups or between 
piroxicam-treated groups. 
Similar results were seen when age at sacrifice was considered (mean 
tumour burden per week of life). The mean tumour burden/week in 
APCMin/+ control mice was 0.77 +/- 0.17 mm2 and 0.04 +/- 0.01 mm2 in 
APCMin/+ piroxicam-treated mice (p = 0.0001, Figure 5-6F, Table 5-11-
Table 5-14). APCMin/+ PPARĮ-/- control mice had a mean tumour 
burden/week of 2.55 +/- 0.72 mm2, whereas in piroxicam-treated 
APCMin/+ PPARĮ-/- mice it was 0.02 +/- 0.01 mm2 (p = 0.0003, Figure 
5-6F, Table 5-11-Table 5-14). There was no significant difference in 
mean tumour burden/week between control groups or between 
piroxicam-treated groups. 
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Figure 5-8 Tumour burden in the small bowel of APCMin/+ & APCMin/+ 33$5Į-/- mice after treatment 
with piroxicam or control diet 
Unpaired t test, *** p <= 0.0001, ns not significant 
E
F
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In summary, these data indicated that the effect of piroxicam on polyp 
number, total tumour burden and average polyp size in the colon and 
small bowel was not mediated via PPARĮ.  
APCMin+/- (control and piroxicam-treated) mice were significantly older 
than APCMin+/- PPARĮ-/- mice at sacrifice. Also, APCMin+/- PPARĮ-/- mice 
weighed more than APCMin+/- mice, but only at the beginning of the 
study. All control and piroxicam-treated mice increased in weight during 
the study, but there was no significant difference in weight at sacrifice 
between APCMin+/- mice and APCMin+/- PPARĮ-/- mice. Conversely, 
mesenteric fat was greater in APCMin+/- PPARĮ-/- mice than APCMin+/- 
mice at sacrifice, but only in control groups and not piroxicam-treated 
groups. 
 
5.7.10 The effect of piroxicam on gene expression in the mouse 
colon 
 
The mean relative quantity (RQ) of gene expression in APCMin/+ normal,   
APCMin/+ tumour, APCMin/+PPARĮ-/- normal and APCMin/+PPARĮ-/- tumour 
piroxicam-treated groups to gene expression in their corresponding 
control groups were calculated from normalised average Ct values of 
Study 2B TaqMan® low density array results. Mean RQ data were 
presented as clustered bar graphs in groups as before (Figure 5-9-
Figure 5-17) using a log10 scale for genes where RQ was greater than 
or equal to two (fold change increase >= 2) or less than or equal to 0.5 
(fold change decrease >=2).  
SPSS 16.0.0.247 was used to perform univariate analysis of variance 
on the same data. Genes were determined as differentially expressed 
due to; the effect of piroxicam treatment, or the effect of an interaction 
between piroxicam treatment and PPARĮ status, or the effect of an 
interaction between piroxicam treatment and tissue type, where p <= 
0.05. These data were presented in groups as defined previously (Table 
5-15-Table 5-23). 
196 
 
For simplicity all table and figure headings have been abbreviated as 
follows; APCMin/+ abbreviated to Min, and APCMin/+ PPARĮ-/- abbreviated 
to PPARĮ-/-. 
 
5.7.10.1 Fatty acid & lipid metabolism 
 
Table 5-15 and Figure 5-9 show expression data for the effect of 
piroxicam on genes implicated in fatty acid and lipid metabolism.  
These data showed that in the piroxicam-treated PPARĮ-/- normal group, 
expression of Cyp2c55 (cytochrome P450, family 2, subfamily c, 
polypeptide 55) was slightly increased (1.75-fold), whereas in the 
piroxicam-treated Min normal group, expression of Cyp2c55 was 
decreased 3.70-fold. This may imply a PPARĮ mediated effect with 
piroxicam treatment (p = 0.049).  
However, in tumour tissue expression of Cyp2c55 in the piroxicam-
treated Min and PPARĮ-/- groups was down-regulated 3.85-fold and 20-
fold respectively (p = 0.04).  
Piroxicam treatment of the Min normal group significantly increased 
expression of Alox12 (arachidonate 12-lipoxygenase) 2.11-fold (p = 
0.044).  Cyp2c55 and Cyp2b10 (cytochrome P450, family 2, subfamily b, 
polypeptide 10) were significantly down-regulated; Cyp2c55 expression 
was reduced 3.70-fold (p = 0.036) and Cyp2b10 expression reduced 
10-fold (p = 0.038) in the piroxicam-treated Min normal group.  
The effect of an interaction between piroxicam and tissue type was 
apparent in five genes, including Cyp2c55; expression of Alox12 and 
Cyp2b10 were up-regulated in piroxicam-treated Min tumour and 
PPARĮ-/- tumour groups. Expression of Alox12 increased 5.80-fold and 
2.81-fold (p = 0.047), and Cyp2b10 increased 2.83-fold and 6.41-fold (p 
= 0.022), in Min tumour and PPARĮ-/- tumour groups respectively.  
Expression of Lrp1 (low density lipoprotein receptor-related protein 1) 
and Ptgis (prostaglandin I2 (prostacyclin) synthase) were down-
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regulated in the piroxicam-treated PPARĮ-/- tumour group only. Lrp1 
expression was reduced 2.5-fold (p = 0.008), and Ptgis expression was 
reduced 2.17-fold (p = 0.017). 
Table 5-15 Effect of piroxicam on genes implicated in fatty acid & lipid metabolism 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ normal, APCMin/+ tumour, APCMin/+33$5Į-/- 
normal and APCMin/+33$5Į-/- tumour samples to expression in corresponding control groups. 
Univariate analysis of variance was used to determine differentially expressed genes with p <= 0.05 
(ns - not significant)  
Min normal 
piroxicam 
Min tumour 
piroxicam 
33$5Į-/- 
normal 
piroxicam 
33$5Į-/- 
tumour 
piroxicam 
Effect of 
piroxicam 
only
Interaction 
between 
piroxicam 
& PPARa
Interaction 
between 
piroxicam 
& tissue
Acot2 0.74 0.26 1.62 0.53 ns ns ns
Alox 12 2.11 5.80 0.87 2.81 0.044 ns 0.047
Alox 15 0.42 2.38 1.23 1.16 ns ns ns
Alox 5ap 1.47 1.14 0.65 1.11 ns ns ns
Angptl4 0.19 0.35 2.85 0.54 ns ns ns
Bdh1 0.75 0.50 0.90 0.56 0.003 ns ns
Cyp11a1 0.93 2.52 1.61 1.24 ns ns ns
Cyp2b10 0.10 2.83 1.80 6.41 0.038 ns 0.022
Cyp2c55 0.27 0.26 1.75 0.05 0.036 0.049 0.04
Decr1 0.67 0.75 0.84 0.59 0.007 ns ns
Ech1 0.74 0.51 1.08 0.48 0.009 ns ns
Echdc2 1.17 1.28 1.06 1.18 ns ns ns
Hadha 0.51 0.56 0.82 0.73 0.005 ns ns
Lrp1 0.93 0.56 1.29 0.40 0.034 ns 0.008
Pla2g2a 0.77 1.23 0.44 1.05 ns ns ns
Ptgis 1.57 0.62 1.29 0.46 ns ns 0.017
Ptgs1 1.61 0.51 0.88 0.86 ns ns ns
Ptgs2 2.35 2.16 0.86 1.14 ns ns ns
Steap4 0.63 1.54 2.23 2.52 0.034 ns ns
Gene
Mean Relative Quantity of gene expression to 
corresponding control group p value
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Figure 5-9 Effect of piroxicam on genes implicated in fatty acid & lipid metabolism 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of 
piroxicam groups to control groups, where RQ was >= 2 or <= to 0.5 
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5.7.10.2 Signal transduction 
 
Table 5-16 and Figure 5-10 show expression data for the effect of 
piroxicam on genes implicated in signal transduction.  
These data show expression of genes in this group were not altered by 
piroxicam via a PPARĮ pathway. 
However, expression of Lama1 (laminin, alpha 1) was up-regulated 
2.29-fold (p = 0.004) and Rhoj (ras homolog gene family, member J) 
was up-regulated 2.14-fold (p = 0.031) in the piroxicam-treated Min 
normal group.  
Also, a significant interaction between piroxicam and tissue type was 
seen in Apcdd1 (adenomatosis polyposis coli down-regulated 1) and 
Lama1.  
Expression of Apcdd1 was increased 2.90-fold and 2.68-fold (p = 0.022) 
in piroxicam-treated Min tumour and PPARĮ-/- tumour groups 
respectively.  
Similarly, Lama1 was up-regulated 2.22-fold and 2.29-fold (p = 0.004) in 
tumour groups as before. 
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Table 5-16 Effect of piroxicam on genes implicated in signal transduction 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ normal, APCMin/+ tumour, APCMin/+33$5Į-/- 
normal and APCMin/+33$5Į-/- tumour samples to expression in corresponding control groups. 
Univariate analysis of variance was used to determine differentially expressed genes with p <= 0.05 
(ns - not significant) 
 
 
Figure 5-10 Effect of piroxicam on genes implicated in signal transduction 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of 
piroxicam groups to control groups, where RQ was >= 2 or <= to 0.5 
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Min tumour 
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piroxicam 
33$5Į-/- 
tumour 
piroxicam 
Effect of 
piroxicam 
only
Interaction 
between 
piroxicam 
& PPARa
Interaction 
between 
piroxicam 
& tissue
Apcdd1 1.14 2.90 1.54 2.68 0.014 ns 0.022
Ereg 1.53 1.53 0.87 0.70 ns ns ns
Ghr 0.71 0.70 1.11 0.82 ns ns ns
Gulp1 1.83 0.57 1.56 0.66 ns ns 0.0001
Il1b 1.20 4.48 0.72 1.79 ns ns ns
Il6 0.24 4.10 1.38 0.21 ns ns ns
Inhba 2.53 3.96 1.14 1.34 ns ns ns
Krt18 0.83 1.06 0.70 1.16 ns ns ns
Lama 1 2.29 2.22 0.61 2.29 0.004 ns 0.004
Lama 5 1.64 1.35 0.81 1.85 ns ns ns
Ppbp 0.34 1.68 0.67 1.17 ns ns ns
Ptger3 0.69 0.67 1.04 0.87 ns ns ns
Rhoj 2.14 1.13 1.23 1.51 0.031 ns ns
Sfrp1 1.91 1.12 1.16 1.01 ns ns ns
Tnf 1.18 1.22 1.59 1.67 ns ns ns
Gene
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5.7.10.3 Transcription 
 
Table 5-15 and Figure 5-9 show expression data for the effect of 
piroxicam on genes implicated in transcription.  
These data showed that in the piroxicam-treated PPARĮ-/- normal group, 
expression of Rorc (RAR-related orphan receptor gamma) was slightly 
decreased (1.75-fold), whereas in the piroxicam-treated Min normal 
group expression of Rorc was decreased 6.25-fold. This may imply a 
PPARĮ mediated effect with piroxicam treatment (p = 0.016).  
Also, expression of Rorc in the piroxicam-treated Min and PPARĮ-/- 
tumour groups was downregulated 4.17-fold and 2.38-fold respectively, 
but this effect was not significant.  
The effect of piroxicam treatment alone was significant in the 
expression of two genes; Nfkbie (nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, epsilon) was up-
regulated 2.15-fold (p = 0.001) and Rorc was down-regulated 6.25-fold 
(p = 0.0001) in the piroxicam-treated Min normal group.  
Expression of Gucy2c (guanylate cyclase 2c) was significantly 
decreased 2.5-fold (p = 0.003) in the piroxicam-treated PPARĮ-/- tumour 
group only. 
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Table 5-17 Effect of piroxicam on genes implicated in transcription 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ normal, APCMin/+ tumour, APCMin/+33$5Į-/- 
normal and APCMin/+33$5Į-/- tumour samples to expression in corresponding control groups. 
Univariate analysis of variance was used to determine differentially expressed genes with p <= 0.05 
(ns - not significant) 
Min normal 
piroxicam 
Min tumour 
piroxicam 
33$5Į-/- 
normal 
piroxicam 
33$5Į-/- 
tumour 
piroxicam 
Effect of 
piroxicam 
only
Interaction 
between 
piroxicam 
& PPARa
Interaction 
between 
piroxicam 
& tissue
Ang 0.89 0.52 0.88 0.23 0.029 ns ns
Arnt2 1.82 1.42 2.05 1.17 ns ns ns
Baz1a 0.96 1.15 0.63 1.12 ns ns 0.037
Cbx7 1.22 0.53 1.46 0.80 ns ns 0.044
Chd8 0.88 0.84 0.90 1.11 ns ns ns
Crem 1.01 0.76 0.85 0.91 ns ns ns
Foxc2 33.31 1.30 0.41 3.62 ns ns ns
Gucy2c 1.20 0.52 1.13 0.40 ns ns 0.003
Id4 2.18 0.59 1.29 0.53 ns ns 0.001
Jun 0.80 0.87 0.52 1.34 ns ns ns
Klf4 0.59 0.38 0.46 0.64 0.0001 ns ns
Meis 1 1.88 0.50 1.67 0.62 ns ns ns
Myc 1.14 1.62 0.83 1.48 ns ns ns
Nfkbie 2.15 1.54 1.45 1.44 0.001 ns ns
Nr1d1 0.59 0.37 0.53 0.28 0.0001 ns ns
Onecut2 1.95 3.98 0.41 1.21 ns ns ns
Phf17 0.80 0.63 0.89 0.87 0.006 ns ns
Pou2af1 1.34 3.14 2.80 0.66 ns ns ns
Rarb 1.73 1.13 1.20 0.98 ns ns ns
Rbms1 0.98 0.99 0.97 1.28 ns ns ns
Rorc 0.16 0.24 0.57 0.42 0.0001 0.016 ns
Tcf12 0.70 0.87 0.99 1.07 ns ns ns
Gene
Mean Relative Quantity of gene expression to 
corresponding control group p value
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Figure 5-11 Effect of piroxicam on genes implicated in transcription 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of 
piroxicam groups to control groups, where RQ was >= 2 or <= to 0.5 
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5.7.10.4 Cell cycle 
 
Table 5-18 and Figure 5-12 show expression data for the effect of 
piroxicam on genes implicated in the cell cycle.  
These data show piroxicam treatment did not significantly effect the 
expression of genes in this group. 
Table 5-18 Effect of piroxicam on genes implicated in the cell cycle 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ normal, APCMin/+ tumour, APCMin/+33$5Į-/- 
normal and APCMin/+33$5Į-/- tumour samples to expression in corresponding control groups. 
Univariate analysis of variance was used to determine differentially expressed genes with p <= 0.05 
(ns - not significant) 
 
 
Figure 5-12 Effect of piroxicam on genes implicated in the cell cycle 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of 
piroxicam groups to control groups, where RQ was >= 2 or <= to 0.5 
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& PPARa
Interaction 
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piroxicam 
& tissue
Apobec3 2.91 3.15 0.89 1.37 ns ns ns
Bin 1 0.82 0.43 1.94 0.33 ns ns ns
Ccnd1 1.56 1.51 1.01 1.18 0.039 ns ns
Cdkn1c 0.97 0.61 1.24 0.86 ns ns ns
Gene
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5.7.10.5 Apoptosis 
 
Table 5-19 and Figure 5-13 show expression data for the effect of 
piroxicam on genes implicated in apoptosis.  
These data showed that in the piroxicam-treated PPARĮ-/- normal group, 
expression of Endod1 (endonuclease domain containing 1) was slightly 
decreased (1.64-fold), whereas in the piroxicam-treated Min normal 
group expression was decreased 2.94-fold. This may imply a PPARĮ 
mediated effect with piroxicam treatment (p = 0.002).  
The effect of piroxicam treatment only was significant in reduction of 
Endod1 expression in the Min normal group (2.94-fold, p = 0.0001).   
Bmf (BCL2 modifying factor) expression was significantly increased 
2.52-fold in the PPARĮ-/- tumour group only (p = 0.01). 
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Table 5-19 Effect of piroxicam on genes implicated in apoptosis 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ normal, APCMin/+ tumour, APCMin/+33$5Į-/- 
normal and APCMin/+33$5Į-/- tumour samples to expression in corresponding control groups. 
Univariate analysis of variance was used to determine differentially expressed genes with p <= 0.05 
(ns - not significant) 
 
 
 
Figure 5-13 Effect of piroxicam on genes implicated in apoptosis 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of 
piroxicam groups to control groups, where RQ was >= 2 or <= to 0.5 
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piroxicam 
& tissue
Apaf1 1.29 0.97 0.92 1.28 ns ns ns
Bcl2l11 0.87 1.44 1.20 1.56 ns ns ns
Bik 1.38 0.80 1.32 1.47 ns ns ns
Bmf 0.94 1.12 1.42 2.52 0.002 0.004 0.01
Endod 1 0.34 0.38 0.61 0.49 0.0001 0.002 ns
Khdc1a 0.06 0.61 1.94 0.12 ns ns ns
Sbk1 0.69 0.85 1.01 1.10 ns ns ns
Gene
Mean Relative Quantity of gene expression to 
corresponding control group p value
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5.7.10.6 Protein transport 
 
Table 5-20 and Figure 5-14 show expression data for the effect of 
piroxicam on genes implicated in protein transport.  
These data showed that in the piroxicam-treated PPARĮ-/- normal group, 
expression of Ap1s3 (adaptor-related protein complex AP-1, sigma 3) 
was slightly decreased (1.72-fold), whereas in the piroxicam-treated Min 
normal group expression was decreased 3.13-fold.  
This difference was highly significant (p = 0.0001) and may imply a 
PPARĮ-mediated effect with piroxicam treatment.  
Ap1s3 expression was also significant with just piroxicam treatment (p = 
0.0001) and in the piroxicam-treated Min tumour group (2.70-fold, p = 
0.033).
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Table 5-20 Effect of piroxicam on genes implicated in protein transport 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ normal, APCMin/+ tumour, APCMin/+33$5Į-/- 
normal and APCMin/+33$5Į-/- tumour samples to expression in corresponding control groups. 
Univariate analysis of variance was used to determine differentially expressed genes with p <= 0.05 
(ns - not significant) 
 
 
Figure 5-14 Effect of piroxicam on genes implicated in protein transport 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of 
piroxicam groups to control groups, where RQ was >= 2 or <= to 0.5 
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Abcc4 1.40 1.23 1.04 1.53 ns ns ns
Alb 0.60 3.05 1.30 0.19 ns ns ns
Ap1s3 0.32 0.37 0.58 1.16 0.0001 0.0001 0.033
Crip 1 0.90 0.91 0.80 0.34 0.02 ns ns
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5.7.10.7 Protein metabolism & modification 
 
Table 5-21 and Figure 5-15 show expression data for the effect of 
piroxicam on genes implicated in protein metabolism & modification.  
These data showed there was no significant difference in expression of 
genes in this group via PPARĮ-mediated piroxicam treatment.  
Expression of Htra1 (HtrA serine peptidase 1) was up-regulated 2.07-
fold in the piroxicam-treated Min normal group (p = 0.0001).  
Htra1 expression was also increased in the piroxicam-treated Min 
tumour (2.29-fold) and PPARĮ tumour (2.43-fold) groups (p = 0.01). 
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Table 5-21 Effect of piroxicam on genes implicated in protein metabolism & modification 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ normal, APCMin/+ tumour, APCMin/+33$5Į-/- 
normal and APCMin/+33$5Į-/- tumour samples to expression in corresponding control groups. 
Univariate analysis of variance was used to determine differentially expressed genes with p <= 0.05 
(ns - not significant) 
 
 
Figure 5-15 Effect of piroxicam on genes implicated in protein metabolism & modification 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of 
piroxicam groups to control groups, where RQ was >= 2 or <= to 0.5 
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Akt3 1.71 0.62 1.10 1.42 ns ns ns
B4galt6 1.26 0.98 0.84 0.80 ns ns ns
Casp 6 0.65 0.98 1.10 1.59 ns 0.037 ns
Cdk4 1.33 1.65 1.02 1.41 0.03 ns ns
Htra1 2.07 2.29 1.23 2.43 0.0001 ns 0.01
Irak 4 0.80 0.82 0.72 0.69 0.001 ns ns
Mep1b 1.02 0.97 0.84 0.13 0.038 0.041 ns
Mmp2 1.48 0.97 1.31 1.10 ns ns ns
Mmp7 0.58 1.36 1.00 1.46 ns ns ns
Pdk2 0.56 0.48 0.83 0.50 0.001 ns ns
Plat 1.54 1.53 1.17 1.31 ns ns ns
Ptprg 0.66 1.00 1.00 1.17 ns ns 0.046
Timp 1 0.83 4.40 0.70 0.97 ns ns ns
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5.7.10.8 Cell adhesion 
 
Table 5-22 and Figure 5-16 show expression data for the effect of 
piroxicam on genes implicated in protein metabolism & modification.  
These data show piroxicam treatment did not significantly affect the 
expression of genes in this group. 
Table 5-22 Effect of piroxicam on genes implicated in cell adhesion 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ normal, APCMin/+ tumour, APCMin/+33$5Į-/- 
normal and APCMin/+33$5Į-/- tumour samples to expression in corresponding control groups. 
Univariate analysis of variance was used to determine differentially expressed genes with p <= 0.05 
(ns - not significant) 
 
 
Figure 5-16 Effect of piroxicam on genes implicated in cell adhesion 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of 
piroxicam groups to control groups, where RQ was >= 2 or <= to 0.5 
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Ctgf 1.67 1.15 0.66 1.03 ns ns ns
Itga6 1.29 1.06 0.96 0.95 ns ns ns
Sell 1.96 5.81 1.70 1.58 ns ns ns
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5.7.10.9 Various cellular functions 
 
Table 5-23 and Figure 5-17 show expression data for the effect of 
piroxicam on genes implicated in toxin metabolism, amino acid 
metabolism and cellular structure. 
These data showed piroxicam treatment was not mediated via PPARĮ 
in the differential expression of genes in this group.  
The effect of just piroxicam treatment decreased expression of Cbr1 
(carbonyl reductase 1) by 2.04-fold (p = 0.001), and increased 
expression of Cryab (crystallin, alpha B) by 3.85-fold (p = 0.045).  
Aoc3 (amine oxidase, copper containing 3) expression decreased in the 
piroxicam-treated PPARĮ tumour group (2.13-fold, p = 0.0001). 
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Table 5-23 Effect of piroxicam on genes implicated in various cellular functions 
 
Mean relative quantity (RQ) of gene expression in APCMin/+ normal, APCMin/+ tumour, APCMin/+33$5Į-/- 
normal and APCMin/+33$5Į-/- tumour samples to expression in corresponding control groups. 
Univariate analysis of variance was used to determine differentially expressed genes with p <= 0.05 
(ns - not significant) 
 
 
Figure 5-17 Effect of piroxicam on genes implicated in various cellular functions 
Gene expression represented on log10 scale clustered bar graph as relative quantity (RQ) of 
piroxicam groups to control groups, where RQ was >= 2 or <= to 0.5 
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Aoc3 3.12 0.59 2.29 0.47 ns ns 0.0001
Cbr1 0.49 0.38 1.26 0.78 0.001 0.0001 ns
Cryab 3.85 1.03 0.93 1.01 0.045 0.035 0.049
Nisch 1.49 0.94 0.96 1.13 ns ns ns
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5.7.11 Validation of Taqman® low density array data: Correlation 
between Study 1B & control groups of Study 2B  
 
Table 5-24 shows the relative quantities (RQ) of genes to APCMin/+ 
normal groups. The three left hand columns show RQ to APCMin/+ 
normal in Study 1B, and the three right hand columns the RQ to 
APCMin/+ normal control group in Study 2B. 
As discussed previously, expression of Apobec3 was greatly increased 
in APCMin/+ PPARĮ-/- mice, and expression of Onecut2 was highly up-
regulated in tumour tissue. These two genes and corresponding data 
are highlighted in red in Table 5-24. 
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Table 5-24 Relative Quantities of gene expression in APCMin/+ tumour, APCMin/+ 33$5Į-/- normal & 
APCMin/+ 33$5Į-/- tumour groups (Study 1B & Study 2B control groups only) to corresponding 
APCMin/+ normal groups (1) 
 
Min 
tumour 
33$5Į-/- 
normal
33$5Į-/- 
tumour
Min tumour 
control
33$5Į-/- normal 
control
33$5Į-/- tumour 
control
Abcc4 1.5 0.9 1.2 0.9 0.8 1.2
Acot2 0.6 0.8 0.5 1.9 0.5 0.8
Akt3 0.6 1.0 0.4 1.0 1.0 0.6
Alb 28.0 1.2 7.6 1.8 0.7 5.8
Alox12 36.3 1.5 29.7 9.9 2.3 33.0
Alox15 4.3 1.3 2.0 1.5 0.3 7.6
Alox5ap 1.7 1.0 1.8 1.5 1.8 2.2
Ang 0.8 0.6 0.2 1.1 0.9 0.8
Angptl4 0.4 0.1 0.3 1.8 0.2 0.8
Aoc3 0.3 1.1 0.4 2.2 1.0 1.0
Ap1s3 0.5 1.0 0.3 0.8 0.5 0.3
Apaf1 1.9 0.9 1.5 1.2 1.0 1.6
Apcdd1 18.0 0.4 10.0 2.9 1.0 7.3
Apobec3 2.1 77.9 128.7 0.8 190.6 251.9
Arnt2 3.5 0.5 6.8 2.5 1.1 7.1
B4galt6 1.5 0.7 1.7 1.4 1.2 2.2
Baz1a 1.4 0.8 1.5 1.2 1.2 1.6
Bcl2l11 2.8 0.9 3.2 0.9 0.7 1.8
Bdh1 0.4 0.6 0.3 1.5 1.1 1.0
Bik 1.8 0.5 0.7 1.1 0.4 0.5
Bin1 0.4 0.9 0.1 0.3 0.2 0.2
Bmf 4.1 1.1 3.6 1.2 0.8 1.5
Casp6 2.9 0.9 2.5 1.2 1.0 1.4
Cbr1 0.3 0.7 0.3 1.1 0.7 0.5
Cbx7 1.4 0.6 0.4 0.9 0.3 0.4
Ccnd1 3.0 1.2 2.7 1.2 1.2 2.3
Cdk4 2.3 0.9 2.1 0.8 1.0 1.6
Cdkn1c 2.2 0.5 2.1 1.7 0.8 2.5
Chd8 1.0 0.8 0.8 0.9 0.9 0.9
Crem 1.7 1.0 1.0 1.0 0.9 0.9
Crip1 0.5 1.4 0.4 0.9 1.2 1.3
Cryab 0.3 0.9 0.3 0.7 1.3 0.6
Ctgf 1.3 1.1 1.1 0.4 0.8 0.6
Cyp11a1 17.0 1.7 17.8 0.6 0.3 3.4
Cyp2b10 97.3 0.9 37.6 2.8 0.1 1.8
Cyp2c55 0.0 0.5 0.1 2.8 0.9 0.8
Decr1 0.4 0.7 0.4 0.9 1.0 0.9
Ech1 0.5 0.6 0.3 1.2 0.8 0.8
Echdc2 4.2 0.8 3.0 1.2 0.9 1.9
Endod1 0.3 0.8 0.2 0.9 1.0 0.4
Ereg 2.7 1.2 3.8 2.8 1.7 8.1
Foxc2 5.3 0.7 2.8 1.6 1.1 1.9
Ghr 0.7 0.8 0.7 0.9 0.7 0.7
Gucy2c 0.4 0.7 0.3 1.3 0.9 0.9
Gulp1 0.4 0.8 0.7 1.3 1.0 0.8
Hadha 0.4 0.9 0.6 1.2 0.7 0.6
Htra1 4.6 1.0 2.6 1.8 1.8 3.6
Id4 0.2 1.2 0.2 0.9 1.2 1.1
Il1b 6.7 0.7 15.9 6.0 2.7 30.0
Il6 7.9 1.4 19.9 3.7 1.2 33.1
Inhba 12.2 2.1 20.5 3.9 1.9 22.6
Irak4 0.8 0.5 0.5 1.1 0.6 0.7
Itga6 2.1 1.2 1.8 1.1 1.0 1.6
Jun 1.5 0.6 1.4 1.4 0.9 1.3
Khdc1a 1.9 0.3 0.3 0.1 0.2 0.8
Klf4 0.2 0.6 0.2 1.1 1.0 0.5
Krt18 2.2 1.2 2.0 1.0 1.4 1.5
Lama1 5.1 0.9 6.0 3.3 3.1 7.4
Lama5 3.7 1.1 4.4 1.1 1.0 1.5
Lrp1 0.6 1.1 0.8 1.3 0.8 1.1
Meis1 0.5 1.3 0.3 1.0 0.7 0.7
Mep1b 0.2 0.9 0.4 2.0 2.0 3.7
Mmp2 1.6 1.2 1.6 1.9 1.6 2.5
Mmp7 185.4 1.4 146.4 14.1 1.1 46.0
Myc 2.4 0.8 2.3 0.9 0.9 1.3
Relative Quantity to APCMin/+  normal (Study 1B)     Relative Quantity to APCMin/+ normal control (Study 2B)
Gene
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Relative Quantities of gene expression in APCMin/+ tumour, APCMin/+ PPARɲ-/- normal & APCMin/+ 
PPARɲ-/- tumour groups (Study 1B & Study 2B control groups only) to corresponding APCMin/+ 
normal groups (2) 
 
 
Data from Table 5-24 were plotted onto scatter plots (Figure 5-18, 
Figure 5-19, Figure 5-20) and bar graphs (Figure 5-21,  
Figure 5-22, Figure 5-23) as matched paired groups; that is APCMin/+ 
tumour, APCMin/+ PPARĮ-/- normal and APCMin/+ PPARĮ-/- tumour groups 
from Study 1B and the corresponding untreated (control) groups from 
Study 2B.  
Min 
tumour 
33$5Į-/- 
normal
33$5Į-/- 
tumour
Min tumour 
control
33$5Į-/- normal 
control
33$5Į-/- tumour 
control
Nfkbie 1.6 0.9 1.8 1.6 1.3 2.8
Nisch 1.2 0.9 1.3 1.0 1.1 1.1
Nr1d1 0.3 0.7 0.3 1.2 1.1 0.7
Onecut2 145.8 1.0 196.8 25.7 2.1 184.9
Pdk2 0.3 0.7 0.3 1.1 0.7 0.6
Phf17 0.6 0.9 0.6 0.8 0.8 0.6
Pla2g2a 37.1 1.1 17.2 4.3 0.8 11.6
Plat 21.0 1.7 20.8 3.0 1.0 9.0
Pou2af1 0.6 0.5 0.4 1.1 0.8 2.7
Ppbp 10.2 1.1 7.8 2.3 0.9 6.7
Ptger3 0.2 0.7 0.2 0.4 0.6 0.3
Ptgis 0.1 1.4 0.2 0.9 0.8 0.8
Ptgs1 0.6 0.5 0.4 1.2 1.1 0.7
Ptgs2 5.1 1.0 6.5 1.9 1.4 5.3
Ptprg 1.3 0.7 0.9 1.0 0.9 1.1
Rarb 3.4 0.4 3.5 1.8 0.7 3.7
Rbms1 2.1 1.5 2.4 1.0 0.8 1.2
Rhoj 3.2 1.1 2.3 1.4 0.9 1.6
Rorc 0.2 0.6 0.1 0.6 0.4 0.3
Sbk1 1.9 1.0 1.7 1.0 0.8 1.3
Sell 0.3 0.2 0.5 1.2 0.8 4.2
Sfrp1 1.0 1.2 1.4 0.7 1.2 1.1
Steap4 4.7 1.7 5.8 1.4 0.5 1.9
Tcf12 2.5 0.8 1.5 1.0 0.8 1.1
Timp1 4.9 2.4 5.1 1.5 1.3 5.3
Tnf 3.7 0.4 2.5 2.0 0.7 2.8
Gene
Relative Quantity to APCMin/+  normal (Study 1B)     Relative Quantity to APCMin/+ normal control (Study 2B)
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Figure 5-18 is a scatter plot showing the correlation between APCMin/+ 
tumour groups. The highly expressed gene Onecut2 is highlighted in 
red. These data were also represented on a bar graph (Figure 5-21) 
which shows good correlation between APCMin/+ tumour groups from 
study 1B and 2B. 
 
 
Figure 5-18 Correlation between expression of genes in APCMin/+ tumour groups of Study 1B & Study 
2B 
Comparison of relative quantity (log10) of gene expression in APCMin/+ tumour group to APCMin/+ 
normal (Study 1B) vs. RQ (log10) of gene expression in APCMin/+ tumour group to APCMin/+ normal 
(Study 2B control groups) represented on scatter plot 
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Figure 5-19 is a scatter plot showing the correlation between APCMin/+ 
PPARĮ-/- normal groups. Apobec3 is highlighted in red. The 
corresponding bar graph ( 
Figure 5-22) shows expression of genes was highly comparable in 
APCMin/+ PPARĮ-/- normal groups of study 1B and 2B.  
 
 
Figure 5-19 Correlation between expression of genes in APCMin/+ 33$5Į-/- normal groups of Study 1B 
& Study 2B 
Comparison of relative quantity (log10) of gene expression in APCMin/+ 33$5Į-/- normal group to 
APCMin/+ normal (Study 1B) vs. RQ (log10) of gene expression in  APCMin/+ 33$5Į-/- normal group to 
APCMin/+ normal (Study 2B control groups) represented on scatter plot 
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Figure 5-20 shows a scatter plot that represents the correlation between 
APCMin/+ PPARĮ-/- tumour groups. Apobec3 and Onecut2 are 
highlighted in red. Figure 5-23 shows that genes have very similar 
expression levels in each of APCMin/+ PPARĮ-/- tumour groups from 
Study 1B and 2B.  
 
 
Figure 5-20 Correlation between expression of genes in APCMin/+ 33$5Į-/- tumour groups of Study 1B 
& Study 2B 
Comparison of relative quantity (log10) of gene expression in APCMin/+ 33$5Į-/- tumour group to 
APCMin/+ normal (Study 1B) vs. RQ (log10) of gene expression in  APCMin/+ 33$5Į-/- tumour group to 
APCMin/+ normal (Study 2B control groups) represented on scatter plot 
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Figure 5-21 Comparative expression of genes in APCMin/+ tumour groups of Study 1B & Study 2B 
Relative quantity (RQ) of gene expression in APCMin/+ tumour group to APCMin/+ normal (Study 1B, 
blue bars) and RQ of gene expression in APCMin/+ tumour group to APCMin/+ normal (Study 2B control 
groups, red bars) represented on log10 scale bar chart  
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Figure 5-22 Comparative expression of genes in APCMin/+ PPARɲ-/- normal groups of Study 1B & 
Study 2B 
Relative quantity (RQ) of gene expression in APCMin/+ PPARɲ-/- normal group to APCMin/+ normal 
(Study 1B, blue bars) and RQ of gene expression in APCMin/+ PPARɲ-/- normal group to APCMin/+ 
normal (Study 2B control groups, red bars) represented on log10 scale bar chart 
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Figure 5-23 Comparative expression of genes in APCMin/+ PPARɲ-/- tumour groups of Study 1B & 
Study 2B 
Relative quantity (RQ) of gene expression in APCMin/+ PPARɲ-/- tumour group to APCMin/+ normal 
(Study 1B, blue bars) and RQ of gene expression in APCMin/+ PPARɲ-/- tumour group to APCMin/+ 
normal (Study 2B control groups, red bars) represented on log10 scale bar chart 
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5.8 Discussion 
 
5.8.1 Are the effects of piroxicam mediated via 33$5Į? 
 
Results from the analyses of polyp burden and gene expression in the 
mouse intestine of APCMin/+ mice and APCMin/+ PPARĮ-/- mice have 
shown that PPARĮ may have a role in preventing development and 
growth of polyps in the mouse intestine. Also, it has previously been 
demonstrated that the PPARĮ ligand methylclophenapate (MCP) 
reduced the number of polyps in the mouse colon and small bowel 
(Jackson et al., 2003).  
The present study investigated the long-term effects of piroxicam (a 
non-selective Cox inhibitor) on survival, polyp formation and gene 
expression in the colon and small bowel of APCMin/+ and APCMin/+ 
33$5Į-/- mice, and whether these effects were mediated via 33$5Į. 
Results of mean age at sacrifice showed APCMin+/- control mice were 
significantly older than APCMin+/- PPARĮ-/- control mice (p = 0.043) which 
could imply that PPARĮ has a role in life expectancy; perhaps due to 
downstream effects of PPARĮ activation such as lipid metabolism, fatty 
acid transport and oxidation (Erol, 2007). 
Also, mice dosed with piroxicam lived considerably longer than control 
mice, and to a greater extent in APCMin+/- mice than APCMin+/- PPARĮ-/- 
mice (p = 0.019). This effect was also reported in a previous study 
investigating the effects of piroxicam on intestinal polyps in APCMin/+ 
mice (Ritland and Gendler, 1999). 
In the colon, polyp number, polyp size and total tumour burden did not 
alter significantly between all groups. However, when corrected for age, 
polyp number, but not polyp size or total polyp burden was significantly 
reduced in all piroxicam-treated mice. This would imply that the polyps 
are larger although fewer in number.  
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Also, in the small bowel, polyp number, polyp size and total tumour 
burden were reduced significantly with piroxicam treatment in both 
APCMin+/- mice and APCMin+/- PPARĮ-/- mice. However, there was no 
significant difference in the number of polyps, polyp size or total tumour 
burden between control groups or between piroxicam-treated groups. 
Similar results were seen when age at sacrifice (per week) was 
considered.  
A study by (Jacoby et al., 1996) reported similar findings to those in the 
present study. Their study showed piroxicam treatment at 100 ppm for 
six weeks significantly reduced polyp numbers in the small bowel from 
16.7 +/- 2.7 in control mice to 3.2 +/- 0.4 (p < 0.0001). Also, polyp 
number in the colon increased from 0.6 +/- 0.3 in control mice to 1.2 +/- 
0.5 (p was not significant).  
Similarly, (Ritland and Gendler, 1999) demonstrated a 94.4% reduction 
(at 100 days old) and 95.7% reduction (at 200 days old) in intestinal 
polyp numbers in APCMin/+ mice given piroxicam at 200 ppm. Their 
study also reported that the distribution of tumours remaining after 
treatment with piroxicam implied that colonic tumours were relatively 
resistant to chemo-suppression.  
The weight of APCMin+/- PPARĮ-/- mice was greater than APCMin+/- mice 
at the start of the present study (p = 0.0083), but there was no 
significant difference in weight in control groups at the end of the study.  
Results showed mice in piroxicam-fed groups were significantly heavier 
at sacrifice than mice in control groups. However, they were also 
significantly older, so an increase in weight would be expected. Also, 
there was no significant difference in the weight of piroxicam-fed 
APCMin+/- mice and piroxicam-fed APCMin+/- PPARĮ-/- mice at sacrifice.  
Growth rate (defined as weight per week of life) in both APCMin+/- mice 
and APCMin+/- PPARĮ-/- mice was significantly reduced with piroxicam 
treatment. However, as piroxicam-fed mice were significantly older than 
non-treated mice, factoring in age skewed the actual growth rate. 
225 
 
Also, there was no significant difference in growth rate between control 
groups or between piroxicam-fed groups.  
The mesenteric fat in APCMin+/- PPARĮ-/- control mice was significantly 
higher than that in APCMin+/- control mice at sacrifice (p = 0.004). Also, 
piroxicam-fed mice had significantly increased mesenteric fat at 
sacrifice compared to control mice. However, this is likely to be due to 
increased survival in piroxicam-treated mice. There was no significant 
difference in mesenteric fat between mice on piroxicam diet.  
The results of the present study and the studies discussed here may 
suggest that in the colon, piroxicam inhibits tumorigenesis and nascent 
polyp development, but not polyp enlargement and carcinogenesis. 
However, the dramatic reduction in the number of polyps in the small 
bowel may have led to increased survival in the piroxicam-treated mice 
and therefore, more time for pre-existing colonic polyps to increase in 
size. 
Analysis of gene expression in the colon of piroxicam-treated APCMin+/- 
and APCMin+/- PPARĮ-/- mice using Taqman® low density arrays 
demonstrated similar gene expression levels in each genotype.  
These data indicated that piroxicam did not act through a PPARĮ 
pathway to significantly affect expression levels of the genes that were 
investigated.  
However, Cyp2b10 (fold change decrease of 10.0, p = 0.038) and 
Cryab (fold change increase of 3.85, p = 0.045) demonstrated 
differential expression due to the effect of piroxicam treatment only.  
In summary, these data indicate that the effect of piroxicam on polyp 
number, polyp size and total tumour burden in the colon and small 
bowel of APCMin+/- and APCMin+/- PPARĮ-/- mice was not mediated via 
PPARĮ.  
In addition, Taqman® low density array analysis of selected gene 
expression in the colon of piroxicam-treated mice indicated that 
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piroxicam does not act through a PPARĮ pathway to significantly affect 
expression levels. 
Taken together, these data suggest that the PPARĮ DQG
cyclooxygenase pathways may act independently to influence polyp 
development in the colon and small bowel Therefore, a potential 
prophylactic and treatment therapy for intestinal cancers could be the 
simultaneous targeting of both pathways with an NSAID, such as 
piroxicam and a PPARĮOLJDQGVXFKDVWKHILEUDWHJURXSRIGUXJV 
 
5.8.2 Comparison of Taqman® low density array data of Study 1B 
& untreated groups of Study 2B 
 
Gene expression results from Study 2B (untreated groups only) were 
compared to Study 1B results to ascertain whether Taqman® low 
density arrays would produce comparable results from two matched 
studies. 
Figure 5-18 and Figure 5-21 show a comparison of gene expression 
results in the APCMin+/- tumour group from Study 1B and the untreated 
APCMin+/- tumour group from Study 2B.  The pattern of gene expression 
in both groups was similar, although expression in Study 1B was 
consistently higher. Expression of Onecut2 (one cut domain, family 
member 2) was highly up-regulated in tumour tissue in both studies.   
Figure 5-19 and  
Figure 5-22 show a comparison of gene expression results in the 
APCMin+/- PPARĮ-/- normal group from Study 1B and the untreated 
APCMin+/- PPARĮ-/- normal group from Study 2B.   
There was very little gene induction in the APCMin+/-PPARĮ-/- normal 
groups which meant expression levels were comparable to levels in 
normal tissue from APCMin/+ mice (See Table 5-24). Apobec3 
(Apolipoprotein B, catalytic polypeptide 3) was an exception. 
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Expression of Apobec3 was significantly increased in both APCMin+/-
PPARĮ-/- normal groups. 
Figure 5-20 and Figure 5-23 show a comparison of gene expression 
results in the APCMin+/-PPARĮ-/- tumour group from Study 1B and the 
untreated APCMin+/-PPARĮ-/- tumour group from Study 2B. There were 
similar gene expression levels between both groups. Apobec3 and 
Onecut2 were both highly up-regulated in both studies.  
In summary, these data show gene expression levels of similar genes 
from two separate matched studies were comparable. The results 
demonstrated good correlation of Taqman® low density array analysis 
from the two studies.  
Apobec3 and Onecut2 have been referred to in previous chapters and 
were confirmed as highly up-regulated in PPARĮ-/- samples and tumour 
samples respectively. These two genes were selected for further 
investigation. The findings and results are discussed in depth in 
Chapter 6. 
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6 Investigation of the role of Apobec3 & Onecut2 in 
tumorigenesis in the colon  
 
6.1 Introduction 
 
Apolipoprotein B DNA dC Æ dU - editing enzyme, catalytic polypeptide 
3 (Apobec3) and Onecut homeobox 2 (Onecut2) were selected for 
further analysis as the large changes in expression levels of these 
genes in the colon in relation to genotype and malignancy respectively 
were the most striking novel results from Affymetrix® microarrays and 
Taqman® low density arrays.  
As reported in previous chapters, analysis of the expression level of 
Apobec3 using Affymetrix® microarrays showed a decrease in APCMin+/-
PPARĮ-/- samples compared to APCMin+/- samples.  
Conversely, Taqman® low density array expression results showed a 
large increase in APCMin+/-PPARĮ-/- samples compared to APCMin+/- 
samples.  
These discrepancies may be explained by methodological differences 
that it is important to resolve because the size of the effects may 
indicate that direct or indirect regulation of Apobec3 is an important 
function of PPARĮ- dependent control.  
Further investigations into these findings are described and discussed 
in this chapter.  
Expression of Onecut2 was consistently high in colonic tumour tissue in 
both Affymetrix® microarrays and Taqman® low density arrays, 
suggesting that the product of this gene may play an important role in 
carcinogenesis.  
To validate these data real time quantitative PCR (RT Q PCR) was 
carried out.  
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6.1.1 Apobec3  
 
Organisms are subject to assault by a vast range of pathogens, and 
have evolved a range of protective measures. The adaptive immune 
responses by antibodies and T cells play a key role in protection from 
infection. However, the innate immune response is an immediate 
response, affording the organism protection from opportunistic or 
zoonotic pathogens (Tosi, 2005).  
A vital part of the innate immune response involves detection and 
clearance of foreign DNA that would cause disruption to the stability of 
host genomes (Ishii and Akira, 2006, Stetson and Medzhitov, 2006). 
Apobec3 proteins play a major part in this. Apobec3 proteins restrict 
foreign gene transfer by deamination25 of cytidines to uridines, which 
are then acted on by uracil DNA glycosylase (UNG), leading to 
degradation of the DNA (Stenglein et al., 2010).  
Apobec3 was named because of significant homology to Apobec1, 
Apobec2 and activation-induced deaminase (AID). All members of 
these families of genes share a conserved cytidine deaminase active 
site (CDA), (Jarmuz et al., 2002). Apobec1 edits a single C residue to U 
on the mRNA encoding Apolipoprotein B (ApoB), introducing a 
premature stop codon and production of a truncated protein with a 
different biological function (Wedekind et al., 2003). The role of 
Apobec2 has not been determined. AID functions in activated B cells 
and randomly edits single-stranded DNA dC residues to dU on the 
immunoglobulin locus to cause immunoglobulin gene diversification 
(Bransteitter et al., 2003). 
The human genome encodes seven Apobec3 proteins (A3A, A3B, A3C, 
A3DE, A3F, A3G and A3H) that are encoded on a single gene cluster 
on chromosome 22. All are cytidine deaminases with specificity for 
single-stranded DNA (Jarmuz et al., 2002). Mice only encode a single 
Apobec3 protein (Mariani et al., 2003). Analysis of the human genome 
                                            
25
 Hydrolysis reaction of cytosine ĺ uracil with the release of ammonia 
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suggests the human Apobec3 gene cluster developed after infection by 
historical exogenous retroviruses that were able to circumvent 
Apobec3±mediated inhibition of viral replication. Therefore, exogenous 
retroviruses may be the cause of selective pressure that promoted the 
amplification and diversification of the human Apobec3 gene (Sawyer et 
al., 2004, Zhang and Webb, 2004). 
A study by (Nik-Zainal et al., 2012) explored patterns of mutations in the 
genomes of EUHDVW FDQFHUV WR DVVHPEOH µPXWDWLRQDO VLJQDWXUHV RI WKH
XQGHUO\LQJ SURFHVVHV¶ (Nik-Zainal et al., 2012). Their study identified 
localised hypermutation (kataegis).  Areas of kataegis differ between 
cancers. However, these areas are generally found with somatic base 
substitutions, usually cytosine at TpC dinucleotides which may suggest 
Apobec family cytidine deaminase genes play a role in carcinogenesis.  
Another study by (Roberts et al., 2012) also identified mutation clusters 
in yeast, and human cancer genomes of multiple myelomas, prostate 
cancers and head and neck squamous cell carcinomas (HNSCCs). 
These were shown to have arisen from simultaneous mutations of 
cytosines or guanines in long single-stranded DNA.  Interestingly, the 
clusters were found to be enriched with a motif targeted by Apobec 
family cytidine deaminases.  
A study by (Ding et al., 2011) suggests human Apobec3G is one of 
several genes that play an important role in mediating colorectal cancer 
hepatic metastasis. Their study showed Apobec3G was highly 
expressed in human hepatic metastatic and primary colorectal tumours. 
Further, the study proposed a novel mechanism for the promotion of 
hepatic metastasis was via Apobec3G directed inhibition of miR-29- 
mediated suppression of Mmp2, although the mechanism for this 
remains to be elucidated.  
Our data showed some evidence that expression of Apobec3 in the 
mouse colon may be mediated by PPARĮ. Therefore, to investigate 
these findings further analyses were performed. 
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6.1.2 Onecut2 
 
Onecut genes are transcription factors that have two conserved 
domains involved in DNA recognition and binding; a cut domain and a 
homeodomain. The cut domain encodes a DNA-binding motif that can 
bind independently, or with the homeodomain. The homeodomain binds 
DNA in a sequence-specific manner in the promoter region of target 
genes, in complex with other transcription factors.   
The mammalian Onecut (OC) family is comprised of OC-1, OC-2 and 
OC-3. OC-1 was originally designated HNF-6, and is expressed in the 
liver, pancreas, brain, spleen and testis, but not the small intestine 
(Lannoy et al., 1998, Lemaigre et al., 1996). OC-2 and OC-3 were 
discovered by homology to OC-1 (Jacquemin et al., 2003, 
Vanhorenbeeck et al., 2002). OC-2 is expressed in the liver, pancreas 
and brain, and crypt and villous epithelium of the small intestine, whilst 
OC-3 is expressed in the stomach and brain, and enteroendocrine cells 
of the small intestine (Maier et al., 2006, Vanhorenbeeck et al., 2007).  
OC genes are important regulators of pancreas and liver development 
(Beaudry et al., 2006, Margagliotti et al., 2007). However, there is very 
little research into the function and role of these genes in the intestine. 
A study by (Dusing et al., 2010) used knockout mouse models of OC-2 
and OC-3, to show that ablation of OC-2 led to a failure to thrive and 
increased mortality in post-natal development in these mice compared 
to wild-type mice. OC-3 ablation had no effect on growth and weight in 
the mice.  
The same study used Affymetrix® microarrays to assess the effect of 
OC-2 on gene expression in the small intestine in mice. (Dusing et al., 
2010) showed that a large percentage of differentially expressed genes 
were involved in transport and lipid metabolism, which may indicate a 
regulatory role for OC-2 in expression of these genes in the small 
intestine.  
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The novelty of our data which showed a large increase in Onecut2 
expression in tumour tissue in the colon led to further investigation of 
this gene. Real time quantitative PCR was used to validate and confirm 
expression levels previously determined by Affymetrix® microarrays 
and Taqman® low density arrays. 
 
6.2 Aims 
x To ascertain the basis of the difference in expression levels of 
Apobec3 in Affymetrix® microarrays and Taqman® low density 
arrays. 
x To confirm the DNA sequence of Mus musculus Apobec3. 
x To determine and validate expression levels of Apobec3 and 
Onecut2 in the mouse colon using Real Time Quantitative PCR.  
 
6.3 Methods 
 
Methods for determination of Apobec3 and Onecut2 expression levels 
in the mouse colon are explained in previous chapters;  
Chapter 3 describes the method used for Affymetrix® microarrays 
(Methods 3.3.7, page 51), Chapter 4 (Methods 4.3.2, page 124) and 
Chapter 5 (Methods 5.5.1, page 171) describe the method used for 
Taqman® low density arrays.   
Expression levels of Onecut2 in all groups were comparable in 
Affymetrix® microarrays and Taqman® low density arrays.  
However, expression of Apobec3 in APCMin/+ 33$5Į-/- normal and 
tumour groups greatly increased in Taqman® low density arrays but not 
Affymetrix® microarrays.  
To ascertain the reason for the discrepancy further investigations were 
carried out. 
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6.3.1 Investigation of differences in Apobec3 gene expression on 
Affymetrix® microarrays & Taqman® low density arrays 
 
Investigation of the Apobec3 gene reference sequences (mRNA) from 
the National Centre for Biotechnology Information (NCBI) show that in 
the mouse there are two variants; NM_001160415.1, variant 1 which 
encodes the longer isoform 1 and NM_030255.3, variant 2 which lacks 
an alternate in-frame exon in the coding region, compared to variant 1. 
The encoded isoform 2 is shorter than isoform 1 as the sequence 
corresponding to exon 5 in isoform 1 is absent (See Table 6-1 and 
Figure 6-1).  
 
Table 6-1 Exon base numbers within Apobec3 genomic & mRNA sequences 
 
DNA 
base numbers
mRNA 
base numbers
Number of 
bases in exon
DNA 
base numbers
mRNA 
base numbers
Number of 
bases in exon
1 1-162 1-162 162 1-162 1-162 162
2 3004-3151 163-310 148 3004-3151 163-310 148
3 5288-5564 311-587 277 5288-5564 311-587 277
4 5704-5818 588-702 115 5704-5818 588-702 115
5 6613-6711 703-801 99
6 13037-13193 802-958 157 13037-13193 703-859 157
7 13934-14195 959-1220 262 13934-14195 860-1121 262
8 14444-14556 1221-1333 113 14444-14556 1122-1234 113
9 14897-16022 1334-2459 1126 14897-16022 1235-2360 1126
Apobec3
Variant 1 Variant 2
Exon
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Figure 6-1 Exons of Apobec3 variant 1 & variant 2 in genomic DNA (to scale) 
Exons
Base pairs
1
1-162
2
3004-3151
3
5288-
5564
4
5704-
5818
5
6613-
6711
6
13037-
13193
7
13934-
14195
9
14897-
16022
8
14444-
14556
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The differences in expression could be explained by the sequences 
used for detection by the two different methodologies which may have 
targeted different parts or different isoforms of the gene.  
Therefore, to determine what may have produced these differences, the 
target sequences of the Apobec3 assays used in Affymetrix® 
microarrays and Taqman® low density arrays were investigated and 
further analysis performed.  
Information about the Apobec3 assay used in the Affymetrix® 
microarrays was accessed from the Affymetrix® web site 
(http://www.affymetrix.com/). The code for the Apobec3 assay was 
identified as 1417470_at. The sequence of the 1417470_at assay was 
aligned against the sequence for Apobec3 variant 1 and then also 
variant 2 using nucleotide BLAST (Basic Local Alignment Search Tool).  
The results of BLAST confirmed the sequence of Affymetrix® assay 
1417470_at matched Apobec3 variant 1 bases 1359 ± 1825 (Figure 
6-2) and variant 2 bases 1260 ± 1726 (Figure 6-3), both within exon 9 of 
the Apobec3 gene. 
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Figure 6-2 mRNA sequence of Apobec3 variant 1 (NM_001160415.1) 
Apobec3 Variant 1 (NM_001160415.1)
1 aaggtggggc ctgcattcac ttggcccggg aggtcagttt cacttctggg ggtcttccat
61 agcctgctca cagaaaatgc aaccccagcg cctggggccc agagctggga tgggaccatt
121 ctgtctggga tgcagccatc gcaaatgcta ttcaccgatc agaaacctga tatctcaaga
181 aacattcaag ttccacttta agaacctagg ctatgccaaa ggccggaaag ataccttctt
241 gtgctatgaa gtgactagaa aggactgcga ttcacccgtc tcccttcacc atggggtctt
301 taagaacaag gacaacatcc acgctgaaat ctgcttttta tactggttcc atgacaaagt
361 actgaaagtg ctgtctccga gagaagagtt caagatcacc tggtatatgt cctggagccc
421 ctgtttcgaa tgtgcagagc agatagtaag gttcctggct acacaccaca acctgagcct
481 ggacatcttc agctcccgcc tctacaacgt acaggaccca gaaacccagc agaatctttg
541 caggctggtt caggaaggag cccaggtggc tgccatggac ctatacgaat ttaaaaagtg
601 ttggaagaag tttgtggaca atggtggcag gcgattcagg ccttggaaaa gactgcttac
661 aaattttaga taccaggatt ctaagcttca ggagattctg agaccttgct acatctcggt
721 cccttccagc tcttcatcca ctctgtcaaa tatctgtcta acaaaaggtc tcccagagac
781 gaggttctgg gtggagggca ggcgaatgga cccgctaagt gaagaggaat tttactcgca
841 gttttacaac caacgagtca agcatctctg ctactaccac cgcatgaagc cctatctatg
901 ctaccagctg gagcagttca atggccaagc gccactcaaa ggctgcctgc taagcgagaa
961 aggcaaacag catgcagaaa tcctcttcct tgataagatt cggtccatgg agctgagcca
1021 agtgacaatc acctgctacc tcacctggag cccctgccca aactgtgcct ggcaactggc
1081 ggcattcaaa agggatcgtc cagatctaat tctgcatatc tacacctccc gcctgtattt
1141 ccactggaag aggcccttcc agaaggggct gtgttctctg tggcaatcag ggatcctggt
1201 ggacgtcatg gacctcccac agtttactga ctgctggaca aactttgtga acccgaaaag
1261 gccgttttgg ccatggaaag gattggagat aatcagcagg cgcacacaaa ggcggctccg
1321 caggatcaag gagtcctggg gtctgcaaga tttggtgaat gactttggaa acctacagct
1381 tggacccccg atgtcttgag aggcaagaag agattcaaga aggtcttttg gtgacccccc
1441 cacccaaccc caagtctagg agaccttttg ttctcctgtt tgtttcccct tttgttttat
1501 cttttgttgt tttgctttgt tttgaagaca gagtctcact gggtagcttg ctactctgga
1561 actcactact agactaagct ggccttaaac tctaaaatcc acctgccagt gccttctgag
1621 agccaggctt aaggtgtgcg ctgcccactc ccagccttaa cccactgtgg cttttccttc
1681 ctctttcttt tattatcttt ttatctcccc tcaccctccc gccatcaata ggtacttaat
1741 tttgtacttg aaatttttaa gttgggccag gcatggtgga gcagcgtgcc tctaatcgca
1801 ggcaggagga tttccacgag cttgaggcta gcctgatcta catagtgggc tccaggacag
1861 ccagaactac acagagaccc tgtctcaaaa ataaatttag atagataaat acataaataa
1921 atggaagaag tcaaagaaag aaagacaaga ttaagttgtg catgattggg tcatatgtgt
1981 ttgaggcagg aggattgcca catcctgggc tatacaatga gaccctgtct caaacaaaac
2041 aaaacaaaac acaccaaaag aacagttttt aaatccccaa acctgaattc ttttctaata
2101 aagtggacaa ccaggcaggc cccctcaccc atcagagtgt gaacatcaag gaagggagcc
2161 agcaaactgg ctcacaggtg agcaagctga ctgcacctga agatcagagt tcagatccca
2221 gcacccacct cctgtagctc acaattgatc taactctagc tccagggtac ctggtgccct
2281 ctcctggact ccatggcacc ccatatatat gtatgtgtgt ttatgtatgt ataatgtgta
2341 cattatatat gcatacatgc aatatataat ttatatgtgt gtgtatatat atatataatg
2401 tatatattat atatctccct gtagttgcaa cccaacccag ttccctctac atagggtgt
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Figure 6-3 mRNA sequence of Apobec3 variant 2 (NM_030255.3) 
 
Apobec3 Variant 2 (NM_030255.3)
1 aaggtggggc ctgcattcac ttggcccggg aggtcagttt cacttctggg ggtcttccat
61 agcctgctca cagaaaatgc aaccccagcg cctggggccc agagctggga tgggaccatt
121 ctgtctggga tgcagccatc gcaaatgcta ttcaccgatc agaaacctga tatctcaaga
181 aacattcaag ttccacttta agaacctagg ctatgccaaa ggccggaaag ataccttctt
241 gtgctatgaa gtgactagaa aggactgcga ttcacccgtc tcccttcacc atggggtctt
301 taagaacaag gacaacatcc acgctgaaat ctgcttttta tactggttcc atgacaaagt
361 actgaaagtg ctgtctccga gagaagagtt caagatcacc tggtatatgt cctggagccc
421 ctgtttcgaa tgtgcagagc agatagtaag gttcctggct acacaccaca acctgagcct
481 ggacatcttc agctcccgcc tctacaacgt acaggaccca gaaacccagc agaatctttg
541 caggctggtt caggaaggag cccaggtggc tgccatggac ctatacgaat ttaaaaagtg
601 ttggaagaag tttgtggaca atggtggcag gcgattcagg ccttggaaaa gactgcttac
661 aaattttaga taccaggatt ctaagcttca ggagattctg aggcgaatgg acccgctaag
721 tgaagaggaa ttttactcgc agttttacaa ccaacgagtc aagcatctct gctactacca
781 ccgcatgaag ccctatctat gctaccagct ggagcagttc aatggccaag cgccactcaa
841 aggctgcctg ctaagcgaga aaggcaaaca gcatgcagaa atcctcttcc ttgataagat
901 tcggtccatg gagctgagcc aagtgacaat cacctgctac ctcacctgga gcccctgccc
961 aaactgtgcc tggcaactgg cggcattcaa aagggatcgt ccagatctaa ttctgcatat
1021 ctacacctcc cgcctgtatt tccactggaa gaggcccttc cagaaggggc tgtgttctct
1081 gtggcaatca gggatcctgg tggacgtcat ggacctccca cagtttactg actgctggac
1141 aaactttgtg aacccgaaaa ggccgttttg gccatggaaa ggattggaga taatcagcag
1201 gcgcacacaa aggcggctcc gcaggatcaa ggagtcctgg ggtctgcaag atttggtgaa
1261 tgactttgga aacctacagc ttggaccccc gatgtcttga gaggcaagaa gagattcaag
1321 aaggtctttt ggtgaccccc ccacccaacc ccaagtctag gagacctttt gttctcctgt
1381 ttgtttcccc ttttgtttta tcttttgttg ttttgctttg ttttgaagac agagtctcac
1441 tgggtagctt gctactctgg aactcactac tagactaagc tggccttaaa ctctaaaatc
1501 cacctgccag tgccttctga gagccaggct taaggtgtgc gctgcccact cccagcctta
1561 acccactgtg gcttttcctt cctctttctt ttattatctt tttatctccc ctcaccctcc
1621 cgccatcaat aggtacttaa ttttgtactt gaaattttta agttgggcca ggcatggtgg
1681 agcagcgtgc ctctaatcgc aggcaggagg atttccacga gcttgaggct agcctgatct
1741 acatagtggg ctccaggaca gccagaacta cacagagacc ctgtctcaaa aataaattta
1801 gatagataaa tacataaata aatggaagaa gtcaaagaaa gaaagacaag attaagttgt
1861 gcatgattgg gtcatatgtg tttgaggcag gaggattgcc acatcctggg ctatacaatg
1921 agaccctgtc tcaaacaaaa caaaacaaaa cacaccaaaa gaacagtttt taaatcccca
1981 aacctgaatt cttttctaat aaagtggaca accaggcagg ccccctcacc catcagagtg
2041 tgaacatcaa ggaagggagc cagcaaactg gctcacaggt gagcaagctg actgcacctg
2101 aagatcagag ttcagatccc agcacccacc tcctgtagct cacaattgat ctaactctag
2161 ctccagggta cctggtgccc tctcctggac tccatggcac cccatatata tgtatgtgtg
2221 tttatgtatg tataatgtgt acattatata tgcatacatg caatatataa tttatatgtg
2281 tgtgtatata tatatataat gtatatatta tatatctccc tgtagttgca acccaaccca
2341 gttccctcta catagggtgt
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Applied Biosystems web site (http://bioinfo.appliedbiosystems.com/) 
was accessed to gain information on assay identification number 
Mm00518791_m1, the Apobec3 assay used on Taqman® low density 
arrays. The assay information identified the amplicon size (129 bases) 
and sequence. 
The amplicon sequence and Apobec3 variant 1 (NM_001160415.1) 
sequence were input into NCBI and a nucleotide BLAST of the two 
sequences was performed. BLAST was also performed for the amplicon 
sequence and Apobec3 variant 2. This confirmed the amplicon 
sequence of Mm00518791_m1 as a match to Apobec3 variant 1 bases 
740-868, crossing exons 5±6 (Figure 6-2). Also, Apobec3 variant 2 
bases 701-769 (60 bases of the amplicon did not match with variant 2) 
(Figure 6-3). This showed that assay Mm00518791_m1 could only 
amplify variant 1 of Apobec3 as variant 2 lacks exon 5.  
In summary, these data demonstrate that Affymetrix® microarrays 
targeted Apobec3 variant 1 or variant 2 and Taqman® low density 
arrays targeted Apobec3 variant 1 only. 
 
6.3.2 Polymerase Chain Reaction (PCR) of the Apobec3 gene 
 
PCR of Apobec3 was performed in APCMin/+ and APCMin/+ 33$5Į-/- 
samples with three sets of primers targeting specific exons of the gene. 
Primers to amplify exon 1 ± exon 9 (Primer pair A), to amplify exon 1 ± 
exon 5 (Primer pair B) and to amplify exon 5 to exon 9 (Primer pair C), 
were designed using NCBI, http://www.ncbi.nlm.nih.gov/tools/primer-
blast/. Sequences of each primer pair are below.  
 
Primer pair A: exon 1- exon 9 
6HTXHQFHV¶ĺ ¶ 
Forward primer GGCCCAGAGCTGGGATGGGA (bases 96 ± 115 Æ) 
Reverse primer AGAGGGAACTGGGTTGGGTTGC (bases 2448 ± 2427 Å) 
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Primer pair B: exon 1 ± exon 5 
6HTXHQFHV¶ĺ ¶ 
Forward primer GGCCCAGAGCTGGGATGGGA (bases 96 ± 115 Æ) 
Reverse primer GCCCTCCACCCAGAACCTCGT (bases 799 ± 779 Å) 
Primer pair C: exon 5 ± exon 9 
6HTXHQFHV¶ĺ ¶ 
Forward primer TGGGTGGAGGGCAGGCGAAT (bases 788 ± 807 Æ) 
Reverse primer AGAGGGAACTGGGTTGGGTTGC (bases 2448 ± 2427 Å) 
Primers were synthesised by Eurofins MWG Operon. They were 
supplied in a lyophilized state and were reconstituted in water following 
PDQXIDFWXUHU¶VLQVWUXFWLRQVWRJLYHDstock concentration of 100 pmol/µl. 
Aliquots of 10 pmol/µl were prepared. Stock and aliquots were all stored 
at -200C until required. 
Figure 6-4 is a schematic figure of Apobec3 variant 1. The position of 
primer pairs A, B and C are shown. 
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Figure 6-4 Schematic of Apobec3 variant 1 showing primer pairs A, B and C 
Primer pair A target sequence exon 1 to exon 9  
(Forward primer bases 96 ± 115 Æ Reverse primer bases 2448 ± 2427 Å) 
Primer pair B target sequence exon 1 to exon 5 
(Forward primer bases 96 ± 115 ÆReverse primer bases 799 ± 779 Å) 
Primer pair C target sequence exon 5 to exon 9  
(Forward primer bases 788 ± 807 ÆReverse primer bases 2448 ± 2427 Å 
EXONS
mRNA base numbers 1-162 163-310 311-587 588-702 703-801 802-958 959-1220 1221-1333 1334-2459
Variant
1
1 2 3 4 5 6 7 8 9
Fwd 96-115 --> GGCCCAGAGCTGGGATGGGA CGTTGGGTTGGGTCAAGGGAGA <-- 2427-2448 Rev
       Fwd 788-807 --> TGGGTGGAGGGCAGGCGAAT
TGCTCCAAGACCCACCTCCCG <-- 779-799 Rev   
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x Preparation of cDNA 
Two APCMin/+ normal (76.4/3 & 70.3/2) and two APCMin/+ PPARɲ-/- 
normal (121.1/3 & 121.1/2) RNA samples from Study 1B were selected 
from storage at -800C.   
The concentration and integrity of the RNA were assessed on a 
NanoDrop® ND-1000 Spectrophotometer and then diluted to 250 ng/µl. 
cDNA was prepared with random primers (page 42) and 500 ng of RNA 
using Affinity Script (Agilent Technologies) following the manufacturer¶s 
protocol.  
x PCR of cDNA 
cDNA samples were prepared for PCR cycling using Phusion® High-
Fidelity DNA polymerase (New England Biolabs) as per the 
PDQXIDFWXUHU¶V protocol but modified with the addition of DMSO at 3% 
of the final volume.  
For a 50 µl reaction the following reagents were added to a PCR tube; 
DMSO 1.5 µl, 5x Phusion HF buffer 10 µl, dNTPs (prepared as on page 
41) 1 µl, water 29 µl, forward primer A 2.5 µl, reverse primer A 2.5 µl, 
template cDNA (undiluted) 3 µl and polymerase 0.5 µl.  
50 ul reactions were similarly prepared using forward primer B and 
reverse primer B, and forward primer C and reverse primer C.  
x Controls 
Two negative controls were used;  
A non-template control (NTC) was used to detect the presence of 
contaminating nucleic acids. Water was added to a PCR reaction 
instead of template cDNA. 
A no enzyme control (NEC) was used to detect genomic DNA 
contamination. The reverse transcriptase enzyme was omitted from 
cDNA preparation of the RNA samples. The samples (templates) were 
then used in PCR reactions. 
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One endogenous positive control was used; 
Primers to detect the Mus musculus Rplp0 (ribosomal protein, large P0) 
gene were used. The primers were added to separate PCR reactions to 
amplify a second target on the cDNA samples (templates).   
All of the PCR reactions were then run on a Bio-Rad T100 thermocycler 
as shown in Table 6-2.  
Table 6-2 Cycling protocol for PCR on Bio-Rad T100 thermocycler 
 
x Agarose gel of PCR products 
Agarose gels were prepared with the addition of ethidium bromide to 
visualise the PCR products. The amplicon size of PCR with primer pairs 
A and C was 2353 and 1661 base pairs respectively. 0.8% agarose 
gels were prepared to detect these PCR products. However, PCR with 
primer pair B produced a smaller amplicon size of 704 base pairs so 
1.5% agarose gels were prepared.  
Preparation of agarose gels is described below.  
To prepare 0.8% gel; 0.4 g agarose was added to 50 ml of 1x TAE 
buffer (page 42) in a conical flask. This was heated to boiling in a 
microwave oven and allowed to cool before the addition of 6 µl of 
ethidium bromide. The gel was cast and allowed to set.  
To prepare 1.5% gel; 0.75 g of agarose was added to 50 ml of 1x TAE 
buffer (page 42) and prepared as above.  
PCR products and DNA ladders (New England Biolabs) were prepared; 
To prepare PCR products, 4 µl of loading buffer was added to 16 µl of 
PCR product (or water for non-template control).  
Melt Anneal/Extend
30 seconds at 980C 30 seconds at 980C 2 minutes at 680C 10 minutes at 720C 40C
PCR (35 Cycles) Final extension HoldInitial denaturation
Times and temperatures
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1 kilobase (kb) ladders were prepared by adding 1 µl of ladder to 4 µl of 
loading buffer and 15 µl of water.  
50 base pair (bp) ladders were prepared by adding 2 µl of ladder to 4 µl 
of loading buffer and 14 µl of water.  
0.8% gels were loaded with 1 kb markers, controls and PCR products 
(from primer pairs A and C), and run at 100 V for 50 minutes.  
1.5% gels were loaded with 50 bp markers, controls and PCR products 
(from primer pair B), and run at 100 V for 50 minutes.  
Bands of DNA corresponding to the expected amplicon sizes from 
primer pairs A (2353 bp) and C (1661 bp) were not seen on the agarose 
gels. However, primer pair B amplified a sequence of ~ 704 base pairs 
as expected which was highly expressed in APCMin/+ PPARĮ-/- normal 
samples (Figure 6-5). These samples were investigated further. 
 
6.3.3 Sequencing of Apobec3 PCR product (primer pair B)  
 
A 1.5% agarose gel was prepared as before, but without addition of 
ethidium bromide.  
PCR products (from amplification of two APCMin/+ PPARĮ-/- normal, 
121.1/3 & 121.1/2 cDNA samples with Primer pair B as before 6.3.2, 
page 239), non-template control (NTC) and a 50 base pair (bp) ladder 
were prepared as previously, but with addition of 2 µl Sybr® Green 1 
nucleic acid gel stain to each tube (page 42). The tubes were incubated 
at room temperature for 5 minutes before addition of loading buffer. 
The agarose gel was loaded with 50 bp markers, PCR products and 
NTC, and run at 100 V for 50 minutes. 
The gel was viewed using a Dark Reader® (Clare Chemical Research). 
DNA bands corresponding to 704 base pairs were excised from the gel 
with a clean, sharp scalpel. The bands were placed into separate pre-
weighed Eppendorf tubes, and the weights of the bands calculated.  
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A QIA gel extraction kit (Qiagen) was used to extract and clean the 
DNA from the agarose, following the manufacturers¶ protocol.  
Sequencing of DNA samples was carried out by Source Bioscience Life 
Sciences, Nottingham, UK (www.lifesciences.sourcebioscience.com).  
 
6.3.4  Real Time Quantitative Polymerase Chain Reaction (RT Q 
PCR) of Apobec3 & Onecut2  
 
The expression levels of Apobec3 and Onecut2 as determined by 
Affymetrix® microarrays and Taqman® low density arrays were 
validated by RT Q PCR. 
Primer Express® software v3.0 (Applied Biosystems) was used to 
design primers and probes for Apobec3 and Onecut2. Two sets of 
primers and probes were designed for Apobec3. The first set was 
designed to cross the boundary of exon 5 and exon 6, to amplify a 
target sequence in Apobec3 variant 1 only. The second set was 
designed to cross the boundary of exon 2 and exon 3, to amplify target 
sequences in both Apobec3 variants 1 and 2. One set of primers and 
probe was designed for Onecut2.  
Primers and probes were synthesised by Eurofins MWG Operon.  
Apobec3 sequences (specific to variant 1 only) 
6HTXHQFHV¶ĺ ¶ 
Forward primer TCTCCCAGAGACGAGGTTCTG 
Reverse primer TTGGTTGTAAAACTGCGAGTAAAATT 
Probe  7**$***&$**&*$¶-)$0¶-TAM) 
Apobec3 sequences (variant 1 and 2) 
6HTXHQFHV¶ĺ ¶ 
Forward primer GGAAAGATACCTTCTTGTGCTATGAA 
Reverse primer CGTGGATGTTGTCCTTGTTCTTAA 
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Probe  7*$&7$*$$$**$&7*&*$77&$&&&*7&¶-)$0¶-TAM) 
Onecut2 sequences 
6HTXHQFHV¶ĺ ¶ 
Forward primer CCAGCGCATGTCTGCCTTA 
Reverse primer TTGTTCCTGTCTTTGTTTGGTTCTT 
Probe  &&7**&$*&$7*&$$$&*&$$$¶-)$0¶-TAM) 
 
Primers and probes were supplied in a lyophilised state. Primers were 
reconstituted in water, and probes in the supplied dilution buffer (10mM 
Tris-HCl; pH 8; 1mM EDTA), folloZLQJ PDQXIDFWXUHU¶V LQVWUXFWLRQV WR
give a stock concentration of 100 pmol/µl. Aliquots at 10 pmol/µl were 
prepared. Stock and aliquots were all stored at -200C until required.  
Actin, beta (ACTB, prepared as on page 41) was used as the reference 
gene for normalisation of all samples.  
Previously prepared aliquots of undiluted RNA samples from Study 1B 
(3.3.6, page 50) and Study 2B (5.5, page 168) were removed from 
storage at -800C; integrity and concentration were assessed on a 
NanoDrop® ND-1000 spectrophotometer. RNA was then diluted with 
DEPC water (prepared as on page 41) to a concentration of 250 ng/µl. 
cDNA was synthesised using 500 ng of RNA and random primers (page 
42) with an M-MLV Reverse Transcriptase kit (Invitrogen) following 
manufacturers protocol.  
5 µl from each newly prepared cDNA sample were pooled for 
preparation of standards. The remainder of each cDNA sample was 
diluted 1:16 with water. Aliquots of the pooled samples (8 µl) and diluted 
cDNA samples (20 µl) were prepared. All were stored at -200C until 
required.  
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To prepare solutions for running a standard curve (sufficient to run two 
plates), an aliquot of pooled samples was defrosted and prepared as 
below: 
STANDARD 1: Pooled samples (8 µl aliquot) + 32 µl water  Æ  defined as NEAT 
STANDARD 2: 20 µl of NEAT + 20 µl water  Æ  1/2 
STANDARD 3: 20 µl of 1/2 + 20 µl water  Æ  1/4 
STANDARD 4: 20 µl of 1/4 + 20 µl water  Æ  1/8 
STANDARD 5: 20 µl of 1/8 + 20 µl water  Æ  1/16 
A standard curve was run on every plate. Each standard (1 - 5) was run 
in triplicate. 
Master mixes were prepared for each plate;  
Preparation of master mix for RT Q PCR with ACTB (reference 
gene), per well;  
6.5 µl* TaqMan Fast universal PCR Master mix, 2x (Applied 
Biosystems), 2.25 µl* water and 1.25 µl* ACTB (primers and probe 
supplied in one tube, see 2.2, page 41), were added to an Eppendorf 
tube, then briefly mixed and centrifuged (*multiplied by number of wells 
to be used on the assay26). 
Preparation of master mix for RT Q PCR with target gene primers 
and probes, per well;  
6.5 µl* TaqMan Fast universal PCR Master mix (2x), 2.5 µl* water, 
0.375 µl* forward primer, 0.375 µl* reverse primer and 0.25 µl* probe 
were added to an Eppendorf tube, then briefly mixed and centrifuged 
(*multiplied by number of wells to be used on the assay). 
Individual 96-well plates were used to assay diluted (1:16) cDNA 
samples from Study 1B and Study 2B, standards and a non-template 
control with;  
                                            
26
 Number of wells per assay = standards (3 x 5) + non template control (1 x 3) + samples n (n x 3) + 10% to 
allow for error 
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x ACTB  
x Apobec3 variant 1 primers and probe  
x Apobec3 variant 1 and 2 primers and probe 
x Onecut2 primers and probe 
10 µl of master mix (prepared as above) was pipetted into each well of 
a plate. 3 µl of either a standard, diluted cDNA sample or non-template 
control (water) were added to appropriate wells in triplicate. Plates were 
sealed, spun on a MPS 1000 mini plate spinner (Labnet International, 
Inc.) then loaded onto a StepOne Plus Real-Time PCR system and 
run as below (Table 6-3).  
Table 6-3 &\FOLQJSURWRFROIRU6WHS2QH3OXV5HDO-Time PCR system 
 
At the end of each cycle protocol, all data were saved and exported into 
an Excel spreadsheet for analysis. Fold change values of Apobec3 and 
Onecut2 expression in all samples relative to APCMin/+ normal/untreated 
samples were calculated from normalised Ct values (relative quantity 
(RQ).  
Also, SPSS 16.0.0.247 was used to calculate univariate analysis of 
variance of normalised Ct values. 
 
6.4 Results 
 
Results of Affymetrix® microarrays for Apobec3 and Onecut2 gene 
expression can be seen in Chapter 3 (Results 3.4.5, page 77). 
Taqman® low density array results can be seen in Chapter 4 (Results 
4.4, page 127) and Chapter 5 (Results 5.7.10, page 195). 
   
Initial Step
Activation Melt Anneal/Extend
HOLD
10 minutes at 95oC 15 seconds at 95oC 60 seconds at 60oC
Times and Temperatures
PCR (40 Cycles)
CYCLE
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6.4.1 Polymerase Chain Reaction (PCR) analysis of the Apobec3 
gene 
 
Products of PCR of APCMin/+ normal and APCMin/+ PPARĮ-/- normal 
samples with primer pairs A, B and C (Methods 6.3.2, page 239) were 
analysed on agarose gels.  
As stated previously, bands of DNA corresponding to the expected 
amplicon sizes from primer pairs A and C were not seen on the agarose 
gels. Therefore, no further analyses were performed using these primer 
pairs.  
However, primer pair B (see below) amplified a sequence of ~ 704 base 
pairs which was highly expressed in APCMin/+ PPARĮ-/- normal samples 
(See Figure 6-5).  
(Primer pair B: Forward primer GGCCCAGAGCTGGGATGGGA, bases 96 ± 115 Æ 
Reverse primer GCCCTCCACCCAGAACCTCGT, bases 799 ± 779 Å) 
The PCR products of the two APCMin/+ PPARĮ-/- normal samples were 
re-run on a 1.5% agarose gel with the addition of Sybr® Green 1 
nucleic acid gel stain. Bands corresponding to 704 base pairs were 
excised and prepared for sequencing as previously described (Methods 
6.3.3, page 244). 
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Figure 6-5 Agarose gel of primer pair B amplicon  
Base pairs
1350
916
766
700
500
Base pairs
1350
916
766
700
500
MW              APC Min/+ normal     APCMin/+ PPARĮ-/- normal       NTC              MW
1 2                  3                   4                 5                    6                   7
1.5% agarose gel of Apobec3 PCR products (primer pair B)
Lanes 1 & 7, MW molecular weight marker (DNA ladder 50 base 
pairs, New England Biolabs
Lanes 2 & 3, APCMin/+ normal
Lanes 4 & 5, APCMin/+ PPARĮ-/- normal
Lane 6, NTC (non-template control)
Lane Lane
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6.4.2 Sequence analysis of Apobec3 gene (primer pair B 
amplicon) 
 
The amplicon sequences for each APCMin/+ PPARĮ-/- normal sample 
(forward and complement) recorded by Source Biosciences were input 
into National Centre for Biotechnology Information (NCBI) BLAST 
(Basic Local Alignment Search Tool) and aligned against the sequence 
for Apobec3 variant 1 (See Figure 6-6) and variant 2 (See Figure 6-7), 
see also Table 6-4 below.  
 
Table 6-4 Alignment of base numbers of Primer pair B amplicon of APCMin/+ PPARĮ-/- normal samples 
against Apobec3 variant 1 & variant 2 
 
Primer pair B amplicon sequences (forward and complement) of APCMin/+ PPARĮ-/- normal samples 
were aligned against the mRNA sequences of Apobec3 variant 1 and variant 2 
 
The results from sequencing show that the forward primer sequences 
aligned with Apobec3 variant 1 from exon 1 to exon 5. Also, both 
reverse primer sequences aligned with Apobec3 variant 1 from exon 5 
to exon 1 (Figure 6-6).  
It can be seen in Table 6-4 that the sequence results did align with 
Apobec3 variant 2 but only to base number 702. This is the end of exon 
4 as Apobec3 variant 2 does not have exon 5.  
Therefore, the results of PCR with primer pair B and subsequent 
sequencing data, may indicate that Apobec3 variant 1 is highly 
expressed in the colon of APCMin/+ PPARĮ-/- mice.  
A possible reason for the lack of bands on the agarose gel after PCR 
with primer pairs A and C is D ODUJH SUHGLFWHG ¶875 XQWUDQVODWHG
region) after the protein coding region. The sequence of the reverse 
Apobec3 variant 1 
base numbers
Apobec3 variant 2 
base numbers
forward 139 - 800 139 - 702
complement 754 - 96 702 - 96
forward 139 - 800 139 - 702
complement 754 - 106 702 - 106
ALIGNMENT
APCM in/+ 33$5Į-/- 
sample number Sequence
121.1/2
121.1/3
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primer was within this region. In addition, the sequence of the 
Affymetrix® probe was also found to be in this region. This provides an 
explanation for both the lack of amplification with primer pairs A and C, 
and the difference observed between Taqman® low density array and 
Affymetrix® microarray data.  
Future work will see primers re-designed to amplify the coding region. 
The gene will then be sequenced.  
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Figure 6-6 mRNA sequence of Apobec3 variant 1 (exons 1 ± 5) 
Primer pair B amplicon sequences (forward and complement) of APCMin/+ PPARĮ-/- normal samples were aligned against the sequence for Apobec3 variant 1 
 
Apobec3 Variant 1 (NM_001160415.1)
1 aaggtggggc ctgcattcac ttggcccggg aggtcagttt cacttctgggggtcttccat
61 agcctgctca cagaaaatgc aaccccagcg cctggggcccagagctggga tgggaccatt
121 ctgtctggga tgcagccatc gcaaatgcta ttcaccgatc agaaacctga tatctcaaga
181 aacattcaag ttccacttta agaacctaggctatgccaaaggccggaaag ataccttctt
241 gtgctatgaa gtgactagaaaggactgcga ttcacccgtc tcccttcacc atggggtctt
301 taagaacaaggacaacatcc acgctgaaat ctgcttttta tactggttcc atgacaaagt
361 actgaaagtg ctgtctccgagagaagagtt caagatcacc tggtatatgt cctggagccc
421 ctgtttcgaa tgtgcagagc agatagtaaggttcctggct acacaccacaacctgagcct
481 ggacatcttc agctcccgcc tctacaacgt acaggaccca gaaacccagc agaatctttg
541 caggctggtt caggaaggag cccaggtggc tgccatggac ctatacgaat ttaaaaagtg
601 ttggaagaag tttgtggaca atggtggcaggcgattcagg ccttggaaaagactgcttac
661 aaattttaga taccaggatt ctaagcttca ggagattctg agaccttgct acatctcggt
721 cccttccagc tcttcatcca ctctgtcaaa tatctgtcta acaaaaggtc tcccagagac
781 gaggttctgg gtggagggcagg
Exon 1
1-162
Exon 2
163-310
Exon 3
311-587
Exon 4
588-702
Exon 5
703-801
Exon 6
802-958
KEY TO COLOURS
Exon junctions
Forward primer B amplicon
from APCMin/+ PPARɲ-/-
samples (bases 139 ± 800)
Reverse primer B amplicon
from APCMin/+ PPARɲ-/-
samples (bases 96 ± 754)
Forward primer
Reverse primer
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Figure 6-7 mRNA sequence of Apobec3 variant 2 (exons 1 ± 4) 
Primer pair B amplicon sequences (forward and complement) of APCMin/+ PPARĮ-/- normal samples were aligned against the sequence for Apobec3 variant 2 
Apobec3 Variant 2 (NM_030255.3)
1 aaggtggggcctgcattcac ttggcccgggaggtcagttt cacttctgggggtcttccat
61 agcctgctcacagaaaatgcaaccccagcg cctggggcccagagctggga tgggaccatt
121 ctgtctggga tgcagccatcgcaaatgcta ttcaccgatcagaaacctga tatctcaaga
181 aacattcaag ttccacttta agaacctaggctatgccaaaggccggaaag ataccttctt
241 gtgctatgaa gtgactagaaaggactgcga ttcacccgtc tcccttcacc atggggtctt
301 taagaacaaggacaacatcc acgctgaaatctgcttttta tactggttccatgacaaagt
361 actgaaagtgctgtctccgagagaagagtt caagatcacc tggtatatgt cctggagccc
421 ctgtttcgaa tgtgcagagcagatagtaaggttcctggct acacaccaca acctgagcct
481 ggacatcttc agctcccgcc tctacaacgt acaggaccca gaaacccagcagaatctttg
541 caggctggtt caggaaggag cccaggtggc tgccatggacctatacgaat ttaaaaagtg
601 ttggaagaag tttgtggacaatggtggcaggcgattcaggccttggaaaa gactgcttac
661 aaattttaga taccaggatt ctaagcttca ggagattctg ag
Exon 1
1-162
Exon 2
163-310
Exon 3
311-587
Exon 4
588-702
KEY TO COLOURS
Exon junctions
Forward primer B amplicon
from APCMin/+ PPARɲ-/-
samples (bases 139 - 702)
Reverse primer B amplicon
from APCMin/+ PPARɲ-/-
samples (bases 96 - 702)
255 
 
6.4.3 Alignment of Apobec3 sequences in Mus musculus & Homo 
sapiens 
 
Protein sequences of mouse Apobec3 were aligned with protein 
sequences of human Apobec3 to determine whether there was any 
similarity. Protein sequences, rather than DNA sequences were used, 
due to the inherent variability of the genetic code. Clustal X version 227 
was used to perform the alignments (Larkin et al., 2007).  
The gi numbers of the sequences used for alignment are listed below 
DDĺDPLQRDFLGV.  
 
Sequence 1: gi|199581417_Apobec3_Mus_musculus   429 aa 
Sequence 2: gi|218511520_APOBEC3H_Homo_sapiens  200 aa 
Sequence 3: gi|38303911_APOBEC3G_Homo_sapiens  79 aa 
Sequence 4: gi|22907044_APOBEC3F_isoform_a_Homo_sapiens 373 aa 
Sequence 5: gi|54873619_APOBEC3F_isoform_b_Homo_sapiens 101 aa 
Sequence 6: gi|187608816_APOBEC3D_Homo_sapiens  386 aa 
Sequence 7: gi|22907039_APOBEC3C_Homo_sapiens  190 aa 
Sequence 8: gi|31753108_APOBEC3B_Homo_sapiens  251 aa 
Sequence 9: gi|219520199_APOBEC3A_Homo_sapiens  181 aa 
 
 
An average quality score for each aligned sequence was generated; a 
high score indicated the sequences were well conserved, whereas a 
low score indicated low conservation. 
Table 6-5 shows the average quality scores for alignments of each 
human Apobec3 protein sequence against mouse Apobec3 protein 
sequence. 
                                            
27
 Clustal X2 is a programme for multiple alignments of nucleic acid and protein sequences 
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Table 6-5 Alignment quality analysis of Apobec3 genes in Mus musculus & Homo sapiens 
 
These data show the sequences of H. Sapiens Apobec3C, H and G 
were most similar to the sequence of M. musculus Apobec3. 
Other average quality scores indicated the degree of similarity between 
each human Apobec3 protein;   
Sequences (Apobec3H: Apobec3G) Aligned. Score: 27 
Sequences (Apobec3H:Apobec3Fa) Aligned. Score: 33 
Sequences (Apobec3H:Apobec3Fb) Aligned. Score: 24 
Sequences (Apobec3H:Apobec3D) Aligned. Score:  33 
Sequences (Apobec3H:Apobec3C) Aligned. Score:  34 
Sequences (Apobec3H:Apobec3B) Aligned. Score:  31 
Sequences (Apobec3H:Apobec3A) Aligned. Score:  34 
Sequences (Apobec3G: Apobec3Fa) Aligned. Score:   82 
Sequences (Apobec3G: Apobec3Fb) Aligned. Score: 78 
Sequences (Apobec3G: Apobec3D) Aligned. Score: 53 
Sequences (Apobec3G: Apobec3C) Aligned. Score: 34 
Sequences (Apobec3G: Apobec3B) Aligned. Score: 53 
Sequences (Apobec3G: Apobec3A) Aligned. Score: 24 
Sequences (Apobec3Fa:Apobec3Fb) Aligned. Score: 74 
Sequences (Apobec3Fa: Apobec3D) Aligned. Score: 79 
Sequences (Apobec3Fa: Apobec3C) Aligned. Score: 78 
Sequences (Apobec3Fa: Apobec3B) Aligned. Score: 68 
Sequences (Apobec3Fa: Apobec3A) Aligned. Score: 43 
Sequences (Apobec3Fb: Apobec3D) Aligned. Score: 45 
Sequences (Apobec3Fb: Apobec3C) Aligned. Score: 30 
Sequences (Apobec3Fb: Apobec3B) Aligned. Score: 44 
Sequences (Apobec3Fb: Apobec3A) Aligned. Score: 27 
Sequences (Apobec3D: Apobec3C) Aligned. Score: 78 
Sequences (Apobec3D: Apobec3B) Aligned. Score: 70 
Average quality score %
Homo sapiens  APOBEC3H 43
Homo sapiens  APOBEC3G 41
Homo sapiens  APOBEC3F isoform a 34
Homo sapiens  APOBEC3F isoform b 33
Homo sapiens  APOBEC3D 34
Homo sapiens  APOBEC3C 47
Homo sapiens  APOBEC3B 37
Homo sapiens  APOBEC3A 39
Alignment with  Mus musculus  Apobec3
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Sequences (Apobec3D: Apobec3A) Aligned. Score: 45 
Sequences (Apobec3C: Apobec3B) Aligned. Score: 53 
Sequences (Apobec3C: Apobec3A) Aligned. Score: 38 
Sequences (Apobec3B: Apobec3A) Aligned. Score:  38 
 
Sequence alignment data were used to generate a phylogenetic tree 
with TreeView28(Page, 1996). See Figure 6-8 below. This represents 
the inferred evolutionary relationship between human Apobec3 and 
mouse Apobec3. 
The tree shows there were three branches from a common ancestral 
node (far left of figure). The node at each subsequent branch 
represents the common ancestor of further descendants. Branch 
lengths give an estimate of time elapsed (left to right).  
Figure 6-8 shows Apobec3G was closely related to Apobec3F isoform a 
and b. In addition, it can be seen Apobec3F isoform a was associated 
to Apobec3C and Apobec3B. Furthermore, Figure 6-8 was also 
supported by the average quality scores of the sequence alignments, 
which demonstrated high scores for these alignments.   
                                            
28
 TreeView is a phylogenetic tree visualisation software 
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Figure 6-8 Phylogenetic relationship between Apobec3 proteins of Mus musculus & Homo sapiens 
The rooted tree was generated using Clustal X2 programme with the neighbour joining (NJ) 29 
method (Saitou and Nei, 1987) and visualised by TreeView.  
                                            
29
 NJ ± algorithm that calculates the distance between each pair of sequences within the multiple alignment 
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6.4.4 Validation of gene expression of Apobec3 & Onecut2 using 
Real Time Quantitative PCR 
 
Study 1B: Investigation of the role of PPARĮ on gene expression 
in the mouse colon 
 
The relative quantity (RQ) of Apobec3 and Onecut2 expression in all 
Study 1B samples relative to APCMin/+ normal samples were calculated 
from normalised Ct values.  
Also, p values to show the statistical significance of the effect of 
PPARĮ, tissue and the interaction of PPARĮ and tissue were calculated 
(Table 6-6). 
These data were in agreement with earlier investigations of Study 1B 
samples using Affymetrix® microarrays and Taqman® low density 
arrays.  
Amplification of Apobec3 with primers and probe specific to Apobec3 
variant 1 showed expression in APCMin/+ PPARĮ-/- samples was 
significantly highly up-regulated compared to APCMin/+ samples (Table 
6-6).  
This verified the findings of Taqman® low density arrays which showed 
high expression in the same samples.  
Similarly, when Apobec3 was amplified with variant 1/2 primers and 
probe, expression levels were comparable to those seen in Affymetrix® 
microarrays. That is, expression in APCMin/+ PPARĮ-/- samples was 
significantly down-regulated compared to APCMin/+ samples (Table 6-6). 
Expression of Onecut2 was confirmed as being significantly highly up-
regulated in tumour tissue compared to normal tissue (Table 6-6).   
260 
 
Table 6-6 Real Time Quantitative PCR of Apobec3 & Onecut2: Study 1B 
 
 
Min tumour 33$5Į-/- normal 33$5Į-/- tumour (IIHFWRI33$5Į Effect of tissue
Interaction 
between 
33$5Į
& tissue
Apobec3 
(primers & probe specific to variant 1) 3.1 +/- 0.02 52.6 +/- 0.22 65.4 +/- 0.20 < 0.0001 not significant not significant
Apobec3 
(primers & probe for variant 1 & variant 2) 2.9 +/- 0.37 0.5 +/- 0.05 0.8 +/- 0.08 < 0.0001 0.001 0.006
Onecut2 167.5 +/- 1.93 1.1 +/- 0.01 141.5 +/- 0.65 not significant 0.012 not significant
Mean relative quantity of gene expression 
to APCM in/+  normal +/- standard error p value
Gene 
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Study 2B: Investigation of the UROH RI 33$5Į LQ WKH HIIHFWV RI
piroxicam on gene expression in the colon  
 
RT Q PCR results were used to calculate the relative quantity (RQ) of 
Apobec3 and Onecut2 expression in all Study 2B samples relative to 
APCMin/+ normal untreated samples from normalised Ct values. 
Similarly, p values to show the statistical significance of the effect of 
PPARĮ only, tissue only and the interaction of PPARĮ and tissue were 
calculated (Table 6-7). 
Also, the effect of piroxicam treatment on RQ of Apobec3 and Onecut2 
expression in all samples relative to APCMin/+ normal untreated samples 
were calculated from normalised Ct values. p values to show the 
statistical significance of the effect of piroxicam treatment only, the 
interaction of PPARĮ and piroxicam treatment, and the interaction of 
tissue and piroxicam treatment were calculated (Table 6-8). 
Real time quantitative PCR (RT Q PCR) of Apobec3 and Onecut2 in 
Study 2B untreated samples (Table 6-7) showed comparable results to 
the earlier Taqman® low density array analysis of the same samples 
(Chapter 5).  
Expression of Apobec3 variant 1 showed significantly high up-regulation 
in APCMin/+ PPARĮ-/- samples compared to APCMin/+ samples (Table 
6-7).  
Similarly, Apobec3 variant 1/2 expression levels were comparable to 
those seen in Affymetrix® microarrays. That is, expression in APCMin/+ 
PPARĮ-/- samples was significantly down-regulated compared to 
APCMin/+ samples (Table 6-7). 
Expression of Onecut2 was confirmed as being significantly highly up-
regulated in tumour tissue compared to normal tissue (Table 6-7).   
Also, these data demonstrated a similar expression pattern of Apobec3 
and Onecut2 to that seen in RT Q PCR analysis of the same genes in 
Study 1B samples (Table 6-6). This confirmed that expression of 
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Apobec3 and Onecut2 in the two sets of samples (Study 1B and Study 
2B untreated samples) were comparable. 
However, RT Q PCR analysis of these genes in Study 2B piroxicam-
treated samples (Table 6-8) produced differing results to those seen in 
Taqman® low density array analysis of the same samples.   
These data indicate that expression levels of Apobec3 variant 1 and 
Onecut2 were significantly increased with piroxicam treatment in 
APCMin/+ PPARĮ-/- samples and in tumour samples respectively (Table 
6-8).  
This contradicts earlier results produced by Taqman® low density 
arrays which found the effect of piroxicam treatment on Apobec3 
expression was not significantly affected by PPARĮ status (Table 5-18). 
Similarly, Taqman® low density array results showed piroxicam 
treatment did not significantly affect Onecut2 expression in tumour 
samples (Table 5-17).  
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Table 6-7 Real Time Quantitative PCR of Apobec3 & Onecut2: Study 2B (untreated samples) 
 
Min tumour 
(untreated)
33$5Į-/- 
normal 
(untreated)
33$5Į-/- 
tumour 
(untreated)
(IIHFWRI33$5Į Effect of tissue
Interaction 
between 
33$5Į	
tissue
Apobec3 
(primers & probe specific to variant 1) 0.8 +/- 0.003 77.2 +/- 0.06 76.2 +/- 0.32 < 0.0001 0.013 0.012
Apobec3 
(primers & probe for variant 1 & variant 2) 0.6 +/- 0.15 0.3 +/- 0.02 0.3 +/- 0.08 0.011 not significant not significant
Onecut2 23.0 +/- 0.14 3.3 +/- 0.01 107.0 +/- 0.64 0.004 < 0.0001 0.005
Mean relative quantity of gene 
expression to APCMin/+  normal 
(untreated) +/- standard error
p value
Gene 
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Table 6-8 Real Time Quantitative PCR of Apobec3 & Onecut2: Study 2B (piroxicam-treated samples) 
 
Min normal 
(piroxicam 
treated)
Min tumour 
(piroxicam 
treated)
33$5Į-/- 
normal 
(piroxicam 
treated)
33$5Į-/- tumour 
(piroxicam 
treated)
Effect of 
treatment
Interaction 
between 
33$5Į
& treatment
Interaction 
between 
tissue 
& treatment
Apobec3 
(primers & probe specific to variant 1) 3.5 +/- 0.01 3.2 +/- 0.02 86.3 +/- 0.29 155.2 +/- 0.21 0.001 0.003 0.011
Apobec3 
(primers & probe for variant 1 & variant 2) 1.1 +/- 0.32 1.5 +/- 0.71 0.4 +/- 0.04 1.0 +/- 0.07 0.03 not significant not significant
Onecut2 2.7 +/- 0.007 113.7 +/- 0.55 1.7 +/- 0.003 343.7 +/- 0.41 0.003 not significant 0.003
p valueMean relative quantity of gene expression 
to APCMin/+  normal (untreated) +/- standard error
Gene 
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6.5 Discussion 
 
Earlier chapters analysed Apobec3 expression in the mouse colon 
using Affymetrix® microarrays and Taqman® low density arrays. The 
two arrays produced differing results; a decrease in Apobec3 
expression was recorded in APCMin/+ PPARĮ-/- samples on Affymetrix® 
microarrays. However, a large increase in Apobec3 expression in the 
same samples was seen with Taqman® low density arrays. These data 
indicated that PPARĮ may be involved in the regulation of Apobec3. 
Therefore, the gene was analysed further.  
A reason for the discrepancy in array results may be due to different 
sequences of the probes on the two arrays. Further investigation 
revealed that there are two isoforms of Apobec3; variant 1 and variant 
2. The sequences of the probes did indeed show that Affymetrix® 
microarrays amplified variant 1 or variant 2, whereas Taqman® low 
density arrays only amplified variant 1 of the gene. These results were 
verified by real time quantitative PCR which showed comparable 
expression levels of Apobec3 to the levels determined on Affymetrix® 
microarrays (variant 1 or 2) and Taqman® low density arrays (variant 1 
only). 
Therefore, these data raised two questions: 
Why do changes in expression of $SREHF ZLWK 33$5Į GHOHWLRQ as 
detected by Affymetrix® microarrays and Taqman® low density arrays 
go in opposite directions? 
How does PPARĮ affect the expression of Apobec3? 
A possible answer to the first question may be the existence of mutation 
clusters which feature many somatic substitutions of cytosine, as 
demonstrated by other studies (Roberts et al., 2012, Nik-Zainal et al., 
2012). These studies strongly support the idea that the Apobec family of 
cytidine deaminases is instrumental in development of a cancer 
genome.  
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Therefore, analysis of the colon cancer genome in mice and humans 
could potentially identify mutation clusters, cytidine deaminase motifs 
and miRNA sequences.      
A potential answer to the second question could be regulation of 
miRNAs by PPARĮ that control expression of Apobec3. As discussed 
earlier, a study by (Ding et al., 2011) suggested existence of a novel 
pathway involving Apobec3 and miRNA-29 in promotion of hepatic 
metastasis.    
PCR was carried out to verify the DNA sequence of Apobec3 variant 1 
and variant 2. However, PCR with primer pairs A and C did not amplify 
the targeted sequences; primer pair A to amplify exon 1 ± exon 9, and 
primer pair C to amplify exon 5 ± exon 9. As discussed previously, this 
is possibly due to the existence of a large predicted ¶875DWWKHHQG
of the protein coding region. However, exon 1 - exon 5 (primer pair B) of 
the gene was sequenced which established that variant 1 of Apobec3 
was highly up-regulated in APCMin/+ PPARĮ-/- samples. Future work will 
be to design new primers to amplify and sequence Apobec3.  
It would also be interesting to establish which isoform of Apobec3 is 
present in the colon; that is whether Apobec3 variant 1 is the only 
isoform or whether there is a combination of both isoforms.  
Alignment of National Centre of Biotechnology Information (NCBI) Mus 
musculus Apobec3 protein sequences against Homo sapiens Apobec3 
protein sequences revealed significant similarity between Mus 
musculus Apobec3 and Homo sapiens Apobec3C, Apobec3H and 
Apobec3G. It would be interesting to determine if there is any functional 
significance in the similarities, and also whether PPARĮ is implicated in 
regulation of this gene in humans. 
Results of Real time quantitative PCR (RT Q PCR) of Apobec3 and 
Onecut2 in Study 1B and Study 2B (untreated samples) showed similar 
results for each gene in each study. Samples in both studies 
demonstrated significant down-regulation of Apobec3 variant 1/2 in 
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APCMin/+ PPARĮ-/- samples, and up-regulation of Onecut2 in tumour 
samples. These data showed that two different sample sets from the 
same mouse models and under similar experimental conditions 
produced comparable data.  
These RT Q PCR results also verified Affymetrix® microarray data of 
Apobec3 variant 1/2 expression and Onecut2 in Study 1B samples, 
which showed significant down-regulation in APCMin/+ PPARĮ-/- samples 
and tumour samples respectively. 
RT Q PCR of piroxicam study (Study 2B) untreated samples 
demonstrated that expression of Apobec3 variant 1 was significantly up-
regulated in APCMin/+ PPARĮ-/- samples (Table 6-7). In addition, these 
data showed piroxicam treatment significantly up-regulated Apobec3 
variant 1 in similar samples (Table 6-8).  
Similarly, RT Q PCR of Onecut2 in Study 2B untreated and piroxicam-
treated samples showed it was significantly up-regulated in tumours 
(Table 6-7, Table 6-8).  
These data show Onecut2 was highly up-regulated in tumour tissue of 
the colon. This may indicate an important role for Onecut2 in 
tumorigenesis in the colon. It would be interesting to investigate how 
silencing of the gene with miRNAs affects tumorigenesis. Additionally, 
establishing the downstream targets of Onecut2 activation could 
potentially lead to identification of new targets for colon cancer therapy.  
This body of work has highlighted some interesting avenues for future 
study. In particular, does PPARĮ have a role in the regulation of 
Apobec3 expression in humans? Or, do miRNAs feature in the control 
of expression levels? 
These possibilities for further research are discussed in detail in 
Chapter 7.  
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7 Discussion & Future Work 
 
7.1 Summary of findings of Study 1 and Study 2 
 
The present studies with APCMin/+ mice and APCMin/+ 33$5Į-/- mice 
were undertaken to support and provide confirmation of previous 
research by (Jackson et al., 2003) which suggested D33$5Į-mediated 
effect in polyp development in the mouse gut.  
The APCMin/+ mouse model was selected for these studies as it has a 
mutated Adenomatous Polyposis Coli (APC) gene similar to the 
mutation observed in human Familial Adenomatous Polyposis (FAP) 
and sporadic colon cancer (Moser et al., 1990). 
Study 1 of this research used two groups of APCMin/+ mice, one group 
with deletion of PPARĮ (APCMin/+ PPARĮ-/-) to investigate the effect of 
PPARĮ on survival and weight, polyp development and gene 
expression in the colon.  
Results of this study showed there was no difference in the ages of 
APCMin/+ mice and APCMin/+ PPARĮ-/- mice at sacrifice, but APCMin/+ 
PPARĮ-/- mice were significantly heavier (p < 0.0001). As discussed 
previously this could be because of the role of PPARĮ in lipid and fatty 
acid metabolism (Desvergne and Wahli, 1999, Kersten et al., 2000). 
However, as food intake was not monitored, it may be that APCMin/+ 
PPARĮ-/- mice consumed more feed. 
The number of polyps in the colon was significantly higher in APCMin/+ 
PPARĮ-/- mice than in APCMin/+ mice (p < 0.0001). Similarly, when age 
at sacrifice was taken into account (number of polyps per week) the 
same result was seen (p < 0.0001).  
However, the difference in number of polyps in the small bowel between 
APCMin/+ PPARĮ-/- mice and APCMin/+ mice was not significant. A similar 
result was seen when age at sacrifice was considered.  
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Polyp number in the small bowel in these mice was high and probably 
led to anaemia (visible sign is pale foot pads - white paw), necessitating 
sacrifice of the mice. Polyp number in the colon was comparatively 
much lower. However, the higher number of polyps in the colon of 
APCMin/+ PPARĮ-/- mice than APCMin/+ mice may suggest that PPARĮ 
has a role in preventing initiation or growth of tumours in the colon.   
Analysis of gene expression in the colon with Affymetrix® microarrays 
demonstrated that the largest source of variation was between tumour 
and normal tissue.  
There were far fewer differentially expressed genes between APCMin/+ 
mice and APCMin/+ PPARĮ-/- mice. Deletion of PPARĮ had little effect on 
gene expression in normal tissue but appeared to have more effect in 
tumour tissue. Therefore, this may indicate that deletion of 33$5Į 
exacerbates the existing APCMin/+ mutation to promote tumorigenesis.  
Differentially expressed gene data from Affymetrix® microarray analysis 
(Comparison groups 1 ± 4) were input into Ingenuity® Pathway Analysis 
(IPA). IPA showed the two top-scoring biological processes were 
growth and proliferation (p = 1.03E-10), and colorectal cancer (p = 
1.66E-07); 95 genes were selected for further analysis. Selection of 
genes was based on molecular function; and fold change and p value 
as previously assessed on Affymetrix® microarrays.  
The 95 genes were analysed on Taqman® low density arrays. 
Expression data of two genes proved particularly interesting; Onecut 
homeobox 2 (Onecut2) and Apolipoprotein B DNA dC Æ dU - editing 
enzyme, catalytic polypeptide 3 (Apobec3).     
Affymetrix® microarrays and Taqman® low density arrays showed that 
Onecut2 was highly up-regulated in tumour tissue in the colon. This was 
a novel finding as this gene had previously been shown to be 
expressed in the small bowel but not the colon (Maier et al., 2006, 
Vanhorenbeeck et al., 2007). Also, a recent study demonstrated a 
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potential regulatory role of Onecut2 in the small bowel (Dusing et al., 
2010).  
Real time quantitative PCR (RT Q PCR) of Onecut2 was performed 
which validated the previous expression levels shown on Affymetrix® 
microarrays and Taqman® low density arrays.  
Therefore, these data may indicate a role for Onecut2 in tumorigenesis 
in the colon.  
Results from Affymetrix® microarrays and Taqman® low density arrays 
for expression of Apobec3 were conflicting. However, both sets of 
results suggested that expression of Apobec3 may be mediated via 
PPARĮ. Affymetrix® microarray results showed expression of the gene 
was down-regulated in APCMin/+ PPARĮ-/- samples. Whereas, Taqman® 
low density array results showed the gene was highly up-regulated in 
similar samples.  
The discrepancy of the results led to investigation of the Apobec3 gene 
and the sequences of the probes used on each array type. 
Investigations showed that there are two isotypes of Apobec3 in the 
mouse; variant 1 and variant 2. Variant 2 is shorter than variant 1 as it 
lacks an alternate in-frame exon in the coding region compared to 
variant 1 (exon 5). It was demonstrated that the probe sequence of 
Apobec3 on Affymetrix® microarrays could target either isotype. 
However, the probe sequence on Taqman® low density arrays matched 
sequence on exon 5 of the Apobec3 gene and therefore could only 
target variant 1.  
To validate these data RT Q PCR of Apobec3 with primers and probes 
designed to amplify variant 1 and variant 2, and variant 1 only was 
performed. Amplification with variant 1/2 primers and probe produced 
comparable levels of expression to levels shown in Affymetrix® 
microarrays. Similarly, variant 1 only primers and probe produced 
expression levels comparable to results of Taqman® low density arrays.   
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How PPARĮ may mediate expression levels of Apobec3, and why 
amplification of different sequences (exons) on the gene should 
produce such differing results could be due to regulation by miRNAs 
(Ding et al., 2011) and/or the existence of mutation clusters (Roberts et 
al., 2012, Nik-Zainal et al., 2012), as discussed earlier. Future work to 
address these questions is suggested later in this chapter.  
Study 2 assessed the long-term effect of piroxicam treatment on 
survival and weight, polyp development and gene expression in the 
colon. Also, whether these effects were mediated via PPARĮ was 
investigated. Mouse models as previously were used and were dosed 
with piroxicam at 100 parts per million (ppm) in their diet or diet only.  
Results from this study demonstrated a striking increase in survival in 
all mice dosed with piroxicam. However, APCMin/+ mice lived 
significantly longer than APCMin/+ PPARĮ-/- mice (p = 0.019). Additionally, 
all piroxicam-treated mice were significantly heavier than non-treated 
mice. However, these mice were significantly older so this result would 
be expected.  
The number of polyps, polyp size and total tumour burden were not 
significantly reduced with piroxicam treatment in the colon. However, 
when age at sacrifice was considered (per week), polyp number but not 
polyp size or total tumour burden was significantly reduced with 
piroxicam treatment. This may indicate that colonic polyps although 
fewer in number may be larger. 
The effect of piroxicam treatment on polyp number, polyp size and total 
tumour burden in the small bowel was dramatic. All were significantly 
reduced in all piroxicam-treated mice, with similar effects seen when 
age at sacrifice was considered.  
The significant reduction in small bowel polyps with piroxicam treatment 
is likely to be the reason for the increase in survival in piroxicam-treated 
mice. The increase in life-span appears to have also had an impact on 
polyp development in the colon. These data may indicate that the effect 
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of piroxicam treatment in the colon may inhibit development of nascent 
polyps but not existing polyp growth.  
Taqman® low density array analysis of selected genes (as previously) 
in piroxicam-treated mice showed similar expression levels in APCMin/+ 
mice and APCMin/+ PPARĮ-/- mice.  
The results of polyp analysis and gene expression taken in combination 
indicated that the effect of piroxicam treatment was not mediated via 
PPARĮ.  
Apobec3 and Onecut2 were previously identified as particular genes of 
interest. Therefore, to validate the findings of the piroxicam treatment 
study (Study 2), RT Q PCR was carried out as before. 
Conversely, results from RT Q PCR indicated a significant PPARĮ 
mediated effect of piroxicam treatment in Apobec3 variant 1 expression 
(p = 0.003). Similarly, expression of Onecut2 was significantly higher in 
tumour tissue with piroxicam treatment (p = 0.003).   
In summary, these studies have demonstrated that deletion of PPARĮ 
produced a phenotype that made development of tumorigenesis in the 
colon more likely.  
In addition, expression of Apobec3 and Onecut2 were shown to be 
highly up-regulated in APCMin/+ PPARĮ-/- samples and tumour samples 
respectively. This may point to a role for these genes in tumorigenesis. 
However, the mechanisms for these effects remain to be elucidated. 
Also, these results indicate the effect of piroxicam treatment was not 
mediated via PPARĮ. However, subsequent analysis of Apobec3 
variant 1 expression with RT Q PCR did point to a PPARĮ mediated 
effect. Similarly, RT Q PCR of Onecut2 showed expression was up-
regulated in tumour tissue with piroxicam treatment.  
It would be interesting to investigate these discrepancies further. Future 
works to examine possible reasons for these, along with other 
suggestions to advance this research are discussed. 
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7.2 Future work 
 
Analysis of Study 1 gene expression data of the mouse colon revealed 
a list of possible 33$5Į-controlled genes, but few of these matched 
those identified in earlier studies (Mandard et al., 2004, 
Rakhshandehroo et al., 2010). Potentially, this could be due to the 
discovery of previously XQUHFRJQLVHG 33$5Į-controlled genes, or 
perhaps pleiotropic effects independent of 33$5Į activation.   
To further investigate these possibilities, a short-term (7 day) study 
treating APCMin/+ and APCMin/+ PPARĮ-/- mice ZLWK WKH SRWHQW 33$5Į
DJRQLVWV¶PHWK\OFORSKHQDSDWH0&3DQGIHQRILEUDWH will be carried out. 
Also, Study 2 gene expression data of the mouse colon indicated that 
the effects of piroxicam treatment were not mediated via 33$5Į 
However, these data also indicated that changes in expression of 
Apobec3 may be mediated via 33$5Į, and conversely, expression of 
this gene was increased with piroxicam treatment. Therefore, to 
address these inconsistencies another short-term (7 day) study will be 
carried out. APCMin/+ and APCMin/+ PPARĮ-/- mice will be treated with 
piroxicam at 100ppm as previously. In addition, the effects of piroxicam 
treatment at 300ppm will be assessed. 
Mouse intestines from both short-term studies will be harvested 
immediately after sacrifice; however, due to the short term nature of the 
study, polyps or tumours would be unlikely to have developed. 
Therefore, instead of collecting separate tumour and normal tissue as 
previously, epithelial cells will be extracted from the colon and the small 
bowel as described (Bartnik et al., 1980, Mahida et al., 1997). Gene 
expression of selected genes in the mouse colon and small bowel will 
be determined using Taqman® low density arrays as before.  
In addition to analysis of the short term effects of the 33$5Į agonists 
MCP and fenofibrate, and piroxicam on gene expression in the colon 
and small bowel, other potential opportunities for further research have 
been presented during the duration of this research. Results from the 
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present studies indicated that two genes, namely Apobec3 and Onecut2 
may have an important role in tumorigenesis in the colon.  
As discussed previously, the mechanism for regulation of Apobec3 
expression may occur via miRNA mediated control of 33$5Į activation. 
In addition, localised mutation of cytosine bases by cytidine deaminases 
such as Apobec3 may have led to the development of a tumour 
phenotype. Therefore, it could be informative to explore the mouse and 
human colon cancer genomes for evidence of localised mutations and 
cytidine deaminase motifs.  
Also, characterisation of the mouse and human transcriptomes using 
high-throughput sequencing (HTS) methods (RNA-Seq) could 
accurately predict the functional properties of RNAs and how these 
functions are altered in disease states (Blencowe et al., 2009).  
Other methods for transcriptomics include a probabilistic inference 
method, for example, Emu, to identify areas of mutational processes; 
mutations in cancer genomes can be explained by a few mutational 
processes such as kataegis C > G and C > T in a TpCpX context 
(Fischer et al., 2013). Also, the ENCODE (Encyclopaedia of DNA 
Elements) project defines functional DNA elements in the human 
genome and includes information on RNA transcripts, transcriptional 
regulator binding sites and chromatin states (Kellis et al., 2014). The 
use of 3 approaches, that is, gene expression, genomic coverage 
(Lander et al., 2001) and evolutionary conservation (Johnsson et al., 
2014) could provide complementary information to determine genomic 
function in human biology and disease.  
In addition, further studies using a mouse model of Apobec3 deletion to 
investigate the effect of Apobec3 on gene expression in the colon and 
small bowel could be instigated.   
As was discussed previously, the design of new primers to amplify and 
sequence the Apobec3 gene could lead to establishing the reasons for 
the apparent differences in expression in APCMin/+ mice and APCMin/+ 
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PPARĮ-/- mice. Also, it would be interesting to determine the isoform/s 
of Apobec3 present in the mouse colon.  
Analysis of the Mus musculus Apobec3 gene sequence against Homo 
sapien Apobec3 sequences demonstrated significant alignments. This 
solicits the question as to whether there is any functional significance in 
these similarities.  
Therefore, gene expression studies using human colonic cell lines 
and/or tissue could be instigated to investigate; 
1. Does Apobec3 have a role in tumorigenesis in the human colon? 
2. Is 33$5Į implicated in the regulation of Apobec3 in the human 
colon?  
In addition, the protein level of Apobec3 could be detected using 
specific antibodies with immunohistochemistry and/or protein 
immunoblots.  
The present studies also defined Onecut2 as a novel gene that was 
highly up-regulated in tumour tissue in the colon, indicating the gene 
may be involved in tumorigenesis. Further analysis of the Affymetrix® 
microarray data and Ingenuity® Pathway Analysis (IPA) may reveal 
downstream targets of Onecut2 that are involved in development of 
cancer. Also, interrogation of the mouse and human transcriptome may 
highlight miRNAs involved in regulation of Onecut2.  
Additionally, further research using human cell based and tissue based 
studies to investigate Onecut2 gene and protein expression are 
proposed.  
As with Apobec3, a further study using a mouse model with Onecut2 
deletion is suggested. A study by (Dusing et al., 2010) showed Onecut2 
was highly expressed in the duodenum of postnatal wild-type mice but 
not in mice where Onecut2 was deleted. Their study showed Onecut2 is 
implicated in the temporal regulation and altered expression levels of 
many genes related to transport and metabolism in the epithelial 
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membrane, and also adenosine deaminase (ADA30). Mice with Onecut2 
deletion have a significantly reduced size and weight, and increased 
mortality compared to wild type mice. Nevertheless, they have a similar 
life-span and fertility to wild-type mice after weaning (Dusing et al., 
2010).  
Analysis of polyp data and Taqman® low density array data from Study 
2 (piroxicam study) indicated that the effects of piroxicam on polyp 
development and gene expression in the mouse gut were not mediated 
by 33$5Į. However, subsequent analysis with RT Q PCR indicated 
Apobec3 and Onecut2 expression may be affected by 33$5Į. 
Therefore, to investigate these anomalous results, the piroxicam study 
could be replicated using cell based or tissue based human studies.  
In summary, this research has confirmed the role of 33$5Į in 
development of a tumour phenotype in APCMin/+ mice. In addition, it 
appears that the effect of piroxicam may not be mediated via 33$5Į. 
However, the mechanisms that produce the effects that were seen 
remain to be elucidated.  
Apobec3 and Onecut2 were shown to be significantly up-regulated in 
APCMin/+ 33$5Į-/- samples and tumour samples respectively, indicating 
they may have an important role in the development of tumorigenesis in 
the mouse colon. Consequently, further investigations into the role and 
function of these two genes in humans are warranted and 
recommended. 
PPARɲ is expressed in many tissues in the body (Table 1-2), therefore, 
there is the real possibility that the results and findings from this study 
may have implications in the development and progression of other 
cancers.  
The rapid increase in available resources for interrogation of the human 
transcriptome could lead to identification of areas of mutational 
processes and RNA transcriptional regulation. For example, areas of 
                                            
30
 ADA is ubiquitous in mammal cells and is a key enzyme in purine metabolism 
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kataegis are found with cytosine base substitutions at TpC 
dinucleotides suggesting Apobec3 plays a role in this. The results and 
findings of the work described here may imply that PPARɲ plays an 
important role in the regulation of Apobec3. Therefore, it is possible that 
Apobec3 or other members of the cytosine deaminase family have a 
similar role in other parts of the body.  
In addition, Onecut2 is also known to be expressed in areas of the body 
other than the colon (6.1.2 page 232). Demonstration that Onecut2 was 
highly expressed in tumour tissue in the colon was a novel finding in 
this work. Therefore, it is feasible that Onecut2 could be implicated in 
tumorigenesis in other cancers.  
Piroxicam, the NSAID used in this study, showed dramatic reductions in 
polyp growth in the mouse intestines. However, the Committee for 
Medicinal Products for Human Use (CHMP, June 2007) has 
recommended restrictions on its use in humans due to increased risk of 
gastro-intestinal side effects and serious skin reactions.  
The current recommendations for first-line treatment of colon cancer are 
surgery and/or folinic acid plus fluorouracil (FOLFOX); NICE guidelines 
[CG 131], December 2014, 
http://www.nice.org.uk/guidance/cg131/chapter/introduction 
The use of aspirin as prophylaxis for colon cancer is not currently 
recommended.  
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Appendices  
 
1. Differentially Expressed Gene (DEG) Lists 
 
Gene Symbol Regulation FCAbsolute p-value
Ang down 9.8 3.31E-02
Rpgrip1 down 8.8 2.24E-02
Ang down 7.3 2.87E-02
D130051D11Rik down 3.4 5.51E-05
Igh /// Ighg1 down 3.1 3.90E-02
Irak4 down 2.7 1.56E-05
Igh down 2.5 3.94E-02
Ppara down 2.4 4.60E-03
Serhl down 2.4 1.44E-03
Erdr1 down 2.2 4.99E-02
EG633640 down 2.2 2.94E-02
Cbx7 down 2.1 3.83E-03
Fabp5 down 2.0 4.94E-02
Tmem117 down 1.9 6.60E-03
Ppara down 1.9 3.19E-02
Fabp5 down 1.9 4.07E-02
Serhl down 1.9 3.02E-03
Acot2 down 1.8 3.38E-02
Higd1a down 1.8 4.87E-02
C920006O11Rik down 1.7 3.60E-02
Ptprg down 1.7 3.63E-03
Slc38a1 down 1.7 1.60E-03
Satb1 down 1.7 4.80E-02
Apobec3 down 1.7 4.09E-03
Mmrn1 up 4.8 1.39E-02
EG665955 up 4.7 1.18E-03
Supt16h up 2.4 9.82E-04
Phf17 up 2.3 1.77E-03
Uba6 up 2.3 9.81E-05
Cntn1 up 2.3 4.23E-02
Cntn1 up 2.1 1.05E-02
LOC433762 up 2.0 1.41E-02
Oasl1 up 1.9 1.44E-02
Celsr1 up 1.8 1.93E-02
Hspa8 up 1.8 3.66E-02
Ifi27l1 up 1.8 4.37E-02
Vcl up 1.7 3.91E-02
Differentially Expressed Genes 
APCMin/+ 33$5Į-/- normal vs. APCMin/+ normal 
(Comparison 1)
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Gene Symbol Regulation FCAbsolute p-value
Ang down 47.8 3.36E-02
Ang4 down 31.0 2.20E-02
Rpgrip1 down 17.1 4.26E-02
Ang down 14.5 1.61E-02
Khdc1a down 11.2 9.40E-03
D130051D11Rik down 9.9 3.23E-05
Apcdd1 down 8.5 3.02E-02
Gpnmb down 6.7 8.33E-05
Cbx6 down 5.7 4.27E-04
Cyp2b10 down 5.1 4.87E-02
Cyp2b10 down 4.9 3.77E-02
Cbx6 down 4.8 8.45E-04
Irx5 down 4.7 2.62E-02
Apobec3 down 4.7 1.65E-04
Ang4 down 4.5 3.97E-02
Greb1 down 4.4 7.72E-03
Alb down 4.2 4.23E-02
Ang down 3.9 1.62E-03
Slc7a8 down 3.9 3.72E-02
Irak4 down 3.9 9.91E-04
Higd1c down 3.5 3.46E-02
Pik3ip1 down 3.3 8.35E-03
Syngr1 down 3.3 6.65E-03
Adh6a down 3.3 3.57E-02
Serhl down 3.2 1.89E-03
Hoxa11 down 3.2 4.64E-02
Entpd3 down 3.1 2.54E-03
Lef1 down 3.1 3.58E-02
1700097N02Rik down 3.0 3.42E-02
Npb down 3.0 5.13E-03
Tbx3 down 2.9 3.15E-02
Col23a1 down 2.9 3.94E-02
Tmed6 down 2.9 4.57E-02
Prkg2 down 2.9 2.34E-02
Sorbs2 down 2.8 4.97E-02
Zc3h6 down 2.8 4.00E-02
4833428M15Rik down 2.7 4.82E-02
Slc38a1 down 2.7 2.94E-04
Tesc down 2.6 3.06E-02
Casp6 down 2.6 2.73E-02
Differentially Expressed Genes 
APCMin/+ PPARɲ-/- tumour vs.  APC Min/+ tumour 
(Comparison 2)
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Gene Symbol Regulation FCAbsolute p-value
1810005K13Rik down 2.6 3.27E-02
Ptprg down 2.6 3.22E-02
Bik down 2.6 1.29E-03
Greb1 down 2.6 3.28E-03
Fam89a down 2.6 2.20E-02
Prei4 down 2.6 2.28E-02
1110034G24Rik down 2.6 3.28E-02
Fgfrl1 down 2.6 9.66E-03
Chd8 down 2.5 4.77E-03
Tesc down 2.5 9.35E-03
Ldhb down 2.5 7.99E-03
1700097N02Rik down 2.5 7.68E-03
Snhg11 down 2.5 3.50E-02
Bik down 2.4 6.34E-04
Rabl4 down 2.4 2.64E-04
Fam69b down 2.4 3.22E-02
Sp6 down 2.4 4.19E-02
C1qtnf6 down 2.4 1.61E-02
Prei4 down 2.4 3.00E-02
Wdr19 down 2.4 2.77E-02
Malat1 down 2.4 2.55E-02
Zfp783 down 2.4 1.10E-02
Atg9b down 2.3 2.61E-02
Sbsn down 2.3 4.04E-02
Nisch down 2.3 3.19E-03
Ldhb down 2.3 3.38E-02
Srd5a3 down 2.2 9.59E-03
2810410L24Rik down 2.2 1.12E-02
Ldhb down 2.2 2.13E-02
2310034G01Rik down 2.2 4.06E-02
Mmp14 down 2.2 3.46E-02
Limch1 down 2.2 3.19E-02
Limch1 down 2.2 1.35E-02
Patz1 down 2.2 1.09E-02
1110059G02Rik down 2.2 4.43E-02
Usp20 down 2.2 3.83E-02
4933429F08Rik down 2.2 3.06E-02
Pvrl4 down 2.2 4.50E-02
Pla2g2a down 2.2 5.40E-04
Trav12n-2 down 2.1 2.87E-02
Differentially Expressed Genes 
APCMin/+ PPARɲ-/- tumour vs.  APC Min/+ tumour 
(Comparison 2)
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Gene Symbol Regulation FCAbsolute p-value
E130012A19Rik down 2.1 7.06E-03
BC057079 down 2.1 3.70E-02
Rabl4 down 2.1 7.90E-04
Comt1 down 2.1 1.12E-02
Prei4 down 2.1 1.96E-02
1700012B15Rik down 2.1 4.51E-03
Svopl down 2.1 4.17E-02
Pvrl4 down 2.1 3.47E-02
Plekhg5 down 2.1 2.32E-02
Hsf2bp down 2.1 4.05E-02
D630039A03Rik down 2.1 3.24E-02
1110059G02Rik down 2.1 1.81E-02
Afap1l1 down 2.0 1.38E-02
Fgfrl1 down 2.0 7.75E-03
Odz4 down 2.0 4.03E-02
9530067D14Rik down 2.0 4.26E-02
2310047M10Rik down 2.0 2.87E-02
Fam109a down 2.0 2.86E-02
Tcf12 down 2.0 3.75E-02
Pcbp4 down 2.0 1.09E-02
Sbsn down 2.0 2.48E-02
Txnrd3 down 2.0 3.38E-02
1500012F01Rik down 2.0 7.78E-04
Mafg down 2.0 4.60E-02
Il17rd down 2.0 2.77E-02
2810408A11Rik down 2.0 1.72E-02
Pacsin3 down 2.0 2.27E-02
BC031353 down 2.0 9.51E-03
Edn3 down 2.0 3.15E-02
Prei4 down 2.0 3.38E-02
Nlk down 2.0 3.23E-02
Ppp4r1l down 1.9 3.86E-02
Serhl down 1.9 1.07E-03
9330133O14Rik down 1.9 2.11E-02
Klc3 down 1.9 4.94E-02
Tnfrsf19 down 1.9 6.74E-03
Hpn down 1.9 2.22E-02
Slc20a2 down 1.9 9.52E-04
Ppp4r1l down 1.9 4.69E-02
B930041F14Rik down 1.9 1.23E-02
Differentially Expressed Genes 
APCMin/+ PPARɲ-/- tumour vs.  APC Min/+ tumour 
(Comparison 2)
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Gene Symbol Regulation FCAbsolute p-value
Wbscr27 down 1.9 7.52E-04
Slc35f2 down 1.9 1.91E-02
Wnt5b down 1.9 3.19E-02
Dkk2 down 1.9 5.60E-03
Nisch down 1.9 4.35E-03
Pacsin3 down 1.9 3.82E-02
Pnp1 /// Pnp2 down 1.9 2.97E-03
C79946 down 1.9 5.80E-03
Zbtb20 down 1.9 4.05E-02
B4galnt4 down 1.9 2.15E-02
Klhl8 down 1.9 3.92E-02
Pik3r3 down 1.9 2.99E-02
Slc41a1 down 1.9 4.80E-02
9030601B04Rik down 1.9 1.11E-03
1700052K11Rik down 1.8 1.18E-02
Cish down 1.8 9.69E-03
Plekha1 down 1.8 4.72E-02
BC062109 down 1.8 3.29E-02
3110045A19Rik down 1.8 2.12E-02
Matr3 down 1.8 1.66E-02
Lass4 down 1.8 3.97E-02
Slc48a1 down 1.8 2.02E-03
A130086G11Rik down 1.8 1.25E-02
Hunk down 1.8 2.42E-02
Fem1c down 1.8 2.79E-02
Fam43a down 1.8 3.28E-02
Ptprg down 1.8 3.12E-02
6720401G13Rik down 1.8 2.82E-02
Six4 down 1.8 9.71E-03
Ptprg down 1.8 1.09E-02
Zfp560 down 1.8 2.89E-02
Neu1 down 1.8 1.46E-02
2310005E10Rik down 1.7 6.74E-03
Clps down 1.7 4.42E-02
Hexdc down 1.7 1.11E-02
Bckdha down 1.7 9.94E-03
C730025P13Rik down 1.7 4.72E-03
Haghl down 1.7 3.59E-02
Zfp688 down 1.7 2.24E-02
6720475J19Rik down 1.7 3.99E-02
Differentially Expressed Genes 
APCMin/+ PPARɲ-/- tumour vs.  APC Min/+ tumour 
(Comparison 2)
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Gene Symbol Regulation FCAbsolute p-value
Cep78 down 1.7 1.84E-02
C230037E05Rik down 1.7 3.15E-02
BC031353 down 1.7 1.02E-02
Zfp783 down 1.7 5.62E-03
Dlx3 down 1.7 2.82E-02
Mblac2 down 1.7 2.31E-03
Ccdc85b down 1.7 2.59E-02
Haus4 down 1.7 1.27E-02
D130062J10Rik down 1.7 3.08E-03
Gadd45g down 1.7 8.81E-03
Trim45 down 1.7 4.80E-02
Ces6 up 15.1 3.30E-02
Ighg up 11.3 2.71E-02
Snca up 9.8 1.25E-03
Lum up 9.5 2.30E-02
Igh-3 /// Ighg up 9.1 3.91E-02
Hsd17b13 up 7.8 2.43E-02
Il6 up 7.4 7.34E-03
Vip up 6.8 2.19E-02
Sfrp1 up 6.2 4.73E-02
Mmrn1 up 6.0 1.05E-02
2010001M09Rik up 5.7 2.36E-02
Aldob up 5.3 2.90E-02
Scin up 4.9 2.93E-02
Slc39a5 up 4.8 2.17E-02
Atp10d up 4.7 4.06E-04
Cntn1 up 4.7 5.42E-03
Selp up 4.5 1.87E-03
Igk-V19-14 up 4.4 3.05E-02
Phf17 up 4.4 7.09E-04
Pck1 up 4.2 8.17E-03
Ccl2 up 4.1 1.05E-02
Col14a1 up 3.7 3.03E-02
Slc5a8 up 3.7 1.86E-02
Chgb up 3.7 4.70E-02
Ncf4 up 3.6 1.11E-02
Il11 up 3.6 2.13E-02
Hspa1a up 3.6 1.08E-02
Ccl11 up 3.6 8.54E-03
Rsad2 up 3.4 9.42E-03
Differentially Expressed Genes 
APCMin/+ PPARɲ-/- tumour vs.  APC Min/+ tumour 
(Comparison 2)
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Gene Symbol Regulation FCAbsolute p-value
Aspn up 3.4 1.07E-02
Flrt3 up 3.4 2.32E-02
B3galt5 up 3.4 3.30E-02
Rsad2 up 3.3 8.07E-03
Sprr1a up 3.3 4.99E-02
Ccl7 up 3.3 8.39E-03
Ccl21a up 3.3 2.73E-02
Cd59a up 3.3 7.22E-03
Flrt3 up 3.2 2.42E-02
Decr1 up 3.2 7.81E-04
Abcb1b up 3.1 9.68E-04
Paqr5 up 3.1 3.07E-02
Gstm3 up 3.1 3.90E-02
Abcc9 up 3.0 1.71E-02
Arnt2 up 3.0 3.04E-02
Clca2 up 3.0 3.96E-02
Supt16h up 3.0 1.03E-02
Atp2c2 up 3.0 1.32E-02
Pdzd3 up 2.9 1.71E-02
Arg2 up 2.9 2.85E-02
Prkce up 2.9 1.93E-02
Ereg up 2.9 3.99E-02
Ephx2 up 2.9 4.83E-02
Id4 up 2.9 8.21E-03
Cyp7b1 up 2.8 1.84E-02
Frzb up 2.8 1.62E-03
Grem2 up 2.8 4.57E-02
Obfc2a up 2.8 1.82E-02
Lgi2 up 2.8 1.24E-02
Gucy1a3 up 2.8 2.54E-02
Epas1 up 2.7 3.83E-02
Fam107b up 2.7 1.05E-02
Igj up 2.6 3.86E-02
Hspa1b up 2.6 4.03E-02
Chl1 up 2.6 3.90E-03
Slc6a14 up 2.6 4.27E-02
1810014B01Rik up 2.6 3.84E-02
Tgfbr3 up 2.6 3.34E-02
Pira2 up 2.6 6.41E-03
Clca1 up 2.6 4.80E-02
Differentially Expressed Genes 
APCMin/+ PPARɲ-/- tumour vs.  APC Min/+ tumour 
(Comparison 2)
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Gene Symbol Regulation FCAbsolute p-value
9930013L23Rik up 2.6 1.35E-02
Hyou1 up 2.5 2.72E-03
Uba6 up 2.5 2.37E-05
Cxcl3 up 2.5 9.32E-03
Trpa1 up 2.5 4.47E-02
Osmr up 2.5 1.58E-02
Igfbp5 up 2.5 4.58E-02
Hspa1b up 2.5 4.69E-02
Vcan up 2.5 5.25E-03
Gja1 up 2.5 1.50E-02
Ap1s2 up 2.5 1.49E-03
Cxcl12 up 2.5 1.43E-02
Lrrk2 up 2.5 4.43E-04
Hspa1b up 2.5 4.35E-02
D730039F16Rik up 2.4 3.02E-02
Plaur up 2.4 1.13E-03
Csf2 up 2.4 1.41E-02
Slpi up 2.4 4.21E-03
Jam2 up 2.4 3.93E-03
Rsad2 up 2.4 4.58E-02
Golph3l up 2.4 7.18E-03
Itgam up 2.4 2.86E-02
Tcf23 up 2.4 9.69E-04
Tgoln1 /// Tgoln2 up 2.3 2.18E-02
Bdh1 up 2.3 4.52E-02
Dnajc3 up 2.3 3.23E-03
2610018G03Rik up 2.3 1.65E-02
Ndn up 2.3 4.69E-02
Vcan up 2.3 1.63E-02
Fam55b up 2.3 1.57E-02
Gja4 up 2.2 2.52E-02
Tgoln1 up 2.2 4.40E-02
Slc40a1 up 2.2 2.86E-02
Dpt up 2.2 2.97E-02
Tspan2 up 2.2 2.65E-02
Aldh1a3 up 2.2 4.64E-02
Prkce up 2.2 6.13E-03
Nr3c1 up 2.2 2.45E-02
Sod3 up 2.2 4.97E-02
Ghr up 2.2 2.68E-03
Differentially Expressed Genes 
APCMin/+ PPARɲ-/- tumour vs.  APC Min/+ tumour 
(Comparison 2)
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Gene Symbol Regulation FCAbsolute p-value
Tnc up 2.2 4.68E-02
Gucy1b3 up 2.2 3.59E-02
Tgoln1 up 2.2 3.56E-02
Ednra up 2.2 4.91E-02
Tmtc3 up 2.2 7.97E-03
S1pr3 up 2.2 4.88E-02
Etnk1 up 2.2 6.46E-03
Col4a5 up 2.2 2.95E-02
2010109K11Rik up 2.2 2.13E-02
Tmem47 up 2.2 2.19E-02
Hgf up 2.2 7.58E-03
Pck1 up 2.2 5.39E-03
P4ha1 up 2.2 1.84E-02
Angptl4 up 2.2 3.55E-02
Hs3st1 up 2.2 2.69E-02
Tff3 up 2.2 3.46E-02
Aspn up 2.1 4.59E-02
Atoh1 up 2.1 8.25E-03
Slc35a1 up 2.1 4.32E-02
Dmp1 up 2.1 4.88E-02
Sema6d up 2.1 1.66E-02
Mef2c up 2.1 8.20E-03
Bnc2 up 2.1 4.75E-02
P2ry14 up 2.1 4.96E-02
Cnnm4 up 2.1 4.03E-02
Ddr2 up 2.1 1.35E-02
Crispld2 up 2.1 2.86E-02
Slc16a9 up 2.1 1.22E-02
Igfbp5 up 2.0 2.83E-02
Rab2b up 2.0 1.77E-02
Adamts4 up 2.0 3.33E-02
Sertad4 up 2.0 4.79E-02
Fzd5 up 2.0 3.43E-02
Tbc1d4 up 2.0 4.87E-02
Pycard up 2.0 3.67E-02
Adamts4 up 2.0 2.46E-02
Zfp9 up 2.0 8.34E-03
Ercc6l up 2.0 1.81E-02
Fgf7 up 2.0 2.42E-02
Ehd2 up 2.0 3.23E-02
Differentially Expressed Genes 
APCMin/+ PPARɲ-/- tumour vs.  APC Min/+ tumour 
(Comparison 2)
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Gene Symbol Regulation FCAbsolute p-value
Gfpt1 up 2.0 1.88E-02
Rabif up 2.0 4.17E-02
Sord up 2.0 1.22E-02
Tm6sf1 up 2.0 1.29E-02
Darc up 2.0 4.69E-03
Tmem195 up 2.0 1.45E-02
5830444B04Rik up 2.0 7.38E-03
Klf6 up 2.0 1.88E-02
Slco2b1 up 2.0 1.46E-02
Txnrd1 up 2.0 3.51E-02
Plod2 up 2.0 1.31E-02
Fgf7 up 2.0 1.63E-02
Btbd3 up 2.0 4.44E-02
Fam107b up 2.0 2.27E-02
St6gal1 up 2.0 4.05E-03
Icam2 up 2.0 3.76E-02
Naalad2 up 2.0 4.28E-02
Atp8a1 up 2.0 3.36E-03
Dock8 up 2.0 3.01E-02
Armcx3 up 1.9 2.92E-02
Il1rn up 1.9 3.40E-02
2610018G03Rik up 1.9 4.37E-02
Ikzf2 up 1.9 4.51E-02
Mapre2 up 1.9 1.02E-02
Eln up 1.9 4.56E-02
Cd59a up 1.9 1.24E-02
Atf2 up 1.9 1.52E-02
Acss2 up 1.9 2.78E-02
Sec24d up 1.9 4.81E-02
Efnb2 up 1.9 1.45E-02
AW987390 up 1.9 3.35E-02
Ndrg4 up 1.9 4.02E-02
Reck up 1.9 1.40E-02
Lgals7 up 1.9 1.88E-02
Il13ra1 up 1.9 4.60E-03
Vhl up 1.9 1.85E-02
Il13ra2 up 1.9 4.79E-02
Ifi27l2b up 1.9 4.67E-02
Ifi27l1 up 1.9 1.66E-02
Rgmb up 1.9 4.73E-02
Differentially Expressed Genes 
APCMin/+ PPARɲ-/- tumour vs.  APC Min/+ tumour 
(Comparison 2)
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Gene Symbol Regulation FCAbsolute p-value
Lats1 up 1.9 3.42E-02
Uba6 up 1.9 2.29E-04
Mapre2 up 1.9 3.82E-02
Socs2 up 1.9 2.61E-02
Cd72 up 1.9 2.80E-02
E030049G20Rik up 1.9 9.81E-03
Pmm2 up 1.9 4.43E-02
Rnf141 up 1.8 4.15E-03
Chpt1 up 1.8 2.63E-02
Fam107b up 1.8 2.86E-02
Golph3l up 1.8 2.06E-02
Crispld2 up 1.8 2.96E-02
Ap1s2 up 1.8 1.96E-02
Rbp7 up 1.8 9.64E-03
Hnrnpc up 1.8 1.98E-03
Piga up 1.8 4.63E-02
St8sia6 up 1.8 2.60E-02
Mier1 up 1.8 3.10E-02
Yy1 up 1.8 1.09E-02
Etnk1 up 1.8 5.37E-03
Gucy1b3 up 1.8 3.88E-02
Dcbld1 up 1.8 9.85E-03
Lgals12 up 1.8 1.49E-02
Nrp1 up 1.8 4.43E-02
Ifi27l1 up 1.8 3.11E-02
Hif1a up 1.8 4.45E-02
Rgs4 up 1.8 6.71E-03
Trim25 up 1.8 1.15E-02
Slc35a3 up 1.8 3.51E-02
Antxr2 up 1.8 4.16E-02
Gstm2 up 1.8 1.62E-02
4732429D16Rik up 1.8 3.26E-02
Itgav up 1.8 1.34E-02
Gigyf2 up 1.8 2.80E-02
Dcn up 1.8 8.12E-03
Nup54 up 1.8 2.38E-02
1110032E23Rik up 1.8 2.16E-03
Mmp10 up 1.8 1.93E-02
Epb4.1l3 up 1.8 1.04E-02
Txnip up 1.8 3.03E-02
Differentially Expressed Genes 
APCMin/+ PPARɲ-/- tumour vs.  APC Min/+ tumour 
(Comparison 2)
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Gene Symbol Regulation FCAbsolute p-value
Ckmt1 up 1.8 3.97E-02
Lgals12 up 1.7 1.31E-02
Lox up 1.7 2.10E-02
Rp2h up 1.7 1.83E-02
Dgkh up 1.7 4.80E-02
Rnf141 up 1.7 2.79E-02
Far1 up 1.7 4.72E-02
Mmrn2 up 1.7 3.29E-02
Tmem106a up 1.7 2.86E-02
Pcolce up 1.7 3.89E-02
Sema6d up 1.7 4.25E-02
Canx up 1.7 5.75E-03
Phlda2 up 1.7 2.01E-02
Armcx2 up 1.7 2.88E-02
Atp8a1 up 1.7 8.01E-03
AU040320 up 1.7 4.31E-02
2810417H13Rik up 1.7 1.06E-02
Gfpt1 up 1.7 4.56E-02
Vps35 up 1.7 4.91E-02
Lin7c up 1.7 5.64E-03
Endod1 up 1.7 3.61E-02
Cpd up 1.7 5.08E-03
Prkx up 1.7 3.64E-02
Bmper up 1.7 3.41E-02
Casd1 up 1.7 1.99E-02
Pja1 up 1.7 3.64E-02
Differentially Expressed Genes 
APCMin/+ PPARɲ-/- tumour vs.  APC Min/+ tumour 
(Comparison 2)
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Gene Symbol Regulation FCAbsolute p-value
Reg3b down 133.0 2.29E-03
Wif1 down 129.8 5.17E-05
Defa5 down 117.3 3.36E-03
Defa24 down 102.9 2.71E-03
Reg3b down 102.7 1.55E-03
Mmp7 down 78.3 1.86E-04
Itln1 down 60.0 1.36E-04
Mt4 down 55.3 1.09E-03
Apcdd1 down 51.5 1.83E-04
Mmp13 down 49.9 1.13E-05
Pla2g2a down 48.5 1.07E-03
Apcdd1 down 46.7 6.64E-04
Expi down 45.3 3.70E-03
Cxcl5 down 44.3 4.82E-04
Arg1 down 43.7 5.16E-07
Onecut2 down 41.7 3.95E-04
Slc38a4 down 40.6 7.13E-05
Mmp10 down 38.3 1.78E-06
Adcy8 down 37.4 5.43E-06
Onecut2 down 36.7 2.07E-04
Apcdd1 down 36.7 3.45E-04
Spp1 down 35.2 1.60E-04
Prox1 down 34.5 3.11E-06
Prox1 down 32.0 6.43E-07
Dkk2 down 32.0 5.36E-07
Reg3g down 30.9 2.73E-03
Gm106 down 30.5 3.01E-04
Notum down 29.8 4.05E-06
Apcdd1 down 29.4 2.93E-04
Nfe2l3 down 29.3 6.65E-05
Onecut2 down 28.3 5.66E-04
Spock2 down 28.3 6.79E-06
Prox1 down 27.3 1.09E-06
Cfi down 27.3 6.54E-04
Tnfrsf11b down 25.7 2.21E-04
Nebl down 25.2 9.97E-04
Slc38a4 down 25.0 7.62E-04
Cxcl1 down 24.8 2.42E-04
Slc30a2 down 24.8 1.92E-05
Tacstd2 down 24.3 6.89E-05
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Alox12 down 23.8 2.04E-05
Pnliprp1 down 23.3 6.55E-04
Serpinb11 down 23.1 1.31E-03
AI747448 down 23.0 8.31E-10
Pnliprp2 down 22.9 6.23E-04
Lcn2 down 22.7 3.14E-03
Myl7 down 21.6 3.70E-05
Alb down 21.0 2.88E-04
Cxcl2 down 20.5 3.26E-03
Khdc1a down 20.4 1.89E-04
Pnliprp2 down 20.2 6.11E-04
Hp down 18.6 5.06E-04
Gm106 down 18.3 3.44E-04
Mmp12 down 18.2 5.40E-06
Sox21 down 18.2 2.72E-04
Nkd1 down 18.2 7.64E-05
Nkd1 down 17.8 2.98E-06
Fam84a down 17.7 8.08E-04
Lrg1 down 16.8 2.39E-03
A730054J21Rik down 16.4 1.83E-04
Prr18 down 15.5 4.75E-05
Pdgfrl down 15.5 1.22E-06
T down 15.5 7.99E-04
Avil down 15.3 1.78E-04
Krt23 down 14.7 1.05E-03
Kif26b down 14.7 7.20E-05
Rnase1 down 14.6 4.24E-05
Sox17 down 14.6 4.55E-03
Plat down 14.3 2.71E-04
Apcdd1 down 13.1 5.94E-04
Isl1 down 12.4 1.72E-03
Tnfrsf19 down 12.4 1.77E-05
Robo1 down 12.3 5.75E-04
Tnfrsf11b down 11.8 1.74E-04
Spock2 down 11.8 1.48E-05
Cubn down 11.7 1.14E-03
Cxcl3 down 11.6 3.19E-05
Il1rl1 down 11.3 3.54E-03
BC007180 down 11.1 4.76E-06
Rnf180 down 11.0 1.62E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Tex15 down 11.0 1.49E-04
Sox4 down 10.9 4.19E-04
Bex1 down 10.8 5.84E-04
Atg9b down 10.6 5.22E-04
Cubn down 10.5 1.12E-03
Marcksl1 down 10.3 3.48E-05
Lgr5 down 9.9 1.23E-03
Ptprz1 down 9.4 4.03E-03
Axin2 down 9.4 3.94E-05
Gprin2 down 9.4 7.54E-06
2900084O13Rik down 9.3 8.03E-04
Fam89a down 9.2 1.71E-07
Ptpro down 9.2 2.87E-04
9930013L23Rik down 9.2 9.86E-05
Isl1 down 9.2 8.34E-04
Adam8 down 9.1 2.19E-06
Prr18 down 9.1 1.28E-05
Sox4 down 9.1 1.12E-04
Odz4 down 9.1 2.59E-03
Marcksl1 down 9.1 5.56E-05
8030425K09Rik down 9.0 1.92E-05
Slco5a1 down 8.8 5.42E-04
Foxq1 down 8.8 2.01E-03
Sox4 down 8.6 1.26E-04
2700046A07Rik down 8.6 1.09E-03
Gata5 down 8.6 6.83E-06
Mt3 down 8.5 7.75E-05
Sp5 down 8.2 1.46E-05
Stra6 down 8.2 1.59E-04
Tbx3 down 8.1 4.45E-03
Sox4 down 8.0 1.44E-05
Odz4 down 8.0 6.30E-04
5730457N03Rik down 8.0 2.71E-03
Tmem173 down 7.9 1.23E-04
Wnt10a down 7.9 3.61E-04
Irx5 down 7.9 8.81E-04
Dusp4 down 7.9 3.70E-04
Gsdma down 7.7 3.29E-05
Tead2 down 7.7 7.52E-05
Asprv1 down 7.6 1.69E-06
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Ptpro down 7.4 8.19E-04
Plxnb1 down 7.4 1.66E-04
Cxcl1 down 7.4 6.40E-04
Rnf43 down 7.3 2.72E-04
Ttc9 down 7.2 5.02E-04
LOC100047138 down 7.2 4.63E-04
Grhl3 down 7.2 6.68E-05
6720475J19Rik down 7.1 1.16E-04
Ecscr down 7.1 7.01E-05
Il1rl1 down 7.1 5.42E-04
Il23a down 7.1 3.61E-03
Jub down 7.1 6.56E-06
Krt36 down 6.9 3.72E-03
Odz4 down 6.8 4.15E-04
Vash2 down 6.8 1.66E-06
Sox4 down 6.7 2.56E-05
BC037703 down 6.7 3.78E-03
Arntl2 down 6.7 1.29E-04
Neto2 down 6.6 2.24E-03
EG664949 down 6.6 2.43E-04
Rem2 down 6.6 2.18E-04
Cldn4 down 6.6 1.21E-03
Padi4 down 6.5 1.30E-03
Dio2 down 6.4 1.93E-04
Arl4c down 6.4 1.39E-04
Inhba down 6.4 5.17E-06
LOC100047138 down 6.3 5.68E-04
Basp1 down 6.2 2.79E-03
Scn2b down 6.1 4.72E-03
Marcksl1 down 6.1 1.15E-04
Fam62c down 6.0 2.15E-03
Mtap down 6.0 1.42E-04
Cited1 down 6.0 1.66E-04
Mtap down 5.9 2.38E-04
100042016 down 5.9 1.74E-04
Igfbp4 down 5.9 1.48E-03
Neurl1a down 5.9 8.65E-04
Bmp7 down 5.8 3.41E-03
Phlda1 down 5.8 7.45E-04
Nfe2l3 down 5.8 6.87E-04
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
327 
 
 
 
Gene Symbol Regulation FCAbsolute p-value
Dyrk3 down 5.8 1.94E-04
Limch1 down 5.8 5.82E-04
Limch1 down 5.7 1.66E-03
Evl down 5.6 2.75E-03
2810404F17Rik down 5.6 1.67E-03
Pcdhb9 down 5.6 1.06E-03
Gpc1 down 5.6 1.52E-04
Tmem173 down 5.5 3.38E-04
Btbd11 down 5.4 2.22E-03
Tnfsf9 down 5.4 2.58E-04
Smox down 5.4 7.07E-04
Gata5 down 5.4 1.64E-05
Chrnb1 down 5.4 1.07E-04
6720418B01Rik down 5.4 6.78E-04
Pmepa1 down 5.3 1.57E-04
Rem2 down 5.3 9.11E-04
Tnfrsf19 down 5.3 1.12E-04
Vangl2 down 5.3 1.58E-04
Evx1 down 5.3 1.50E-04
Tubb2b down 5.3 1.95E-03
Axin2 down 5.2 2.52E-04
Tubb2a-ps2 down 5.2 3.39E-03
Prei4 down 5.1 1.02E-03
Pgm2l1 down 5.1 2.24E-04
Mex3a down 5.0 8.87E-06
Ascl2 down 5.0 1.99E-03
Htra1 down 5.0 4.25E-04
Cd244 down 4.9 3.58E-03
Slc16a10 down 4.9 1.13E-03
Rgs12 down 4.9 1.07E-04
Pgm2l1 down 4.8 1.02E-03
Tbx3 down 4.8 4.38E-03
Htra1 down 4.8 1.06E-03
Abcc4 down 4.8 2.07E-04
Ephb6 down 4.8 3.16E-03
Prmt1 down 4.7 1.06E-03
Scn2b down 4.7 3.96E-04
Macc1 down 4.7 4.33E-03
Ramp3 down 4.7 1.00E-03
Elavl2 down 4.7 1.02E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Cdh13 down 4.6 5.15E-04
Ctxn1 down 4.6 4.04E-03
Znrf3 down 4.5 7.41E-04
Ascl2 down 4.5 1.81E-03
Wnt5a down 4.5 4.51E-04
Rnf32 down 4.5 7.41E-04
Nav2 down 4.5 7.39E-04
Sox21 down 4.4 6.66E-05
Tcf4 down 4.4 2.18E-04
Mtap down 4.4 1.73E-03
Wnt6 down 4.4 2.28E-03
Wnt6 down 4.4 4.38E-04
Tmeff1 down 4.4 3.80E-03
Mapk4 down 4.4 3.37E-03
6720475J19Rik down 4.3 5.69E-05
Pvrl4 down 4.3 4.28E-04
Tcf4 down 4.3 1.19E-04
Slc7a2 down 4.3 1.05E-03
Slc18a1 down 4.2 4.57E-03
2810037O22Rik down 4.2 3.59E-04
Foxc2 down 4.2 1.30E-04
BC057079 down 4.2 2.07E-04
Slc18a1 down 4.2 2.25E-03
Entpd3 down 4.2 1.04E-03
Ifitm3 down 4.1 5.84E-04
2700094K13Rik down 4.1 3.77E-04
Btbd11 down 4.1 1.08E-03
Bcl2l11 down 4.1 1.01E-03
Nav2 down 4.1 1.30E-03
Tcf4 down 4.1 9.48E-05
Mex3d down 4.1 3.00E-04
Lef1 down 4.1 4.91E-05
Tnfrsf12a down 4.0 5.91E-04
Ptgr1 down 4.0 1.97E-03
Pmepa1 down 4.0 8.14E-04
Pla1a down 4.0 1.88E-03
Sema3f down 4.0 2.89E-04
Nr4a2 down 4.0 4.75E-03
Il11 down 4.0 3.17E-03
Echdc2 down 3.9 3.62E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Tgif2 down 3.9 6.77E-04
Mex3b down 3.9 2.95E-04
Amot down 3.9 8.15E-04
Igfbp4 down 3.9 1.88E-03
Prss12 down 3.9 4.77E-03
Cdh13 down 3.8 9.53E-04
Rdh10 down 3.8 2.29E-03
Wnt5a down 3.8 3.04E-03
Mmp14 down 3.8 3.82E-04
Timp1 down 3.8 5.29E-04
Krt7 down 3.8 4.84E-05
Nuak1 down 3.8 2.07E-03
Ascl2 down 3.8 6.04E-04
Tcf4 down 3.8 2.99E-03
Elk3 down 3.8 8.55E-04
Slc44a2 down 3.8 4.41E-04
Tcf4 down 3.7 1.71E-03
Cyp11a1 down 3.7 1.42E-03
Snx10 down 3.7 1.09E-03
Smox down 3.7 2.92E-04
Lef1 down 3.7 1.82E-03
Slc41a1 down 3.7 1.85E-03
Cd244 down 3.7 2.13E-03
Rnf183 down 3.6 3.25E-05
Csnk1e down 3.6 5.39E-04
Nav2 down 3.6 2.80E-04
Bcl2l11 down 3.6 2.90E-03
Bmf down 3.6 3.89E-03
Arl4c down 3.6 2.03E-04
B4galnt4 down 3.6 4.11E-03
Marcksl1 down 3.6 4.17E-05
E030016H06Rik down 3.5 2.59E-03
A330049M08Rik down 3.5 2.04E-03
Mmp14 down 3.5 8.50E-04
Igfbp4 down 3.5 1.41E-03
Higd1c down 3.5 3.43E-03
Nanos1 down 3.5 1.47E-04
Lamp2 down 3.5 5.80E-04
ENSMUSG00000073000 down 3.5 1.82E-03
2700081O15Rik down 3.5 4.76E-04
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Ptpre down 3.4 1.23E-03
9530048O09Rik down 3.4 4.76E-04
Bcl2l11 down 3.4 1.34E-03
Avpi1 down 3.4 4.30E-04
Nr4a2 down 3.4 4.06E-03
Camta1 down 3.4 2.02E-03
Adamts12 down 3.4 2.73E-03
4921525O09Rik down 3.4 3.46E-04
Klhl8 down 3.4 3.20E-04
D17H6S56E-5 down 3.3 3.18E-03
Serpine2 down 3.3 4.41E-03
Hebp2 down 3.3 9.04E-04
Prss22 down 3.3 1.73E-04
Rbms3 down 3.3 4.83E-03
Tiam1 down 3.3 2.62E-04
Hunk down 3.3 1.62E-04
Col18a1 down 3.3 4.71E-03
Map4k4 down 3.3 3.96E-04
Vim down 3.3 2.93E-03
Igfbp4 down 3.3 1.38E-03
Il17rd down 3.3 6.71E-04
4732423E21Rik down 3.3 4.59E-03
Spns2 down 3.3 2.76E-04
Krt6a down 3.2 2.68E-04
Ly6e down 3.2 1.35E-03
Tmem184c down 3.2 4.38E-03
1700017B05Rik down 3.2 1.01E-03
Vangl2 down 3.2 1.28E-04
Sh3pxd2b down 3.2 7.41E-04
Fgfrl1 down 3.2 4.40E-03
4631416L12Rik down 3.2 7.99E-04
Ptpre down 3.2 2.16E-04
Lamp2 down 3.2 1.66E-04
Casp6 down 3.2 1.26E-03
Col18a1 down 3.1 2.81E-03
Prei4 down 3.1 1.42E-03
Psapl1 down 3.1 1.17E-03
Zfp518b down 3.1 3.32E-05
Csgalnact1 down 3.1 1.16E-03
Sema4c down 3.1 2.03E-04
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Slc16a3 down 3.1 3.70E-04
Apobec3 down 3.1 1.25E-03
Bcl2l11 down 3.1 3.34E-03
Vill down 3.0 2.24E-04
Csnk1e down 3.0 3.48E-04
Nme4 down 3.0 1.45E-04
Gpld1 down 3.0 5.53E-04
Tnfrsf12a down 3.0 3.77E-03
Elk3 down 3.0 5.07E-04
Gusb down 3.0 2.78E-04
Rhoj down 3.0 1.79E-03
Ddit4l down 3.0 1.49E-03
4732490B19Rik down 3.0 7.15E-04
Mafg down 3.0 4.97E-04
Pdlim4 down 3.0 2.99E-03
Vim down 3.0 2.30E-03
Fam60a down 3.0 4.55E-05
Pcdhb21 down 3.0 1.21E-03
Csrnp2 down 2.9 1.32E-04
D15Wsu126e down 2.9 1.48E-03
Tnik down 2.9 3.94E-03
Gpx2 down 2.9 7.76E-04
Map4k4 down 2.9 6.41E-04
Rcc2 down 2.9 8.86E-04
Dbn1 down 2.9 4.02E-04
Pea15a down 2.9 1.38E-03
Stx1a down 2.9 6.55E-04
Sepn1 down 2.9 4.63E-03
D17H6S56E-5 down 2.9 1.24E-03
Map4k4 down 2.9 1.35E-03
Adam12 down 2.9 2.06E-04
Mtap down 2.9 1.18E-03
Rac3 down 2.9 1.32E-03
Usp22 down 2.9 1.28E-04
Nlk down 2.9 1.20E-03
Lama5 down 2.8 3.86E-04
Ccnd1 down 2.8 2.64E-03
Phldb2 down 2.8 4.33E-03
Phlda3 down 2.8 1.85E-03
Rgs12 down 2.8 2.22E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Mex3a down 2.8 4.85E-05
Tubb5 down 2.8 1.05E-03
Rtn4rl1 down 2.8 8.39E-04
Klc3 down 2.8 2.92E-05
Zbtb12 down 2.8 1.99E-05
Dpysl3 down 2.8 1.97E-03
Patz1 down 2.8 1.19E-03
Sh3kbp1 down 2.8 4.71E-03
Rbm24 down 2.8 1.12E-03
Pvrl4 down 2.7 4.17E-04
Prkd1 down 2.7 3.46E-03
4930426D05Rik down 2.7 2.98E-04
Ddah2 down 2.7 1.06E-04
Sox6 down 2.7 4.17E-03
Cdk4 down 2.7 4.47E-03
Smarcc1 down 2.7 1.69E-04
Slc39a6 down 2.7 3.79E-03
Cdk4 down 2.7 3.89E-03
Cdk4 down 2.7 3.81E-03
Mafg down 2.7 8.36E-04
Tcfe2a down 2.7 1.26E-03
Slc25a30 down 2.7 2.73E-04
Sh3kbp1 down 2.7 3.16E-03
2310008H09Rik down 2.7 1.70E-04
Abhd12 down 2.7 3.59E-03
S100a11 down 2.7 2.97E-04
Iffo2 down 2.7 5.89E-04
D730005E14Rik down 2.7 1.59E-03
Hopx down 2.7 2.21E-03
Nhp2 down 2.6 6.09E-05
Mpzl1 down 2.6 4.08E-03
Klhl8 down 2.6 3.21E-04
Elk3 down 2.6 2.50E-04
Stx1a down 2.6 4.25E-04
Cbx6 down 2.6 1.20E-03
Cep72 down 2.6 1.91E-04
Cep78 down 2.6 3.12E-04
Hopx down 2.6 9.34E-04
Pacsin3 down 2.6 1.45E-03
Bcam down 2.6 1.55E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Pxdn down 2.6 4.11E-03
Ckap4 down 2.6 4.59E-03
Efna4 down 2.6 1.79E-03
Runx1 down 2.6 3.61E-03
Sbk1 down 2.6 1.04E-03
Plcd3 down 2.6 6.97E-06
Nhp2 down 2.6 1.27E-05
Psapl1 down 2.6 2.91E-04
Armc10 down 2.6 1.94E-04
Hist3h2ba down 2.6 3.90E-03
Zdhhc15 down 2.5 4.67E-03
Ifitm2 down 2.5 3.30E-03
Ezh2 down 2.5 2.95E-03
Aspscr1 down 2.5 3.21E-06
Slc25a30 down 2.5 7.66E-04
Plscr3 down 2.5 2.12E-04
Wdr6 down 2.5 4.76E-03
Iffo2 down 2.5 6.21E-04
2010109K09Rik down 2.5 2.63E-03
9430064K01Rik down 2.5 6.53E-04
Smarcc1 down 2.5 1.33E-03
Lgi2 down 2.5 4.48E-03
Zfp703 down 2.5 4.61E-03
Ets2 down 2.5 2.05E-04
Dlg5 down 2.5 3.33E-05
1700017B05Rik down 2.5 2.49E-03
Bok down 2.5 2.47E-03
Ppp1r14b down 2.5 4.26E-03
Sypl down 2.5 3.48E-03
Nme1 down 2.5 8.85E-05
Hoxa9 down 2.5 1.92E-03
Zfp451 down 2.5 1.63E-03
Dpysl3 down 2.4 1.27E-03
9430081I23Rik down 2.4 4.74E-03
C79946 down 2.4 6.10E-04
Fmnl2 down 2.4 2.89E-03
Zfp90 down 2.4 1.06E-03
Apaf1 down 2.4 3.01E-03
Vasn down 2.4 3.23E-03
Arhgdig down 2.4 3.69E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Prdx2 down 2.4 2.21E-04
Smoc1 down 2.4 3.76E-03
Rnf122 down 2.4 3.25E-03
5730601F06Rik down 2.4 2.48E-04
2610301F02Rik down 2.4 7.34E-04
Cbx2 down 2.4 1.35E-03
Myc down 2.4 4.30E-03
Vangl2 down 2.4 2.24E-05
Epb4.1l5 down 2.4 9.98E-04
Neto2 down 2.4 1.32E-03
Lysmd2 down 2.4 4.98E-03
Hmgb3 down 2.4 1.84E-05
Lama5 down 2.4 2.63E-04
Slco5a1 down 2.4 1.09E-03
Cbx6 down 2.4 1.74E-04
Usp11 down 2.4 1.49E-03
Ypel1 down 2.4 8.28E-04
Pcdhb16 down 2.4 4.05E-03
Skap2 down 2.4 4.64E-04
6720460F02Rik down 2.4 2.05E-03
Runx1 down 2.4 2.72E-03
Map4k4 down 2.4 7.22E-04
Slc25a30 down 2.3 1.97E-03
Rtn4 down 2.3 2.80E-03
6820402I19Rik down 2.3 2.45E-03
Slc44a2 down 2.3 2.34E-04
Abcg1 down 2.3 3.54E-03
Cdca7 down 2.3 2.61E-03
E430016P22Rik down 2.3 5.28E-04
Cdc42ep1 down 2.3 1.34E-03
Wisp1 down 2.3 4.76E-04
Qtrt1 down 2.3 7.26E-04
Tulp3 down 2.3 6.71E-05
Rasal2 down 2.3 1.41E-03
Pabpc1 down 2.3 1.49E-03
Pabpn1 down 2.3 1.58E-03
Chic2 down 2.3 1.38E-03
Neurl1a down 2.3 2.63E-03
Krt18 down 2.3 8.48E-04
Lif down 2.3 4.55E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Fhl2 down 2.2 2.63E-03
Rab11fip5 down 2.2 6.88E-04
Rnmt down 2.2 3.54E-03
5430404G13Rik down 2.2 3.23E-03
Tbcel down 2.2 4.76E-03
Gtf2i down 2.2 2.78E-03
Ptplb down 2.2 4.53E-03
Rere down 2.2 2.96E-03
Notch1 down 2.2 2.72E-05
Cnn3 down 2.2 6.52E-04
Vgll4 down 2.2 1.91E-03
Rpl13a down 2.2 1.77E-03
Etv6 down 2.2 2.77E-03
Mmp14 down 2.2 4.52E-04
Itga6 down 2.2 1.31E-03
Nop56 down 2.2 2.73E-03
Rnf122 down 2.2 2.11E-03
D930015E06Rik down 2.2 4.73E-04
Sbk1 down 2.2 2.44E-03
Stmn1 down 2.2 3.14E-03
Nap1l1 down 2.2 2.75E-03
8030447M02Rik down 2.2 1.65E-03
Tmod3 down 2.2 2.22E-03
100042016 down 2.2 2.06E-03
Nap1l1 down 2.2 1.88E-04
Cpsf6 down 2.2 2.59E-03
Patz1 down 2.2 1.11E-03
5730601F06Rik down 2.2 3.11E-03
Traf4 down 2.2 1.42E-03
Skp1a down 2.2 1.07E-03
Abhd12 down 2.2 1.67E-03
Apex1 down 2.2 2.03E-03
Cnn3 down 2.2 2.28E-03
Cd276 down 2.2 2.24E-04
Gng10 down 2.2 4.63E-04
Ext1 down 2.1 4.08E-03
Ets2 down 2.1 2.75E-04
Nhsl1 down 2.1 4.94E-05
Gar1 down 2.1 2.42E-04
Nap1l1 down 2.1 4.61E-04
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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2700023E23Rik down 2.1 2.14E-03
Spnb3 down 2.1 4.58E-03
Rtn4 down 2.1 3.73E-03
Nap1l1 down 2.1 1.20E-03
2610201A13Rik down 2.1 3.25E-04
1190003J15Rik down 2.1 7.33E-04
Rbms1 down 2.1 2.96E-03
Sh3tc2 down 2.1 1.52E-03
Gm22 down 2.1 1.56E-03
Napepld down 2.1 2.73E-03
Hdac2 down 2.1 2.96E-03
Hoxa10 down 2.1 3.23E-04
Mex3c down 2.1 3.43E-03
Etv6 down 2.1 5.03E-06
Steap2 down 2.1 4.12E-03
Syngr1 down 2.1 9.66E-04
Ikbkap down 2.1 9.42E-04
Pdgfb down 2.1 1.84E-03
Clcn3 down 2.1 1.75E-04
Ift81 down 2.1 2.35E-03
Cnn3 down 2.1 4.91E-03
Hnrnpa1 down 2.1 3.14E-03
Mettl11a down 2.1 2.39E-05
Hmgn1 down 2.1 1.58E-04
Ptk7 down 2.1 1.95E-04
Cd47 down 2.1 1.61E-03
Ccdc125 down 2.1 3.79E-03
Fam40a down 2.1 3.02E-04
Cnn3 down 2.1 1.90E-03
Fam129b down 2.1 2.86E-04
Zfand5 down 2.1 5.97E-04
F830028O17Rik down 2.1 4.52E-03
Metap2 down 2.1 4.10E-04
9530048O09Rik down 2.1 1.53E-03
2610024B07Rik down 2.0 3.40E-03
2810026P18Rik down 2.0 4.44E-03
Tbcel down 2.0 2.84E-03
Sdc1 down 2.0 3.02E-03
Ppl down 2.0 2.39E-03
Zfp282 down 2.0 8.79E-04
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Atxn10 down 2.0 1.92E-03
Nup155 down 2.0 2.62E-03
Hmgn1 down 2.0 2.12E-04
Apex1 down 2.0 4.83E-03
Nkd1 down 2.0 9.28E-04
Gpx1 down 2.0 1.45E-04
Rnmt down 2.0 4.74E-04
Slc7a5 down 2.0 2.83E-03
Nap1l1 down 2.0 7.81E-04
Cul7 down 2.0 2.09E-03
2310008H09Rik down 2.0 1.60E-03
Fam115a down 2.0 1.42E-03
Xpot down 2.0 4.61E-04
Ltv1 down 2.0 1.19E-03
Atxn10 down 2.0 1.19E-03
Fam40a down 2.0 1.16E-03
Fbf1 down 2.0 8.53E-04
Aqp8 up 33.6 3.59E-03
Ces6 up 22.2 8.29E-04
Cnn1 up 19.0 4.17E-03
Sult1a1 up 18.7 1.47E-03
Selenbp1 up 16.9 2.47E-03
Selenbp1 up 16.8 2.11E-03
Maob up 16.2 7.68E-04
Aadac up 15.6 1.03E-03
Myh11 up 15.0 1.70E-03
Aldh1a7 up 15.0 3.67E-03
Ces2 up 14.7 2.28E-03
Synpo2 up 14.1 1.94E-03
Scin up 13.8 9.69E-04
Synm up 13.4 1.28E-03
Akr1c14 up 12.4 1.59E-03
Abca8a up 12.4 4.74E-04
Pck1 up 12.3 1.15E-03
Ndn up 12.3 4.84E-05
Cbr3 up 11.9 2.30E-03
Dpyd up 11.8 1.33E-03
Ugt1a1 up 11.4 2.80E-03
Pgm5 up 11.4 3.00E-04
Actg2 up 11.3 1.21E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Usp2 up 10.8 7.61E-04
Ndn up 10.7 1.26E-04
Ndn up 10.7 9.81E-05
Sult1c2 up 10.6 3.57E-03
Acer1 up 10.4 1.74E-03
Des up 10.4 2.78E-03
Abcb1a up 10.2 2.29E-03
Hsd3b2 up 9.9 3.33E-03
Mep1a up 9.8 4.51E-03
Grem2 up 9.7 5.37E-04
Foxp2 up 9.7 3.19E-03
Abcb1a up 9.6 2.11E-03
Car3 up 9.5 1.11E-03
Slc26a3 up 9.2 4.06E-04
Tpm2 up 9.0 1.18E-03
Slc5a8 up 8.9 2.74E-03
Itih5 up 8.5 3.94E-03
Synm up 8.5 1.39E-03
Aldob up 8.2 2.02E-03
Slc16a5 up 8.1 3.05E-03
Rims1 up 8.1 1.75E-03
Trpm6 up 7.9 4.12E-03
Gstm3 up 7.9 2.85E-03
Ndn up 7.8 9.31E-05
Fa2h up 7.8 2.18E-03
Apob up 7.8 2.99E-03
Gucy1a3 up 7.7 3.23E-05
Otc up 7.7 2.11E-04
0610005C13Rik up 7.7 1.64E-03
Ugt1a1 up 7.6 4.21E-03
Tpm2 up 7.6 1.23E-03
Tmprss8 up 7.6 4.65E-03
Tagln up 7.5 1.30E-03
Id4 up 7.5 4.66E-03
Vdr up 7.5 2.50E-03
Slc26a2 up 7.4 4.69E-03
Pdlim3 up 7.4 5.11E-04
Sspn up 7.2 7.47E-05
Cyp2s1 up 7.2 2.20E-03
100042999 /// Sprr2a up 7.1 4.80E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Entpd5 up 7.0 1.57E-03
Foxp2 up 7.0 2.96E-03
Mamdc2 up 7.0 4.82E-03
Myl9 up 6.9 4.31E-04
Abcg2 up 6.9 3.89E-03
Ugt1a1 up 6.7 2.43E-03
Entpd5 up 6.6 2.67E-03
Mylk up 6.6 3.44E-04
Vdr up 6.6 2.73E-03
Fgfbp1 up 6.5 6.14E-04
Aoc3 up 6.5 1.31E-05
Ccl28 up 6.4 4.97E-03
Acer1 up 6.3 1.68E-03
Tnxb up 6.2 7.77E-05
Kcnd3 up 6.2 1.40E-03
Pdlim3 up 6.1 1.37E-03
Mgll up 6.0 3.44E-03
Mgll up 6.0 3.12E-03
Mep1b up 6.0 1.93E-03
Es22 up 5.9 3.53E-03
Slc24a3 up 5.8 2.22E-04
Slc13a2 up 5.8 4.96E-03
Kcnf1 up 5.8 1.71E-03
Dhrs11 up 5.7 2.91E-04
Ntn1 up 5.7 4.21E-04
Ogn up 5.7 6.18E-04
Tgfbr3 up 5.6 1.94E-03
Maoa up 5.6 1.47E-03
Ccl28 up 5.6 4.08E-03
Cth up 5.5 4.50E-04
Clic5 up 5.5 4.39E-03
LOC73899 up 5.5 2.78E-03
Rims1 up 5.5 1.46E-03
Clybl up 5.4 3.09E-04
9530008L14Rik up 5.4 3.21E-03
Entpd5 up 5.4 1.90E-03
Cd36 up 5.3 5.60E-04
Slco2b1 up 5.3 2.04E-03
Ahcyl2 up 5.3 8.91E-04
Myo15b up 5.3 4.78E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Dpyd up 5.3 1.14E-03
Enpep up 5.3 2.30E-03
Sparcl1 up 5.2 8.01E-04
Dpt up 5.2 8.40E-04
B130021B11Rik up 5.1 2.59E-03
Scn7a up 5.1 1.01E-03
Gstm3 up 5.1 1.62E-03
Prkaa2 up 5.1 3.13E-03
Scn7a up 5.1 2.21E-03
Cxcl12 up 5.1 2.93E-04
Ppp1r12b up 5.1 9.00E-05
Esrrg up 5.0 2.78E-04
Entpd5 up 5.0 2.92E-03
Fmo1 up 5.0 2.68E-03
Tns1 up 5.0 9.25E-04
Bche up 5.0 4.92E-03
Cyp2d22 up 5.0 3.22E-03
Sdpr up 4.9 3.34E-03
B3galnt1 up 4.9 2.57E-04
Dio1 up 4.9 1.04E-03
Gpr160 up 4.8 3.67E-03
Tspan2 up 4.8 1.60E-03
Maoa up 4.8 7.54E-04
Iyd up 4.8 1.45E-03
Gstm2 up 4.8 8.06E-04
Pkdcc up 4.8 1.32E-03
Smtn up 4.8 4.96E-04
Pcdh24 up 4.8 2.95E-03
Myom1 up 4.7 4.71E-03
Abcc3 up 4.7 1.43E-03
Gm967 up 4.7 3.58E-03
Cpe up 4.7 3.83E-03
Mfap5 up 4.7 3.08E-04
Mylk up 4.7 1.90E-04
Pck1 up 4.6 4.28E-03
Sorbs1 up 4.6 2.65E-03
Entpd5 up 4.6 2.63E-03
Tns1 up 4.6 7.34E-04
Sdpr up 4.6 2.41E-03
2610027H17Rik up 4.6 2.96E-04
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Adcy5 up 4.6 3.25E-04
Fxyd1 up 4.6 1.53E-04
Bdh1 up 4.5 6.98E-04
Enpp2 up 4.5 7.11E-04
Gstt1 up 4.5 1.35E-05
Nr3c2 up 4.5 1.97E-03
Wscd2 up 4.5 1.73E-04
Speg up 4.5 9.12E-04
0610040B09Rik up 4.5 1.34E-03
Cox7a1 up 4.5 1.24E-03
Synpo2 up 4.4 4.81E-03
Prkaa2 up 4.4 2.57E-03
LOC100046086 up 4.4 7.01E-04
2010003H20Rik up 4.4 2.04E-03
Glod5 up 4.4 1.25E-03
Sorbs1 up 4.4 1.64E-03
Sdpr up 4.4 1.75E-03
Sorbs1 up 4.3 6.12E-04
Rbpms2 up 4.3 6.88E-04
Lhfpl2 up 4.3 1.21E-03
Slc25a34 up 4.3 3.23E-04
Pcp4 up 4.3 1.88E-03
Abcc9 up 4.3 2.46E-03
Espn up 4.3 3.16E-03
Slco2a1 up 4.2 3.40E-04
EG240055 up 4.2 1.23E-03
2010012P19Rik up 4.2 2.29E-03
Ugdh up 4.2 4.08E-03
Lims2 up 4.2 1.66E-04
Gstm1 up 4.2 8.29E-04
Lhfpl2 up 4.2 9.44E-04
Gm967 up 4.1 1.28E-04
Ssbp2 up 4.1 3.34E-03
Myo15b up 4.0 2.27E-03
Chrdl1 up 4.0 3.13E-04
Retsat up 3.9 1.44E-04
Bnc2 up 3.9 8.74E-04
Hhip up 3.9 4.26E-04
Acta2 up 3.9 2.10E-04
Gstm1 up 3.9 1.33E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Hhip up 3.8 4.32E-04
Slco2a1 up 3.8 1.53E-03
Kcnk5 up 3.8 1.03E-03
Tns1 up 3.8 2.97E-03
Foxd2 up 3.8 4.64E-03
Cideb up 3.8 4.59E-05
Cryl1 up 3.8 9.53E-04
LOC552901 up 3.7 2.85E-03
Chrdl1 up 3.7 4.90E-04
Meis1 up 3.7 2.46E-04
Dst up 3.7 1.50E-03
Lmod1 up 3.7 3.26E-03
5730409N24Rik up 3.7 3.67E-03
Pdzd3 up 3.7 9.36E-04
Cryl1 up 3.7 1.11E-03
Rspo3 up 3.7 1.09E-03
Trpm6 up 3.7 4.99E-03
Pycard up 3.7 8.22E-04
Synpo2 up 3.6 8.06E-04
Calb2 up 3.6 3.71E-03
Ppfia3 up 3.6 3.68E-03
Mylk up 3.6 6.14E-04
Hlf up 3.6 2.72E-03
Prkg1 up 3.5 5.10E-04
Metrnl up 3.5 1.21E-03
Mab21l2 up 3.5 2.61E-04
Slc4a4 up 3.5 4.24E-03
Sorbs1 up 3.5 3.00E-05
Ppargc1b up 3.5 9.63E-04
Prkaa2 up 3.4 1.29E-03
Hhip up 3.4 9.00E-04
Akap12 up 3.4 1.51E-03
Dgkh up 3.4 6.93E-04
Scg5 up 3.4 2.87E-03
Rgs7bp up 3.4 8.45E-04
Stmn2 up 3.4 3.38E-03
9130016M20Rik up 3.4 3.93E-03
Mxd1 up 3.4 1.62E-03
Hspb7 up 3.4 4.09E-03
2310044G17Rik up 3.3 1.41E-04
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Reck up 3.3 8.70E-04
Cds1 up 3.3 3.22E-03
Me2 up 3.3 2.15E-03
Slc9a3r1 up 3.3 7.41E-04
Ssbp2 up 3.3 3.33E-03
Tmem117 up 3.3 3.21E-03
2010001M06Rik up 3.3 9.96E-04
Mertk up 3.2 1.38E-04
Cd36 up 3.2 1.56E-03
Klf4 up 3.2 3.12E-03
4931406C07Rik up 3.2 3.71E-03
Cbs up 3.2 1.78E-03
Sntg2 up 3.2 2.22E-03
Ptgis up 3.2 3.64E-03
Myocd up 3.2 4.06E-03
Slc9a3r1 up 3.2 1.45E-03
Ctdspl up 3.2 6.35E-04
Sord up 3.2 1.67E-03
Pkia up 3.2 1.42E-03
Entpd8 up 3.2 2.26E-04
Slc9a3r1 up 3.2 1.42E-03
Popdc2 up 3.1 1.79E-03
Iqgap2 up 3.1 1.73E-03
AI605517 up 3.1 2.66E-03
Etv1 up 3.1 1.43E-03
Mupcdh up 3.1 2.47E-03
Pcdh21 up 3.1 5.85E-04
Slc25a20 up 3.1 1.64E-03
Zfp385b up 3.1 2.88E-03
Stk10 up 3.1 1.23E-03
Retsat up 3.1 2.77E-04
Fzd5 up 3.1 8.61E-04
9130409J20Rik up 3.1 2.85E-03
Fam13a up 3.1 3.12E-03
Sdc2 up 3.1 4.34E-03
Chrdl1 up 3.1 8.05E-04
Itm2a up 3.1 9.13E-04
Mustn1 up 3.1 2.72E-03
Qpct up 3.1 2.31E-03
Mapre2 up 3.1 1.02E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Prkce up 3.1 3.38E-03
Sdc2 up 3.1 4.81E-03
Tmem171 up 3.0 4.83E-04
Acad11 /// Nphp3 up 3.0 1.50E-05
Ddr2 up 3.0 7.76E-04
Cmbl up 3.0 6.18E-04
Itga7 up 3.0 2.43E-03
Abcc9 up 3.0 1.97E-03
Tlr1 up 3.0 1.45E-03
Mpdz up 3.0 8.40E-04
Fam13a up 3.0 1.40E-03
Fahd1 up 3.0 1.97E-03
Aldh1b1 up 3.0 2.10E-03
Dst up 3.0 1.40E-03
Cisd1 up 3.0 9.61E-04
Acss1 up 3.0 6.18E-04
Gstm1 up 3.0 9.41E-04
Cbr1 up 3.0 1.96E-04
Mrvi1 up 3.0 2.48E-03
Synpo up 3.0 1.07E-03
Gstt3 up 2.9 5.87E-05
Tmlhe up 2.9 1.17E-04
4931406C07Rik up 2.9 4.21E-03
Clrn3 up 2.9 1.22E-03
Mxd1 up 2.9 1.82E-03
Ndn up 2.9 1.54E-04
Arhgap26 up 2.9 1.06E-05
1810014F10Rik up 2.9 6.19E-04
Gulp1 up 2.9 3.12E-03
2310044G17Rik up 2.9 4.38E-03
Sgce up 2.9 4.45E-04
Clcn2 up 2.9 6.10E-04
9130004J05Rik up 2.8 2.06E-03
Acad11 /// Nphp3 up 2.8 3.68E-05
Gulp1 up 2.8 7.12E-04
Cds1 up 2.8 1.43E-03
Ppp1r3c up 2.8 1.73E-04
Sh3gl2 up 2.8 1.42E-03
Kcne4 up 2.8 1.68E-03
Il17rc up 2.8 2.58E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Fgf13 up 2.8 2.97E-03
Car2 up 2.8 2.24E-03
Meis1 up 2.8 3.31E-03
LOC100036521 up 2.8 3.57E-04
Trim31 up 2.8 8.67E-05
Filip1 up 2.8 2.48E-03
Slc30a1 up 2.8 2.91E-03
3110049J23Rik up 2.8 3.06E-03
Pdk2 up 2.8 1.54E-03
Plcd1 up 2.8 2.14E-03
Cspg4 up 2.8 6.30E-04
100041434 up 2.8 2.46E-03
Sepp1 up 2.8 1.77E-03
Tspan2 up 2.7 1.90E-03
Heph up 2.7 3.34E-04
Anks4b up 2.7 9.35E-04
Sh3gl2 up 2.7 1.40E-03
Galm up 2.7 4.30E-03
1110032E23Rik up 2.7 9.18E-04
Tspan1 up 2.7 1.58E-03
2010003K11Rik up 2.7 3.05E-03
Meis2 up 2.7 1.18E-03
Tmlhe up 2.7 4.56E-04
Fam26e up 2.7 1.77E-03
Satb2 up 2.7 6.86E-04
Tmlhe up 2.7 7.00E-04
Pde3a up 2.6 3.97E-03
Mtm1 up 2.6 4.10E-03
Frat2 up 2.6 9.27E-04
4930539E08Rik up 2.6 4.28E-03
Rfk up 2.6 3.56E-03
Prkg1 up 2.6 4.01E-03
Naprt1 up 2.6 3.54E-04
Rgs7bp up 2.6 7.05E-04
Nedd4l up 2.6 4.12E-04
Pcca up 2.6 3.76E-04
Postn up 2.6 3.09E-03
Msra up 2.6 2.56E-03
1110032E23Rik up 2.6 2.83E-03
Echdc3 up 2.6 8.77E-04
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Fbxo25 up 2.6 8.10E-04
Ppp1r14d up 2.6 5.53E-04
Uap1 up 2.6 1.69E-03
Ndrg4 up 2.6 3.41E-03
Mapre2 up 2.5 3.85E-03
Ank2 up 2.5 3.87E-03
Neurod1 up 2.5 1.80E-03
Pfkfb4 up 2.5 1.21E-03
Lclat1 up 2.5 2.19E-03
Mapk12 up 2.5 6.25E-04
Ush1c up 2.5 2.67E-03
Tgfb1i1 up 2.5 1.19E-04
Gucy2c up 2.5 1.82E-03
Cacna2d2 up 2.5 1.55E-03
Epb4.1l3 up 2.5 1.96E-03
B130021B11Rik up 2.5 3.94E-03
Mkrn1 up 2.5 2.64E-03
Kcnk5 up 2.5 5.15E-04
Ech1 up 2.5 1.64E-03
Uap1 up 2.5 1.95E-03
Mfsd8 up 2.5 3.66E-03
Hdgfrp3 up 2.5 4.64E-03
Hdgfrp3 up 2.5 4.25E-03
Epb4.1l3 up 2.4 3.02E-04
Pank3 up 2.4 1.62E-03
Bdh1 up 2.4 3.38E-04
Galm up 2.4 1.70E-03
Erlin1 up 2.4 9.70E-04
2310044G17Rik up 2.4 3.75E-03
Tmem106a up 2.4 3.50E-03
Pttg1ip up 2.4 4.55E-03
Fibin up 2.4 2.71E-03
Endod1 up 2.4 4.21E-03
Mapre2 up 2.4 2.32E-03
5033414D02Rik up 2.4 2.22E-03
Brpf3 up 2.4 2.04E-03
Tesk2 up 2.4 2.30E-03
9030425E11Rik up 2.4 2.12E-03
Plcd1 up 2.4 2.84E-04
Clmn up 2.4 2.16E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Myo1a up 2.4 3.36E-03
Ankhd1 /// Eif4ebp3 up 2.4 4.73E-03
Tspyl4 up 2.4 6.73E-04
9030425L15Rik up 2.4 1.41E-03
Ipmk up 2.4 9.54E-04
Hnf4a up 2.3 1.50E-03
B3gnt2 up 2.3 2.14E-04
AI317158 up 2.3 3.19E-03
Fam110c up 2.3 9.66E-04
Txnip up 2.3 3.67E-03
Plcl2 up 2.3 9.80E-04
Fam161a up 2.3 2.38E-03
Plce1 up 2.3 2.02E-03
Jph2 up 2.3 2.59E-03
Itpk1 up 2.3 1.27E-03
Tspan3 up 2.3 3.25E-04
Cryl1 up 2.3 2.37E-03
Epas1 up 2.3 3.65E-04
Cpt1a up 2.3 2.46E-03
Gli2 up 2.3 1.71E-03
Slc22a18 up 2.3 9.25E-04
Entpd2 up 2.3 9.86E-04
Srr up 2.3 1.20E-03
Abcc9 up 2.3 3.78E-03
Suclg2 up 2.3 1.41E-03
Ndrg4 up 2.3 4.90E-03
Gng3 up 2.3 3.38E-03
Cacnb2 up 2.3 3.54E-03
1700040L02Rik up 2.3 3.07E-03
Pld1 up 2.3 1.65E-03
Sri up 2.3 2.13E-03
Suclg2 up 2.2 8.51E-04
Nudt19 up 2.2 6.33E-04
1300010F03Rik up 2.2 1.19E-05
1300010F03Rik up 2.2 4.70E-04
B3gnt2 up 2.2 9.75E-05
Rasgef1b up 2.2 2.39E-03
Slc2a4 up 2.2 4.45E-03
Selm up 2.2 4.91E-03
Plekha8 up 2.2 3.70E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Slc2a4 up 2.2 5.68E-04
Prkca up 2.2 3.95E-03
Tmem82 up 2.2 1.95E-03
Slc44a4 up 2.2 4.29E-04
Pld1 up 2.2 5.80E-04
Hadh up 2.2 6.83E-05
Nsg2 up 2.2 1.50E-03
Serhl up 2.2 1.64E-03
Wfdc1 up 2.2 2.62E-03
Myh14 up 2.2 1.50E-03
Slc22a23 up 2.2 4.88E-03
D4Bwg0951e up 2.2 2.96E-03
Fmo2 up 2.2 3.21E-03
Ccdc68 up 2.2 3.41E-03
Bin1 up 2.2 1.55E-03
Dopey2 up 2.1 7.34E-04
Tgfb3 up 2.1 4.85E-03
Aldh1a2 up 2.1 2.72E-03
Ccng2 up 2.1 2.88E-03
Fnbp1 up 2.1 7.69E-04
Plekhg6 up 2.1 2.89E-03
Nedd4l up 2.1 3.19E-03
Tep1 up 2.1 2.05E-05
Gdnf up 2.1 3.28E-03
Chchd10 up 2.1 8.94E-04
Flna up 2.1 1.82E-03
Zzef1 up 2.1 2.37E-03
Ints6 up 2.1 2.01E-03
Tst up 2.1 2.22E-03
Smpdl3a up 2.1 3.75E-03
Foxo3 up 2.1 5.72E-04
Runx1t1 up 2.1 1.07E-03
Oxsm up 2.1 4.53E-04
Lrp1 up 2.1 2.25E-03
Syne1 up 2.1 2.35E-03
Pdss1 up 2.1 3.86E-03
Arl4d up 2.1 1.37E-04
Hlx up 2.1 1.96E-03
Fam110c up 2.0 3.27E-04
Klc4 up 2.0 9.26E-04
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Plscr4 up 2.0 1.43E-03
Gstt2 up 2.0 3.01E-03
Nr1i2 up 2.0 2.02E-03
Man1a up 2.0 5.91E-04
Ifi30 up 2.0 5.79E-04
Abhd6 up 2.0 1.87E-03
Pttg1ip up 2.0 4.89E-03
Hadha up 2.0 3.91E-03
Atp6v0a2 up 2.0 3.67E-04
Hadh up 2.0 6.05E-04
Acadm up 2.0 3.20E-03
Differentially Expressed Genes 
APCMin/+ normal vs.  APCMin/+ tumour 
(Comparison 3)
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Gene Symbol Regulation FCAbsolute p-value
Reg3g down 115.9 6.04E-06
Reg3b down 114.8 9.68E-05
Reg3b down 107.0 9.62E-05
Mmp7 down 63.9 1.26E-08
Onecut2 down 54.1 7.44E-08
Wif1 down 49.9 5.04E-05
Defa24 down 47.6 1.59E-05
Onecut2 down 44.1 1.03E-07
Cfi down 42.5 7.40E-07
Slc38a4 down 41.2 1.13E-05
Mmp13 down 40.7 1.10E-05
Lcn2 down 39.9 6.71E-07
S100a9 down 39.4 4.48E-05
S100a8 down 38.1 5.06E-05
Defa5 down 37.4 1.25E-03
Mmp10 down 35.8 2.28E-05
Onecut2 down 35.7 2.56E-07
Spp1 down 35.4 6.17E-06
Arg1 down 34.1 1.04E-05
Tnfrsf11b down 34.0 8.88E-06
Cxcl2 down 31.0 3.86E-06
Cxcl3 down 30.1 1.19E-07
Cxcl5 down 30.1 2.86E-05
Cxcl1 down 27.5 5.62E-05
Gm106 down 25.3 9.96E-06
Dkk2 down 24.9 7.56E-09
Adcy8 down 21.6 2.37E-06
Itln1 down 20.3 1.13E-03
Mmp12 down 19.8 1.08E-07
Slc38a4 down 19.0 1.78E-05
Il6 down 18.3 4.36E-05
Prox1 down 18.3 1.10E-05
Expi down 17.8 5.33E-04
1190003M12Rik down 17.4 7.54E-04
Lrg1 down 16.9 1.83E-05
Nfe2l3 down 16.8 3.68E-06
Saa3 down 16.2 7.18E-04
Lgals2 down 16.1 8.04E-04
Prox1 down 15.1 1.30E-05
Pnliprp1 down 15.0 1.29E-04
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Hp down 15.0 4.07E-06
Apcdd1 down 14.4 3.45E-04
Gm106 down 14.0 1.44E-05
Prkg2 down 13.8 3.00E-03
Pla2g2a down 13.7 7.89E-06
Plat down 13.7 1.60E-04
Apcdd1 down 13.4 1.31E-03
Il1rl1 down 13.4 9.47E-04
T down 13.1 1.86E-06
Slc30a2 down 12.9 6.56E-05
Notum down 12.3 8.59E-05
Prox1 down 12.3 2.41E-05
Sox17 down 12.2 1.95E-03
9930013L23Rik down 12.2 2.09E-04
Apcdd1 down 12.2 1.61E-03
Myl7 down 12.1 3.20E-04
Clu down 11.9 4.24E-05
AI747448 down 11.6 2.94E-03
Ttc9 down 11.5 7.26E-08
Il1b down 11.3 1.11E-06
BC037703 down 10.9 1.29E-05
Spock2 down 10.8 3.39E-03
Clu down 10.8 5.59E-05
Krt23 down 10.7 1.18E-05
Cxcl1 down 10.3 2.88E-05
Clec4e down 10.3 2.22E-07
Tnfrsf11b down 10.2 6.37E-06
Clu down 10.2 3.96E-05
A730054J21Rik down 9.4 6.86E-05
Clu down 9.3 3.67E-05
Cp down 9.3 7.77E-08
Il11 down 9.3 6.43E-04
Ptgs2 down 9.2 3.17E-04
Robo1 down 9.2 2.60E-04
Prkg2 down 9.2 1.71E-03
Nkd1 down 9.2 1.95E-04
Nkd1 down 8.8 2.87E-05
Prr18 down 8.8 1.11E-05
1190003M12Rik down 8.7 2.23E-03
Il1rl1 down 8.7 2.48E-05
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Tnfrsf19 down 8.6 1.35E-07
Gata5 down 8.3 3.47E-06
Ptgs2 down 8.2 4.09E-04
Marcksl1 down 7.9 8.54E-04
Cp down 7.9 1.67E-07
Cp down 7.7 7.18E-07
Avil down 7.6 3.69E-06
Dio2 down 7.5 6.97E-04
Sox21 down 7.4 8.19E-04
Mmp9 down 7.4 8.25E-07
Pcdhb9 down 7.4 1.49E-05
Pdgfrl down 7.3 3.41E-04
Cp down 7.3 8.55E-08
Lgr5 down 7.2 3.48E-07
Inhbb down 7.2 6.09E-06
Kif26b down 6.7 2.72E-04
Mmp9 down 6.7 4.56E-06
Marcksl1 down 6.6 1.56E-03
Sox4 down 6.6 1.24E-04
Npnt down 6.5 7.88E-04
Dusp4 down 6.5 1.58E-04
Sp5 down 6.5 7.76E-06
Ptpro down 6.4 3.14E-05
Ppbp down 6.4 2.67E-04
Tmem173 down 6.3 6.23E-05
Otop2 down 6.3 6.77E-07
Sox4 down 6.3 1.08E-04
Foxq1 down 6.3 2.69E-04
Ier3 down 6.3 2.01E-05
Isl1 down 6.2 1.09E-03
Neto2 down 6.1 5.01E-06
Fam84a down 6.0 6.29E-05
Adamts12 down 5.9 1.34E-08
Ptpro down 5.9 4.55E-05
Padi4 down 5.9 1.37E-04
Lgals2 down 5.8 4.80E-03
Clec4d down 5.8 3.69E-04
Bex1 down 5.8 1.59E-04
Adamts4 down 5.8 2.53E-04
Adam8 down 5.8 8.99E-06
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
F5 down 5.8 1.69E-04
Cp down 5.7 1.29E-05
Sox4 down 5.7 6.72E-06
Npnt down 5.7 2.62E-04
Sox4 down 5.6 2.13E-04
Socs3 down 5.6 1.32E-05
Alb down 5.6 7.57E-04
Arnt2 down 5.6 1.36E-06
5830408B19Rik down 5.6 4.36E-03
A330049M08Rik down 5.5 3.68E-06
Rarb down 5.5 1.85E-04
Mtap down 5.5 1.21E-04
Samd5 down 5.5 4.57E-03
Phlda1 down 5.5 6.46E-05
Selp down 5.5 5.80E-04
Basp1 down 5.4 8.12E-05
H19 down 5.4 2.83E-04
Serpine2 down 5.4 1.80E-03
Il23a down 5.4 6.47E-04
Arntl2 down 5.3 1.95E-06
Mtap down 5.3 1.28E-04
Prkg2 down 5.2 8.16E-04
Inhba down 5.2 3.05E-04
Tubb2b down 5.1 1.06E-06
Cyp11a1 down 5.0 1.51E-05
Sema7a down 5.0 8.38E-05
Rnase1 down 5.0 2.86E-03
Marcksl1 down 5.0 7.28E-04
Tbx3 down 5.0 1.19E-03
Jub down 5.0 2.57E-04
Atg9b down 5.0 7.69E-06
Odz4 down 5.0 3.61E-05
Evl down 5.0 6.10E-04
8030425K09Rik down 5.0 1.92E-04
Tbx3 down 5.0 2.24E-03
Cxcl14 down 5.0 3.26E-03
Arl4c down 5.0 1.12E-05
6720475J19Rik down 4.9 1.05E-06
Sox4 down 4.9 8.13E-05
Socs3 down 4.9 3.45E-05
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Igfbp5 down 4.9 2.33E-03
Ltbp2 down 4.8 4.80E-04
Tead2 down 4.8 2.86E-04
Rnf43 down 4.7 2.05E-04
Prss22 down 4.6 4.21E-06
Cldn4 down 4.6 8.47E-04
Stra6 down 4.6 2.55E-03
Odz4 down 4.6 4.94E-04
Ifitm1 down 4.6 1.70E-05
Gata5 down 4.5 1.81E-05
Ereg down 4.5 2.36E-03
Ecscr down 4.5 1.26E-04
Cd244 down 4.5 2.50E-04
Lox down 4.4 7.16E-04
Mcpt2 down 4.4 4.33E-03
Pion down 4.4 1.30E-04
Plaur down 4.4 1.82E-04
Gp49a /// Lilrb4 down 4.3 1.46E-04
Pmepa1 down 4.3 3.31E-03
Fam89a down 4.3 5.16E-04
Limch1 down 4.3 3.28E-05
Elk3 down 4.3 1.14E-04
Lyz1 down 4.3 2.47E-06
Isl1 down 4.3 1.30E-03
Lox down 4.2 8.23E-04
Etv5 down 4.2 8.87E-04
Igfbp4 down 4.2 5.75E-04
Smoc2 down 4.2 6.96E-04
Prr18 down 4.2 2.35E-04
Bmp7 down 4.2 2.33E-04
Vash2 down 4.2 7.00E-05
Adcy1 down 4.2 2.72E-03
Smox down 4.2 9.53E-05
Igf1 down 4.1 3.15E-03
Nfe2l3 down 4.1 1.31E-03
Abca1 down 4.1 5.33E-06
Wnt5a down 4.1 9.37E-04
Steap4 down 4.1 1.73E-03
Vangl2 down 4.1 8.01E-04
Igfbp4 down 4.1 1.39E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Igf1 down 4.1 1.33E-03
Dyrk3 down 4.1 7.07E-07
Rhox5 down 4.1 1.20E-03
Abcc4 down 4.1 3.76E-04
Slco5a1 down 4.1 6.21E-04
Lama1 down 4.0 9.35E-06
Axin2 down 4.0 2.04E-03
Pgm2l1 down 4.0 1.94E-03
Fam55c down 4.0 1.08E-03
Marcksl1 down 4.0 3.74E-04
Stc1 down 3.9 4.32E-05
Wnt5a down 3.9 4.03E-04
Pitpnc1 down 3.9 5.85E-07
Cited1 down 3.9 2.07E-04
Tmem173 down 3.8 1.50E-04
A130040M12Rik down 3.8 1.88E-03
D0H4S114 down 3.8 1.88E-03
Smoc2 down 3.8 1.36E-03
Rem2 down 3.8 1.15E-03
Pla1a down 3.8 9.43E-05
Tcf7 down 3.7 1.27E-04
Hdc down 3.7 4.17E-06
Ccl2 down 3.7 2.96E-04
Fgfrl1 down 3.7 3.88E-03
Pgm2l1 down 3.7 1.52E-03
Ly6d down 3.7 2.85E-03
Chrnb1 down 3.7 1.18E-03
Limd2 down 3.6 1.40E-04
Mfsd2 down 3.6 1.26E-04
Fpr2 down 3.6 1.10E-03
A330021E22Rik down 3.6 2.56E-05
Clec4n down 3.6 3.80E-05
Stx11 down 3.6 9.49E-06
Pthlh down 3.5 1.86E-03
Socs3 down 3.5 5.34E-05
Fam167a down 3.5 6.53E-05
Wisp1 down 3.5 1.29E-03
Pla2g12a down 3.5 4.39E-05
Odz4 down 3.5 6.49E-04
Plxnb1 down 3.5 1.18E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Bmf down 3.5 2.45E-03
Etv5 down 3.5 8.60E-04
Adamts4 down 3.5 9.14E-05
Ramp3 down 3.5 5.66E-04
Lyz1 down 3.5 3.45E-06
Sulf1 down 3.5 4.76E-03
Abca1 down 3.4 7.65E-05
Cd44 down 3.4 6.06E-04
6720475J19Rik down 3.4 9.65E-06
Cldn2 down 3.4 3.52E-04
Thbs2 down 3.4 3.69E-03
Lect2 down 3.4 1.59E-03
Igf1 down 3.4 5.34E-04
Trpa1 down 3.4 1.72E-03
Htra1 down 3.3 4.90E-03
Bmp7 down 3.3 7.72E-04
Tnfsf9 down 3.3 1.89E-04
Rdh10 down 3.3 6.76E-05
Btc down 3.3 5.13E-04
Clec7a down 3.3 3.81E-03
Prkd1 down 3.3 4.90E-03
Smox down 3.3 1.38E-04
Map4k4 down 3.3 5.02E-04
Slc15a3 down 3.3 1.25E-04
Csgalnact1 down 3.2 1.54E-03
Runx1 down 3.2 2.05E-04
Igfbp4 down 3.2 4.34E-04
Abca1 down 3.2 4.64E-05
Tanc2 down 3.2 7.78E-04
Arl4c down 3.2 3.68E-07
9430081I23Rik down 3.2 6.49E-04
Cd44 down 3.2 5.16E-05
Sox6 down 3.2 1.39E-03
Mex3d down 3.2 6.23E-04
Htra1 down 3.2 3.04E-03
Bcl2l11 down 3.2 3.22E-04
Sirpb1 down 3.2 7.61E-04
Stx1a down 3.1 1.48E-06
Col18a1 down 3.1 5.37E-04
Mycl1 down 3.1 1.45E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Cdkn1c down 3.1 3.84E-03
2700094K13Rik down 3.1 6.46E-05
Col18a1 down 3.1 4.27E-04
9530048O09Rik down 3.1 1.98E-05
Cldn2 down 3.1 1.52E-03
Gpm6b down 3.1 1.76E-04
Slc7a11 down 3.1 6.44E-05
Igfbp4 down 3.1 5.58E-04
Pmepa1 down 3.1 2.66E-03
Sulf2 down 3.1 5.84E-04
Igf1 down 3.1 1.60E-03
B4galnt4 down 3.1 5.16E-04
Snx10 down 3.1 1.55E-04
Gls2 down 3.1 1.49E-04
Foxq1 down 3.1 9.34E-04
Myo1b down 3.1 4.27E-06
Mtap down 3.1 1.04E-03
Macc1 down 3.1 3.23E-03
Myo1b down 3.0 1.55E-05
Bcl2l11 down 3.0 8.17E-05
Pcdhb16 down 3.0 1.30E-03
C630043F03Rik down 3.0 4.20E-05
Mmp14 down 3.0 1.64E-03
D0H4S114 down 3.0 3.38E-03
Pcdhb17 down 3.0 1.30E-03
Igfbp4 down 3.0 5.99E-04
Sh3pxd2b down 3.0 6.46E-04
Il1r2 down 3.0 3.83E-06
Lmo2 down 3.0 3.33E-04
Fscn1 down 3.0 2.52E-03
Myo1b down 3.0 1.84E-05
Tcf4 down 3.0 7.42E-04
Scara3 down 3.0 2.00E-03
Zfpm1 down 3.0 3.27E-05
Slc18a1 down 3.0 3.94E-03
Gpc1 down 3.0 3.69E-03
Shf down 3.0 3.58E-04
Palmd down 3.0 2.12E-03
4732490B19Rik down 2.9 3.48E-06
Elk3 down 2.9 6.65E-05
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
358 
 
 
 
Gene Symbol Regulation FCAbsolute p-value
Steap4 down 2.9 7.36E-04
Tmtc4 down 2.9 6.98E-06
Cyr61 down 2.9 2.28E-03
Cd44 down 2.9 1.72E-04
Cdh13 down 2.9 8.55E-04
Phgdh down 2.9 2.67E-06
Mex3a down 2.9 1.02E-03
Tgif1 down 2.9 5.76E-05
Sox21 down 2.9 2.48E-03
Etv5 down 2.9 1.59E-03
Nav2 down 2.9 2.82E-03
Runx1 down 2.9 4.10E-04
Tanc2 down 2.9 1.06E-03
Chst11 down 2.9 3.03E-03
Sulf2 down 2.9 2.10E-03
Icam1 down 2.8 1.69E-04
Cyba down 2.8 5.97E-06
Tmtc4 down 2.8 1.15E-05
Clec4n down 2.8 1.54E-04
Tesc down 2.8 3.53E-03
Cyr61 down 2.8 2.02E-03
Vill down 2.8 1.26E-04
Rbms3 down 2.8 1.33E-03
Bcl2a1a down 2.8 9.67E-04
Mmp14 down 2.8 1.42E-03
Ifitm3 down 2.8 7.28E-04
Gp1bb down 2.8 3.52E-03
Elk3 down 2.8 3.36E-04
Casp6 down 2.8 7.51E-05
Tspan12 down 2.8 1.72E-05
Ddit4 down 2.8 2.10E-05
Cadm1 down 2.8 2.54E-03
Tcf4 down 2.8 2.95E-03
Ptgr1 down 2.8 1.53E-04
Znrf3 down 2.8 7.44E-04
Cd244 down 2.8 4.26E-04
Sema3e down 2.8 2.59E-03
Tbx3 down 2.8 1.20E-03
Tcf4 down 2.8 2.76E-03
Pxdn down 2.8 3.42E-05
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Tnfaip2 down 2.7 1.25E-03
Csf2rb down 2.7 1.08E-04
Tmem184c down 2.7 2.31E-04
Map4k4 down 2.7 9.40E-05
Dock4 down 2.7 2.42E-05
Plek down 2.7 3.07E-04
Lamp2 down 2.7 2.34E-05
Fam60a down 2.7 6.73E-06
Rnf183 down 2.7 6.63E-04
Fam125b down 2.7 4.21E-05
Tcf4 down 2.7 2.79E-03
Tcf4 down 2.7 3.28E-03
Mpzl1 down 2.7 4.68E-05
Ppic down 2.7 1.62E-03
Map4k4 down 2.7 7.86E-04
Stx1a down 2.7 5.61E-06
Bcl2l11 down 2.6 4.12E-04
Rgs12 down 2.6 1.35E-03
Cxcr4 down 2.6 1.76E-03
Crem down 2.6 1.86E-04
Slc41a1 down 2.6 1.01E-04
Steap1 down 2.6 5.81E-04
Rps6ka6 down 2.6 1.86E-03
Rnf32 down 2.6 9.12E-04
Echdc2 down 2.6 4.60E-03
Fam62c down 2.6 1.86E-03
Zfp647 down 2.6 8.96E-05
Phgdh down 2.6 6.43E-07
Fmnl2 down 2.6 1.37E-05
Pion down 2.6 2.59E-04
Srgn down 2.6 3.54E-05
Afap1l1 down 2.6 2.14E-03
Ascl2 down 2.6 3.25E-03
Rbms3 down 2.6 2.24E-03
Irg1 down 2.6 5.80E-05
Sema3f down 2.6 1.18E-03
2610028L16Rik down 2.6 3.12E-06
D17H6S56E-5 down 2.6 2.31E-03
Col5a2 down 2.6 3.97E-03
Angptl4 down 2.6 2.18E-04
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Myo1b down 2.5 3.56E-04
Slc39a6 down 2.5 3.51E-03
Nrg1 down 2.5 1.57E-04
Mtap down 2.5 1.13E-03
Chsy1 down 2.5 4.55E-05
Fam65b down 2.5 1.97E-04
Nbea down 2.5 3.55E-04
Otop3 down 2.5 1.26E-03
Myo1b down 2.5 2.62E-05
Myo1b down 2.5 1.49E-05
Igfbp4 down 2.5 3.73E-03
8430436O14Rik down 2.5 6.27E-04
4631416L12Rik down 2.5 7.12E-05
Phgdh down 2.5 7.18E-06
Hebp2 down 2.5 1.25E-04
Csf2rb down 2.5 2.90E-04
Btc down 2.5 2.20E-03
Prkd1 down 2.5 3.27E-03
Spns2 down 2.5 6.34E-04
Hmgcll1 down 2.5 1.19E-05
Cdh13 down 2.5 3.22E-03
Tiam1 down 2.5 1.61E-06
Amot down 2.5 3.04E-04
Cadm1 down 2.5 2.84E-03
6430514M23Rik down 2.5 2.04E-07
Plek down 2.5 2.87E-04
Dock11 down 2.5 1.63E-04
Csf2rb2 down 2.5 4.61E-04
AI467606 down 2.5 1.37E-03
Slc39a10 down 2.4 3.52E-03
Prex2 down 2.4 5.24E-04
9530048O09Rik down 2.4 4.06E-05
Ptpre down 2.4 2.28E-04
Nfil3 down 2.4 1.62E-03
Cadm1 down 2.4 4.38E-03
Csnk1e down 2.4 4.37E-04
Csnk1e down 2.4 7.44E-04
D17H6S56E-5 down 2.4 2.27E-03
Sema3e down 2.4 6.37E-04
Gusb down 2.4 8.41E-05
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
AI120166 down 2.4 7.65E-04
Vangl2 down 2.4 5.13E-04
Smoc1 down 2.4 5.39E-05
Lamp2 down 2.4 1.78E-04
Zfp703 down 2.4 2.64E-03
Sox6 down 2.4 1.27E-03
Kif12 down 2.4 2.56E-03
Mpzl1 down 2.4 2.92E-05
5430404G13Rik down 2.4 4.99E-03
Myc down 2.4 1.55E-06
Tgif2 down 2.4 8.33E-04
Pfkfb3 down 2.4 2.93E-04
Cep55 down 2.4 7.73E-06
Tesc down 2.4 2.18E-03
Map4k4 down 2.4 1.28E-04
Steap2 down 2.4 2.15E-03
Odz3 down 2.4 4.23E-03
Slc44a2 down 2.4 1.38E-03
Tnfaip8l1 down 2.4 7.57E-05
Lamp2 down 2.4 3.69E-05
Ptpre down 2.4 6.23E-04
Crem down 2.4 1.66E-04
Gusb down 2.3 2.85E-05
Slc39a10 down 2.3 3.72E-03
Hunk down 2.3 1.73E-04
Spon1 down 2.3 2.64E-05
Zfp518b down 2.3 1.34E-03
2310008H09Rik down 2.3 1.47E-04
Acot1 down 2.3 2.29E-03
Fgfrl1 down 2.3 2.02E-03
Prei4 down 2.3 1.19E-03
Nme4 down 2.3 8.31E-04
Ttc9 down 2.3 6.30E-04
Cks1b down 2.3 9.34E-07
Gm98 down 2.3 2.61E-04
2310016C08Rik down 2.3 3.77E-04
Tnfrsf19 down 2.3 8.40E-06
Sap30 down 2.3 1.84E-04
Grasp down 2.3 9.85E-04
Col1a1 down 2.3 3.22E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
C630043F03Rik down 2.3 2.02E-03
Slc16a3 down 2.3 3.46E-03
Slc19a2 down 2.3 1.86E-05
Arid5b down 2.3 1.77E-03
Pea15a down 2.3 3.01E-03
Cxcl16 down 2.3 2.08E-04
D16Ertd472e down 2.3 4.33E-04
Itgav down 2.3 2.04E-03
2210408K08Rik down 2.3 1.64E-04
Runx1 down 2.3 4.64E-06
Bcl11a down 2.3 1.76E-04
Ms4a6d down 2.3 3.28E-03
Cks1b down 2.3 1.17E-05
Enc1 down 2.3 3.02E-04
Steap2 down 2.3 1.83E-03
Rtn4 down 2.3 1.97E-05
Bok down 2.3 1.05E-04
Pla2g7 down 2.3 2.40E-04
Tcf12 down 2.3 1.07E-04
Prmt1 down 2.2 1.45E-03
Myef2 down 2.2 1.26E-07
Chic2 down 2.2 3.38E-04
Csf3r down 2.2 1.56E-03
Bcl2l11 down 2.2 8.52E-04
5430407P10Rik down 2.2 1.23E-03
Ascl2 down 2.2 3.69E-03
Nfkbie down 2.2 2.76E-04
Psat1 down 2.2 4.37E-03
Enc1 down 2.2 3.61E-04
Odz3 down 2.2 2.20E-03
Usp22 down 2.2 3.82E-04
Csrnp2 down 2.2 8.71E-04
BC057079 down 2.2 1.36E-03
Pcdhb21 down 2.2 5.47E-04
Sox9 down 2.2 1.54E-03
Pctk2 down 2.2 7.74E-05
Patz1 down 2.2 9.90E-04
Lyz2 down 2.2 2.74E-03
Casp6 down 2.2 5.05E-04
Lrp8 down 2.2 1.39E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Runx2 down 2.2 1.92E-04
Slain1 down 2.2 4.10E-03
Dctd down 2.2 1.99E-03
Cd24a down 2.2 2.37E-03
Armc10 down 2.2 1.46E-05
Sirpb1 down 2.2 2.28E-03
Sema4c down 2.2 1.61E-03
Nap1l1 down 2.2 1.52E-04
Jun down 2.2 4.32E-03
Sbk1 down 2.2 1.47E-04
Avpi1 down 2.2 3.91E-03
Cdk4 down 2.2 5.16E-04
Klhl8 down 2.2 1.65E-03
Wdr6 down 2.2 7.30E-04
Nap1l1 down 2.2 2.18E-05
Gja1 down 2.2 6.58E-04
Habp2 down 2.2 3.08E-04
Nlk down 2.1 4.40E-03
1700017B05Rik down 2.1 2.97E-04
Slc19a2 down 2.1 1.65E-04
6720460F02Rik down 2.1 2.27E-04
Sox9 down 2.1 1.65E-03
8430436O14Rik down 2.1 3.54E-03
Gch1 down 2.1 4.12E-03
Zfp451 down 2.1 2.14E-04
Arhgdig down 2.1 4.37E-03
Bub1 down 2.1 8.44E-05
Samsn1 down 2.1 1.52E-03
Mafg down 2.1 8.31E-04
Cd300lf /// LOC100047115 down 2.1 6.36E-05
Chic2 down 2.1 1.03E-03
Lamp2 down 2.1 5.55E-05
Baz1a down 2.1 1.71E-06
Rtn4 down 2.1 6.32E-06
2210010C17Rik down 2.1 2.09E-04
Pcgf6 down 2.1 2.37E-05
Usp22 down 2.1 1.95E-04
Gja1 down 2.1 3.91E-04
Depdc1a down 2.1 3.81E-04
AI467606 down 2.1 1.45E-04
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Vav2 down 2.1 4.48E-04
Mirhg1 down 2.1 1.93E-05
Ifitm2 down 2.1 8.17E-04
B4galt6 down 2.1 1.81E-03
2310008H09Rik down 2.1 3.16E-05
Gch1 down 2.1 1.75E-03
Pira2 down 2.1 1.73E-03
Angpt4 down 2.1 3.85E-03
Gja1 down 2.1 7.28E-04
1110008L16Rik down 2.1 2.13E-04
Myef2 down 2.1 2.45E-06
Tubb5 down 2.1 5.76E-04
Lef1 down 2.1 6.62E-04
Srpx2 down 2.1 5.15E-04
Lama5 down 2.1 2.07E-03
Lysmd2 down 2.1 1.37E-03
Rps9 down 2.1 1.04E-05
Cebpb down 2.1 3.14E-03
B4galt6 down 2.1 7.27E-05
2610201A13Rik down 2.1 2.95E-03
Bmp1 down 2.1 4.64E-03
Pdgfc down 2.1 1.80E-03
Slc25a30 down 2.1 7.55E-04
Nap1l1 down 2.1 9.66E-05
1700017B05Rik down 2.1 3.53E-03
Hnrnpa1 down 2.1 2.98E-04
2010109K09Rik down 2.1 7.67E-05
Niacr1 down 2.1 1.03E-05
Cdc42ep1 down 2.1 8.33E-04
Zdhhc15 down 2.1 7.34E-04
Psip1 down 2.1 6.97E-04
Fabp5 down 2.1 9.26E-04
Ikbkap down 2.1 3.32E-04
D16Ertd472e down 2.1 1.11E-03
Lrp8 down 2.1 4.73E-04
Ttc26 down 2.1 3.88E-04
Sema3e down 2.0 2.49E-05
Sypl down 2.0 3.69E-06
Bcl11a down 2.0 8.43E-04
Fxyd3 down 2.0 1.26E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
D930015E06Rik down 2.0 4.38E-03
Tle1 down 2.0 6.86E-04
Hoxa9 down 2.0 1.69E-03
B930098A02Rik down 2.0 2.11E-03
Snhg6 down 2.0 1.44E-04
Tnf down 2.0 1.42E-04
Steap1 down 2.0 7.50E-04
Slc25a30 down 2.0 9.96E-04
Ttc8 down 2.0 3.57E-03
Spg20 down 2.0 5.62E-04
Kif23 down 2.0 5.01E-04
Slc7a6 down 2.0 7.53E-04
Baz1a down 2.0 2.67E-06
Ncl down 2.0 4.66E-06
Fabp5 down 2.0 1.82E-03
Trem1 down 2.0 3.83E-04
Tcf12 down 2.0 1.76E-05
1110001D15Rik down 2.0 3.71E-03
Mafg down 2.0 2.85E-03
Ccr1 down 2.0 1.53E-03
Pitpnc1 down 2.0 2.79E-04
Gas2l3 down 2.0 6.02E-04
Itgav down 2.0 1.29E-04
2310008H09Rik down 2.0 8.34E-05
D1Ertd564e down 2.0 3.83E-04
Ets1 down 2.0 6.12E-05
Trit1 down 2.0 7.48E-04
Hdc down 2.0 1.69E-04
Zfand5 down 2.0 6.36E-04
Hey1 down 2.0 3.93E-03
Bace1 down 2.0 2.67E-03
Aqp8 up 19.7 2.09E-04
Slc26a3 up 16.8 1.38E-05
Slc26a3 up 15.7 3.58E-05
Car4 up 13.7 5.86E-06
Car4 up 12.8 6.49E-06
Slc26a3 up 12.7 2.86E-05
Synm up 12.4 3.94E-05
Sult1a1 up 11.5 3.82E-04
Sycn up 11.0 1.16E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Cnn1 up 10.7 1.56E-04
Sycn up 10.4 9.23E-04
Maob up 9.2 1.94E-04
Des up 8.8 1.08E-04
Synpo2 up 8.8 1.06E-04
Myh11 up 8.8 1.47E-05
Synm up 8.6 1.31E-05
Rims1 up 8.1 6.79E-07
Trpm6 up 7.9 3.71E-04
Eno3 up 7.9 3.26E-03
Pgm5 up 7.5 3.35E-05
Selenbp1 up 7.5 2.09E-04
Clic5 up 7.2 1.61E-04
Slc26a3 up 7.1 2.55E-04
Selenbp1 up 7.1 2.27E-04
Actg2 up 7.0 8.24E-05
Mamdc2 up 6.9 4.61E-06
Abat up 6.9 3.90E-05
Clic5 up 6.6 2.14E-04
Abca8a up 6.5 1.93E-05
Vip up 6.5 7.38E-05
Tpm2 up 6.3 1.61E-05
Clic5 up 6.0 2.29E-04
Usp2 up 5.9 5.57E-04
Pdlim3 up 5.9 1.05E-05
Scg2 up 5.9 7.68E-05
Rims1 up 5.8 3.87E-07
Foxp2 up 5.8 2.84E-05
Itih5 up 5.8 1.95E-04
Itih5 up 5.8 6.90E-05
Tnni1 up 5.6 3.59E-03
Acta2 up 5.6 6.06E-04
Tppp3 up 5.5 4.67E-04
Ndn up 5.4 1.30E-04
Pdlim3 up 5.4 6.51E-06
Akr1c14 up 5.4 1.24E-05
Acer1 up 5.4 8.87E-05
Aadac up 5.3 4.04E-03
Fgf13 up 5.3 2.68E-06
Gcg up 5.2 7.34E-04
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Clic5 up 5.2 2.26E-04
Ndn up 5.2 9.37E-05
Tpm2 up 5.2 1.28E-05
Itih5 up 5.2 1.50E-04
Esrrg up 5.1 1.41E-04
Myl9 up 5.1 4.70E-05
Kcnf1 up 5.1 9.70E-06
Hao3 up 5.0 5.64E-04
Tagln up 5.0 1.09E-04
Foxp2 up 5.0 2.17E-05
Sh3bgr up 5.0 2.68E-03
Ppp1r12b up 4.9 4.24E-06
Tppp up 4.9 3.86E-05
Scin up 4.9 1.01E-03
Foxp2 up 4.8 3.74E-05
Ndn up 4.7 1.86E-04
Sgk2 up 4.7 1.34E-03
Synpo2 up 4.7 3.29E-04
Cpe up 4.6 2.94E-06
Wscd2 up 4.6 2.49E-06
Sspn up 4.6 2.21E-05
Art3 up 4.6 9.31E-05
Tns1 up 4.6 7.64E-05
Trpm6 up 4.6 8.86E-04
Smtn up 4.5 4.59E-05
Myom1 up 4.4 7.73E-06
Kcnd3 up 4.4 3.56E-06
Tnxb up 4.3 9.35E-04
Iyd up 4.3 6.02E-04
Cyp2d34 up 4.3 7.85E-04
Id4 up 4.2 8.24E-04
Mylk up 4.2 1.37E-05
Slc26a2 up 4.2 3.08E-06
Tns1 up 4.1 1.54E-04
Hspb6 up 4.1 1.35E-04
Cox7a1 up 4.1 3.64E-04
Cyp2s1 up 4.0 1.86E-04
Acer1 up 4.0 9.44E-05
Slc20a1 up 4.0 4.79E-03
Pck1 up 3.9 1.03E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Tns1 up 3.9 3.06E-04
Hspb7 up 3.9 6.03E-04
Fmo2 up 3.9 1.68E-04
Sparcl1 up 3.8 2.47E-05
Sdpr up 3.8 6.11E-06
Cyp2d22 up 3.8 1.44E-04
Pcp4l1 up 3.8 9.94E-04
Pck1 up 3.8 9.80E-04
Slc24a3 up 3.8 1.77E-05
Vdr up 3.7 6.59E-05
2010110P09Rik up 3.7 2.17E-04
Pcx up 3.7 5.73E-04
Sdpr up 3.7 6.74E-05
Slc13a2 up 3.6 5.14E-04
Ndn up 3.6 1.34E-04
Sdpr up 3.6 3.02E-05
Fmo1 up 3.6 4.81E-03
Pcx up 3.6 2.69E-04
Klf4 up 3.6 2.25E-06
Grem2 up 3.6 2.04E-04
Slc20a1 up 3.6 1.81E-03
Adcy5 up 3.6 3.75E-06
Prdx6 up 3.6 1.16E-04
Gal3st2 up 3.6 2.49E-03
Lipg up 3.6 5.97E-04
Chrdl1 up 3.5 7.50E-07
Fmo2 up 3.5 2.44E-04
Htr4 up 3.5 9.10E-04
Fgfbp1 up 3.5 1.02E-03
Synpo2 up 3.5 2.40E-03
Pcp4 up 3.5 4.84E-03
Lims2 up 3.5 1.32E-05
Slc16a5 up 3.5 3.36E-03
2010003H20Rik up 3.5 1.62E-03
Rasd2 up 3.5 5.29E-05
Stmn2 up 3.5 4.49E-05
Ogn up 3.5 6.64E-04
Sprr2a up 3.5 6.84E-04
Rbpms2 up 3.4 2.06E-05
Dhrs11 up 3.4 7.35E-04
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Vdr up 3.4 1.35E-04
Mylk up 3.4 1.65E-05
Tcfcp2l1 up 3.4 7.60E-08
Fmo2 up 3.4 2.85E-04
Fxyd1 up 3.4 7.36E-05
Dbp up 3.3 3.00E-03
Myo15b up 3.3 2.16E-03
Hpgd up 3.3 9.95E-05
Chrdl1 up 3.3 1.35E-06
Sult1c2 up 3.3 3.11E-03
Lipg up 3.3 8.63E-04
Gstm3 up 3.3 4.16E-03
Enpp2 up 3.3 4.26E-04
Gstm2 up 3.3 1.98E-07
Usp2 up 3.2 2.16E-03
Id4 up 3.2 5.29E-04
Ptgis up 3.2 2.54E-03
Slc6a4 up 3.2 3.36E-03
Ogn up 3.2 5.21E-04
Ccl28 up 3.2 9.22E-04
Mylk up 3.2 1.57E-05
0610005C13Rik up 3.2 3.00E-04
Ppp1r14a up 3.1 1.29E-04
B130021B11Rik up 3.1 8.38E-07
Kcnk5 up 3.1 5.04E-05
Matn2 up 3.1 4.91E-03
Ccl28 up 3.1 1.12E-03
Sorbs1 up 3.1 1.09E-05
Scn7a up 3.1 2.46E-06
Sorbs1 up 3.1 9.83E-05
Tspan2 up 3.1 9.76E-05
Maoa up 3.1 3.75E-03
Lmod1 up 3.1 3.34E-05
Lhfpl2 up 3.1 2.45E-04
Fcgbp up 3.1 1.34E-03
Abcg2 up 3.0 2.49E-03
Hpgd up 3.0 2.47E-03
Lhfpl2 up 3.0 7.68E-04
Hlf up 3.0 2.78E-04
Aoc3 up 3.0 1.10E-04
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
2010003K11Rik up 3.0 2.83E-04
Sult1b1 up 3.0 6.17E-04
Qpct up 3.0 9.33E-07
5730409N24Rik up 3.0 1.65E-06
0610040B09Rik up 3.0 2.71E-03
Scn7a up 2.9 1.87E-06
Cryab up 2.9 9.72E-04
Me2 up 2.9 4.63E-03
Hsd17b2 up 2.9 3.30E-03
Pdk2 up 2.9 1.26E-03
Scnn1a up 2.9 1.29E-05
Ntn1 up 2.9 1.37E-04
Mrvi1 up 2.9 1.71E-03
Lrig3 up 2.9 5.49E-05
4930539E08Rik up 2.9 7.60E-04
Slc25a34 up 2.9 1.03E-03
Sorbs1 up 2.9 3.17E-05
Ahcyl2 up 2.9 2.79E-03
Syn2 up 2.9 1.02E-03
Chgb up 2.9 1.09E-03
Zbtb16 up 2.9 4.39E-03
S3-12 up 2.9 5.36E-04
Pcx up 2.8 2.04E-05
Sntg2 up 2.8 3.25E-05
Phlppl up 2.8 2.72E-04
Acta2 up 2.8 1.31E-04
Cryab up 2.8 8.18E-04
Car2 up 2.8 2.61E-04
Foxp2 up 2.8 6.78E-05
Pdzk1ip1 up 2.8 2.71E-03
Sorbs1 up 2.8 1.30E-04
Gm967 up 2.8 2.43E-03
Gucy1a3 up 2.8 7.65E-04
C630028N24Rik up 2.8 8.30E-04
Uchl1 up 2.8 1.27E-04
Itga8 up 2.8 4.62E-03
Gstm1 up 2.8 1.74E-05
Rorc up 2.7 1.94E-05
Cyp2d22 up 2.7 1.67E-04
Slco2b1 up 2.7 1.28E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Chga up 2.7 1.03E-03
Slc16a1 up 2.7 5.39E-04
Nr3c2 up 2.7 3.63E-05
Sema4g up 2.7 1.23E-04
Slco2a1 up 2.7 3.97E-04
Il17rc up 2.7 2.89E-04
Slc4a4 up 2.7 1.82E-03
Trnp1 up 2.7 1.77E-04
Pln up 2.7 3.77E-03
Filip1 up 2.7 7.56E-05
Myh11 up 2.7 5.02E-04
Klf4 up 2.7 3.40E-06
9530009M10Rik up 2.7 2.03E-05
5033414D02Rik up 2.7 6.27E-04
Gstm1 up 2.7 2.29E-05
Calb2 up 2.7 6.74E-05
Gstm3 up 2.7 2.72E-03
Lrig3 up 2.7 5.20E-04
Prkg1 up 2.6 2.51E-05
Cav1 up 2.6 4.30E-03
Fam129a up 2.6 2.29E-03
AI844685 up 2.6 8.16E-04
Fam129a up 2.6 1.21E-03
Meis1 up 2.6 1.67E-04
Rasgef1b up 2.6 1.91E-04
Cryl1 up 2.6 1.38E-04
2310044G17Rik up 2.6 1.08E-04
Gstt1 up 2.6 1.22E-04
Ppp1r3c up 2.6 4.78E-04
Prph up 2.6 2.85E-06
Pcdh24 up 2.6 4.36E-03
Cryl1 up 2.6 1.36E-04
Mxd1 up 2.6 4.88E-06
Chpt1 up 2.6 3.57E-03
Lrig3 up 2.6 3.20E-05
Ssbp2 up 2.5 5.14E-04
Fez1 up 2.5 6.15E-04
Kcnk5 up 2.5 2.61E-04
Gm967 up 2.5 4.61E-03
Bche up 2.5 2.01E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Tgfbr3 up 2.5 6.65E-04
Cspg4 up 2.5 4.78E-03
Ndrg2 up 2.5 4.37E-04
Abcc3 up 2.5 2.47E-03
2610027H17Rik up 2.5 3.49E-04
Gsn up 2.5 3.87E-03
Slco2a1 up 2.5 1.70E-04
Gng4 up 2.5 3.23E-03
Pln up 2.5 2.30E-03
Clcn2 up 2.5 2.16E-04
Tcf3 up 2.5 4.45E-03
AI451617 up 2.5 3.55E-03
Rgs7bp up 2.5 5.20E-05
Clybl up 2.5 2.24E-03
Plbd1 up 2.5 4.38E-03
Prdx6 up 2.5 4.96E-05
Atp1a1 up 2.5 4.33E-04
Jph2 up 2.5 2.47E-05
Synpo2 up 2.4 2.74E-03
Tsc22d3 up 2.4 1.22E-04
Myocd up 2.4 9.41E-05
Tsc22d3 up 2.4 5.90E-05
Tpm2 up 2.4 1.35E-04
Rab11fip4 up 2.4 1.31E-05
Gsn up 2.4 3.66E-03
Fahd1 up 2.4 2.72E-04
Tspan2 up 2.4 2.83E-05
Per2 up 2.4 1.23E-04
Hdgfrp3 up 2.4 4.77E-05
Crip1 up 2.4 1.55E-04
Tesk2 up 2.4 2.57E-04
Gstm1 up 2.4 8.61E-05
Dtna up 2.4 2.34E-04
Cbr2 up 2.4 2.38E-04
Rhbdl2 up 2.4 5.21E-04
Sult2b1 up 2.4 1.02E-03
Zfp467 up 2.4 8.01E-05
Lass4 up 2.4 3.05E-03
Acss2 up 2.4 4.05E-04
Meis2 up 2.4 1.35E-04
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Cnnm4 up 2.4 2.58E-04
Cds1 up 2.4 1.35E-03
Cabc1 up 2.4 3.73E-05
Mxd1 up 2.4 1.57E-04
Gsdmc2 /// Gsdmc4 up 2.4 9.16E-05
Syt1 up 2.4 9.90E-05
Myo15b up 2.4 2.34E-03
Rhbdl2 up 2.4 2.59E-03
Ppargc1b up 2.4 2.39E-03
Pyroxd2 up 2.4 9.94E-04
Scg3 up 2.3 6.81E-05
Tspan1 up 2.3 1.72E-05
Acpp up 2.3 3.18E-03
Fam26e up 2.3 1.17E-04
Hsd11b2 up 2.3 9.35E-04
Hhip up 2.3 4.16E-04
Zfp385b up 2.3 2.50E-04
Styk1 up 2.3 9.88E-05
Slc6a14 up 2.3 4.89E-03
2010001M06Rik up 2.3 2.39E-03
Kazald1 up 2.3 1.34E-06
Plp1 up 2.3 2.11E-05
Bdh1 up 2.3 3.59E-03
Pmp22 up 2.3 8.27E-04
Dgkh up 2.3 5.22E-04
9130404H23Rik up 2.3 2.71E-03
Entpd8 up 2.3 1.12E-04
Casq2 up 2.3 3.88E-04
Cideb up 2.3 2.16E-03
Stmn3 up 2.3 6.23E-05
Plscr4 up 2.3 1.95E-06
Chpt1 up 2.3 3.92E-04
Fbxo32 up 2.3 2.44E-04
Popdc2 up 2.3 2.77E-04
Mustn1 up 2.3 1.41E-03
Stk10 up 2.3 3.54E-04
Flnc up 2.3 4.53E-03
Ctdspl up 2.3 2.78E-05
Agpat4 up 2.3 5.68E-05
Cntn1 up 2.2 1.78E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Slc2a4 up 2.2 8.37E-04
Stim1 up 2.2 7.83E-04
Zan up 2.2 5.22E-05
Mupcdh up 2.2 5.49E-04
Hspb7 up 2.2 3.27E-03
Gfpt1 up 2.2 1.70E-03
Mertk up 2.2 6.74E-04
Hhip up 2.2 2.43E-05
Ssbp2 up 2.2 1.34E-04
Tpcn1 up 2.2 5.84E-05
Gstt3 up 2.2 1.91E-04
Asb2 up 2.2 1.71E-04
Muc3 up 2.2 2.45E-06
Per2 up 2.2 8.13E-04
Atp1a1 up 2.2 1.36E-04
Hk1 up 2.2 5.58E-05
Fam161a up 2.2 7.32E-07
Flnc up 2.2 3.62E-03
Nsg2 up 2.2 6.04E-04
Chpt1 up 2.2 1.06E-03
Tcf21 up 2.2 1.46E-03
Frat2 up 2.2 1.78E-04
Tgfb1i1 up 2.2 1.89E-03
Synpo up 2.2 6.79E-06
Rhbdl2 up 2.2 4.84E-03
Klhl23 up 2.2 7.97E-06
Agpat4 up 2.2 6.05E-05
Clrn3 up 2.2 1.33E-03
Cbr1 up 2.2 1.02E-03
Cacna2d2 up 2.2 3.59E-05
Ush1c up 2.2 7.18E-05
9130009M17Rik up 2.2 7.15E-07
Ryr3 up 2.2 3.55E-05
5730414M22Rik up 2.2 1.70E-03
Marveld1 up 2.2 7.19E-04
Gsdmc up 2.2 4.99E-03
Tlr1 up 2.2 3.67E-03
Ceacam20 up 2.2 2.59E-03
Adam23 up 2.2 2.20E-04
Anks4b up 2.2 1.86E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Nkd2 up 2.2 1.53E-05
Ckm up 2.2 1.87E-04
Ank1 up 2.2 2.96E-04
Fbxo32 up 2.2 1.78E-04
S1pr3 up 2.1 2.50E-03
Sdc2 up 2.1 5.41E-05
Kank2 up 2.1 4.57E-04
Ggt6 up 2.1 1.20E-05
Ccdc32 up 2.1 3.20E-04
Plekhb1 up 2.1 1.79E-05
Per3 up 2.1 7.91E-05
Hlf up 2.1 1.94E-04
Vipr1 up 2.1 9.88E-06
Enpp2 up 2.1 9.41E-05
2310044G17Rik up 2.1 6.02E-05
Tmem171 up 2.1 1.84E-03
Nos1 up 2.1 5.20E-04
2310044G17Rik up 2.1 7.31E-05
2900046F13Rik up 2.1 9.66E-04
Nr1d1 up 2.1 3.56E-04
Cisd1 up 2.1 3.03E-04
Bcas1 up 2.1 2.23E-03
Meg3 up 2.1 4.88E-03
Ankhd1 /// Eif4ebp3 up 2.1 5.23E-04
Kcnmb1 up 2.1 3.27E-04
Fgfr3 up 2.1 4.06E-04
Prkce up 2.1 5.85E-05
Rgs7bp up 2.1 3.78E-05
Aldh2 up 2.1 2.11E-04
Slc39a5 up 2.1 3.75E-03
Usp53 up 2.1 6.01E-04
Reln up 2.1 9.01E-04
Meis2 up 2.1 2.83E-03
D730039F16Rik up 2.1 1.74E-05
Zfp467 up 2.1 2.33E-05
Satb2 up 2.1 1.41E-04
D730039F16Rik up 2.1 1.50E-04
2810432L12Rik up 2.1 1.94E-03
9030425E11Rik up 2.1 1.35E-04
Zfp467 up 2.1 1.73E-05
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Tspan2 up 2.1 7.95E-05
Cys1 up 2.1 1.03E-04
Cacnb2 up 2.1 1.15E-04
Arl4d up 2.1 6.27E-07
Akt3 up 2.1 4.54E-03
Hhip up 2.1 1.71E-03
3110049J23Rik up 2.1 2.26E-03
Rab27a up 2.1 2.06E-03
Tgoln1 up 2.1 4.32E-03
Per3 up 2.1 3.22E-05
Slc25a12 up 2.1 1.79E-03
1810014F10Rik up 2.1 4.53E-03
Ppp1r14d up 2.1 2.08E-03
Ssbp2 up 2.1 1.19E-03
Mpdz up 2.1 8.94E-04
Atoh1 up 2.1 9.67E-04
Gnao1 up 2.1 3.07E-05
Klf9 up 2.1 1.36E-04
Ndn up 2.1 1.04E-05
Ccbl2 up 2.1 2.24E-03
Slc2a13 up 2.1 1.97E-03
Sdr42e1 up 2.1 4.04E-03
Cdx1 up 2.0 1.43E-04
Sema3a up 2.0 4.84E-04
Akap12 up 2.0 4.61E-05
Myo1a up 2.0 9.96E-04
Tgoln1 up 2.0 1.61E-03
Garnl4 up 2.0 4.24E-05
Iqgap2 up 2.0 2.36E-03
Il17re up 2.0 5.11E-05
Ttll7 up 2.0 6.91E-04
Prkcb up 2.0 2.70E-03
Slc4a4 up 2.0 3.67E-03
Rab3b up 2.0 3.86E-04
Acad11 /// Nphp3 up 2.0 3.98E-03
Ipmk up 2.0 4.78E-03
Etv1 up 2.0 2.37E-05
Cd109 up 2.0 3.60E-03
Reck up 2.0 4.20E-05
Marveld1 up 2.0 1.22E-03
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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Gene Symbol Regulation FCAbsolute p-value
Sdc2 up 2.0 4.14E-05
Hk1 up 2.0 8.11E-05
Nlrp9b up 2.0 9.35E-05
Hhip up 2.0 2.14E-04
Depdc6 up 2.0 1.30E-05
Galm up 2.0 4.86E-03
Golph3l up 2.0 2.79E-03
Cryl1 up 2.0 1.39E-04
Usp53 up 2.0 1.19E-04
Cnnm4 up 2.0 1.95E-05
Slc2a4 up 2.0 4.30E-06
Sdc2 up 2.0 2.38E-04
Ddx26b up 2.0 9.48E-05
Differentially Expressed Genes 
APCMin/+  PPARɲ-/- normal vs. APCMin/+  PPARɲ-/- tumour 
(Comparison 4)
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2. Number of differentially regulated probe sets in Comparison 
groups 1 ± 4 
 
Comparison 1 (APCMin/+PPARĮ-/- normal vs. APCMin/+ normal)  
Comparison 2 (APCMin/+PPARĮ-/- tumour vs. APCMin/+ tumour)  
Comparison 3 (APCMin/+ normal vs. APCMin/+ tumour) 
Comparison 4 (APCMin/+PPARĮ-/- normal vs. APCMin/+PPARĮ-/- tumour) 
 
Criteria for selection of differentially regulated probes in Comparison 1 & Comparison 2 was fold 
change >= 1.7, p <= 0.05 
Criteria for selection of differentially regulated probes in Comparison 3 & Comparison 4 was fold 
change >= 2, p < = 0.005 
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